RU2791992C2 - Solubilized apirases, methods and applications - Google Patents
Solubilized apirases, methods and applications Download PDFInfo
- Publication number
- RU2791992C2 RU2791992C2 RU2021100711A RU2021100711A RU2791992C2 RU 2791992 C2 RU2791992 C2 RU 2791992C2 RU 2021100711 A RU2021100711 A RU 2021100711A RU 2021100711 A RU2021100711 A RU 2021100711A RU 2791992 C2 RU2791992 C2 RU 2791992C2
- Authority
- RU
- Russia
- Prior art keywords
- seq
- apyrase
- deletion
- acute
- amino acids
- Prior art date
Links
Images
Abstract
Description
ОБЛАСТЬ ТЕХНИКИFIELD OF TECHNOLOGY
Настоящее изобретение относится к разработке и терапевтическому применению солюбилизированных полипептидных апираз, фармацевтических композиций и способам, применимым для предупреждения и лечения повреждения тканей.The present invention relates to the development and therapeutic use of solubilized polypeptide apyrases, pharmaceutical compositions and methods useful for the prevention and treatment of tissue damage.
ПРЕДПОСЫЛКИ ИЗОБРЕТЕНИЯBACKGROUND OF THE INVENTION
Апираза (ATP-дифосфатаза, аденозиндифосфатаза, ADPаза или ATP-дифосфогидролаза) представляет собой группу ферментов, связанных с цитоплазматической мембраной, активных в отношении как ди-, так и трифосфатов нуклеотидов (NDP и NTP) и гидролизующих NTP с получением монофосфатов нуклеотидов (NMP) в ходе двух отдельных последовательных стадий, протекающих с высвобождением фосфата, при этом NDP выступают в качестве промежуточных соединений. Большинство экто-ATPаз, которые встречаются на клеточной поверхности и гидролизуют внеклеточные нуклеотиды, принадлежат к данному семейству ферментов. Они отличаются от ATPаз, которые специфично гидролизуют ATP, тем, что гидролизуют как ATP, так и ADP.Apyrase (ATP-diphosphatase, adenosine diphosphatase, ADPase, or ATP-diphosphohydrolase) is a group of cytoplasmic membrane-associated enzymes that are active on both nucleotide di- and triphosphates (NDP and NTP) and hydrolyze NTP to produce nucleotide monophosphates (NMP) in two separate sequential steps that release phosphate, with NDPs acting as intermediates. Most of the ecto-ATPases that occur on the cell surface and hydrolyze extracellular nucleotides belong to this family of enzymes. They differ from ATPases, which specifically hydrolyze ATP, in that they hydrolyze both ATP and ADP.
Первая ставшая известной человеческая апираза - эктонуклеозидтрифосфатдифосфогидролаза-1 (ген: ENTPD1, белок: NTPDаза 1), также известная как кластер дифференцировки 39 (CD39, UniProt P49961, или SEQ ID NO: 1) - представляет собой фермент, локализованный на клеточной поверхности, с каталитическим центром, обращенным во внеклеточное пространство.The first known human apyrase, ectonucleoside triphosphate diphosphohydrolase-1 (gene: ENTPD1, protein: NTPDase 1), also known as cluster of differentiation 39 (CD39, UniProt P49961, or SEQ ID NO: 1), is a cell surface localized enzyme with catalytic center facing the extracellular space.
В известном семействе CD39 человека его представитель CD39L3 известен как эктоапираза (экто-ATPDаза) и в отношении биохимической активности занимает промежуточное положение между CD39 и CD39L1 (экто-ATPазой). В частности, CD39L3 человека был солюбилизирован и очищен для терапевтических целей, например, как раскрыто в US7247300B1 (включенном в данный документ посредством ссылки) или включено в данный документ под SEQ ID NO: 3.In the known human CD39 family, its representative CD39L3 is known as ectoapyrase (ecto-ATPDase) and is intermediate in biochemical activity between CD39 and CD39L1 (ecto-ATPase). In particular, human CD39L3 has been solubilized and purified for therapeutic purposes, for example, as disclosed in US7247300B1 (incorporated herein by reference) or incorporated herein under SEQ ID NO: 3.
КРАТКОЕ ОПИСАНИЕ ИЗОБРЕТЕНИЯBRIEF DESCRIPTION OF THE INVENTION
Настоящее изобретение, помимо прочего, основано на неожиданном обнаружении того, что некоторые модификации солюбилизированной человеческой апиразы, такой как CD39 человека, приводят к получению удивительно активного белка, который в то же время является безопасным и простым в изготовлении.The present invention based, inter alia, on the unexpected finding that certain modifications to a solubilized human apyrase, such as human CD39, result in a surprisingly active protein that is both safe and easy to manufacture.
В соответствии с первым аспектом настоящего изобретения предусмотрена солюбилизированная человеческая апираза, содержащая по меньшей мере две модификации, выбранные из перечня, состоящего из N-концевой делеции, C-концевой делеции и модификации центральной области.According to a first aspect of the present invention, there is provided a solubilized human apyrase containing at least two modifications selected from the list consisting of an N-terminal deletion, a C-terminal deletion and a central region modification.
В одном варианте осуществления солюбилизированная человеческая апираза содержит N-концевую делецию, C-концевую делецию и модификацию по типу делеции.In one embodiment, the solubilized human apyrase contains an N-terminal deletion, a C-terminal deletion, and a deletion type modification.
В одном варианте осуществления модификация центральной области включает делецию одной или нескольких аминокислот. В другом варианте осуществления модификация центральной области включает точечную мутацию одной или нескольких аминокислот, такую как мутация по типу замены. В еще одном варианте осуществления модификация центральной области представляет собой комбинацию делеции одной или нескольких аминокислот и точечной мутации, такой как мутация по типу замены, одной или нескольких аминокислот.In one embodiment, the modification of the central region includes the deletion of one or more amino acids. In another embodiment, the modification of the central region includes a point mutation of one or more amino acids, such as a substitution type mutation. In yet another embodiment, the central region modification is a combination of a deletion of one or more amino acids and a point mutation, such as a substitution type mutation, of one or more amino acids.
N-концевая делеция может представлять собой делецию от 30 до 50 аминокислот на N-конце последовательности CD39 дикого типа согласно SEQ ID NO: 1, такую как делеция 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 или 50 аминокислот. В предпочтительном варианте осуществления N-концевая делеция представляет собой делецию 34, 37, 38 или 45 аминокислот.An N-terminal deletion may be a 30 to 50 amino acid deletion at the N-terminus of the wild-type CD39 sequence according to SEQ ID NO: 1, such as 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 , 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50 amino acids. In a preferred embodiment, the N-terminal deletion is a 34, 37, 38 or 45 amino acid deletion.
C-концевая делеция может представлять собой делецию от 20 до 40 аминокислот на C-конце последовательности CD39 дикого типа согласно SEQ ID NO: 1, такую как делеция 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 или 40 аминокислот. В предпочтительном варианте осуществления C-концевая делеция представляет собой делецию 22, 29 или 37 аминокислот.The C-terminal deletion may be a deletion of 20 to 40 amino acids at the C-terminus of the wild-type CD39 sequence according to SEQ ID NO: 1, such as
Делеция в центральной области может представлять собой делецию от 10 до 15 последовательно расположенных аминокислот последовательности CD39 дикого типа согласно SEQ ID NO: 1, такую как делеция 10, 11, 12, 13, 14 или 15 аминокислот. В предпочтительном варианте осуществления делеция в центральной области представляет собой делецию 12 аминокислот, таких как аминокислоты под номерами от 193 до 204, по отношению к последовательности CD39 дикого типа согласно SEQ ID NO: 1.A deletion in the central region may be a deletion of 10 to 15 consecutive amino acids of the wild-type CD39 sequence according to SEQ ID NO: 1, such as a deletion of 10, 11, 12, 13, 14 or 15 amino acids. In a preferred embodiment, the deletion in the central region is a 12 amino acid deletion, such as amino acids 193 to 204, relative to the wild-type CD39 sequence according to SEQ ID NO: 1.
В одном варианте осуществления солюбилизированная человеческая апираза содержит одну, две, три, четыре или пять точечных мутаций по отношению к последовательности CD39 дикого типа согласно SEQ ID NO: 1, выбранных из группы, состоящей из K71E, N73Q, V95A, G102D, Y104S, T106S, R113M, L149M, V151A, E173D, T229A, L254M, K258R, W263R, E276D, N292Q, R304G, I319T, N327Q, A362N, F365S, N371Q, K405N, Y412F, L424Q, H436D, I437N, F439S, G441D, N457Q, P463S, и S469R.In one embodiment, the solubilized human apyrase contains one, two, three, four or five point mutations relative to the sequence of wild-type CD39 according to SEQ ID NO: 1 selected from the group consisting of K71E, N73Q, V95A, G102D, Y104S, T106S , R113M, L149M, V151A, E173D, T229A, L254M, K258R, W263R, E276D, N292Q, R304G, I319T, N327Q, A362N, F365S, N371Q, K405N, Y412F, L424Q, H436D, I437N, F439S, G441D, N457Q, P463S , and S469R.
В одном варианте осуществления солюбилизированная человеческая апираза содержит последовательность, выбранную из группы, состоящей из SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 32, SEQ ID NO: 54, SEQ ID NO: 56, SEQ ID NO: 70, SEQ ID NO: 76, и SEQ ID NO: 78. In one embodiment, the solubilized human apyrase contains a sequence selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 32, SEQ ID NO: 54, SEQ ID NO: 56, SEQ ID NO: 70, SEQ ID NO: 76, and SEQ ID NO: 78.
В одном варианте осуществления солюбилизированная человеческая апираза содержит последовательность, выбранную из группы, состоящей из SEQ ID NO: 131, SEQ ID NO: 133, SEQ ID NO: 135, SEQ ID NO: 137, SEQ ID NO: 139 и SEQ ID NO: 141.In one embodiment, the solubilized human apyrase contains a sequence selected from the group consisting of SEQ ID NO: 131, SEQ ID NO: 133, SEQ ID NO: 135, SEQ ID NO: 137, SEQ ID NO: 139, and SEQ ID NO: 141.
В одном конкретном варианте осуществления солюбилизированная человеческая апираза содержит последовательность, выбранную из группы, состоящей из SEQ ID NO: 213, SEQ ID NO: 227, SEQ ID NO: 219, SEQ ID NO: 227, SEQ ID NO: 217, SEQ ID NO: 209, SEQ ID NO: 221, SEQ ID NO: 72, SEQ ID NO: 215, SEQ ID NO: 223, SEQ ID NO: 211, SEQ ID NO: 58 и SEQ ID NO: 229.In one specific embodiment, the solubilized human apyrase contains a sequence selected from the group consisting of SEQ ID NO: 213, SEQ ID NO: 227, SEQ ID NO: 219, SEQ ID NO: 227, SEQ ID NO: 217, SEQ ID NO : 209, SEQ ID NO: 221, SEQ ID NO: 72, SEQ ID NO: 215, SEQ ID NO: 223, SEQ ID NO: 211, SEQ ID NO: 58 and SEQ ID NO: 229.
В одном конкретном варианте осуществления солюбилизированная человеческая апираза состоит из последовательности, выбранной из группы, состоящей из SEQ ID NO: 213, SEQ ID NO: 227, SEQ ID NO: 219, SEQ ID NO: 227, SEQ ID NO: 217, SEQ ID NO: 209, SEQ ID NO: 221, SEQ ID NO: 72, SEQ ID NO: 215, SEQ ID NO: 223, SEQ ID NO: 211, SEQ ID NO: 58 и SEQ ID NO: 229.In one specific embodiment, the solubilized human apyrase consists of a sequence selected from the group consisting of SEQ ID NO: 213, SEQ ID NO: 227, SEQ ID NO: 219, SEQ ID NO: 227, SEQ ID NO: 217, SEQ ID NO: 209, SEQ ID NO: 221, SEQ ID NO: 72, SEQ ID NO: 215, SEQ ID NO: 223, SEQ ID NO: 211, SEQ ID NO: 58 and SEQ ID NO: 229.
В предпочтительном варианте осуществления солюбилизированная человеческая апираза содержит последовательность, выбранную из группы, состоящей из SEQ ID NO: 58, SEQ ID NO: 72 и SEQ ID NO: 229.In a preferred embodiment, the solubilized human apyrase contains a sequence selected from the group consisting of SEQ ID NO: 58, SEQ ID NO: 72, and SEQ ID NO: 229.
В одном варианте осуществления солюбилизированная человеческая апираза содержит SEQ ID NO: 58. В одном варианте осуществления солюбилизированная человеческая апираза содержит SEQ ID NO: 72. В одном варианте осуществления солюбилизированная человеческая апираза содержит SEQ ID NO: 229.In one embodiment, the solubilized human apyrase comprises SEQ ID NO: 58. In one embodiment, the solubilized human apyrase comprises SEQ ID NO: 72. In one embodiment, the solubilized human apyrase comprises SEQ ID NO: 229.
В предпочтительном варианте осуществления солюбилизированная человеческая апираза состоит из последовательности, выбранной из группы, состоящей из SEQ ID NO: 58, SEQ ID NO: 72 и SEQ ID NO: 229.In a preferred embodiment, the solubilized human apyrase consists of a sequence selected from the group consisting of SEQ ID NO: 58, SEQ ID NO: 72 and SEQ ID NO: 229.
В одном варианте осуществления солюбилизированная человеческая апираза состоит из SEQ ID NO: 58. В одном варианте осуществления солюбилизированная человеческая апираза состоит из SEQ ID NO: 72. В одном варианте осуществления солюбилизированная человеческая апираза состоит из SEQ ID NO: 229.In one embodiment, the solubilized human apyrase consists of SEQ ID NO: 58. In one embodiment, the solubilized human apyrase consists of SEQ ID NO: 72. In one embodiment, the solubilized human apyrase consists of SEQ ID NO: 229.
В соответствии со вторым аспектом настоящего изобретения настоящее изобретение относится к фармацевтической композиции, содержащей терапевтически эффективную дозу апиразы согласно первому аспекту настоящего изобретения и один или несколько предусмотренных фармацевтически приемлемых носителей.According to a second aspect of the present invention, the present invention relates to a pharmaceutical composition comprising a therapeutically effective dose of apyrase according to the first aspect of the present invention and one or more pharmaceutically acceptable carriers provided.
В одном варианте осуществления фармацевтическая композиция дополнительно содержит один или несколько дополнительных активных ингредиентов.In one embodiment, the pharmaceutical composition further comprises one or more additional active ingredients.
В соответствии с третьим аспектом настоящего изобретения предусмотрена выделенная апираза согласно первому аспекту для применения в качестве лекарственного препарата.According to a third aspect of the present invention, an isolated apyrase according to the first aspect is provided for use as a drug.
В соответствии с четвертым аспектом настоящего изобретения предусмотрена выделенная апираза согласно первому аспекту для применения в лечении повреждения тканей.According to a fourth aspect of the present invention, an isolated apyrase according to the first aspect is provided for use in the treatment of tissue injury.
Повреждение тканей может представлять собой острое повреждение головного мозга (инсульт); острую полиорганную недостаточность; отсроченную функцию трансплантата после трансплантации почки или других солидных органов; ожог; лучевое поражение; острое повреждение в связи с травмой и/или гипоксией, такое как острый респираторный дистресс-синдром (ARDS) или повреждение легких; острое повреждение почек, такое как острое повреждение почек вследствие хирургической операции на органах грудной клетки (например, замены аортального клапана, аортокоронарного шунтирования), или сепсиса, или рабдомиолиза, или токсических эффектов антибиотиков или других лекарственных препаратов; острое повреждение миокарда.Tissue damage can be acute brain injury (stroke); acute multiple organ failure; delayed graft function after transplantation of a kidney or other solid organs; burn; radiation damage; acute injury due to trauma and/or hypoxia, such as acute respiratory distress syndrome (ARDS) or lung injury; acute kidney injury, such as acute kidney injury due to chest surgery (eg, aortic valve replacement, coronary artery bypass grafting), or sepsis, or rhabdomyolysis, or toxic effects of antibiotics or other drugs; acute myocardial injury.
В другом варианте осуществления четвертый аспект настоящего изобретения относится к выделенной апиразе согласно первому аспекту настоящего изобретения для применения в лечении острого повреждения почек, ассоциированного с хирургической операцией на сердце. In another embodiment, the fourth aspect of the present invention provides an isolated apyrase according to the first aspect of the present invention for use in the treatment of acute kidney injury associated with cardiac surgery.
В другом варианте осуществления четвертый аспект настоящего изобретения относится к выделенной апиразе согласно первому аспекту настоящего изобретения для применения в лечении отсроченной функции трансплантата (DGF), острого респираторного дистресс-синдрома (ARDS), острого инфаркта миокарда (AMI), травматического повреждения головного мозга (TBI)/острого ишемического инсульта (AIS), ишемически-реперфузионного повреждения (IRI) или их комбинаций, часто называемых формами полиорганной недостаточности (MOF).In another embodiment, the fourth aspect of the present invention provides an isolated apyrase according to the first aspect of the present invention for use in the treatment of delayed graft function (DGF), acute respiratory distress syndrome (ARDS), acute myocardial infarction (AMI), traumatic brain injury (TBI )/acute ischemic stroke (AIS), ischemia-reperfusion injury (IRI), or combinations thereof, often referred to as forms of multiple organ failure (MOF).
В одном варианте осуществления солюбилизированная человеческая апираза, применяемая для лечения острого повреждения почек, ассоциированного с хирургической операцией на сердце, содержит аминокислотную последовательность под SEQ ID NO: 58. In one embodiment, the solubilized human apyrase used to treat acute kidney injury associated with cardiac surgery contains the amino acid sequence of SEQ ID NO: 58.
В одном варианте осуществления солюбилизированная человеческая апираза, применяемая для лечения острого повреждения почек, ассоциированного с хирургической операцией на сердце, содержит аминокислотную последовательность под SEQ ID NO: 72. В одном варианте осуществления солюбилизированная человеческая апираза, применяемая для лечения острого повреждения почек, ассоциированного с хирургической операцией на сердце, содержит аминокислотную последовательность под SEQ ID NO: 229.In one embodiment, the solubilized human apyrase used to treat acute kidney injury associated with cardiac surgery contains the amino acid sequence of SEQ ID NO: 72. In one embodiment, the solubilized human apyrase used to treat acute kidney injury associated with cardiac surgery. operation on the heart, contains the amino acid sequence under SEQ ID NO: 229.
В дополнительном предпочтительном варианте осуществления настоящее изобретение относится к применению выделенной апиразы согласно первому аспекту настоящего изобретения для лечения острого повреждения почек, ассоциированного с сепсисом. In a further preferred embodiment, the present invention relates to the use of an isolated apyrase according to the first aspect of the present invention for the treatment of acute kidney injury associated with sepsis.
В одном варианте осуществления четвертого аспекта солюбилизированная человеческая апираза для применения в лечении острого повреждения почек, ассоциированного с сепсисом, содержит аминокислотную последовательность под SEQ ID NO: 58.In one embodiment of the fourth aspect, the solubilized human apyrase for use in the treatment of sepsis-associated acute kidney injury comprises the amino acid sequence of SEQ ID NO: 58.
В одном варианте осуществления четвертого аспекта солюбилизированная человеческая апираза для применения в лечении острого повреждения почек, ассоциированного с сепсисом, содержит аминокислотную последовательность под SEQ ID NO: 72.In one embodiment of the fourth aspect, the solubilized human apyrase for use in the treatment of sepsis-associated acute kidney injury comprises the amino acid sequence of SEQ ID NO: 72.
В одном варианте осуществления четвертого аспекта солюбилизированная человеческая апираза для применения в лечении острого повреждения почек, ассоциированного с сепсисом, содержит аминокислотную последовательность под SEQ ID NO: 229.In one embodiment of the fourth aspect, the solubilized human apyrase for use in the treatment of sepsis-associated acute kidney injury comprises the amino acid sequence of SEQ ID NO: 229.
В соответствии с пятым аспектом настоящего изобретения предусмотрен способ лечения повреждения тканей у субъекта-человека, включающий введение указанному субъекту терапевтически эффективной дозы солюбилизированной человеческой апиразы согласно первому аспекту. Один вариант осуществления пятого аспекта настоящего изобретения относится к способу лечения острого повреждения почек, ассоциированного с хирургической операцией на сердце, включающему введение субъекту, нуждающемуся в таком лечении, терапевтически эффективной дозы выделенной апиразы согласно первому аспекту настоящего изобретения.According to a fifth aspect of the present invention, there is provided a method for treating tissue damage in a human subject, comprising administering to said subject a therapeutically effective dose of a solubilized human apyrase according to the first aspect. One embodiment of the fifth aspect of the present invention relates to a method of treating acute kidney injury associated with cardiac surgery, comprising administering to a subject in need of such treatment, a therapeutically effective dose of isolated apyrase according to the first aspect of the present invention.
Другой вариант осуществления пятого аспекта настоящего изобретения относится к способу лечения отсроченной функции трансплантата (DGF), острого респираторного дистресс-синдрома (ARDS), острого инфаркта миокарда (AMI), травматического повреждения головного мозга (TBI)/острого ишемического инсульта (AIS), ишемически-реперфузионного повреждения (IRI) или их комбинаций, часто называемых формами полиорганной недостаточности (MOF), включающему введение субъекту, нуждающемуся в таком лечении, терапевтически эффективной дозы выделенной апиразы согласно первому аспекту настоящего изобретения.Another embodiment of the fifth aspect of the present invention relates to a method for treating delayed graft function (DGF), acute respiratory distress syndrome (ARDS), acute myocardial infarction (AMI), traumatic brain injury (TBI)/acute ischemic stroke (AIS), ischemic -reperfusion injury (IRI) or combinations thereof, often referred to as forms of multiple organ failure (MOF), comprising administering to a subject in need of such treatment, a therapeutically effective dose of isolated apyrase according to the first aspect of the present invention.
В одном варианте осуществления пятого аспекта солюбилизированная человеческая апираза, применяемая в способе лечения острого повреждения почек, ассоциированного с хирургической операцией на сердце, содержит аминокислотную последовательность под SEQ ID NO: 58, SEQ ID NO: 72 или SEQ ID NO: 229.In one embodiment of the fifth aspect, the solubilized human apyrase used in the method of treating acute kidney injury associated with cardiac surgery comprises the amino acid sequence of SEQ ID NO: 58, SEQ ID NO: 72, or SEQ ID NO: 229.
Один вариант осуществления пятого аспекта настоящего изобретения относится к способу лечения острого повреждения почек, ассоциированного с сепсисом, включающему введение субъекту, нуждающемуся в таком лечении, терапевтически эффективной дозы выделенной апиразы согласно первому аспекту настоящего изобретения.One embodiment of the fifth aspect of the present invention relates to a method of treating acute kidney injury associated with sepsis, comprising administering to a subject in need of such treatment, a therapeutically effective dose of isolated apyrase according to the first aspect of the present invention.
В одном варианте осуществления пятого аспекта солюбилизированная человеческая апираза, применяемая в способе лечения острого повреждения почек, ассоциированного с сепсисом, содержит аминокислотную последовательность под SEQ ID NO: 58, SEQ ID NO: 72 или SEQ ID NO: 229. Повреждение тканей может представлять собой острое повреждение головного мозга (инсульт); острую полиорганную недостаточность; отсроченную функцию трансплантата после трансплантации почки или других солидных органов; ожог; лучевое поражение; острое повреждение в связи с травмой и/или гипоксией, такое как острый респираторный дистресс-синдром (ARDS) или повреждение легких; острое повреждение почек, такое как острое повреждение почек вследствие хирургической операции на органах грудной клетки (например, замены аортального клапана, аортокоронарного шунтирования), или сепсиса, или рабдомиолиза, или токсических эффектов антибиотиков или других лекарственных препаратов; острое повреждение миокарда.In one embodiment of the fifth aspect, the solubilized human apyrase used in the method of treating sepsis-associated acute kidney injury comprises the amino acid sequence of SEQ ID NO: 58, SEQ ID NO: 72, or SEQ ID NO: 229. The tissue injury may be an acute brain damage (stroke); acute multiple organ failure; delayed graft function after transplantation of a kidney or other solid organs; burn; radiation damage; acute injury due to trauma and/or hypoxia, such as acute respiratory distress syndrome (ARDS) or lung injury; acute kidney injury, such as acute kidney injury due to chest surgery (eg, aortic valve replacement, coronary artery bypass grafting), or sepsis, or rhabdomyolysis, or toxic effects of antibiotics or other drugs; acute myocardial injury.
В соответствии с шестым аспектом настоящего изобретения предусмотрена выделенная молекула нуклеиновой кислоты, кодирующая любую апиразу согласно первому аспекту.According to a sixth aspect of the present invention, there is provided an isolated nucleic acid molecule encoding any apyrase according to the first aspect.
В соответствии с седьмым аспектом настоящего изобретения предусмотрен клонирующий или экспрессионный вектор, содержащий одну или несколько последовательностей нуклеиновой кислоты согласно шестому аспекту, где вектор является подходящим для рекомбинантного получения выделенной апиразы согласно первому аспекту.According to a seventh aspect of the present invention, there is provided a cloning or expression vector comprising one or more nucleic acid sequences according to the sixth aspect, wherein the vector is suitable for recombinant production of the isolated apyrase according to the first aspect.
В соответствии с восьмым аспектом настоящего изобретения предусмотрена клетка-хозяин, содержащая один или несколько клонирующих или экспрессионных векторов согласно седьмому аспекту.According to an eighth aspect of the present invention, there is provided a host cell comprising one or more cloning or expression vectors according to the seventh aspect.
В соответствии с девятым аспектом настоящего изобретения предусмотрен способ получения апиразы согласно первому аспекту, включающий культивирование клетки-хозяина по восьмому аспекту, очистку и извлечение указанной апиразы.According to a ninth aspect of the present invention, there is provided a method for producing apyrase according to the first aspect, comprising culturing a host cell according to the eighth aspect, purifying and recovering said apyrase.
КРАТКОЕ ОПИСАНИЕ ГРАФИЧЕСКИХ МАТЕРИАЛОВBRIEF DESCRIPTION OF GRAPHICS
На фигуре 1 представлено выравнивание последовательностей;The figure 1 shows the alignment of sequences;
на фигуре 2A представлен уровень экспрессии CD39 человека в содержащей его надосадочной жидкости, определенный с помощью вестерн-блоттинга с применением антитела к APP в соответствии с вариантом осуществления;Figure 2A shows the expression level of human CD39 in a supernatant containing it, determined by Western blotting using an anti-APP antibody according to an embodiment;
на фигуре 2B представлен уровень экспрессии вариантов CD39 человека с делецией цистеинового мостика в содержащей их надосадочной жидкости, определенный с помощью вестерн-блоттинга с применением антитела к APP в соответствии с вариантом осуществления;Figure 2B shows the level of expression of human CD39 variants with a cysteine bridge deletion in the supernatant containing them, determined by Western blotting using an anti-APP antibody according to an embodiment;
на фигуре 3 представлен график, демонстрирующий результаты твердофазного анализа ATPазы для вариантов CD39;Figure 3 is a graph showing the results of the ATPase AP analysis for CD39 variants;
на фигуре 4 представлен график, демонстрирующий твердофазное расщепление ATP на клетках HEK293, трансформированных с помощью вариантов CD39 человека в соответствии с вариантом осуществления;Figure 4 is a graph showing solid phase ATP cleavage on HEK293 cells transformed with human CD39 variants according to the embodiment;
на фигуре 5 представлена схема вектора в соответствии с вариантом осуществления;Figure 5 is a diagram of a vector according to an embodiment;
на фигуре 6 представлена модель ферментативной активности на основе стационарного приближения;figure 6 shows a model of enzymatic activity based on a stationary approximation;
на фигуре 7 представлен обзор кинетических данных и аппроксимация моделью для белка в соответствии с вариантом осуществления;Figure 7 provides an overview of kinetic data and model fit for a protein according to an embodiment;
на фигуре 8 представлен обзор кинетических данных и аппроксимация моделью для белка в соответствии с вариантом осуществления;Figure 8 provides an overview of kinetic data and model fit for a protein according to an embodiment;
на фигуре 9 представлен обзор кинетических данных и аппроксимация моделью для белка в соответствии с вариантом осуществления;Figure 9 provides an overview of kinetic data and model fit for a protein according to an embodiment;
на фигуре 10 представлено схематическое изображение условий эксперимента;Figure 10 is a schematic representation of the experimental conditions;
на фигуре 11 представлен график, демонстрирующий уровни AMP для белков в соответствии с вариантами осуществления; иFigure 11 is a graph showing AMP levels for proteins according to embodiments; And
на фигуре 12 представлены графики, демонстрирующие результаты, полученные in vivo, для белков в соответствии с вариантами осуществления.Figure 12 is a graph showing in vivo results for proteins according to the embodiments.
ПОДРОБНОЕ ОПИСАНИЕ ИЗОБРЕТЕНИЯDETAILED DESCRIPTION OF THE INVENTION
Настоящее изобретение, помимо прочего, основано на неожиданном обнаружении того, что некоторые модификации солюбилизированного CD39 приводят к получению удивительно активного белка, который является безопасным и простым в изготовлении.The present invention based, among other things, on the unexpected finding that certain modifications to solubilized CD39 result in a surprisingly active protein that is safe and easy to manufacture.
Как будет показано в конкретных примерах ниже, предпочтительным вариантом осуществления является солюбилизированная человеческая апираза, содержащая по меньшей мере две модификации, выбранные из перечня, состоящего из N-концевой делеции, С-концевой делеции и делеции в центральной области, такая как солюбилизированная человеческая апираза, содержащая последовательность, выбранную из группы, состоящей из SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 32, SEQ ID NO: 54, SEQ ID NO: 56, SEQ ID NO: 70, SEQ ID NO: 76, и SEQ ID NO: 78.As will be shown in the specific examples below, a preferred embodiment is a solubilized human apyrase containing at least two modifications selected from a list consisting of an N-terminal deletion, a C-terminal deletion, and a deletion in the central region, such as solubilized human apyrase, containing a sequence selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 32, SEQ ID NO: 54, SEQ ID NO: 56, SEQ ID NO: 70, SEQ ID NO: 76 , and SEQ ID NO: 78.
Авторами настоящего изобретения были опробованы несколько разных стратегий модификации последовательности с целью получения солюбилизированной человеческой апиразы как с сохраненной активностью, так и со способностью экспрессироваться, так, чтобы в то же время не вводить слишком много модификаций из-за риска повышения иммуногенности и, таким образом, повышенного риска безопасности. Неожиданно оказалось, что одной из модификаций последовательности, которая, как обнаруживалось, одновременно повышала как эффективность, так и способность к экспрессии у человеческой апиразы и в то же время не добавляла слишком высокий риск иммуногенности, являлась делеция в центральном участке - так называемая модификация дельта-MIL (ΔMIL).Several different sequence modification strategies have been tried by the present inventors in order to obtain a solubilized human apyrase with both retained activity and expressibility, while at the same time not introducing too many modifications due to the risk of increasing immunogenicity and thus increased security risk. Unexpectedly, one of the sequence modifications that was found to simultaneously increase both the efficiency and the ability to express in human apyrase, and at the same time did not add too high a risk of immunogenicity, was a deletion in the central region - the so-called delta modification. MIL (∆MIL).
Для повышения экспрессии солюбилизированной человеческой апиразы в соответствии с вариантами осуществления настоящего изобретения проводили тестирование N-концевых экспрессионных меток. Различные N-концевые экспрессионные метки известны из уровня техники, однако неожиданно оказалось, что не все метки функционировали. Авторы настоящего изобретения обнаружили, что функционировали только некоторые из меток, что нельзя было предугадать.To increase the expression of solubilized human apyrase, N-terminal expression tags were tested in accordance with embodiments of the present invention. Various N-terminal expression tags are known in the art, however surprisingly not all of the tags were functional. The inventors of the present invention found that only some of the labels functioned, which was unpredictable.
Этими N-концевыми метками были SEQ ID NO: 131, SEQ ID NO: 133, SEQ ID NO: 135, SEQ ID NO: 137, SEQ ID NO: 139 или SEQ ID NO: 141. Как показано в данном документе, особенно предпочтительными метками являются SEQ ID NO: 133, SEQ ID NO: 135 или SEQ ID NO: 137.These N-terminal tags were SEQ ID NO: 131, SEQ ID NO: 133, SEQ ID NO: 135, SEQ ID NO: 137, SEQ ID NO: 139, or SEQ ID NO: 141. As shown herein, particularly preferred the labels are SEQ ID NO: 133, SEQ ID NO: 135, or SEQ ID NO: 137.
Конкретные подробности изложены в примерах 9-13 ниже. Тем не менее, с целью иллюстрации непредсказуемой природы этих примеров в таблице 1 приведен сравнительный сводный обзор.Specific details are set forth in Examples 9-13 below. However, to illustrate the unpredictable nature of these examples, Table 1 provides a comparative summary.
1. Определения1. Definitions
Для облегчения практического осуществления настоящего изобретения специалистом в данной области во всем настоящем описании используются следующие термины.To facilitate the practical implementation of the present invention by a person skilled in the art throughout the present description, the following terms are used.
Термины "CD39" и "hCD39" используются в качестве синонимов во всем настоящем изобретении и, если не указано иное, означают кластер дифференцировки 39 (CD39) человека в соответствии с UniProt P49961 или SEQ ID NO: 1.The terms "CD39" and "hCD39" are used interchangeably throughout the present invention and, unless otherwise indicated, refer to the human cluster of differentiation 39 (CD39) according to UniProt P49961 or SEQ ID NO: 1.
Термин "апираза" относится к человеческой апиразе, если не указано иное. Термин "солюбилизированная апираза", используемый в данном документе, означает, что апираза, которая, будучи белком дикого типа, существует в форме, связанной с клеточной мембраной, была модифицирована таким образом, что она больше не связана с клеточной мембраной, а существует в растворимом состоянии, т. е. больше не заякорена на клеточной мембране.The term "apirase" refers to human apyrase unless otherwise indicated. The term "solubilized apyrase" as used herein means that the apyrase, which, being a wild-type protein, exists in a form bound to the cell membrane, has been modified so that it is no longer bound to the cell membrane, but exists in a soluble form. state, i.e. no longer anchored to the cell membrane.
Аббревиатура "MIL" относится к петле, взаимодействующей с мембраной, которая представляет собой центральную часть белка CD39 дикого типа (человека), взаимодействующую с клеточной мембраной, в дополнение к N-концевой и C-концевой частям, которые физически заякорены в клеточной мембране. Термин "дельта-MIL" или "ΔMIL" относится к делеции последовательности MIL в CD39 дикого типа (человека).The abbreviation "MIL" refers to the membrane-interacting loop, which is the central portion of the wild-type (human) CD39 protein interacting with the cell membrane, in addition to the N-terminal and C-terminal portions, which are physically anchored to the cell membrane. The term "delta-MIL" or "ΔMIL" refers to a deletion of the MIL sequence in wild-type (human) CD39.
Термин "приблизительно" по отношению к числовому значению х означает, например, +/- 10%. В случае использования перед числовым диапазоном или перечнем чисел термин "приблизительно" применяется к каждому числу в ряду, например, фразу "приблизительно 1-5" следует интерпретировать как "от приблизительно 1 до приблизительно 5", или, например, фразу "приблизительно 1, 2, 3, 4" следует интерпретировать как "приблизительно 1, приблизительно 2, приблизительно 3, приблизительно 4 и т. д."The term "about" in relation to the numerical value of x means, for example, +/- 10%. When used before a numerical range or list of numbers, the term "about" applies to each number in the series, for example, the phrase "about 1-5" should be interpreted as "from about 1 to about 5", or, for example, the phrase "about 1, 2, 3, 4" should be interpreted as "about 1, about 2, about 3, about 4, etc."
Слово "по сути" не исключает "полностью", например, композиция, которая "по сути не содержит" Y, может полностью не содержать Y. В случае необходимости слово "по сути" может быть опущено из определения по настоящему изобретению.The word "substantially" does not exclude "completely", for example, a composition that is "substantially free" of Y may be completely free of Y. If necessary, the word "substantially" may be omitted from the definition of the present invention.
Термин "содержащий" охватывает "включающий", а также "состоящий", например, композиция, "содержащая" X, может состоять исключительно из X или может включать что-либо дополнительное, например X+Y.The term "comprising" encompasses "comprising" as well as "comprising", for example, a composition "comprising" X may consist solely of X, or may include something additional, such as X+Y.
Термин "идентичность" в отношении нативного полипептида и его функционального производного определяется в данном документе как процентная доля аминокислотных остатков в последовательности-кандидате, которые идентичны остаткам соответствующего нативного полипептида после выравнивания последовательностей и, при необходимости, введения гэпов для достижения максимального процента идентичности, и без учета каких-либо консервативных замен в качестве части идентичности последовательностей. Ни N- или C-концевые удлинения, ни вставки не должны рассматриваться как уменьшающие идентичность. Способы и компьютерные программы для выравнивания хорошо известны. Процент идентичности можно определить с помощью стандартных алгоритмов выравнивания, например, с помощью средства поиска основного локального выравнивания (BLAST), описанного Altshul et al. ((1990) J. Mol. Biol., 215: 403-410); алгоритма Needleman et al. ((1970) J. Mol. Biol., 48: 444-453) или алгоритма Meyers et al. ((1988) Comput. Appl. Biosci., 4: 11-17). Набором параметров может служить матрица весов Blosum 62 со штрафом за введение гэпа 12, штрафом за продление гэпа 4 и штрафом за гэп со сдвигом рамки считывания 5. Процент идентичности между двумя аминокислотными или нуклеотидными последовательностями также можно определить с помощью алгоритма E. Meyers и W. Miller ((1989) CABIOS, 4:11-17), который был включен в программу ALIGN (версии 2.0), с использованием таблицы весов замен остатков PAM120, штрафа за удлинение гэпа 12 и штрафа за введение гэпа 4.The term "identity" in relation to a native polypeptide and its functional derivative is defined herein as the percentage of amino acid residues in a candidate sequence that are identical to those of the corresponding native polypeptide after sequence alignment and, if necessary, gapping to achieve the maximum percent identity, and without taking into account any conservative substitutions as part of the sequence identity. Neither N- or C-terminal extensions nor insertions should be considered as reducing identity. Methods and computer programs for alignment are well known. Percent identity can be determined using standard alignment algorithms, such as the Basic Local Alignment Finder (BLAST) described by Altshul et al. ((1990) J. Mol. Biol., 215: 403-410); algorithm of Needleman et al. ((1970) J. Mol. Biol., 48: 444-453) or the algorithm of Meyers et al. ((1988) Comput. Appl. Biosci., 4: 11-17). The parameter set can be a Blosum 62 weight matrix with a gap penalty of 12, a gap extension penalty of 4, and a frameshift gap penalty of 5. The percent identity between two amino acid or nucleotide sequences can also be determined using the algorithm of E. Meyers and W. Miller ((1989) CABIOS, 4:11-17), which was included in the ALIGN program (version 2.0), using the PAM120 residue substitution weight table, a gap extension penalty of 12, and a gap insertion penalty of 4.
Термин "аминокислота(аминокислоты)" относится, например, ко всем встречающимся в природе L-α-аминокислотам и включает D-аминокислоты. Фраза "вариант аминокислотной последовательности" относится к молекулам с некоторыми отличиями в их аминокислотных последовательностях по сравнению с последовательностями согласно настоящему изобретению. Варианты аминокислотной последовательности белка согласно настоящему изобретению, например, с указанной последовательностью, по-прежнему обладают активностью апиразы. Варианты аминокислотной последовательности включают варианты с заменой (варианты, в которых был удален по меньшей мере один аминокислотный остаток и другая аминокислота вставлена на его место в то же положение в полипептиде согласно настоящему изобретению), варианты со вставкой (варианты с одной или несколькими аминокислотами, вставленными в непосредственной близости от аминокислоты в определенном положении в полипептиде согласно настоящему изобретению) и варианты с делецией (варианты, в которых одна или несколько аминокислот удалены в полипептиде согласно настоящему изобретению). The term "amino acid(s)" refers, for example, to all naturally occurring L-α-amino acids and includes D-amino acids. The phrase "variant amino acid sequence" refers to molecules with some differences in their amino acid sequences compared to the sequences according to the present invention. Variants of the amino acid sequence of the protein according to the present invention, for example, with the specified sequence, still have apyrase activity. Amino acid sequence variants include substitution variants (variants in which at least one amino acid residue has been removed and another amino acid inserted in its place at the same position in the polypeptide of the present invention), insertion variants (variants with one or more amino acids inserted in close proximity to an amino acid at a specific position in a polypeptide of the present invention) and deletion variants (variants in which one or more amino acids are deleted in a polypeptide of the present invention).
Термин "лечение" или "лечить" в данном документе определен как применение или введение субъекту апиразы согласно настоящему изобретению или применение или введение субъекту или в выделенную ткань или линию клеток, полученную от субъекта, фармацевтической композиции, содержащей указанную апиразу, где у субъекта имеется повреждение тканей, симптом, ассоциированный с повреждением тканей, где целью является ослабление, уменьшение интенсивности или улучшение течения повреждения тканей или любых ассоциированных симптомов повреждения тканей, помимо прочего, посредством снижения уровней внеклеточного ATP. The term "treatment" or "treat" is defined herein as the use or administration to a subject of an apyrase of the present invention, or the use or administration to a subject, or to an isolated tissue or cell line derived from a subject, of a pharmaceutical composition containing said apyrase, wherein the subject has a lesion. tissue, a symptom associated with tissue damage, where the goal is to alleviate, reduce the intensity or improve the course of tissue damage or any associated symptoms of tissue damage, among other things, by reducing the levels of extracellular ATP.
Термин "лечение" предназначен также для обозначения применения или введения субъекту фармацевтической композиции, содержащей апиразу, или применение или введение в выделенную ткань или линию клеток, полученную от субъекта, фармацевтической композиции, содержащей апиразу по настоящему изобретению, где у субъекта имеется повреждение тканей или симптом, ассоциированный с повреждением тканей, где целью является ослабление, уменьшение интенсивности или улучшение течения повреждения тканей или любых ассоциированных симптомов повреждения тканей.The term "treatment" is also intended to refer to the use or administration to a subject of a pharmaceutical composition containing an apyrase, or the use or administration to an isolated tissue or cell line derived from a subject of a pharmaceutical composition containing an apyrase of the present invention, where the subject has tissue damage or a symptom associated with tissue damage, where the goal is to reduce, reduce the intensity or improve the course of tissue damage or any associated symptoms of tissue damage.
Термин "предупреждать" или "предупреждение" относится к профилактическому или предупредительному лечению; он относится к задержке начала проявления или предупреждению начала проявления заболевания, нарушений и/или симптомов, ассоциированных с ним.The term "prevent" or "prevention" refers to prophylactic or preventive treatment; it refers to delaying the onset or preventing the onset of a disease, disorder and/or symptoms associated therewith.
Как используется в данном документе, субъект "нуждается в" лечении, если в результате такого лечения такой субъект получил бы пользу с биологической, медицинской точки зрения или с точки зрения качества его жизни. As used herein, a subject "needs" treatment if such treatment would result in such a subject benefiting from a biological, medical, or quality of life point of view.
Термин "фармацевтически приемлемый" означает нетоксичный материал, который не препятствует эффективности биологической активности активного(активных) ингредиента(ингредиентов). The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s).
Используемый в данном документе термин "вводить" или "введение" рассматриваемого соединения означает предоставление соединения по настоящему изобретению и его пролекарств субъекту, нуждающемуся в лечении. Введение "в комбинации с" одним или несколькими дополнительными терапевтическими средствами включает одновременное (параллельное) и последовательное введение в любом порядке и любым путем введения.As used herein, "administering" or "administering" a compound in question means providing a compound of the present invention and its prodrugs to a subject in need of treatment. Administration "in combination with" one or more additional therapeutic agents includes simultaneous (parallel) and sequential administration in any order and by any route of administration.
Используемый в данном документе термин "терапевтически эффективная доза" относится к дозе (количеству) апиразы, которая является эффективной при введении однократной или многократных доз пациенту (такому как человек) для лечения, предупреждения, предупреждения начала проявления, излечения, задержки, снижения тяжести, уменьшения интенсивности по меньшей мере одного симптома нарушения или рецидивирующего нарушения или продления выживаемости пациента свыше ожидаемой при отсутствии такого лечения. В случае его применения в отношении индивидуального активного ингредиента (например, апиразы), который вводится отдельно, данный термин относится только к этому ингредиенту. В случае его применения в отношении комбинации данный термин относится к объединенным дозам или количествам активных ингредиентов, которые приводят к терапевтическому эффекту, независимо от того, вводят ли их в комбинации, последовательно или одновременно.As used herein, the term "therapeutically effective dose" refers to a dose (amount) of apyrase that is effective when administered in single or multiple doses to a patient (such as a human) to treat, prevent, prevent onset, cure, delay, reduce severity, reduce the intensity of at least one symptom of the disorder or recurrent disorder or prolongation of the patient's survival beyond that expected in the absence of such treatment. When applied to an individual active ingredient (eg apyrase) administered separately, the term refers to that ingredient only. When applied to a combination, the term refers to the combined doses or amounts of active ingredients that result in a therapeutic effect, whether administered in combination, sequentially or simultaneously.
Фраза "схема дозирования" означает схему, применяемую для лечения болезни, например, протокол введения доз, применяемый во время лечения повреждения тканей. The phrase "dosing regimen" means a regimen used to treat a disease, such as a dosing protocol used during the treatment of tissue injury.
Фраза "средства для введения" используется для обозначения любого доступного инструмента для системного введения лекарственного средства пациенту, в том числе без ограничения предварительно заполненного шприца, флакона и шприца, шприца-ручки, автоинжектора, капельницы и пакета для внутривенного (i. v.) введения, помпы, пластырной помпы и т. д. С помощью таких изделий пациент может сам вводить лекарственное средство (т. е. вводить лекарственное средство себе самостоятельно), или лекарственное средство может вводить врач.The phrase "injection means" is used to refer to any available device for the systemic administration of a drug to a patient, including, without limitation, a pre-filled syringe, a vial and a syringe, a syringe pen, an auto-injector, an intravenous (i.v.) dropper and bag, a pump, a patch pump, etc. With these devices, the patient may self-administer the drug (i.e. self-administer the drug), or the drug may be administered by a doctor.
2. Пример 1: CD39, не связанный с мембраной2. Example 1: Non-membrane bound CD39
Апираза CD39 человека дикого типа (hCD39, UniProt P49961 или SEQ ID NO: 1) в естественных условиях заякорена в клеточной мембране с помощью трансмембранного домена на N-конце (предположительно представленного а. к. 17-37), предполагаемой центральной петли, взаимодействующей с мембраной (MIL, предположительно представленной а. к. 193-204), и C-концевого трансмембранного домена (предположительно представленного а. к. 479-499). Для обеспечения возможности экспрессии растворимого варианта CD39 с использованием клетки-хозяина, являющейся клеткой млекопитающего, несколько элементов последовательности CD39 модифицировали с получением не связанного с мембраной, или солюбилизированного, белка. Природную лидерную последовательность и N-концевую трансмембранную область заменяли на секреторную лидерную последовательность и метку для очистки (SEQ ID NO: 133). Границы внеклеточного домена CD39 изменяли для оптимизации параметров экспрессии, очистки и активности (аминокислоты №№ 38-476 из SEQ ID NO: 1, аминокислоты №№ 39-469 из SEQ ID NO: 1, аминокислоты 46-461 из SEQ ID NO: 1 и аминокислоты 46-476 из SEQ ID NO: 1 соответственно). Влияние цистеиновых остатков и дисульфидных мостиков на склонность к агрегации и ферментативную активность систематически оценивали путем замены цистеиновых остатков аланином или путем укорачивания петли, образуемой дисульфидным мостиком (SEQ ID NO: 107, 109, 111, 113 и 115). Фрагмент из гидрофобных аминокислот был описан в работе, посвященной структуре CD39 крысы (Zebisch et al, J.Mol. Biol. (2012), 415, 288-306, CD39 крысы дикого типа, Uniprot P97687, представленный под SEQ ID NO: 2), и есть основания полагать, что данная петля может взаимодействовать с клеточной мембраной (MIL). Авторы применяли эти полученные данные к последовательности CD39 человека путем выравнивания последовательностей и получали варианты CD39 с делецией петли (CD39ΔMIL или EP28, представленные под SEQ ID NO: 4). Проводили оценку влияния делеции (или дельта/Δ) MIL на уровень экспрессии функционального CD39 и термическую стабильность.Wild-type human CD39 apyrase (hCD39, UniProt P49961 or SEQ ID NO: 1) is naturally anchored to the cell membrane by a transmembrane domain at the N-terminus (presumably represented by a.k. 17-37), a putative central loop interacting with membrane (MIL, presumably represented by a.k. 193-204), and a C-terminal transmembrane domain (presumably represented by a.k. 479-499). To allow expression of a soluble CD39 variant using a mammalian host cell, several elements of the CD39 sequence were modified to produce a non-membrane-bound or solubilized protein. The natural leader sequence and the N-terminal transmembrane region were replaced with a secretory leader sequence and a purification tag (SEQ ID NO: 133). CD39 extracellular domain boundaries were altered to optimize expression, purification and activity parameters (amino acids #38-476 of SEQ ID NO: 1, amino acids #39-469 of SEQ ID NO: 1, amino acids 46-461 of SEQ ID NO: 1 and amino acids 46-476 of SEQ ID NO: 1, respectively). The effect of cysteine residues and disulfide bridges on aggregation propensity and enzymatic activity was systematically assessed by replacing cysteine residues with alanine or by shortening the loop formed by the disulfide bridge (SEQ ID NOS: 107, 109, 111, 113 and 115). A fragment of hydrophobic amino acids has been described in a study on the structure of rat CD39 (Zebisch et al, J. Mol. Biol. (2012), 415, 288-306, wild-type rat CD39, Uniprot P97687, presented under SEQ ID NO: 2) , and there is reason to believe that this loop can interact with the cell membrane (MIL). We applied these findings to the human CD39 sequence by sequence alignment and generated loop deletion variants of CD39 (CD39ΔMIL or EP28 represented under SEQ ID NO: 4). The influence of the deletion (or delta/Δ) of MIL on the expression level of functional CD39 and thermal stability was assessed.
Как можно видеть на фигуре 1, на которой показано выравнивание последовательностей SEQ ID NO: 1 и SEQ ID NO: 4, N-концевые аминокислоты 1-27, C-концевые аминокислоты 477-510 и аминокислоты 193-204 центральной петли, взаимодействующей с мембраной (MIL), подвергали делеции в wtCD39 (SEQ ID NO: 1) с образованием CD39ΔMIL (SEQ ID NO: 4).As can be seen in Figure 1, which shows the sequence alignment of SEQ ID NO: 1 and SEQ ID NO: 4, N-terminal amino acids 1-27, C-terminal amino acids 477-510 and amino acids 193-204 of the central membrane interacting loop (MIL) were deleted in wtCD39 (SEQ ID NO: 1) to form CD39ΔMIL (SEQ ID NO: 4).
Проводили изучение влияния различных модификаций последовательностей на термическую стабильность. Кроме того, проводили изучение влияния различных модификаций последовательностей на выход экспрессии и содержание мономеров на клетках CHO.The effect of various sequence modifications on thermal stability was studied. In addition, the effect of various sequence modifications on the expression yield and monomer content on CHO cells was studied.
(1) Способы(1) Ways
(a) Получение экспрессионных плазмид(a) Preparation of expression plasmids
Последовательности ДНК, кодирующие hCD39 с различными вариантами границ и делецией петли, взаимодействующей с мембраной (MIL), заказывали в GeneArt (Life Technologies Inc., Регенсбург, Германия) с оптимизацией кодонов для Homo sapiens. Последовательности, кодирующие варианты hCD39, субклонировали с применением стандартных методик молекулярной биологии из векторов, полученных в GeneArt, или их вариантов, полученных в собственной лаборатории, в экспрессионный вектор, подходящий для секреции в клетках млекопитающих. В модифицированных олигонуклеотидах были намечены мутации по типу замены цистеина на аланин, присутствующие в вариантах с делецией цистеинового мостика, и после последующей стадии сборочной ПЦР полученные фрагменты субклонировали в тот же экспрессионный вектор, упомянутый ранее. Элементы экспрессионного вектора включают промотор (тандем энхансер-промотор цитомегаловируса (CMV)), сигнальную последовательность для облегчения секреции, сигнал полиаденилирования и терминатор транскрипции (ген гормона роста крупного рогатого скота (BGH)), элемент, обеспечивающий возможность эписомальной репликации и репликации у прокариот (например, точку начала репликации SV40 и ColE1 или другие, известные из уровня техники), и элементы для обеспечения возможности отбора (ген устойчивости к ампициллину и маркер устойчивости к зеоцину). Перечень усеченных, солюбилизированных вариантов CD39 человека представлен в таблице 2, где нумерация аминокислотных модификаций проведена по отношению к SEQ ID NO: 1.DNA sequences encoding hCD39 with various border variants and a membrane interacting loop (MIL) deletion were ordered from GeneArt (Life Technologies Inc., Regensburg, Germany) with codon optimization for Homo sapiens. The hCD39 variant coding sequences were subcloned using standard molecular biology techniques from GeneArt derived vectors or in-house derived variants thereof into an expression vector suitable for secretion in mammalian cells. The modified oligonucleotides were targeted for cysteine to alanine mutations present in cysteine bridge deletion variants, and after a subsequent assembly PCR step, the resulting fragments were subcloned into the same expression vector mentioned earlier. Expression vector elements include a promoter (cytomegalovirus (CMV) enhancer-promoter tandem), a signal sequence to facilitate secretion, a polyadenylation signal and a transcription terminator (bovine growth hormone (BGH) gene), an element enabling episomal replication and replication in prokaryotes ( for example, the origin of replication SV40 and ColE1 or others known in the art), and elements to enable selection (ampicillin resistance gene and zeocin resistance marker). A list of truncated, solubilized human CD39 variants is presented in Table 2 , where amino acid modifications are numbered relative to SEQ ID NO: 1.
(b) Микромасштабная экспрессия вариантов hCD39(b) Microscale expression of hCD39 variants
Клетки 293-6E (раскрытые в WO2006096989A2, включенной в данный документ посредством ссылки) были выбраны для микромасштабного эксперимента в качестве одной из предпочтительных линий клеток-хозяев для транзиентной экспрессии белков при отсутствии сыворотки крови. Трансфекцию проводили с применением FuGene HD (Roche Applied Science, кат. № 04709705001) в качестве реагента для трансфекции. Клетки 293-6E культивировали в виде суспензионной культуры с использованием бессывороточной культуральной среды V3 (BioConcept, кат. № V3-K) для трансфекции и размножения клеток. Клетки выращивали во встряхиваемых колбах Corning (Corning, Тьюксбери, Массачусетс) на орбитальном шейкере (100-120 об./мин.) в увлажненном инкубаторе при 5% CO2 (в колбах, содержащих посевную культуру). Для трансфекции клетки в посевных культурах следует поддерживать в экспоненциальной фазе роста (при показателях плотности клеток от 5×105 до 3×106/мл), и они должны демонстрировать жизнеспособность > 90%. Показатели плотности клеток за пределами данного диапазона приводят либо к лаг-фазе после разбавления, либо к снижению эффективности трансфекции. Cells 293-6E (disclosed in WO2006096989A2, incorporated herein by reference) were selected for microscale experiment as one of the preferred host cell lines for transient expression of proteins in the absence of blood serum. Transfection was performed using FuGene HD (Roche Applied Science, cat. no. 04709705001) as a transfection reagent. 293-6E cells were cultured as a suspension culture using V3 serum-free culture medium (BioConcept cat. no. V3-K) for transfection and cell expansion. Cells were grown in Corning shake flasks (Corning, Tewkesbury, MA) on an orbital shaker (100-120 rpm) in a humidified 5% CO 2 incubator (in flasks containing inoculum). For transfection, cells in seed cultures should be maintained in an exponential growth phase (at cell densities of 5x10 5 to 3x10 6 /ml) and should demonstrate >90% viability. Cell densities outside this range either result in a lag phase after dilution or a decrease in transfection efficiency.
Для микромасштабных (0,5 мл) трансфекций аликвоту клеток отбирали из посевных культур и доводили до 0,5×106 клеток/мл с помощью бессывороточной культуральной среды V3. Раствор ДНК (называемый раствором 1) получали путем разбавления 0,5 мкг экспрессионных плазмид для hCD39 в 14 мкл бессывороточной культуральной среды V3, затем 2,3 мкл раствора FuGene HD также разбавляли в 14 мкл бессывороточной культуральной среды V3 (раствор 2). Оба раствора инкубировали в течение 5-10 мин. при комнатной температуре (RT). Затем раствор 2 добавляли в раствор 1 при осторожном перемешивании и инкубировали в течение еще 5-15 минут при комнатной температуре. Смесь для трансфекции затем добавляли к 0,5 мл клеток с плотностью 0,5×106 клеток/мл, высеянных в 48-луночный планшет для культивирования тканей (Corning, Тьюксбери, Массачусетс), и планшет помещали на орбитальный шейкер (300 об./мин.) в увлажненном инкубаторе при 5% CO2. Культуру собирали через 3 дня после трансфекции посредством центрифугирования при 4000 об./мин. в течение 10 минут при 4°C (Heraeus Multifuge 3 S-R, Thermo Scientific, Рокфорд, Иллинойс). Извлеченную надосадочную жидкость культуры клеток хранили при 4°C до дальнейшей обработки.For microscale (0.5 ml) transfections, an aliquot of cells was taken from the seed cultures and adjusted to 0.5×10 6 cells/ml with serum-free V3 culture medium. A DNA solution (referred to as solution 1) was prepared by diluting 0.5 µg of hCD39 expression plasmids in 14 µl of V3 serum-free culture medium, then 2.3 µl of FuGene HD solution was also diluted in 14 µl of V3 serum-free culture medium (solution 2). Both solutions were incubated for 5-10 min. at room temperature (RT). Then solution 2 was added to
(c) Вестерн-блот-анализ надосадочной жидкости, полученной при микромасштабной экспрессии(c) Western blot analysis of the supernatant obtained from microscale expression
Вестерн-блот-анализ надосадочной жидкости, полученной при микромасштабной экспрессии, проводили с целью проверки экспрессии и правильного образования рекомбинантных вариантов hCD39. 8 мкл надосадочной жидкости разбавляли в загрузочном буфере E-PAGE™ (4x, Invitrogen, № EPBNF-01) и загружали в 8% гель E-Page 48 (Invitrogen, № EP04808) в невосстанавливающих условиях. Прогон в геле проводили с помощью устройства Mother E-Base (Invitrogen) в течение 23 минут, и белки переносили на нитроцеллюлозную мембрану (Invitrogen IB301001) с помощью системы iBlot (Invitrogen) в соответствии с инструкциями производителя (7-минутный прогон). После 3-кратного промывания в TBS/0,05 Tween20 (TBST) мембрану инкубировали в течение 1 часа в присутствии 5% молока/TBST при осторожном взбалтывании с последующей инкубацией в течение 1 часа в присутствии 4 мкг/мл раствора антитела к APP мыши (антитела, вырабатываемого против пептидного фрагмента белка-предшественника амилоида (APP), применяемого для мечения белков, которое получено в собственной лаборатории Novartis), разбавленного в 2% молоке/TBST. После дополнительных 3 стадий промывания мембрану инкубировали в присутствии разведенного 1:1000 антитела к IgG мыши, конъюгированного со щелочной фосфатазой (Sigma-Aldrich, A5153-1ML), разбавленного в 2% молоке/TBST, и снова промывали 3 раза в TBST с последующей стадией ополаскивания в TBS. Сигнал проявляли в течение 1-5 минут с помощью SIGMAFAST™ BCIP®/NBT (Sigma-Aldrich, № B5655-25TAB) в соответствии с инструкциями производителя, и сигнал прерывали путем ополаскивания мембраны водой.Western blot analysis of the microscale expression supernatant was performed to verify the expression and correct formation of recombinant hCD39 variants. 8 μl of the supernatant was diluted in E-PAGE™ loading buffer (4x, Invitrogen, # EPBNF-01) and loaded onto an 8% E-Page 48 gel (Invitrogen, # EP04808) under non-reducing conditions. A gel run was performed with a Mother E-Base (Invitrogen) for 23 minutes, and proteins were transferred to a nitrocellulose membrane (Invitrogen IB301001) using an iBlot system (Invitrogen) according to the manufacturer's instructions (7-minute run). After washing 3 times in TBS/0.05 Tween20 (TBST), the membrane was incubated for 1 hour in the presence of 5% milk/TBST with gentle agitation, followed by incubation for 1 hour in the presence of 4 μg/ml of anti-mouse APP antibody solution ( an antibody raised against a peptide fragment of the amyloid precursor protein (APP) used for labeling proteins, obtained in-house by Novartis) diluted in 2% milk/TBST. After an additional 3 washing steps, the membrane was incubated in the presence of a 1:1000 diluted anti-mouse IgG alkaline phosphatase-conjugated antibody (Sigma-Aldrich, A5153-1ML) diluted in 2% milk/TBST and washed again 3 times in TBST followed by rinses in TBS. The signal was developed for 1-5 minutes with SIGMAFAST™ BCIP®/NBT (Sigma-Aldrich, no. B5655-25TAB) according to the manufacturer's instructions, and the signal was terminated by rinsing the membrane with water.
(d) Твердофазный анализ AxPаз(d) Solid phase analysis of AxPase
Формы активности ATPазы, ADPазы и AMPазы определяли с помощью системы для выявления фосфата PiColorLock Gold (Innova Biosciences, кат. № 303-0030) у иммобилизованных на планшете вариантов hCD39 из надосадочной жидкости, полученной при микромасштабной экспрессии (твердофазный анализ AxPаз). Данный способ оказался менее чувствительным по сравнению с анализом в растворе (жидкофазным анализом AxPаз), рекомендованным производителем, но потенциально обладал преимуществом в виде снижения активности AxPаз, опосредованного ферментами клетки-хозяина, потенциально присутствующими в надосадочной жидкости, полученной при микромасштабной экспрессии. 20 мкл антитела к APP мыши из 10 мкг/мл раствора антитела (антитела, вырабатываемого против пептидного фрагмента белка-предшественника амилоида (APP), применяемого для мечения белков, которое получено в собственной лаборатории Novartis), разбавленного в PBS, добавляли в каждую лунку 384-луночного прозрачного планшета MaxiSorp (Nunc) и инкубировали в течение ночи при 4°C. После трех промываний с помощью TBST лунки блокировали на 1 час с помощью 100 мкл 5% молока/TBST при комнатной температуре при осторожном взбалтывании. После трех дополнительных стадий промывания 20 мкл надосадочной жидкости, полученной при микромасштабной экспрессии, в серийном разведении в 2% молоке/TBST добавляли в лунки в трех повторностях и инкубировали в течение 2 часов при комнатной температуре при осторожном взбалтывании. Затем лунки снова промывали четыре раза с помощью 100 мкл TBST и два раза с помощью 80 мкл 50 мM Tris-Cl/5 мM MgCl2, pH 7,5. 30 мкл 80 мкM раствора аденозинфосфата, разбавленного в 50 мM Tris-Cl/5 мM MgCl2, pH 7,5 (ATP: SIGMA A2383, ADP: SIGMA A2754) добавляли к каждой из трех повторностей и инкубировали в течение 24 часов при 37°C. Сигнал проявляли с помощью 7,5 мкл смеси реагентов Gold, полученной в соответствии с инструкциями производителя, в течение 10 минут, и реакцию останавливали с помощью 3 мкл стабилизатора. Показатели поглощения считывали при 620 нм с помощью прибора TECAN GeniOS Pro.ATPase, ADPase, and AMPase activity patterns were determined using the PiColorLock Gold Phosphate Detection System (Innova Biosciences, cat. no. 303-0030) in plate-immobilized hCD39 variants from microscale expression supernatant (AxPase solid-phase analysis). This method proved to be less sensitive than the solution assay (AxPase liquid phase assay) recommended by the manufacturer, but potentially had the advantage of reducing AxPase activity mediated by host cell enzymes potentially present in the supernatant obtained from microscale expression. 20 µl of anti-mouse APP antibody from a 10 µg/ml solution of an antibody (an antibody raised against a peptide fragment of amyloid precursor protein (APP) used to label proteins, which is obtained in Novartis' own laboratory) diluted in PBS was added to each well 384 -well transparent tablet MaxiSorp (Nunc) and incubated overnight at 4°C. After three washes with TBST, the wells were blocked for 1 hour with 100 μl of 5% milk/TBST at room temperature with gentle agitation. After three additional washing steps, 20 µl of microscale expression supernatant serially diluted in 2% milk/TBST was added to the wells in triplicate and incubated for 2 hours at room temperature with gentle agitation. The wells were then washed again four times with 100 μl TBST and twice with 80
(2) Результаты(2) Results
(a) Эффект границ, делеции петли, взаимодействующей с мембраной (MIL), и делеции цистеинового мостика в отношении уровня экспрессии hCD39(a) Effect of borders, membrane interacting loop (MIL) deletion, and cysteine bridge deletion on hCD39 expression level
С целью оценки уровня экспрессии различных вариантов hCD39 соответствующие экспрессионные плазмиды вводили путем трансфекции в двух повторностях в 0,5 мл клеток 293-6E, и проводили вестерн-блоттинг (с детекторными Ab к APP) надосадочной жидкости, полученной через 3 дня после трансфекции. Результаты представлены на фигуре 2A и фигуре 2B.In order to assess the level of expression of various hCD39 variants, the corresponding expression plasmids were introduced by transfection in duplicate into 0.5 ml of 293-6E cells, and a Western blot (with detector Abs to APP) was performed on the supernatant obtained 3 days after transfection. The results are presented in figure 2A and figure 2B.
Результаты указывали на более высокий уровень экспрессии hCD39, начинающегося с aa38, по сравнению с aa46. Границы N-концевой области, так же как и делеция MIL, по-видимому, не оказывали значительного влияния на уровень экспрессии. Также наблюдали более высокий уровень экспрессии hCD39 с делецией первого или четвертого цистеинового мостика в случае с hCD39 (aa46-461). Более высокий уровень экспрессии при делеции первого цистеинового мостика подтверждали также с использованием остова hCD39 (aa46-461) ΔMIL.The results indicated a higher level of expression of hCD39 starting with aa38 compared to aa46. The borders of the N-terminal region, as well as the deletion of MIL, apparently did not significantly affect the level of expression. Also observed a higher expression level of hCD39 with a deletion of the first or fourth cysteine bridge in the case of hCD39 (aa46-461). A higher level of expression upon deletion of the first cysteine bridge was also confirmed using the backbone of hCD39 (aa46-461) ΔMIL.
(b) Эффект границ, делеции петли, взаимодействующей с мембраной (MIL), и делеции цистеинового мостика в отношении активности hCD39(b) Effect of borders, membrane interacting loop (MIL) deletion, and cysteine bridge deletion on hCD39 activity
Ферментативную активность CD39 измеряли с помощью твердофазного анализа AxPаз с использованием вышеописанных образцов надосадочной жидкости. Результаты представлены на фигуре 3 и фигуре 4, а также в таблице 3.CD39 enzymatic activity was measured by AxPase solid phase analysis using the supernatant samples described above. The results are presented in figure 3 and figure 4, as well as in table 3 .
Делеция MIL, по-видимому, повышала долю функционально экспрессирующихся рекомбинантных белков CD39. Различные варианты границ не демонстрировали какого-либо значительного влияния на активность активных hCD39. Результаты указывали на значительно сниженную или полностью устраненную активность ATPазы для всех вариантов с делецией цистеинового мостика. Аналогичные результаты получали в ходе твердофазного анализа ADPазы. Таким образом, неожиданно оказалось, что модификацией последовательности, которая повышала как эффективность, так и способность к экспрессии у CD39, являлась модификация дельта-MIL (ΔMIL).The deletion of MIL appeared to increase the proportion of functionally expressed recombinant CD39 proteins. The different boundary variants did not show any significant effect on active hCD39 activity. The results indicated a significantly reduced or completely eliminated ATPase activity for all variants with a deletion of the cysteine bridge. Similar results were obtained during the solid phase analysis of ADPase. Thus, surprisingly, the sequence modification that increased both the efficiency and the ability to express in CD39 was the delta-MIL (ΔMIL) modification.
3. Пример 2: экспрессионные метки3. Example 2: expression marks
С целью улучшения экспрессионных свойств кандидатов проводили тестирование различных экспрессионных меток.In order to improve the expression properties of candidates, various expression labels were tested.
Тестировали различные экспрессионные метки на основе N-концевой части IL-2 (SEQ ID NO: 131), представленные в таблице 4. Экспрессионную метку aa1-16 согласно SEQ ID NO: 131 синтезировали в GeneArt.Various expression tags based on the N-terminal portion of IL-2 (SEQ ID NO: 131) shown in Table 4 were tested. The aa1-16 expression tag according to SEQ ID NO: 131 was synthesized at GeneArt.
Все экспрессионные метки тестировали по отношению к CD39ΔMIL, представленному под SEQ ID NO: 4. Все конструкции содержат метку APP и метку His.All expression tags were tested against CD39ΔMIL shown under SEQ ID NO: 4. All constructs contain an APP tag and a His tag.
Вектор pRS5a, представленный на фигуре 5, применяли для экспрессии. Пары праймеров соответствовали представленным в таблице 4.The pRS5a vector shown in Figure 5 was used for expression. The primer pairs corresponded to those presented in Table 4 .
Температура отжига составляла 64°C во всех случаях.The annealing temperature was 64°C in all cases.
Раствор для ПЦР получали посредством смешивания 1 мкл исходного раствора матричной ДНК, 25 мкл полимеразы Kapa HiFi HotStart (от Kapa Biosystems/KK2602). Использовали 1,5 мкл прямого праймера, 1,5 мкл обратного праймера и доводили конечный объем до 50 мкл с помощью H2O.A PCR solution was prepared by mixing 1 µl template DNA stock solution, 25 µl Kapa HiFi HotStart polymerase (from Kapa Biosystems/KK2602). 1.5 µl forward primer, 1.5 µl reverse primer were used and the final volume was adjusted to 50 µl with H 2 O.
ПЦР-реакцию проводили в соответствии с порядком, приведенным в таблице 5.The PCR reaction was carried out in accordance with the order given in Table 5 .
После завершения ПЦР-реакции проводили экстракцию ДНК с помощью набора Wizard® SV Gel and PCR Clean-Up, Promega, № 9282, с элюированием в 30 мкл в 1 колонке в соответствии с инструкциями производителя.After completion of the PCR reaction, DNA extraction was performed using the Wizard® SV Gel and PCR Clean-Up kit, Promega, #9282, eluting with 30 µl in 1 column according to the manufacturer's instructions.
Вставки и вектор вырезали с использованием фермента, поставляемого New England Biolabs (NEB), NruI-HF (NEB № R3192) и NotI-HF (NEB № R3189), в буфере CutSmart(R). Время реакции составляло 3 часа при 37°C.Inserts and vector were excised using enzyme supplied by New England Biolabs (NEB), NruI-HF (NEB # R3192) and NotI-HF (NEB # R3189) in CutSmart(R) buffer. The reaction time was 3 hours at 37°C.
Лигирование проводили в течение ночи в присутствии дефосфорилированного вектора с помощью набора для быстрого дефосфорилирования и лигирования ДНК фирмы Roche № 04898117001 в соответствии с действительным протоколом производителя.Ligation was performed overnight in the presence of the dephosphorylated vector using Roche Rapid Dephosphorylation and DNA Ligation Kit No. 04898117001 according to the manufacturer's actual protocol.
На следующий день отбирали отдельные колонии для выделения ДНК в миниколичествах и анализа последовательностей с использованием прямого праймера P270 (SEQ ID NO: 165) и обратного праймера P271 (SEQ ID NO: 166).The following day, individual colonies were selected for DNA extraction in miniquantities and sequence analysis using forward primer P270 (SEQ ID NO: 165) and reverse primer P271 (SEQ ID NO: 166).
Кроме того, тестировали несколько белковых последовательностей, известных из уровня техники как повышающих экспрессию, в соответствии с таблицей 6.In addition, several protein sequences known in the art to increase expression were tested according to Table 6 .
Полученные тестируемые комбинации представлены в таблице 7.The resulting test combinations are shown in Table 7.
Ни одна из меток, известных из предшествующего уровня техники и представленных в таблице 6, не обеспечивала экспрессию белка (данные не показаны). Это было неожиданно, поскольку из предшествующего уровня техники известно, что такие последовательности должны повышать экспрессию.None of the labels known from the prior art and presented in table 6, did not provide protein expression (data not shown). This was unexpected since it is known in the prior art that such sequences should increase expression.
4. Пример 3: дополнительные мутации4. Example 3: additional mutations
Для того, чтобы улучшить характеристики растворимого CD39 и сделать его пригодным для фармацевтической разработки, в CD39ΔMIL EP28 вводили дополнительные модификации, представленные под SEQ ID NO: 4. Различные мутации и варианты с мутациями показаны в таблице 8 и пронумерованы в соответствии с положениями аминокислот в CD39 дикого типа, представленном под SEQ ID NO: 1.In order to improve the characteristics of soluble CD39 and make it suitable for pharmaceutical development, further modifications were made to CD39ΔMIL EP28 as shown under SEQ ID NO: 4. Various mutations and variants with mutations are shown in Table 8 and numbered according to the amino acid positions in CD39. wild type shown under SEQ ID NO: 1.
VKEKYLSE->
-QERWLRD404-411:
VKEKYLSE->
-QERWLRD
Две мутации в активном центре приводят к более высокой активности (365 и 412).Two mutations in the active site result in higher activity (365 and 412).
5. Пример 4: удаление сайта гликозилирования5. Example 4: removal of the glycosylation site
С использованием варианта EP14, приведенного выше, проверяли эффект сайтов гликозилирования посредством введения точечных мутаций в соответствии с таблицей 9, пронумерованных в соответствии с положениями аминокислот в CD39 дикого типа, представленном под SEQ ID NO: 1.Using the EP14 variant above, the effect of glycosylation sites was tested by introducing point mutations according to Table 9, numbered according to the amino acid positions in wild-type CD39 shown under SEQ ID NO: 1.
(a) Материалы и способы(a) Materials and Methods
Для клонирования применяли экспрессионный вектор pRS5a (фигура 5). Применяли праймеры, представленные в таблице 10.For cloning, the pRS5a expression vector was used (FIG. 5). The primers shown in Table 10 were used.
Для проведения ПЦР применяли набор для сайт-направленного мутагенеза QuikChange Lightning (Agilent, № 210519-5) в соответствии с инструкциями производителя.For PCR, the QuikChange Lightning site-directed mutagenesis kit (Agilent, no. 210519-5) was used according to the manufacturer's instructions.
На следующий день отбирали отдельные колонии для выделения ДНК в миниколичествах и проводили анализ последовательностей с использованием прямого праймера P270 (SEQ ID NO: 165) и обратного праймера P271 (SEQ ID NO: 166).The next day, single colonies were selected for DNA extraction in mini-amounts and sequence analysis was performed using forward primer P270 (SEQ ID NO: 165) and reverse primer P271 (SEQ ID NO: 166).
Чтобы убедиться в правильности в том числе и остова вектора (из-за мутагенеза), секвенированный фрагмент вставки клонировали в новый остов вектора pRS5a (фигура 5) с применением следующего способа.To ensure that the vector backbone was correct (due to mutagenesis), the sequenced fragment of the insert was cloned into a new pRS5a vector backbone (FIG. 5) using the following method.
Вектор получали с использованием остова вектора под SEQ ID NO: 36 с экспрессионной меткой под SEQ ID NO: 135, содержащей APP_HIS-метку, при концентрации исходного раствора 3,3 мкг/мкл. The vector was generated using a vector backbone of SEQ ID NO: 36 with an expression tag of SEQ ID NO: 135 containing an APP_HIS tag at a stock solution concentration of 3.3 µg/µl.
Вектор расщепляли посредством смешивания 10 мкг векторной ДНК, 0,4 мкл HindIII (100 ед/мкл, NEB), 2 мкл EcoRI (20 ед/мкл, NEB), 5 мкл буфера CutSmart в 10x концентрации (NEB), H2O до конечного объема 50 мкл. Расщепление проводили в течение 3 часов при 37°C.The vector was digested by mixing 10 μg vector DNA, 0.4 μl HindIII (100 U/μl, NEB), 2 μl EcoRI (20 U/μl, NEB), 5 μl CutSmart buffer at 10x concentration (NEB), H 2 O to
Дефосфорилирование проводили с помощью телячьей кишечной щелочной фосфатазы (CIP, NEB, № M0290L), 10 ед/мкл. Непосредственно после расщепления к расщепленному вектору добавляли 3 мкл CIP и инкубировали в течение 30 мин. при 37°C. Расщепленный и дефосфорилированный вектор загружали в препаративный 0,8% агарозный гель c TAE, вырезали полоску, соответствующую по размеру вектору с ~ 6100 п. о. Очистку проводили с помощью набора Wizard® SV Gel and PCR Clean-Up, Promega, № 9282, с элюированием в 100 мкл в 1 колонке. Концентрация, определенная по OD при 260 нм, составляла 64 нг/мкл.Dephosphorylation was performed with calf intestinal alkaline phosphatase (CIP, NEB, no. M0290L), 10 U/µl. Immediately after digestion, 3 μl of CIP was added to the digested vector and incubated for 30 min. at 37°C. The cleaved and dephosphorylated vector was loaded onto a preparative 0.8% agarose gel with TAE, and a strip corresponding to the size of the vector c ~ 6100 bp was cut out. Purification was performed using the Wizard® SV Gel and PCR Clean-Up kit, Promega, #9282, eluting with 100 µl in 1 column. The concentration determined by OD at 260 nm was 64 ng/µl.
Расщепление фрагментов-вставок с мутациями проводили посредством смешивания 42,5 мкл ДНК (~ 3-5 мкг на каждую ДНК), 5 мкл буфера CutSmart в 10x концентрации, NEB № B7204S, 0,4 мкл HindIII-HF, 100 ед/мкл, NEB № R3104S, 2 мкл EcoRI-HF, 20 ед/мкл, NEB № R3103L, и доводили объем до 50 мкл с помощью H2O. Расщепление проводили в течение 3 часов при 37°C в аппарате для ПЦР. Расщепленные вставки загружали в препаративный 0,8% агарозный гель с TAE, вырезали полоску, соответствующую по размеру вектору с ~ 1400 п. о. Очистку проводили с помощью набора Wizard® SV Gel and PCR Clean-Up, Promega, № 9282, с элюированием в 30 мкл в 1 колонке. Концентрация, определенная по OD при 260 нм, составляла 1-25 нг/мкл.Cleavage of mutated insert fragments was performed by mixing 42.5 µl of DNA (~3-5 µg per DNA), 5 µl of CutSmart buffer at 10x concentration, NEB #B7204S, 0.4 µl of HindIII-HF, 100 U/µl, NEB # R3104S, 2 µl EcoRI-HF, 20 U/µl, NEB # R3103L, and adjusted to 50 µl with H 2 O. Digestion was performed for 3 hours at 37° C. in a PCR machine. The cleaved inserts were loaded onto a preparative 0.8% agarose gel with TAE, and a strip corresponding in size to the ~1400 bp vector was cut out. Purification was performed using the Wizard® SV Gel and PCR Clean-Up kit, Promega, #9282, eluting with 30 µl in 1 column. The concentration determined by OD at 260 nm was 1-25 ng/µl.
Лигирование (при соотношении вектор:вставка ~ 1:10) проводили с помощью набора для быстрого лигирования ДНК № K1423 фирмы Thermo Scientific. 4 мкл 5x буфера для лигирования смешивали с 1 мкл лигазы, 2 мкл фрагмента вектора, расщепленного с помощью HindIII/EcoRI, при концентрации исходного раствора 64 нг/мкл, 13 мкл фрагмента-вставки, расщепленного с помощью HindIII/EcoR, при концентрации исходного раствора 1-25 нг/мкл. Лигирование проводили в течение 10 минут при RT.Ligation (at a ratio of vector:insert ~ 1:10) was performed using a kit for rapid DNA ligation no. K1423 from Thermo Scientific. 4 µl of 5x ligation buffer was mixed with 1 µl of ligase, 2 µl of vector fragment digested with HindIII/EcoRI at stock concentration of 64 ng/µl, 13 µl of insert fragment digested with HindIII/EcoR at stock concentration 1-25 ng/µl. Ligation was performed for 10 minutes at RT.
Трансформацию проводили посредством инкубации 10 мкл лигазной смеси с 80 мкл химически компетентных клеток XL1Blue (Novartis, FS/RL) в течение 30 мин. на льду. Подвергали тепловому шоку в течение 45 секунд при 42°C в инкубаторе Eppendorf с последующей инкубацией в течение 2 мин. на льду. После этого добавляли 1 мл среды 2YT с последующей инкубацией в течение 1,5 часа при 37°C на шейкере Eppendorf (800 об./мин.) Клетки центрифугировали в течение 3 мин. при 7000 об./мин., и колонии высевали на чашки с LB/карбенициллином/глюкозой с последующей инкубацией в течение ночи при 37°C.Transformation was performed by incubating 10 μl of the ligation mixture with 80 μl of chemically competent XL1Blue cells (Novartis, FS/RL) for 30 min. on ice. Heat shock for 45 seconds at 42° C. in an Eppendorf incubator followed by a 2 min incubation. on ice. After that, 1 ml of 2YT medium was added, followed by incubation for 1.5 hours at 37°C on an Eppendorf shaker (800 rpm). The cells were centrifuged for 3 minutes. at 7000 rpm, and the colonies were plated with LB/carbenicillin/glucose, followed by overnight incubation at 37°C.
На следующий день отбирали отдельные колонии для выделения ДНК в миниколичествах и проводили анализ последовательностей с использованием прямого праймера P270 (SEQ ID NO: 165) и обратного праймера P271 (SEQ ID NO: 166).The next day, single colonies were selected for DNA extraction in mini-amounts and sequence analysis was performed using forward primer P270 (SEQ ID NO: 165) and reverse primer P271 (SEQ ID NO: 166).
Правильные последовательности вводили путем трансфекции в клетки HEK293 в соответствии с 7 днями экспрессии и масштабом 200 мл.The correct sequences were transfected into HEK293 cells according to 7 days of expression and 200 ml scale.
Использовали следующий материал:Used the following material:
Клетки почки эмбриона человека, конститутивно экспрессирующие большой T-антиген SV40 (HEK293-T), например, ATCC11268Human embryonic kidney cells constitutively expressing the SV40 large T antigen (HEK293-T), e.g., ATCC11268
Полиэтиленимин "MAX" MW 40000 (PEI) (Polysciences, кат. № 24765), растворенный в H2O при RT, доведенный до pH 7,05 с помощью NaOHPolyethyleneimine "MAX" MW 40000 (PEI) (Polysciences cat. no. 24765) dissolved in H2O at RT, adjusted to pH 7.05 with NaOH
Бессывороточная культуральная среда M11V3 (BioConcept, Швейцария, кат. № V3-K)Serum-free culture medium M11V3 (BioConcept, Switzerland, cat. no. V3-K)
ДНК: полученная с помощью набора Qiagen DNA Midiprep (№ 12943) в соответствии с протоколом, рекомендованным поставщикомDNA: Obtained with Qiagen DNA Midiprep Kit (#12943) according to vendor recommended protocol
Всю работу с культурами клеток для транзиентных трансфекций выполняли с использованием адаптированных к суспензионному культивированию клеток HEK293-T, выращиваемых в бессывороточной среде M11V3.All work with cell cultures for transient transfections was performed using suspension-adapted HEK293-T cells grown in serum-free M11V3 medium.
Клетки выращивали во встряхиваемых колбах Corning (Corning, США) на орбитальном шейкере (115 об./мин.) в увлажненном CO2-инкубаторе при 5% CO2 (в колбах, содержащих посевную культуру).Cells were grown in Corning shake flasks (Corning, USA) on an orbital shaker (115 rpm) in a humidified CO 2 incubator at 5% CO 2 (in flasks containing inoculum).
Используемые клетки находились в экспоненциальной фазе роста (плотность клеток от 5×105 до 3×106/мл) и характеризовались жизнеспособностью > 90%.The cells used were in the exponential growth phase (cell density from 5×10 5 to 3×10 6 /ml) and were characterized by >90% viability.
Трансфекцию проводили в небольшом масштабе (в данном случае 20/50 или 100 мкл) с использованием клеток, которые подсчитывали, и соответствующее количество клеток доводили до 1,4×106 клеток/мл с помощью среды M11V3. Применяли 36% клеточную суспензию в конечном объеме трансфекции.Transfection was carried out on a small scale (in this
Раствор ДНК (раствор 1) получали посредством разбавления 1 мг/л конечного объема ДНК в 7% конечного объема M11V3 и осторожного перемешивания. Для предотвращения загрязнения культур из-за ДНК, не подвергнутой стерилизующей фильтрации, после подпитки в трансфекционную среду добавляли пенициллин/стрептомицин. Затем конечный объем 3 мг/л раствора PEI разбавляли в 7% конечного объема M11V3 и осторожно перемешивали (раствор 2). Оба раствора инкубировали в течение 5-10 мин. при комнатной температуре (RT). После этого раствор 2 добавляли к раствору 1 при осторожном перемешивании и инкубировали в течение еще 5-15 минут при RT. После инкубации смесь для трансфекции добавляли к клеткам, и культуру культивировали в течение четырех часов (115 об./мин., 37°C, 5% CO2).A DNA solution (solution 1) was prepared by diluting 1 mg/l of the final volume of DNA in 7% of the final volume of M11V3 and gently mixing. Penicillin/streptomycin was added to the transfection medium after feeding to prevent contamination of the cultures due to DNA not subjected to sterilizing filtration. Then a final volume of 3 mg/l PEI solution was diluted in 7% of the final volume of M11V3 and mixed gently (solution 2). Both solutions were incubated for 5-10 min. at room temperature (RT). After that, solution 2 was added to
Надосадочную жидкость собирали спустя 7 дней экспрессии.The supernatant was collected after 7 days of expression.
Центрифугировали при 4500 об./мин., 4°C (Heraeus Multifuge 3 S-R) в течение 15 мин.Centrifuged at 4500 rpm, 4°C (Heraeus Multifuge 3 S-R) for 15 min.
Осветляли путем пропускания через стерильный фильтр на 0,22 мкм (фильтр Stericup, Thermo Scientific, кат. № 567-0020).Clarified by passing through a 0.22 µm sterile filter (Stericup filter, Thermo Scientific, cat. no. 567-0020).
Достигали очищения надосадочной жидкости для проведения дальнейших стадий. 1 мл образца надосадочной жидкости использовали для IPC на колонке Open Access APP.Achieved purification of the supernatant for further steps. A 1 ml supernatant sample was used for IPC on an Open Access APP column.
Флаконы для образцов представляли собой стеклянные обжимные флаконы объемом 2 мл, Agilent, номер по каталогу 5182-0543, с обжимными пробками размером 11 мм, номер по каталогу 5040-4667.The sample vials were 2 ml glass crimp vials, Agilent part number 5182-0543, with 11 mm crimp stoppers, part number 5040-4667.
Белок очищали с помощью аффинной хроматографии на иммобилизованных ионах металлов (IMAC) на Aekta Pure или Aekta Avant (GE Healthcare) в соответствии со следующим протоколом с использованием колонки HisTrap HP объемом 5 мл (GE Life Sciences, номер заказа 17-5248-02). Технические требования представлены в таблице 11.The protein was purified by immobilized metal ion affinity chromatography (IMAC) on Aekta Pure or Aekta Avant (GE Healthcare) according to the following protocol using a 5 ml HisTrap HP column (GE Life Sciences, order number 17-5248-02). Technical requirements are presented in table 11.
Используемые буферы составляли в соответствии с таблицей 12 и таблицей 13.The buffers used were according to Table 12 and Table 13.
Полученный белок в соответствии с таблицей 14 сохраняли.The resulting protein in accordance with table 14 was stored.
(b) Результаты и их интерпретация(b) Results and their interpretation
Улучшение свойств мутантных форм в том, что касается выхода и пика мономеров при проведении аналитической SEC не наблюдалось. Исходный белок (EP14) с экспрессионной меткой согласно SEQ ID NO: 137 демонстрировал лучший выход и наиболее высокий пик мономеров при проведении анализа. Наиболее низкий выход, а также наиболее низкий пик мономеров достигался при использовании мутантной формы N371Q.Improvement in the properties of the mutant forms in terms of yield and peak of monomers during analytical SEC was not observed. The parent protein (EP14) with an expression tag according to SEQ ID NO: 137 showed the best yield and the highest monomer peak in the assay. The lowest yield as well as the lowest monomer peak was achieved using the N371Q mutant.
6. Пример 5: комбинации6. Example 5: Combinations
С целью попытки дополнительного улучшения свойств некоторые мутации, введенные согласно примеру 3 выше, использовали в комбинации в соответствии с таблицей 15, представленной ниже. Мутации пронумерованы в соответствии с положениями аминокислот в CD39 дикого типа, представленном под SEQ ID NO: 1.In order to try to further improve the properties, some of the mutations introduced according to example 3 above were used in combination in accordance with table 15 below. Mutations are numbered according to amino acid positions in wild-type CD39 shown under SEQ ID NO: 1.
(a) Материалы и способы(a) Materials and Methods
Применяли праймеры в соответствии с таблицей 16.Primers were applied according to Table 16 .
Постановку ПЦР-реакции осуществляли с использованием следующей схемы пипетирования:The PCR reaction was set up using the following pipetting scheme:
5 мкл 10x реакционного буфера,5 µl 10x reaction buffer,
1 мкл двухнитевой ДНК-матрицы (концентрация исходного раствора 100 нг/мкл),1 µl double-stranded DNA template (
1,5 мкл праймера 1,1.5
1,5 мкл праймера 2,1.5 µl primer 2,
1 мкл смеси dNTP,1 µl dNTP mix,
1,5 мкл реагента QuickSolution,1.5 µl QuickSolution Reagent,
35,5 мкл H2O (до конечного объема 50 мкл) и35.5 µl H 2 O (to a final volume of 50 µl) and
1 мкл фермента QuikChange Lightning.1 µl QuikChange Lightning Enzyme.
Использовали параметры циклов ПЦР в соответствии с таблицей 17.The parameters of PCR cycles were used in accordance with Table 17.
Непосредственно после проведения реакции в каждую реакционную смесь добавляли 2 мкл фермента DpnI, перемешивали и инкубировали в течение 5 мин. при 37°C.Immediately after the reaction, 2 µl of the DpnI enzyme was added to each reaction mixture, mixed, and incubated for 5 min. at 37°C.
Введение в ультракомпетентные клетки XL10-Gold путем трансформации проводили следующим образом. Клетки размораживали на льду. Использовали 45 мкл на трансформацию и добавляли 2 мкл B-ME в каждый флакон. Затем добавляли 3 мкл продукта ПЦР, расщепленного с помощью DpnI, и инкубировали в течение 30 мин. на льду в пробирках BD объемом 15 мл. После этого образцы подвергали тепловому шоку в течение 40 секунд и инкубировали на льду в течение 2 мин. Затем добавляли 950 мкл среды SOC с последующей инкубацией в течение 1,5 часа при 37°C во встряхивателе-инкубаторе. Наконец, клетки высевали на чашки с LB/карбенициллином и инкубировали в течение ночи при 37°C. На следующий день отбирали отдельные колонии для выделения ДНК в миниколичествах и анализа последовательностей.Introduction to ultracompetent cells XL10-Gold by transformation was carried out as follows. Cells were thawed on ice. Used 45 µl per transformation and added 2 µl of B-ME to each vial. Then 3 µl of the PCR product digested with DpnI was added and incubated for 30 min. on ice in 15 ml BD tubes. After that, the samples were subjected to heat shock for 40 seconds and incubated on ice for 2 minutes. Then, 950 μl of SOC medium was added, followed by incubation for 1.5 hours at 37° C. in an incubator shaker. Finally, cells were plated on LB/carbenicillin plates and incubated overnight at 37°C. The next day, individual colonies were selected for DNA extraction in mini-amounts and sequence analysis.
Правильные последовательности вводили путем трансфекции в клетки HEK293, как описано в примере 4.The correct sequences were introduced by transfection into HEK293 cells as described in Example 4.
Белок очищали с помощью аффинной хроматографии на иммобилизованных ионах металлов (IMAC) в соответствии с нижеследующим. Использовали 95 мл надосадочной жидкости (~ 4 мл от всего объема сохраняли для анализа (IPC)).The protein was purified by immobilized metal ion affinity chromatography (IMAC) as follows. 95 ml of the supernatant was used (~4 ml of the total volume was saved for analysis (IPC)).
Используемый материалMaterial used
Агароза никель-NTA, Qiagen, кат. №/ID: 30230, хроматографические колонки Poly-Prep, пустые, BioRad, № 731-1550, буфер для IMAC A, pH 7,4 (содержащий 20 мM буфера NaPO4 и 50 мM имидазола). Буфер для IMAC B, pH 7,4 (содержащий 20 мM буфера NaPO4 и 300 мM имидазола). TBS (в 10x концентрации, разбавленный до 1x концентрации с помощью воды MilliQ). Центрифужный фильтрующий блок Amicon Ultra-4 с мембраной Ultracel-10, 10K, UFC801096.Nickel-NTA agarose, Qiagen, cat. No./ID: 30230, Poly-Prep chromatography columns, empty, BioRad, No. 731-1550, buffer for IMAC A, pH 7.4 (containing 20 mM NaPO 4 buffer and 50 mM imidazole). Buffer for IMAC B, pH 7.4 (containing 20 mM NaPO 4 buffer and 300 mM imidazole). TBS (at 10x concentration, diluted to 1x concentration with MilliQ water). Amicon Ultra-4 centrifugal filter unit with Ultracel-10, 10K, UFC801096 membrane.
Стадии процессаProcess steps
1. Подготовка колонок с использованием 1 мл агарозы никель-NTA от Qiagen (= 0,5 мл CV)1. Prepare columns using 1 ml of Qiagen nickel-NTA agarose (= 0.5 ml of CV)
2. Уравновешивание с помощью 10 CV IMAC A2. Balancing with 10 CV IMAC A
3. Загрузка 15/45 мл SN в колонку (сбор материала, протекающего через колонку)3. Loading 15/45 ml SN into the column (collecting material flowing through the column)
4. Промывание с помощью 10 CV IMAC A (сбор в пробирку Falcon объемом 15 мл)4. Wash with 10 CV IMAC A (collect in 15 ml Falcon tube)
5. Элюирование в 6,5 CV IMAC B5. Elution in 6.5 CV IMAC B
6. Определение концентрации элюата6. Determination of eluate concentration
7. Концентрирование 3,5 мл образца до ~ 400 мкл с помощью центрифужного фильтрующего блока Amicon Ultra-4 10K7. Concentration of 3.5 ml sample to ~400 µl using an Amicon Ultra-4 10K centrifuge filter block
8. Замена буфера путем добавления TBS и центрифугирования при 50008. Buffer exchange by adding TBS and centrifugation at 5000
Образцы анализировали с помощью аналитической SEC, используя 40 мкл каждого образца и используя гель для белка с 12 мкл каждого образца.Samples were analyzed by analytical SEC using 40 µl of each sample and using protein gel with 12 µl of each sample.
Полученный белок сохраняли.The resulting protein was saved.
(b) Результаты и их интерпретация(b) Results and their interpretation
Результаты показаны в таблице 18.The results are shown in Table 18.
Сайты для протеазыSites for protease
Наблюдалось отсутствие выхода/очень низкий выход при вставке сайта для матриптазы. При использовании сайта для фурина наблюдался ~ 40% выход (но в то же время для трансфекции использовали только 50% ДНК, так как она представляла собой котрансфекцию с плазмидой, кодирующей фурин).No yield/very low yield was observed when inserting the matriptase site. When using the site for furin, ~40% yield was observed (but at the same time, only 50% of DNA was used for transfection, since it was a co-transfection with a plasmid encoding furin).
Усечения IL2IL2 Truncations
Все варианты усечений, в которых содержатся aa1-3, приводили к сопоставимым результатам, и результат для aa1-3 в отдельности мог быть немного ниже по сравнению с другими, однако это могло объясняться варьированием между образцами. Усечение aa4-12 приводило к отсутствию экспрессии белка. Отличий между усечениями в EP28, который, подобно всем остальным вариантам EP, содержал линкер TSS между начальной последовательностью IL2 и белком hCD39, обнаружено не было.All truncations containing aa1-3 produced comparable results, and the result for aa1-3 alone could be slightly lower than the others, but this could be due to variation between samples. Truncation of aa4-12 resulted in a lack of protein expression. No differences were found between the truncations in EP28, which, like all other EP variants, contained a TSS linker between the initial IL2 sequence and the hCD39 protein, was not found.
КомбинацииCombinations
Комбинации с EP19 (L424Q) не приводили к значительному улучшению экспрессии белка.Combinations with EP19 (L424Q) did not lead to a significant improvement in protein expression.
Комбинации с EP1 (R113M) демонстрировали более низкий уровень агрегации при проведении аналитической SEC. NEG726 хорошо экспрессировался, однако демонстрировал наихудшие показатели агрегации по сравнению со всеми тестируемыми вариантами (~ 37%). Комбинация EP14xEP17 не приводила к какому-либо дополнительному улучшению (F365S+Y412F).Combinations with EP1 (R113M) showed a lower level of aggregation during analytical SEC. NEG726 was well expressed, but showed the worst aggregation rates compared to all tested variants (~37%). The combination of EP14xEP17 did not result in any additional improvement (F365S+Y412F).
7. Пример 6: клонирование конечных кандидатов7. Example 6: End Candidate Cloning
Отобранные клинические кандидаты, представленные в таблице 19 ниже, подвергались экспрессии для дополнительного тестирования.The selected clinical candidates shown in Table 19 below were expressed for further testing.
исходная)EP28aa1-3 (leader/
original)
исходная)EP28aa1-6 (leader/
original)
Использовали следующие праймеры.The following primers were used.
Постановку ПЦР-реакции осуществляли с использованием следующей схемы пипетирования:The PCR reaction was set up using the following pipetting scheme:
0,25 мкл DMSO,0.25 µl DMSO,
20 нг вектора,20 ng of vector,
1,5 мкл вставки (45 нг/мкл),1.5 µl insert (45 ng/µl),
2 мкл 5x буфера HF,2 µl 5x HF buffer,
0,1 мкл полимеразы Phusion,0.1 µl Phusion polymerase,
0,08 мкл смеси dNTP,0.08 µl dNTP mix,
10-x мкл ddH2O10-x µl ddH 2 O
Использовали параметры циклов ПЦР в соответствии с таблицей 17.The parameters of PCR cycles were used in accordance with Table 17.
Непосредственно после проведения реакции в каждую реакционную смесь добавляли 0,5 мкл фермента DpnI, перемешивали и инкубировали в течение 2 часов при 37°C.Immediately after the reaction, 0.5 μl of DpnI enzyme was added to each reaction mixture, mixed and incubated for 2 hours at 37°C.
Введение в ультракомпетентные клетки XL10-Gold путем трансформации проводили следующим образом. Клетки размораживали на льду. Использовали 45 мкл на трансформацию и добавляли 2 мкл B-ME в каждый флакон. Затем добавляли 3 мкл продукта ПЦР, расщепленного с помощью DpnI, и инкубировали в течение 30 мин. на льду в пробирках BD объемом 15 мл. После этого образцы подвергали тепловому шоку в течение 40 секунд и инкубировали на льду в течение 2 мин. Затем добавляли 950 мкл среды SOC с последующей инкубацией в течение 1,5 часа при 37°C во встряхивателе-инкубаторе. Наконец, клетки высевали на чашки с LB/карбенициллином и инкубировали в течение ночи при 37°C. На следующий день отбирали отдельные колонии для выделения ДНК в миниколичествах и анализа последовательностей.Introduction to ultracompetent cells XL10-Gold by transformation was carried out as follows. Cells were thawed on ice. Used 45 µl per transformation and added 2 µl of B-ME to each vial. Then 3 µl of the PCR product digested with DpnI was added and incubated for 30 min. on ice in 15 ml BD tubes. After that, the samples were subjected to heat shock for 40 seconds and incubated on ice for 2 minutes. Then, 950 μl of SOC medium was added, followed by incubation for 1.5 hours at 37° C. in an incubator shaker. Finally, cells were plated on LB/carbenicillin plates and incubated overnight at 37°C. The next day, individual colonies were selected for DNA extraction in mini-amounts and sequence analysis.
Все конструкции субклонировали в генетическое окружение нового вектора, чтобы убедиться в правильности последовательностей. Для этого все конструкции амплифицировали с помощью ПЦР со вставкой линкеров G4S и с последующим расщеплением с помощью HindIII/EcoRI.All constructs were subcloned into the genetic environment of the new vector to ensure correct sequences. To do this, all constructs were amplified by PCR with the insertion of G4S linkers and followed by digestion with HindIII/EcoRI.
Полученный белок сохраняли.The resulting protein was saved.
8. Пример 7: получение белков для сравнения8. Example 7: obtaining proteins for comparison
(1) Нулевые мутации(1) Null mutations
С целью получения белков для отрицательного контроля для исследований in vivo одну/две мутации вставляли в исходный белок CD39ΔMIL человека (EP28). Эти мутации, как описано в литературе, устраняли или снижали ферментативную активность данного белка. Мутации находились в положениях E174A и S218A.In order to obtain negative control proteins for in vivo studies, one/two mutations were inserted into the original human CD39ΔMIL protein (EP28). These mutations, as described in the literature, eliminated or reduced the enzymatic activity of this protein. The mutations were at positions E174A and S218A.
Использовали следующие праймеры.The following primers were used.
Постановку ПЦР-реакции осуществляли с использованием следующей схемы пипетирования:The PCR reaction was set up using the following pipetting scheme:
5 мкл 10x реакционного буфера,5 µl 10x reaction buffer,
1 мкл двухнитевой ДНК-матрицы (концентрация исходного раствора 100 нг/мкл),1 µl double-stranded DNA template (
1,5 мкл праймера 1,1.5
1,5 мкл праймера 2,1.5 µl primer 2,
1 мкл смеси dNTP,1 µl dNTP mix,
1,5 мкл реагента QuickSolution,1.5 µl QuickSolution Reagent,
35,5 мкл H2O (до конечного объема 50 мкл) и35.5 µl H 2 O (to a final volume of 50 µl) and
1 мкл фермента QuikChange Lightning.1 µl QuikChange Lightning Enzyme.
Использовали параметры циклов ПЦР в соответствии с таблицей 17.The parameters of PCR cycles were used in accordance with Table 17.
Непосредственно после проведения реакции в каждую реакционную смесь добавляли 2 мкл фермента DpnI, перемешивали и инкубировали в течение 5 мин. при 37°C.Immediately after the reaction, 2 µl of the DpnI enzyme was added to each reaction mixture, mixed, and incubated for 5 min. at 37°C.
Введение в ультракомпетентные клетки XL10-Gold путем трансформации проводили следующим образом. Клетки размораживали на льду. Использовали 45 мкл на трансформацию и добавляли 2 мкл B-ME в каждый флакон. Затем добавляли 3 мкл продукта ПЦР, расщепленного с помощью DpnI, и инкубировали в течение 30 мин. на льду в пробирках BD объемом 15 мл. После этого образцы подвергали тепловому шоку в течение 40 секунд и инкубировали на льду в течение 2 мин. Затем добавляли 950 мкл среды SOC с последующей инкубацией в течение 1,5 часа при 37°C во встряхивателе-инкубаторе. Наконец, клетки высевали на чашки с LB/карбенициллином и инкубировали в течение ночи при 37°C. На следующий день отбирали отдельные колонии для выделения ДНК в миниколичествах и анализа последовательностей.Introduction to ultracompetent cells XL10-Gold by transformation was carried out as follows. Cells were thawed on ice. Used 45 µl per transformation and added 2 µl of B-ME to each vial. Then 3 µl of the PCR product digested with DpnI was added and incubated for 30 min. on ice in 15 ml BD tubes. After that, the samples were subjected to heat shock for 40 seconds and incubated on ice for 2 minutes. Then, 950 μl of SOC medium was added, followed by incubation for 1.5 hours at 37° C. in an incubator shaker. Finally, cells were plated on LB/carbenicillin plates and incubated overnight at 37°C. The next day, individual colonies were selected for DNA extraction in mini-amounts and sequence analysis.
Правильные последовательности вводили путем трансфекции в клетки HEK293 в соответствии со следующим протоколом.The correct sequences were introduced by transfection into HEK293 cells according to the following protocol.
Буфер для расщепления получали с использованием 10 мкг векторной ДНК, 0,4 мкл HindIII (100 ед/мкл, NEB), 2 мкл EcoRI (20 ед/мкл, NEB), 5 мкл буфера CutSmart в 10x концентрации (NEB) и H2O до конечного объема 50 мкл. Реакцию расщепления проводили в течение 3 часов при 37°C.Digestion buffer was prepared using 10 μg vector DNA, 0.4 μl HindIII (100 U/μl, NEB), 2 μl EcoRI (20 U/μl, NEB), 5 μl CutSmart buffer at 10x concentration (NEB) and H 2 O to a final volume of 50 µl. The cleavage reaction was carried out for 3 hours at 37°C.
Непосредственно после расщепления проводили реакцию дефосфорилирования. Телячью кишечную щелочную фосфатазу (10 ед/мкл, CIP, NEB, № M0290L) добавляли (3 мкл) к смеси с расщепленным вектором и инкубировали в течение 30 мин. при 37°C.Immediately after cleavage, a dephosphorylation reaction was carried out. Bovine intestinal alkaline phosphatase (10 U/µl, CIP, NEB, no. M0290L) was added (3 µl) to the digested vector mixture and incubated for 30 min. at 37°C.
Расщепленный и дефосфорилированный вектор субклонировали для проверки последовательности.The digested and dephosphorylated vector was subcloned for sequence verification.
Правильные последовательности вводили путем трансфекции в клетки HEK293 в соответствии со следующим протоколом.The correct sequences were introduced by transfection into HEK293 cells according to the following protocol.
Экспрессию в течение 7 дней проводили с использованием следующего материала: 1. Клетки почек эмбриона человека, конститутивно экспрессирующие большой T-антиген SV40 (HEK293-T, ATCC11268); 2. Полиэтиленимин "MAX" MW 40000 (PEI) (Polysciences, кат. № 24765).Expression for 7 days was performed using the following material: 1. Human embryonic kidney cells constitutively expressing the SV40 large T antigen (HEK293-T, ATCC11268); 2. Polyethyleneimine "MAX" MW 40000 (PEI) (Polysciences cat. no. 24765).
Раствор PEI получали посредством тщательного растворения 1 г PEI в 900 мл воды для культивирования клеток при комнатной температуре (RT). Затем его нейтрализовали с помощью NaOH для получения конечного pH 7,05. Наконец, объем доводили до 1 л, и раствор фильтровали через фильтр на 0,22 мкм, разделяли на аликвоты и замораживали при -80°C до дальнейшего применения. Размороженная аликвота может быть повторно заморожена до 3 раз при -20°C, но не должна длительно храниться при -20°C.The PEI solution was prepared by carefully dissolving 1 g of PEI in 900 ml of cell culture water at room temperature (RT). It was then neutralized with NaOH to give a final pH of 7.05. Finally, the volume was adjusted to 1 L and the solution was filtered through a 0.22 µm filter, aliquoted and frozen at -80° C. until further use. A thawed aliquot can be refrozen up to 3 times at -20°C, but should not be stored at -20°C for long periods.
Бессывороточная культуральная среда M11V3 (BioConcept, Швейцария, кат. № V3-K).Serum-free culture medium M11V3 (BioConcept, Switzerland, cat. no. V3-K).
Всю работу с культурами клеток для транзиентных трансфекций выполняли с использованием адаптированных к суспензионному культивированию клеток HEK293-T, выращиваемых в бессывороточной среде M11V3.All work with cell cultures for transient transfections was performed using suspension-adapted HEK293-T cells grown in serum-free M11V3 medium.
Для осуществления трансфекций в небольшом масштабе (< 5 л) клетки выращивали во встряхиваемых колбах Corning (Corning, США) на орбитальном шейкере (100 об./мин.) в увлажненном CO2-инкубаторе при 5% CO2 (в колбах, содержащих посевную культуру).For small-scale transfections (<5 L), cells were grown in Corning shake flasks (Corning, USA) on an orbital shaker (100 rpm) in a humidified CO 2 incubator at 5% CO 2 (in flasks containing inoculum). culture).
Как правило, клетки в посевных культурах должны находиться в экспоненциальной фазе роста (при плотности клеток от 5×105 до 3×106/мл) и характеризоваться жизнеспособностью > 90%. Показатели плотности клеток за пределами данного диапазона приводят либо к лаг-фазе после разделения, либо к снижению эффективности трансфекции.As a general rule, cells in seed cultures should be in an exponential growth phase (at cell densities between 5x10 5 and 3x10 6 /ml) and have >90% viability. Cell densities outside this range either result in a lag phase after separation or a decrease in transfection efficiency.
Для осуществления трансфекции в небольшом масштабе (в данном случае 2 л) аликвоту клеток отбирали из посевных культур и доводили до 1,4×106 клеток/мл в 36% конечного объема среды M11V3.For transfection on a small scale (in this case 2 L), an aliquot of cells was taken from seed cultures and adjusted to 1.4×10 6 cells/ml in 36% of the final volume of M11V3 medium.
Раствор ДНК (раствор 1) получали посредством разбавления 1 мг/л конечного объема ДНК в 7% конечного объема M11V3 и осторожного перемешивания. Для предотвращения загрязнения культур данный раствор можно отфильтровать с помощью фильтра на 0,22 мкм (например, Millipore Stericup). В данном случае из-за небольшого объема стерилизующую фильтрацию не проводили. Затем конечный объем 3 мг/л раствора PEI разбавляли в 7% конечного объема M11V3 и осторожно перемешивали (раствор 2). Оба раствора инкубировали в течение 5-10 мин. при комнатной температуре (RT). После этого раствор 2 добавляли к раствору 1 при осторожном перемешивании и инкубировали в течение еще 5-15 минут при RT (во время инкубации не следует снова перемешивать, так как PEI покрывает/конденсирует ДНК в виде положительно заряженных частиц, которые связываются с анионными остатками клеточной поверхности и переносятся в клетку посредством эндоцитоза). После инкубации смесь для трансфекции добавляют к клеткам, и культуру культивируют в течение четырех часов (10 об./мин., 37°C, 6% CO2).A DNA solution (solution 1) was prepared by diluting 1 mg/l of the final volume of DNA in 7% of the final volume of M11V3 and gently mixing. To prevent contamination of cultures, this solution can be filtered with a 0.22 µm filter (eg Millipore Stericup). In this case, sterilizing filtration was not carried out due to the small volume. Then a final volume of 3 mg/l PEI solution was diluted in 7% of the final volume of M11V3 and mixed gently (solution 2). Both solutions were incubated for 5-10 min. at room temperature (RT). After that, solution 2 was added to
Наконец, культуру подпитывают оставшимися 50% конечного объема среды M11V3 в соответствии со следующим примером. Объем инокуляции: 36 мл при 1,4×106 клеток/мл.Finally, the culture is fed with the remaining 50% of the final volume of M11V3 medium according to the following example. Inoculation volume: 36 ml at 1.4×10 6 cells/ml.
Раствор 1: 7 мл среды M11V3 со 100 мкг плазмидной ДНК. Раствор 2: 7 мл среды M11V3 с 300 мкг PEI (300 мкл).Solution 1: 7 ml of M11V3 medium with 100 µg of plasmid DNA. Solution 2: 7 ml M11V3 medium with 300 µg PEI (300 µl).
Подпитка: 50 мл M11V3, общий объем 100 мл.Make-up: 50 ml M11V3,
Белок очищали с помощью аффинной хроматографии на иммобилизованных ионах металлов (IMAC) в соответствии с нижеследующим. Использовали 95 мл надосадочной жидкости (~ 4 мл от всего объема сохраняли для анализа (IPC)).The protein was purified by immobilized metal ion affinity chromatography (IMAC) as follows. 95 ml of the supernatant was used (~4 ml of the total volume was saved for analysis (IPC)).
Используемый материалMaterial used
Агароза никель-NTA, Qiagen, кат. №/ID: 30230, хроматографические колонки Poly-Prep, пустые, BioRad, № 731-1550, буфер для IMAC A, pH 7,4 (содержащий 20 мM буфера NaPO4 и 50 мM имидазола). Буфер для IMAC B, pH 7,4 (содержащий 20 мM буфера NaPO4 и 300 мM имидазола). TBS (в 10x концентрации, разбавленный до 1x концентрации с помощью воды MilliQ). Центрифужный фильтрующий блок Amicon Ultra-4 с мембраной Ultracel-10, 10K, UFC801096.Nickel-NTA agarose, Qiagen, cat. No./ID: 30230, Poly-Prep chromatography columns, empty, BioRad, No. 731-1550, buffer for IMAC A, pH 7.4 (containing 20 mM NaPO 4 buffer and 50 mM imidazole). Buffer for IMAC B, pH 7.4 (containing 20 mM NaPO 4 buffer and 300 mM imidazole). TBS (at 10x concentration, diluted to 1x concentration with MilliQ water). Amicon Ultra-4 centrifugal filter unit with Ultracel-10, 10K, UFC801096 membrane.
Стадии процессаProcess steps
1. Подготовка колонок с использованием 1 мл агарозы никель-NTA от Qiagen (= 0,5 мл CV)1. Prepare columns using 1 ml of Qiagen nickel-NTA agarose (= 0.5 ml of CV)
2. Уравновешивание с помощью 10 CV IMAC A2. Balancing with 10 CV IMAC A
3. Загрузка 15/45 мл SN в колонку (сбор материала, протекающего через колонку)3. Loading 15/45 ml SN into the column (collecting material flowing through the column)
4. Промывание с помощью 10 CV IMAC A (сбор в пробирку Falcon объемом 15 мл)4. Wash with 10 CV IMAC A (collect in 15 ml Falcon tube)
5. Элюирование в 6,5 CV IMAC B5. Elution in 6.5 CV IMAC B
6. Определение концентрации элюата6. Determination of eluate concentration
7. Концентрирование 3,5 мл образца до ~ 400 мкл с помощью центрифужного фильтрующего блока Amicon Ultra-4 10K7. Concentration of 3.5 ml sample to ~400 µl using an Amicon Ultra-4 10K centrifuge filter block
8. Замена буфера путем добавления TBS и центрифугирования при 50008. Buffer exchange by adding TBS and centrifugation at 5000
Образцы анализировали с помощью аналитической SEC, используя 40 мкл каждого образца и используя гель для белка с 12 мкл каждого образца.Samples were analyzed by analytical SEC using 40 µl of each sample and using protein gel with 12 µl of each sample.
Полученный белок сохраняли.The resulting protein was saved.
(2) Белок с MIL(2) Protein with MIL
Проводили клонирование EP14aa1-3 с петлей, взаимодействующей с мембраной (aa193-204), и ПЦР с перекрывающимися праймерами.EP14aa1-3 was cloned with a membrane interacting loop (aa193-204) and PCR with overlapping primers.
Использовали следующие праймеры.The following primers were used.
Постановку ПЦР-реакции осуществляли с использованием следующей схемы пипетирования:The PCR reaction was set up using the following pipetting scheme:
1,2 мкл полимеразы Phusion Hot Start,1.2 µl Phusion Hot Start Polymerase,
24 мкл 5x буфера HF,24 µl 5x HF buffer,
0,96 мкл 100 мM dNTP (по 25 мM каждого dNTP),0.96
0,6 мкл прямого праймера,0.6 µl forward primer,
0,6 мкл обратного праймера,0.6 µl reverse primer,
92,64 мкл H2O, обработанной с помощью DEPC.92.64 µl H 2 O treated with DEPC.
Использовали параметры циклов ПЦР в соответствии с таблицей 17.The parameters of PCR cycles were used in accordance with Table 17.
Непосредственно после проведения реакции в каждую реакционную смесь добавляли 2 мкл фермента DpnI, перемешивали и инкубировали в течение 2 часов при 37°C.Immediately after the reaction, 2 μl of DpnI enzyme was added to each reaction mixture, mixed and incubated for 2 hours at 37°C.
Трансформацию проводили посредством переноса 2 мкл продукта ПЦР в 96-луночный планшет для ПЦР и охлаждения на льду. Добавляли 20 мкл химически компетентных бактерий STELLAR и осторожно перемешивали путем однократного пипетирования вверх и вниз. Образцы инкубировали в течение 30 минут на льду и затем в течение 45 с при 42°C в приборе для проведения ПЦР, затем еще раз инкубировали в течение 60 с на льду. Наконец, добавляли 90 мкл среды SOC и инкубировали в течение 1 часа при 37°C. Всю смесь для трансфекции высевали на чашки с LB/ампициллином или LB/карбенициллином и выращивали в течение ночи при 37°C.Transformation was performed by transferring 2 μl of the PCR product to a 96-well PCR plate and cooling on ice. 20 µl of chemically competent STELLAR bacteria were added and mixed gently by pipetting up and down once. Samples were incubated for 30 minutes on ice and then for 45 seconds at 42°C in a PCR instrument, then incubated again for 60 seconds on ice. Finally, 90 μl of SOC medium was added and incubated for 1 hour at 37°C. The entire transfection mix was seeded onto LB/ampicillin or LB/carbenicillin plates and grown overnight at 37°C.
Полученный белок EP14 с MIL с аминокислотной последовательностью согласно SEQ ID NO: 155 сохраняли.The resulting EP14 protein with MIL with the amino acid sequence according to SEQ ID NO: 155 was saved.
9. Пример 8: ферментативная активность9. Example 8: enzymatic activity
Характеристики кандидатов, полученных в предыдущих примерах, получали с помощью анализа ферментативной активности.Characteristics of the candidates obtained in the previous examples were obtained using the analysis of enzymatic activity.
Использовали следующие реагенты: буфер, не содержащий Pi, физиологический раствор, не содержащий фосфат (140 мM NaCl, 5 мM KCl, 1 мM MgCl2, 2 мM CaCl2, 10 мM Hepes, pH 7,4); и буфер, не содержащий Pi+2% BSA, физиологический раствор, не содержащий фосфат, с 20 мг/мл BSA; белок CD39 (согласно SEQ ID NO: 1); ATP.The following reagents were used: Pi-free buffer, phosphate-free saline (140 mM NaCl, 5 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 10 mM Hepes, pH 7.4); and Pi-free + 2% BSA buffer, phosphate-free saline with 20 mg/ml BSA; CD39 protein (according to SEQ ID NO: 1); ATP.
Раствор CD39 в двух повторностях получали в концентрации 2 мкг/мл. Раствор ATP в двух повторностях получали в концентрации 1000 мM из 15 мкл исходного раствора ATP+1185 мкл буфера, и его общий объем составлял 1,2 мл.The CD39 solution was prepared in duplicate at a concentration of 2 μg/ml. The ATP solution was prepared in duplicate at a concentration of 1000 mM from 15 μl of the stock solution of ATP+1185 μl of buffer, and its total volume was 1.2 ml.
Ферментативную реакцию изучали путем смешивания 60 мкл ATP с 60 мкл CD39 или 60 мкл буфера, не содержащего Pi, в качестве контроля в 48-луночных планшетах для ПЦР, заполненных 120 мкл конечного раствора/лунка. Конечная концентрация составляла 500 мкM для ATP и 1 мкг/мл для CD39.The enzymatic reaction was studied by mixing 60 µl of ATP with 60 µl of CD39 or 60 µl of Pi-free buffer as a control in 48-well PCR plates filled with 120 µl of final solution/well. The final concentration was 500 μM for ATP and 1 μg/ml for CD39.
Образцы инкубировали при 37°C в течение 0, 5, 15, 30, 60, 90 и 150 минут соответственно. Затем образцы оценивали с помощью анализа высвобождения Pi или HPLC.Samples were incubated at 37°C for 0, 5, 15, 30, 60, 90 and 150 minutes, respectively. The samples were then evaluated by Pi release assay or HPLC.
(1) Анализ высвобождения Pi(1) Pi release analysis
(a) Материалы и способы(a) Materials and Methods
Реагенты получали с помощью стандартного набора для выявления Pi в соответствии с инструкциями производителя.Reagents were prepared using a standard Pi detection kit according to the manufacturer's instructions.
Калибровочную кривую для Pi получали с помощью разбавления в воде. Получали серийное разведение 1:2 исходного раствора Pi (100 мкM): 450 мкл+450 мкл воды. Концентрация согласно калибровочной кривой составляла 50 мкM/25 мкM/12,5 мкM/6,25 мкM/3,1 мкM/1,5 мкM/0 мкM.A calibration curve for Pi was obtained by dilution in water. A 1:2 serial dilution of Pi stock solution (100 μM) was prepared: 450 μl + 450 μl water. The concentration according to the calibration curve was 50 μM/25 μM/12.5 μM/6.25 μM/3.1 μM/1.5 μM/0 μM.
Получали смесь реагентов Gold: 4 мл реагента Gold+40 мкл ускорителя (для 3 планшетов). В 96-луночном планшете образцы разбавляли 1:10 в H2O (разбавление в воде: 10 мкл образца+90 мкл H2O). 50 мкл разбавленного в соотношении 1:10 образца распределяли в каждую лунку 96-луночного планшета с половинным объемом лунок (Corning, 3690). 12,5 мкл смеси реагентов Gold добавляли в каждую лунку (25% объема образца), и образцы инкубировали в течение 10 минут при комнатной температуре. Показатели поглощения считывали при 635 нм.Received a mixture of reagents Gold: 4 ml reagent Gold+40 μl of the accelerator (for 3 tablets). In a 96-well plate, the samples were diluted 1:10 in H 2 O (water dilution: 10 µl sample+90 µl H2O). 50 μl of the 1:10 diluted sample was dispensed into each well of a 96-well half-well plate (Corning, 3690). 12.5 μl of the Gold reagent mix was added to each well (25% sample volume) and the samples were incubated for 10 minutes at room temperature. Absorption values were read at 635 nm.
(b) Результаты и их интерпретация(b) Results and their interpretation
Сравнительные результаты для кандидатов показаны в таблице 26.Comparative results for candidates are shown in Table 26.
Ферментативную активность измеряли путем добавления 500 мкM ATP к ферменту и анализа концентрации ATP, ADP, AMP с помощью HPLC (описание способа приведено ниже) с течением времени. Полученные кинетические кривые аппроксимировали моделью, представленной на фигуре 6, для получения констант ферментативных реакций. По константе ферментативной реакции Kcat ферменты располагались в следующем порядке (от низкой активности к высокой активности): EP28 (wt), EP17, EP14, EP15.Enzymatic activity was measured by adding 500 μM ATP to the enzyme and analyzing the concentration of ATP, ADP, AMP by HPLC (method description below) over time. The obtained kinetic curves were approximated by the model shown in figure 6 to obtain the constants of enzymatic reactions. According to the enzymatic reaction constant Kcat, the enzymes were arranged in the following order (from low activity to high activity): EP28 (wt), EP17, EP14, EP15.
На фигуре 7 показаны кинетические данные и аппроксимация моделью для EP28. На фигуре 8 показаны кинетические данные и аппроксимация моделью для EP14. На фигуре 9 показаны кинетические данные и аппроксимация моделью для EP15.Figure 7 shows kinetic data and model fit for EP28. Figure 8 shows kinetic data and model fit for EP14. Figure 9 shows kinetic data and model fit for EP15.
Обзор констант ферментативных реакций для EP28 (wt), EP14, EP15 и EP17 показан в таблице 27. По сравнению с вариантом дикого типа (WT) три новых варианта демонстрировали повышенную каталитическую активность. Важно отметить, что новые варианты демонстрировали четкое повышение каталитической константы скорости (kcat) и каталитической эффективности (kcat/Km). Поскольку приводимые концентрации субстрата ATP и ADP во время повреждения тканей и тромбоза превышают приводимое значение Km, данное повышение kcat и kcat/Km, по всей вероятности, преобразуется в более высокую активность in vivo.An overview of the enzymatic reaction constants for EP28 (wt), EP14, EP15 and EP17 is shown in Table 27 . Compared to the wild-type (WT) variant, the three new variants showed increased catalytic activity. Importantly, the new variants showed a clear increase in catalytic rate constant (kcat) and catalytic efficiency (kcat/Km). Because reported substrate concentrations of ATP and ADP during tissue injury and thrombosis exceed the reported Km value, this increase in kcat and kcat/Km is likely to translate into higher in vivo activity.
(2) Валидационный анализ методом HPLC (кинетические характеристики и дозозависимый ответ)(2) Validation analysis by HPLC method (kinetic characteristics and dose-response)
(a) Материалы и способы(a) Materials and Methods
Кандидатов тестировали с помощью валидационного анализа методом HPLC. 70 мкл каждого образца переносили в стеклянные флаконы для проведения HPLC.Candidates were tested using HPLC validation analysis. 70 μl of each sample was transferred into glass vials for HPLC.
Калибровочные образцы получали с использованием 5 мM исходных растворов, показанных в таблице 28.Calibration samples were prepared using the 5 mM stock solutions shown in Table 28 .
1000 мкM По 20 мкл каждого исходного раствора смешивали во флаконе для HPLC1000
500 мкM 20 мкл 1 мM+20 мкл H2O500
100 мкM 10 мкл 1 мM+90 мкл H2O100 µM 10
10 мкM 10 мкл 100 мкM+90 мкл H2O10 µM 10
1 мкM 10 мкл 10 мкM+90 мкл H2O1 µM 10 µl 10 µM+90 µl H 2 O
Разделение с помощью HPLC проводили с использованием системы Agilent 1100 с капиллярным насосом (G1376A), дегазатором (G1379A), ALS (G1329A), термостатом (G1330B), колоночным отделением (G1316A) и DAD (G1315A). Растворитель A: 10 мM KH2PO4 (04243, Riedel-de Haën) + 2 мM бромида TBA, pH 7,0 (86857-10G-F, Fluka) и растворитель B: 10 мM KH2PO4/ACN 1/1+2 мM бромида TBA, pH 5,5. Колонка: Nucleodur 300-5 C18 EC, 2×150 мм, 5 мкм, Macherey-Nagel 760185.20, партия E14100258 36654055. Температура колонки составляла 40°C, объем вводимой пробы составлял 10 мкл, скорость потока составляла 0,3 мл/мин., и градиент представлял собой 0-3': 0% B; 3-23': 0-95% B, линейный; 23-28': 95% B, линейный; 28-29': 95-0% B, линейный; 5' - время перерыва перед следующим анализом. DAD: 247 нм и 259 нм.HPLC separations were performed using an Agilent 1100 system with capillary pump (G1376A), degasser (G1379A), ALS (G1329A), thermostat (G1330B), column compartment (G1316A), and DAD (G1315A). Solvent A: 10 mM KH 2 PO 4 (04243, Riedel-de Haën) + 2 mM TBA bromide, pH 7.0 (86857-10G-F, Fluka) and Solvent B: 10 mM KH2PO4/
Разделение с помощью UPLC проводили с использованием UPLC I класса от Waters. Растворитель A: 10 мM KH2PO4/10 мM K2HPO4 1/1+2 мM бромида TBA, pH 7,0. Растворитель B: 10 мM KH2PO4/ACN 1/1+2 мM бромида TBA, pH 5,5. Колонка: Fortis Bio C18, 2,1×50 мм, 5 мкм, di2chrom BIO318-020301 SN H03161210-2. Температура колонки составляла 40°C, объем вводимой пробы составлял 10 мкл, скорость потока составляла 0,5 мл/мин., и градиент представлял собой 0-1': 0% B; 1-8': 0-55% B, линейный; 8-10': 55% B; 10-11': 55-0% B, линейный; 14' - время остановки. DAD работал при 247 нм и 259 нм.UPLC separation was performed using Waters class I UPLC. Solvent A: 10 mM KH 2 PO 4 /10 mM K 2 HPO 4 1/1 + 2 mM TBA bromide, pH 7.0. Solvent B: 10 mM KH 2 PO 4 /
(b) Результаты(b) Results
Результаты можно видеть на фигурах 7, 8, 9 и 11, на которых показаны кинетические данные и аппроксимация моделью для кандидатов в соответствии с различными вариантами осуществления.The results can be seen in Figures 7, 8, 9 and 11 showing kinetic data and model fit for candidates according to various embodiments.
10. Пример 9: активность in vitro, первоначальный скрининг10. Example 9: in vitro activity, initial screening
Варианты CD39 от EP1 до EP24, описанные в предыдущих примерах, клонировали в вектор экспрессии у млекопитающих pRS5a_лидерная_APP_His (фигура 5) без лидерной последовательности IL2 и без начальной последовательности IL2.The CD39 variants EP1 to EP24 described in the previous examples were cloned into the mammalian expression vector pRS5a_leader_APP_His (Figure 5) without the IL2 leader sequence and without the initial IL2 sequence.
(a) Материалы и способы(a) Materials and Methods
Проводили экспрессию хитов EP в небольшом масштабе (в масштабе 20/50 мл) в HEK293 (трансфекция с использованием PEI) в течение 7 дней с последующей IPC с помощью APP-HPLC (как описано выше). EP hits were expressed on a small scale (20/50 ml scale) in HEK293 (transfection using PEI) for 7 days followed by IPC with APP-HPLC (as described above).
Очистка белка из 15/45 мл надосадочной жидкости культуры клеток с помощью колонок с Ni-NTA (0,5 мл CV);Protein purification from 15/45 ml cell culture supernatant using Ni-NTA columns (0.5 ml CV);
Элюирование с помощью 6 CV буфера для IMAC B (20 мM буфера NaPO4, 300 мM имидазола, pH 7,4);Elute with 6 CV of IMAC B buffer (20 mM NaPO4 buffer, 300 mM imidazole, pH 7.4);
Концентрирование и повторное забуферивание очищенного белка в TBS, pH 7,4;Concentration and re-buffering of the purified protein in TBS, pH 7.4;
Анализ белка с помощью геля для белка методом аналитической SEC;Protein gel analysis using analytical SEC method;
Доставка всех вариантов и трех контролей (исходного hCD39-dMIL, или EP28, с начальной последовательностью IL2 и без нее и 8M-варианта без начальной последовательности IL2): 90-200 мкл очищенного белка в TBS, pH 7,4Delivery of all variants and three controls (stock hCD39-dMIL, or EP28, with and without initial IL2 sequence and 8M variant without initial IL2 sequence): 90-200 µl of purified protein in TBS, pH 7.4
(b) Результаты и их интерпретация(b) Results and their interpretation
Результаты обобщены в таблице 29 ниже.The results are summarized in Table 29 below.
Все образцы находились в TBS, pH 7,4, и имели метки APP (SEQ ID NO: 247) и His (SEQ ID NO: 249).All samples were in TBS, pH 7.4, and labeled APP (SEQ ID NO: 247) and His (SEQ ID NO: 249).
Только исходный CD39ΔMIL человека (EP28) имел начальную последовательность IL2 длиной 15 аминокислот - aa1-15 (SEQ ID NO: 133).Only the original human CD39ΔMIL (EP28) had an initial 15 amino acid IL2 sequence, aa1-15 (SEQ ID NO: 133).
Анализ высвобождения Pi BOENKTH1-0252824, двойное выявление для значений через 60 и 180 мин.Pi release analysis BOENKTH1-0252824, dual detection for 60 and 180 min values.
[мг/мл]Concentration
[mg/ml]
[микромолярная]Concentration
[micromolar]
[мл]Overall volume
[ml]
11. Пример 10: активность in vitro, уточненный скрининг11. Example 10: in vitro activity, refined screening
Подгруппу, состоящую из 12 мутантных форм, тестировали во второй раз, но с начальной последовательностью IL-2, обеспечивающей возможность большего масштаба экспрессии.A subgroup of 12 mutants was tested a second time, but with an initial IL-2 sequence allowing for greater scale expression.
(a) Материалы и способы(a) Materials and Methods
Вектор экспрессии у млекопитающих pRS5a_лидерная_APP_His с начальной последовательностью IL2 длиной 15 аминокислот - aa1-15 (SEQ ID NO: 133) (фигура 5). Экспрессия хитов EP в небольшом масштабе (в масштабе 50/100 мл) в HEK293 (трансфекция с использованием PEI) в течение 7 дней с последующей IPC с помощью APP-HPLC (как описано выше).Mammalian expression vector pRS5a_APP_His leader with 15 amino acid initial IL2 sequence - aa1-15 (SEQ ID NO: 133) (Figure 5). Expression of EP hits on a small scale (50/100 ml scale) in HEK293 (transfection using PEI) for 7 days followed by IPC with APP-HPLC (as described above).
Очистка белка из 45/95 мл надосадочной жидкости культуры клеток с помощью колонок с Ni-NTA (0,5 мл CV)Protein purification from 45/95 ml cell culture supernatant using Ni-NTA columns (0.5 ml CV)
Элюирование с помощью 6 CV буфера для IMAC B (20 мM буфера NaPO4, 300 мM имидазола, pH 7,4)Elute with 6 CV of IMAC B buffer (20 mM NaPO4 buffer, 300 mM imidazole, pH 7.4)
Концентрирование и повторное забуферивание очищенного белка в TBS, pH 7,4 Concentration and re-buffering of the purified protein in TBS, pH 7.4
Анализ белка с помощью геля для белка методом аналитической SECProtein Gel Analysis by Analytical SEC
Доставка всех вариантов и контроля (исходного hCD39-dMIL, или EP28, с начальной последовательностью IL2 aa1-15 (SEQ ID NO: 133)):Delivery of all variants and controls (original hCD39-dMIL, or EP28, with initial IL2 sequence aa1-15 (SEQ ID NO: 133)):
500 мкл очищенного белка в TBS, pH 7,4500 µl purified protein in TBS, pH 7.4
(b) Результаты и их интерпретация(b) Results and their interpretation
Результаты обобщены в таблице 30, таблице 31 и таблице 32 ниже.The results are summarized in table 30, table 31 and table 32 below.
[мг/мл]Concentration
[mg/ml]
[микромолярная]Concentration
[micromolar]
[мл]Overall volume
[ml]
[мг]Yield/46 or 16 ml
[mg]
(Аналитическая SEC)Peak monomers (%)
(Analytical SEC)
(Аналитическая SEC)Destruction (%)
(Analytical SEC)
[кДа]MW
[kDa]
[M-1*см-1]E
[M-1*cm-1]
[мг/мл]Concentration
[mg/ml]
[микромолярная]Concentration
[micromolar]
[мл]Overall volume
[ml]
12. Пример 11: активность in vivo, pK12. Example 11: in vivo activity, pK
(a) Материалы и способы(a) Materials and Methods
Для определения PK-свойств in vivo 10 мг/кг соединения в конечной концентрации 10 мг/мл в буфере PBS вводили внутривенно (1 мл/кг) через хвостовую вену 4 самкам мышей C57BL/6, находящимся в сознании. Мышей получали из WIGA, и их масса тела составляла около 22 г. Всю работу с живыми организмами проводили в соответствии с законодательством Швейцарии о защите прав животных.To determine PK properties in vivo, 10 mg/kg of the compound at a final concentration of 10 mg/ml in PBS buffer was administered intravenously (1 ml/kg) via the tail vein to 4 conscious female C57BL/6 mice. The mice were obtained from WIGA and weighed about 22 g. All work with living organisms was carried out in accordance with Swiss animal rights law.
Цельную кровь собирали (50 мкл на каждый момент времени) через 0,25, 3, 8, 24 и 48 часов после введения дозы в малообъемные пробирки для сыворотки крови с помощью Minivette POCT. Сыворотку крови отделяли и применяли для определения концентрации.Whole blood was collected (50 μl at each time point) at 0.25, 3, 8, 24, and 48 hours post-dose in low-volume serum tubes using the Minivette POCT. Serum was separated and used to determine the concentration.
Технология Gyrolab представляет собой автоматизированный иммунологический анализ в нанолитровом масштабе с использованием аффинного проточного формата, который проводится посредством центробежных сил и выявления с помощью лазерно-индуцированной флуоресценции. Гранулы, покрытые стрептавидином, были предварительно упакованы в колонки для аффинной хроматографии в Gyrolab Bioaffy CD. Каждый CD содержал 112 колонок. Колонки для аффинного захвата содержали по 15 нл на каждую микроструктуру. Вводимые образцы поступали внутрь под действием капиллярного эффекта. Биотинилированный реагент для захвата связывался с гранулами, покрытыми стрептавидином. Затем вводили раствор аналита, который связывался с захватывающими молекулами. Наконец, применяли проявляющий реагент, меченный флуорофором. В случае с CD39 в анализе использовали два разных считываемых показателя в зависимости от наличия метки APP.Gyrolab technology is an automated nanoliter-scale immunoassay using an affinity flow format that is performed by centrifugal force and detection by laser-induced fluorescence. The streptavidin-coated beads were pre-packed into affinity chromatography columns in Gyrolab Bioaffy CD. Each CD contained 112 columns. The affinity capture columns contained 15 nL per microstructure. The introduced samples entered inside under the action of the capillary effect. The biotinylated capture reagent bound to the streptavidin-coated beads. An analyte solution was then injected, which bound to the capturing molecules. Finally, a developing reagent labeled with a fluorophore was used. In the case of CD39, two different readings were used in the analysis depending on the presence of the APP label.
1) Антитело к CD39 (40035) и антитело к APP (27431) показаны на фигуре 10A.1) Anti-CD39 antibody (40035) and anti-APP antibody (27431) are shown in Figure 10A.
2) Fab (40035) и предварительно полученная смесь антитело к Fc/антитело к CD39 (40044) в соотношении 1:1 (все конструкции EP28aa1-16) показаны на фигуре 10B. Антитело 40044 теряет активность при биотинилировании посредством связывания с аминогруппой, следовательно, биотинилированию подвергали только антитело 40035.2) Fab (40035) and a 1:1 anti-Fc/anti-CD39 antibody (40044) premix (all EP28aa1-16 constructs) are shown in Figure 10B. Antibody 40044 loses activity upon biotinylation through binding to the amino group, therefore, only antibody 40035 was biotinylated.
Все калибровочные кривые для конструкций CD39 разбавляли в Rexxip A, содержащем 5% (об./об.) сыворотки крови мыши в серии разведений 1:2. Применяемый диапазон концентраций для конструкций, меченных с помощью APP, составлял от 5000 нг/мл до 9,77 нг/мл, а для EP28aa1-16 он составлял от 10000 нг/мл до 9,77 нг/мл. Все образцы сыворотки крови мышей разбавляли в соотношении 1:100 в Rexxip A, содержащем 5% (об./об.) сыворотки крови мыши. Образцы конструкций CD39 для QC разбавляли в Rexxip A, содержащем 5% (об./об.) сыворотки крови мыши (50 и 500 нг/мл для конструкций с меткой APP и 500 и 1000 нг/мл для EP28aa1-16). Конечная концентрация для всех биотинилированных захватывающих реагентов составляла 0,1 мг/мл, и меченное флуоресцентной меткой детекторное антитело разбавляли до 10 нM в Rexxip F.All calibration curves for CD39 constructs were diluted in Rexxip A containing 5% (v/v) mouse serum in a 1:2 dilution series. The applicable concentration range for APP labeled constructs was 5000 ng/mL to 9.77 ng/mL and for EP28aa1-16 it was 10000 ng/mL to 9.77 ng/mL. All mouse serum samples were diluted 1:100 in Rexxip A containing 5% (v/v) mouse serum. Samples of CD39 QC constructs were diluted in Rexxip A containing 5% (v/v) mouse serum (50 and 500 ng/ml for APP-labeled constructs and 500 and 1000 ng/ml for EP28aa1-16). The final concentration for all biotinylated capture reagents was 0.1 mg/mL and the fluorescently labeled detection antibody was diluted to 10 nM in Rexxip F.
(b) Результат и его интерпретация(b) Result and its interpretation
Результаты обобщены в таблице 33. Как можно видеть, все кандидаты демонстрировали одинаковые PK-свойства. Поэтому отбор кандидата производили не на основе PK-свойств.The results are summarized in Table 33. As can be seen, all candidates exhibited the same PK properties. Therefore, the selection of a candidate was not made on the basis of PK-properties.
13. Пример 12. Активность in vivo, модель AKI13. Example 12 In Vivo Activity, AKI Model
(a) Материалы и способы(a) Materials and Methods
Нефрэктомию правой почки проводили до начала клинической ситуации I/R. Вторую почку удаляли во избежание действия компенсаторных механизмов, которые полностью меняют динамику биологических процессов. Анестезированных животных, дышащих самостоятельно, помещали на гомеотермическое одеяло гомеотермической системы мониторинга и накрывали стерильной марлей. Температуру тела регистрировали с помощью ректального зонда и контролировали в диапазоне от 36,5 до 37,5°C во избежание гипотермии. Животных анестезировали, брили и подвергали дезинфекции (бетасептик). После произведения разреза по срединной линии/лапаротомии содержимое брюшной полости отодвигали влево и удаляли правую почку. Мочеточник и кровеносные сосуды разъединяли и перевязывали (9-0 Ethicon), затем почку удаляли.Nephrectomy of the right kidney was performed before the onset of the clinical situation I/R. The second kidney was removed to avoid the action of compensatory mechanisms that completely change the dynamics of biological processes. Anesthetized animals breathing spontaneously were placed on a homeothermic blanket of a homeothermic monitoring system and covered with sterile gauze. Body temperature was recorded using a rectal probe and controlled in the range from 36.5 to 37.5°C to avoid hypothermia. Animals were anesthetized, shaved and disinfected (betaseptic). After making a midline incision/laparotomy, the contents of the abdominal cavity were moved to the left and the right kidney was removed. The ureter and blood vessels were severed and ligated (9-0 Ethicon), then the kidney was removed.
Индуцирование I/R-повреждения: непосредственно после нефрэктомии правой почки содержимое брюшной полости отодвигали вправо и отсекали левую почечную артерию для индуцирования ишемии почки. Induction of I/R injury: Immediately after nephrectomy of the right kidney, the contents of the abdominal cavity were moved to the right and the left renal artery was cut off to induce renal ischemia.
Клипсы для микроаневризмы применяли для наложения зажима на сосудистую ножку, чтобы блокировать ток крови к почке и индуцировать ишемию почки. Продолжительность ишемии почки отсчитывали от момента наложения зажима. Произошедшую ишемию подтверждали по изменению цвета почки с красного на темно-фиолетовый за несколько секунд. После индуцирования ишемии клипсы для микроаневризмы удаляли, и изменение цвета почки на красный указывало на реперфузию.Microaneurysm clips were used to clamp the vascular pedicle to block blood flow to the kidney and induce renal ischemia. The duration of renal ischemia was counted from the moment the clamp was applied. The occurrence of ischemia was confirmed by a change in the color of the kidney from red to dark purple in a few seconds. After induction of ischemia, the microaneurysm clips were removed and a red color change of the kidney indicated reperfusion.
(b) Результат и его интерпретация(b) Result and its interpretation
Результат показан на фигуре 12. Кандидаты демонстрировали дозозависимый ответ in vivo, который коррелировал с их удельной активностью in vitro. На фигуре 12A показаны результаты для исходной EP28, на фигуре 12B показаны результаты для EP1xEP17, и на фигуре 12C показаны результаты для EP14. Как можно увидеть, EP28 и EP1xEP17 демонстрируют сходные дозозависимые ответы, при этом EP14 с более высокой активностью in vitro демонстрирует полную эффективность в более низкой дозе.The result is shown in Figure 12. The candidates showed a dose-dependent in vivo response that correlated with their in vitro specific activity. Figure 12A shows the results for the original EP28, Figure 12B shows the results for EP1xEP17, and Figure 12C shows the results for EP14. As can be seen, EP28 and EP1xEP17 show similar dose-dependent responses, with EP14 with higher in vitro activity showing full efficacy at a lower dose.
14. Пример 13: титр, выход и возможность разработки14. Example 13: Title, Yield, and Development Opportunity
Для целей изготовления выбранных кандидатов в коммерческом масштабе важно иметь возможность экспрессировать их с относительно высоким выходом. Что касается терапевтических белков, данная задача может быть менее простой по сравнению с терапевтическими антителами из-за сложности формата в дополнение к отсутствию технологии обогащения, которая обеспечивает возможность отбора высокопродуктивных клонов.For the purposes of manufacturing selected candidates on a commercial scale, it is important to be able to express them in relatively high yield. For therapeutic proteins, this task may be less straightforward than with therapeutic antibodies due to the complexity of the format, in addition to the lack of an enrichment technology that allows selection of highly productive clones.
Оба кандидата, EP14aa1-3 и EP28aa1-3, обладали сопоставимыми техническими характеристиками, которые представляли сложность. В частности, низкие титры экспрессии более ранних экспрессионных партий (данные не показаны) влияют на затраты на производство или могут быть даже еще более низкими после увеличения масштаба производства, поскольку контроль белков клетки-хозяина не является надежным. Both candidates, EP14aa1-3 and EP28aa1-3, had comparable technical characteristics, which presented a challenge. In particular, low expression titers from earlier expression batches (data not shown) affect production costs or may be even lower after scale-up because control of host cell proteins is not reliable.
С целью попытки улучшения экспрессии белка с помощью раннего отбора клонов для обоих кандидатов требовалась разработка индивидуального способа очистки. Для этого получали пулы клеток, экспрессирующих кандидаты EP28aa1-3 и EP14aa1-3. In order to attempt to improve protein expression by early selection of clones for both candidates, the development of an individual purification method was required. For this, pools of cells expressing candidates EP28aa1-3 and EP14aa1-3 were obtained.
Исходную линию клеток CHO применяли в качестве линии клеток-хозяев для получения линии клеток, экспрессирующих EP28aa1-16/EP14aa1-3. Линию клеток-хозяев получали из линии клеток CHO-K1, хорошо известной специалисту в данной области, способом, описанным, например, в патентных заявках WO2015092737 и WO2015092735, обе из которых включены в данный документ посредством ссылки во всей своей полноте. Один флакон с линией СНО использовали для получения рекомбинантной линии клеток, экспрессирующих EP28aa1-16/EP14aa1-3.The original CHO cell line was used as a host cell line to obtain a cell line expressing EP28aa1-16/EP14aa1-3. The host cell line was derived from the CHO-K1 cell line, well known to the person skilled in the art, by the method described, for example, in patent applications WO2015092737 and WO2015092735, both of which are incorporated herein by reference in their entirety. One vial of the CHO line was used to generate a recombinant cell line expressing EP28aa1-16/EP14aa1-3.
Клетки выращивали в среде для культивирования с определенным химическим составом. Для каждой трансфекции добавляли один мкг плазмидной ДНК, линеаризованной с помощью SwaI - экспрессионного вектора, кодирующего EP28aa1-16/EP14aa1-3. Реакцию трансфекции проводили в среде для культивирования с определенным химическим составом. The cells were grown in a culture medium with a specific chemical composition. For each transfection, one μg of plasmid DNA, linearized with SwaI, an expression vector encoding EP28aa1-16/EP14aa1-3, was added. The transfection reaction was carried out in a culture medium with a specific chemical composition.
Трансфекции проводили посредством электропорации с использованием системы AMAXA Gene Pulser в соответствии с инструкциями производителя. Исходные клетки СНО, используемые для трансфекции, находились в экспоненциальной фазе роста с показателями жизнеспособности клеток более 95%. Всего было проведено три трансфекции с использованием 5×106 клеток для каждой трансфекции. Сразу после трансфекции клетки переносили во встряхиваемые колбы, содержащие среду для культивирования с определенным химическим составом. Transfections were performed by electroporation using the AMAXA Gene Pulser system according to the manufacturer's instructions. The original CHO cells used for transfection were in an exponential growth phase with cell viability greater than 95%. A total of three transfections were performed using 5×10 6 cells for each transfection. Immediately after transfection, the cells were transferred to shake flasks containing culture medium with a defined chemical composition.
Пулы клеток инкубировали в течение 48 часов при 36,5°С и 10% СО2 перед началом процесса отбора. Процедуру отбора осуществляли с использованием селектируемого маркера, кодируемого вектором экспрессии. Через 48 ч. после трансфекции и роста в условиях низкого содержания фолата применяли дополнительное селективное давление путем добавления 10 нМ MTX к среде для культивирования с определенным химическим составом. Через 21 день после начала отбора с помощью MTX появлялись популяции пулов, состоящие преимущественно из клеток, устойчивых к MTX. После извлечения пулов клетки замораживали. Для определения концентрации EP28aa1-16/EP14aa1-3 были сформированы стандартные подпитываемые партии в среде для культивирования с определенным химическим составом. Для определения концентрации продукта применяли обращенно-фазовую хроматографию (RPC). Пулы клеток СНО, продуцирующие EP28aa1-16/EP14aa1-3, использовали для процедуры FACS-сортировки отдельных клеток/печати клеток, чтобы получить индивидуализированные клональные линии клеток.Cell pools were incubated for 48 hours at 36.5°C and 10% CO 2 before starting the selection process. The selection procedure was carried out using a selectable marker encoded by the expression vector. 48 hours after transfection and growth under low folate conditions, additional selective pressure was applied by adding 10 nM MTX to the chemistred culture medium. 21 days after the start of selection with MTX, pool populations appeared, consisting predominantly of cells resistant to MTX. After the pools were removed, the cells were frozen. To determine the concentration of EP28aa1-16/EP14aa1-3, standard fed-batch batches were formed in a culture medium with a specific chemical composition. Reverse phase chromatography (RPC) was used to determine the product concentration. Pools of CHO cells producing EP28aa1-16/EP14aa1-3 were used in a FACS single cell sorting/cell printing procedure to obtain individualized clonal cell lines.
15. Пример 14: терапевтическое применение15. Example 14: therapeutic application
Было установлено, что внеклеточный ATP, активирующий P2X7R, имеет четкую связь с несколькими заболеваниями, такими как усиление реакции "трансплантат против хозяина" (Wilhelm et al. Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. Nature Medicine 16:12, pages 1434-1439 (2010).)Graft - versus-host disease is enhanced by extracellular ATP activating P2X 7 R. Nature Medicine 16:12, pages 1434-1439 (2010).)
Кроме того, исследования как in vitro, так и in vivo указывают на то, что CD39 является апиразой, важной для функционального состояния сердечно-сосудистой системы, благодаря регуляции уровней ADP. Известно, что апираза ингибирует агрегацию тромбоцитов, метаболизируя внеклеточный ADP. In addition, both in vitro and in vivo studies indicate that CD39 is an apyrase important for cardiovascular function through the regulation of ADP levels. Apyrase is known to inhibit platelet aggregation by metabolizing extracellular ADP.
Человеческая апираза не связывается с тромбоцитами с помощью ковалентной связи по сравнению с другими средствами терапии, такими как клопидогрел (Plavix™), который необратимо связывается с рецептором ADP на поверхности тромбоцита. Это обеспечивает возможность более быстрого устранения терапевтической блокады и, следовательно, более безопасного подхода к ведению пациентов с избыточной активацией тромбоцитов. Это обеспечивает более безопасный подход к ведению пациентов с избыточной активацией тромбоцитов.Human apyrase does not covalently bind to platelets compared to other therapies such as clopidogrel (Plavix™), which binds irreversibly to the ADP receptor on the platelet surface. This allows faster resolution of therapeutic blockade and therefore a safer approach to managing patients with excessive platelet activation. This provides a safer approach to managing patients with excessive platelet activation.
Таким образом, существует четкое основание для терапевтического применения соединений, которые снижают уровни внеклеточного ATP, таких как соединения согласно настоящему изобретению.Thus, there is a clear rationale for the therapeutic use of compounds that reduce extracellular ATP levels, such as the compounds of the present invention.
Конкретными неограничивающими примерами терапевтических путей применения соединений согласно настоящему изобретению являются острое повреждение органа в связи с травмой и/или гипоксией, такое как острый респираторный дистресс-синдром (ARDS), повреждение легких, почечная недостаточность, острое повреждение почек (AKI), в том числе острое повреждение почек после обходного аортокоронарного шунтирования, отсроченная функция трансплантата после трансплантации (в том числе ксенотрансплантации) почки или других солидных органов или сосудистое заболевание, такое как окклюзионное заболевание сосудов, трансплантация и ксенотрансплантация, лечение индивидуумов, страдающих от инсульта, заболевания коронарных артерий или повреждения, являющегося результатом инфаркта миокарда, атеросклероза, артериосклероза, эмболии, преэклампсии, ангиопластики, повреждения сосудов, трансплантации, неонатальной гипоксически-ишемической энцефалопатии, ишемических нарушений, ассоциированных с тромбоцитами, в том числе ишемии легкого, коронарной ишемии и церебральной ишемии, ишемически-реперфузионного повреждения (IRI), тромботических нарушений, в том числе тромбоза коронарных артерий, тромбоза церебральных артерий, внутрисердечного тромбоза, тромбоза периферических артерий и венозного тромбоза, отсроченной функции трансплантата после трансплантации (в том числе ксенотрансплантации) почки или других солидных органов. Другими неограничивающими примерами терапевтических путей применения соединений согласно настоящему изобретению являются лечение ожогов или лучевого поражения, сепсиса, улучшение заживления ран, уменьшение кровотечения или риска кровотечения, предупреждения повреждения органов, реакции “трансплантат против хозяина” или предупреждение отторжения трансплантата.Specific non-limiting examples of therapeutic routes for the compounds of the present invention are acute organ injury due to trauma and/or hypoxia, such as acute respiratory distress syndrome (ARDS), lung injury, renal failure, acute kidney injury (AKI), including acute kidney injury after coronary artery bypass grafting, delayed graft function after transplantation (including xenotransplantation) of a kidney or other solid organs, or vascular disease such as vascular occlusive disease, transplantation and xenotransplantation, treatment of individuals suffering from stroke, coronary artery disease or injury resulting from myocardial infarction, atherosclerosis, arteriosclerosis, embolism, preeclampsia, angioplasty, vascular injury, transplantation, neonatal hypoxic-ischemic encephalopathy, platelet-associated ischemic disorders, including lung ischemia, coronary ischemia and cerebral ischemia, ischemia-reperfusion injury (IRI), thrombotic disorders, including coronary artery thrombosis, cerebral artery thrombosis, intracardiac thrombosis, peripheral arterial thrombosis and venous thrombosis, delayed graft function after transplantation (including xenotransplantation) of the kidney or other solid organs. Other non-limiting examples of therapeutic uses for the compounds of the present invention are the treatment of burns or radiation injury, sepsis, improvement of wound healing, reduction of bleeding or risk of bleeding, prevention of organ damage, graft versus host disease, or prevention of transplant rejection.
Особенно предпочтительными терапевтическими путями применения соединений согласно настоящему изобретению является острое повреждение почек (AKI), такое как острое повреждение почек после обходного аортокоронарного шунтирования, или сепсиса, или рабдомиолиза. Это состояние повышает смертность пациентов, и для него не существует стандарта оказания медицинской помощи (SoC). Основными причинами возникновения AKI в отделении интенсивной терапии являются: сепсис (47,5%), обширная хирургическая операция (34%), кардиогенный шок (27%), гиповолемия (26%) и воздействие нефротоксических соединений (19%). Кроме того, AKI представляет собой независимый серьезный фактор риска развития хронического заболевания почек (CKD). У 20-30% пациентов после проведения обширной хирургической операции на сердце появляется острое повреждение почек. Другой предпочтительный вариант осуществления относится к применению выделенной апиразы согласно настоящему изобретению для лечения острого повреждения почек, ассоциированного с хирургической операцией на сердце. Particularly preferred therapeutic routes for the compounds of the present invention are acute kidney injury (AKI), such as acute kidney injury following coronary artery bypass grafting or sepsis or rhabdomyolysis. This condition increases patient mortality and there is no standard of care (SoC) for it. The main causes of AKI in the intensive care unit are: sepsis (47.5%), major surgery (34%), cardiogenic shock (27%), hypovolemia (26%), and exposure to nephrotoxic compounds (19%). In addition, AKI is an independent major risk factor for chronic kidney disease (CKD). Acute kidney injury develops in 20-30% of patients after major heart surgery. Another preferred embodiment relates to the use of the isolated apyrase of the present invention for the treatment of acute kidney injury associated with cardiac surgery.
В другом варианте осуществления настоящее изобретение относится к выделенной апиразе согласно настоящему изобретению для применения в лечении отсроченной функции трансплантата (DGF), острого респираторного дистресс-синдрома (ARDS), острого инфаркта миокарда (AMI), травматического повреждения головного мозга (TBI)/острого ишемического инсульта (AIS) или их комбинаций, часто называемых формами полиорганной недостаточности (MOF).In another embodiment, the present invention provides an isolated apyrase of the present invention for use in the treatment of delayed graft function (DGF), acute respiratory distress syndrome (ARDS), acute myocardial infarction (AMI), traumatic brain injury (TBI)/acute ischemic stroke (AIS) or combinations thereof, often referred to as forms of multiple organ failure (MOF).
16. Острое повреждение почек (AKI) является частым осложнением сепсиса. У 28% пациентов с сепсисом появляется AKI. В дополнительном предпочтительном варианте осуществления настоящее изобретение относится к применению выделенной апиразы согласно настоящему изобретению для лечения острого повреждения почек, ассоциированного с сепсисом. Пример 15: терапевтические композиции16. Acute kidney injury (AKI) is a common complication of sepsis. AKI develops in 28% of patients with sepsis. In a further preferred embodiment, the present invention relates to the use of the isolated apyrase of the present invention for the treatment of acute kidney injury associated with sepsis. Example 15 Therapeutic Compositions
Терапевтические белки обычно составляют либо в водной форме, готовой для введения, либо в виде лиофилизата для восстановления подходящим разбавителем перед введением. Белок может быть составлен либо в виде лиофилизата, либо в виде водной композиции, например, в предварительно заполненных шприцах.Therapeutic proteins are usually formulated either in an aqueous form ready for administration or as a lyophilisate for reconstitution with a suitable diluent prior to administration. The protein can be formulated either as a lyophilisate or as an aqueous composition, for example in pre-filled syringes.
Подходящий состав может представлять собой водную фармацевтическую композицию или лиофилизат, которые могут быть восстановлены с получением раствора с высокой концентрацией активного ингредиента, представляющего собой терапевтический белок, и низким уровнем агрегации белка для доставки пациенту. Высокие концентрации белка являются применимыми, поскольку они позволяют снизить количество материала, который должен быть доставлен пациенту (дозу). Сниженные объемы введения доз позволяют минимизировать время, которое занимает доставка пациенту фиксированной дозы. Водные композиции по настоящему изобретению с высокой концентрацией белков являются особенно подходящими для подкожного введения.A suitable formulation may be an aqueous pharmaceutical composition or lyophilisate which can be reconstituted to provide a solution with a high concentration of the therapeutic protein active ingredient and a low level of protein aggregation for delivery to a patient. High protein concentrations are useful because they reduce the amount of material that must be delivered to the patient (dose). Reduced dosing volumes minimize the time it takes to deliver a fixed dose to a patient. Aqueous compositions of the present invention with a high concentration of proteins are particularly suitable for subcutaneous administration.
Таким образом, настоящее изобретение предусматривает водную фармацевтическую композицию, подходящую для введения субъекту, например, для подкожного введения, содержащую терапевтический белок.Thus, the present invention provides an aqueous pharmaceutical composition suitable for administration to a subject, for example, for subcutaneous administration, containing a therapeutic protein.
Терапевтический белок может применяться как фармацевтическая композиция в случае объединения с фармацевтически приемлемым носителем. В дополнение к терапевтическому белку такая композиция может содержать носители, различные разбавители, наполнители, соли, буферы, стабилизаторы, солюбилизаторы и другие материалы, хорошо известные в данной области техники. Характеристики носителя будут зависеть от пути введения. Фармацевтические композиции для применения в раскрытых способах также могут содержать дополнительные терапевтические средства для лечения конкретного целевого нарушения.The therapeutic protein may be used as a pharmaceutical composition when combined with a pharmaceutically acceptable carrier. In addition to the therapeutic protein, such a composition may contain carriers, various diluents, excipients, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The characteristics of the carrier will depend on the route of administration. Pharmaceutical compositions for use in the disclosed methods may also contain additional therapeutic agents for the treatment of the particular target disorder.
17. Пример 16: путь введения17. Example 16: route of administration
Как правило, белки согласно настоящему изобретению вводят с помощью инъекции, например, внутривенно, внутрибрюшинно либо подкожно. Способы осуществления этого введения известны средним специалистам в данной области. Также может быть возможным получение композиций, которые можно вводить местно или перорально или которые могут быть способны к проникновению через слизистые оболочки. Специалисту в данной области будет понятно, что могут использоваться любые подходящие средства для введения, подходящие для конкретного выбранного пути введения.Typically, the proteins of the present invention are administered by injection, for example intravenously, intraperitoneally, or subcutaneously. Methods for carrying out this administration are known to those of ordinary skill in the art. It may also be possible to prepare compositions that can be administered topically or orally, or that can be mucosally penetrable. One skilled in the art will appreciate that any suitable means of administration suitable for the particular route of administration chosen may be used.
Примеры возможных путей введения включают парентеральный (например, внутривенный (I. V., или IV), внутримышечный (IM), внутрикожный, подкожный (S. C., или SC) или инфузию), пероральный и легочный (например, ингаляцию), назальный, трансдермальный (местный), чресслизистый, внутриартериальный, непрерывную инфузию и ректальное введение. Растворы или суспензии, используемые для парентерального, внутрикожного или подкожного применения, могут содержать следующие компоненты: стерильный разбавитель, такой как вода для инъекции, солевой раствор, нелетучие масла, полиэтиленгликоли, глицерин, пропиленгликоль или другие синтетические растворители; антибактериальные средства, такие как бензиловый спирт или метилпарабены; антиоксиданты, такие как аскорбиновая кислота или бисульфит натрия; хелатирующие средства, такие как этилендиаминтетрауксусная кислота; буферы, такие как ацетаты, цитраты или фосфаты, и средства для регуляции тоничности, такие как хлорид натрия или декстроза. Показатель pH можно регулировать с помощью кислот или оснований, таких как хлористоводородная кислота или гидроксид натрия. Препарат для парентерального введения может быть герметично заключен в ампулы, одноразовые шприцы или многодозовые флаконы, изготовленные из стекла или пластика.Examples of possible routes of administration include parenteral (eg, intravenous (I.V., or IV), intramuscular (IM), intradermal, subcutaneous (S.C., or SC) or infusion), oral and pulmonary (eg, inhalation), nasal, transdermal (topical) , transmucosal, intra-arterial, continuous infusion and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous administration may contain the following components: a sterile diluent such as water for injection, saline, fixed oils, polyethylene glycols, glycerin, propylene glycol, or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates; and agents for the regulation of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases such as hydrochloric acid or sodium hydroxide. The parenteral formulation may be sealed in ampoules, disposable syringes or multi-dose vials made of glass or plastic.
Терапию с помощью апиразы можно начинать с введения "нагрузочной дозы" белков согласно настоящему изобретению субъекту, нуждающемуся в терапии. Под выражением "нагрузочная доза" подразумевается начальная доза белков согласно настоящему изобретению, которую вводят субъекту, где доза вводимых белков согласно настоящему изобретению находится в диапазоне более высоких доз. "Нагрузочную дозу" можно вводить в виде однократного введения, например, однократной инфузии, при которой белки вводят IV, или в виде многократных введений, например, многократных инфузий, при которых белки вводят IV, при условии, что полную "нагрузочную дозу" вводят в течение приблизительно 24-часового периода (или в течение первого месяца, если необходимо многократное внутривенное введение, что зависит от тяжести заболевания). После введения "нагрузочной дозы" субъекту затем вводят одну или несколько дополнительных терапевтически эффективных доз белков согласно настоящему изобретению. Последующие терапевтически эффективные дозы можно вводить, например, в соответствии с еженедельным режимом введения доз или один раз в две недели, один раз в три недели или один раз в четыре недели. В таких вариантах осуществления последующие терапевтически эффективные дозы, как правило, находятся в диапазоне более низких доз. Apyrase therapy can be initiated by administering a "loading dose" of the proteins of the present invention to a subject in need of therapy. By "loading dose" is meant the initial dose of proteins of the present invention that is administered to a subject where the dose of proteins of the present invention administered is in the higher dose range. The "loading dose" can be administered as a single administration, for example, a single infusion, in which the proteins are administered IV, or as multiple administrations, for example, multiple infusions, in which the proteins are administered IV, provided that the full "loading dose" is administered in over a period of approximately 24 hours (or within the first month if multiple intravenous injections are needed, depending on the severity of the disease). Following administration of a "loading dose", the subject is then administered one or more additional therapeutically effective doses of the proteins of the present invention. Subsequent therapeutically effective doses may be administered, for example, according to a weekly dosing regimen or once every two weeks, once every three weeks, or once every four weeks. In such embodiments, subsequent therapeutically effective doses are typically in the lower dose range.
В качестве альтернативы в некоторых вариантах осуществления после введения "нагрузочной дозы" последующие терапевтически эффективные дозы белка согласно настоящему изобретению вводят в соответствии с "поддерживающим режимом", где терапевтически эффективную дозу белков согласно настоящему изобретению вводят один раз в месяц, один раз в 6 недель, один раз в два месяца, один раз в 10 недель, один раз в три месяца, один раз в 14 недель, один раз в четыре месяца, один раз в 18 недель, один раз в пять месяцев, один раз в 22 недели, один раз в шесть месяцев, один раз в 7 месяцев, один раз в 8 месяцев, один раз в 9 месяцев, один раз в 10 месяцев, один раз в 11 месяцев или один раз в 12 месяцев. В таких вариантах осуществления терапевтически эффективные дозы белков согласно настоящему изобретению находятся в диапазоне более низких доз, в частности, в том случае, если последующие дозы вводят с более короткими интервалами, например, от одного раза в две недели до одного раза в месяц, или в диапазоне более высоких доз, в частности, в том случае, если последующие дозы вводят с более длительными интервалами, например, когда последующие дозы вводят с интервалом от одного месяца до 12 месяцев.Alternatively, in some embodiments, following the administration of a "loading dose", subsequent therapeutically effective doses of the protein of the present invention are administered according to a "maintenance regimen", wherein the therapeutically effective dose of the proteins of the present invention is administered once a month, once every 6 weeks, once every two months, once every 10 weeks, once every three months, once every 14 weeks, once every four months, once every 18 weeks, once every five months, once every 22 weeks, once at six months, once every 7 months, once every 8 months, once every 9 months, once every 10 months, once every 11 months, or once every 12 months. In such embodiments, therapeutically effective doses of the proteins of the present invention are in the lower dose range, in particular if subsequent doses are administered at shorter intervals, for example, from once every two weeks to once a month, or in range of higher doses, in particular if subsequent doses are administered at longer intervals, for example when subsequent doses are administered at intervals of one month to 12 months.
Временные рамки введения доз, как правило, измеряют со дня введения первой дозы активного соединения, который также известен как "исходный уровень". Однако разные лечащие врачи используют различные способы наименования.The time frame for dosing is generally measured from the day the first dose of the active compound is administered, which is also known as "baseline". However, different physicians use different naming conventions.
Следует отметить, что неделя ноль некоторыми лечащими врачами может называться неделей 1, при этом день ноль некоторыми лечащими врачами может называться днем один. Таким образом, возможно, что разные врачи будут обозначать, например, дозу как подлежащую введению в течение недели 3/в день 21, в течение недели 3/в день 22, в течение недели 4/в день 21, в течение недели 4/в день 22, ссылаясь при этом на один и тот же режим введения доз. В целях обеспечения соответствия первая неделя введения доз будет называться в данном документе неделей 0, при этом первый день введения доз будет называться днем 1. Однако специалисту в данной области будет понятно, что этот способ наименования используется просто для обеспечения соответствия и не должен рассматриваться как ограничивающий, т. е. еженедельное введение доз представляет собой предоставление еженедельной дозы белка, вне зависимости от того, ссылается ли врач на конкретную неделю как на "неделю 1" или "неделю 2". Пример схем дозирования, указанных в данном документе, находится на фигурах 1 и 2. Следует понимать, что доза не обязательно должна предоставляться в точный момент времени, например, дозу, которая должна вводиться примерно в день 29, можно было бы предоставлять, например, в период от дня 24 до дня 34, например, в день 30, при условии, что она предоставляется в соответствующую неделю.It should be noted that week zero may be referred to as
Используемая в данном документе фраза "контейнер, содержащий достаточное количество белка для обеспечения возможности доставки [обозначенной дозы]" используется для обозначения того, что данный контейнер (например, флакон, ручка, шприц) размещает в себе объем белка (например, в качестве части фармацевтической композиции), который можно использовать для предоставления требуемой дозы. В качестве примера, если требуемая доза составляет 500 мг, то врач-клиницист может использовать 2 мл из контейнера, который содержит состав на основе белка с концентрацией 250 мг/мл, 1 мл из контейнера, который содержит состав на основе белка с концентрацией 500 мг/мл, 0,5 мл из контейнера, который содержит состав на основе белка с концентрацией 1000 мг/мл и т. д. В каждом таком случае эти контейнеры содержат достаточное количество белка для обеспечения возможности доставки требуемой дозы 500 мг.As used herein, the phrase "a container containing a sufficient amount of protein to allow delivery of the [designated dose]" is used to mean that a given container (e.g., vial, pen, syringe) accommodates a volume of protein (e.g., as part of a pharmaceutical composition) that can be used to provide the desired dose. As an example, if the required dose is 500 mg, then the clinician may use 2 ml from a container that contains a 250 mg/ml protein formulation, 1 ml from a container that contains a 500 mg protein formulation. /ml, 0.5 ml from a container that contains a 1000 mg/ml protein formulation, etc. In each such case, these containers contain sufficient protein to allow delivery of the required 500 mg dose.
Используемая в данном документе фраза "составленный в дозировке, обеспечивающей возможность доставки [обозначенной дозы] посредством [пути введения]" используется для обозначения того, что данная фармацевтическая композиция может использоваться для предоставления требуемой дозы белка посредством обозначенного пути введения (например, s. c. или i. v.). В качестве примера, если требуемая доза для подкожного введения составляет 500 мг, то врач-клиницист может использовать 2 мл состава на основе белка, имеющего концентрацию 250 мг/мл, 1 мл состава на основе белка, имеющего концентрацию 500 мг/мл, 0,5 мл состава на основе белка, имеющего концентрацию 1000 мг/мл, и т. д. В каждом таком случае эти составы на основе белка имеют достаточно высокую концентрацию для обеспечения возможности подкожной доставки белка. Подкожная доставка обычно требует доставки объемов, составляющих менее чем приблизительно 2 мл, предпочтительно объема, составляющего приблизительно 1 мл или меньше. Однако более высокие объемы можно доставлять в течение некоторого периода времени, используя, например, механизм пластыря/помпы.As used herein, the phrase "formulated at a dosage capable of delivering the [designated dose] via the [route of administration]" is used to indicate that the pharmaceutical composition can be used to deliver the desired dose of protein via the designated route of administration (e.g., s.c. or i.v.) . As an example, if the required dose for subcutaneous administration is 500 mg, then the clinician can use 2 ml of a protein-based formulation having a concentration of 250 mg/ml, 1 ml of a protein-based formulation having a concentration of 500 mg/ml, 0, 5 ml of a protein-based formulation having a concentration of 1000 mg/ml, etc. In each such case, these protein-based formulations are at a high enough concentration to allow subcutaneous delivery of the protein. Subcutaneous delivery typically requires delivery in volumes of less than about 2 ml, preferably a volume of about 1 ml or less. However, higher volumes can be delivered over a period of time using, for example, a patch/pump mechanism.
В данном документе раскрыто применение белка для изготовления лекарственного препарата для лечения повреждения тканей у пациента, где лекарственный препарат составлен с возможностью помещения в контейнеры, где каждый контейнер имеет достаточное количество белка для обеспечения возможности доставки по меньшей мере приблизительно 75 мг, 150 мг, 300 мг или 600 мг белка на единицу дозы.Disclosed herein is the use of a protein in the manufacture of a medicament for the treatment of tissue injury in a patient, wherein the medicament is formulated to be placed in containers where each container has sufficient protein to allow delivery of at least about 75 mg, 150 mg, 300 mg or 600 mg of protein per unit dose.
В данном документе раскрыто применение белка для изготовления лекарственного препарата для лечения повреждения тканей у пациента, где лекарственный препарат составлен в дозировке, обеспечивающей возможность системной доставки (например, i. v. или s. c. доставки) 75 мг, 150 мг, 300 мг или 600 мг белка на единицу дозы.This document discloses the use of a protein for the manufacture of a drug for the treatment of tissue damage in a patient, where the drug is formulated at a dosage that allows systemic delivery (for example, i.v. or s.c. delivery) of 75 mg, 150 mg, 300 mg or 600 mg of protein per unit doses.
18. Пример 17: наборы18. Example 17: Sets
Настоящее изобретение также охватывает наборы для лечения пациента с повреждением тканей (в зависимости от обстоятельств) с помощью белка. Такие наборы содержат белок (например, в жидкой или лиофилизированной форме) или фармацевтическую композицию, содержащую белок (описанный выше). Дополнительно такие наборы могут содержать средства для введения белка (например, шприц и флакон, предварительно заполненный шприц, предварительно заполненный шприц-ручку, пластырь/помпу) и инструкции по применению. В инструкциях может раскрываться предоставление пациенту белка в виде части конкретной схемы дозирования. Такие наборы могут также содержать дополнительные терапевтические средства (описанные выше) для лечения псориаза, например, для доставки в комбинации с герметично заключенным белком.The present invention also encompasses kits for treating a patient with tissue damage (as the case may be) with a protein. Such kits contain a protein (eg, in liquid or lyophilized form) or a pharmaceutical composition containing a protein (described above). Additionally, such kits may contain means for administering the protein (eg, syringe and vial, pre-filled syringe, pre-filled pen, patch/pump) and instructions for use. The instructions may disclose providing a protein to a patient as part of a particular dosing regimen. Such kits may also contain additional therapeutic agents (described above) for the treatment of psoriasis, for example, to be delivered in combination with a sealed protein.
Фраза "средства для введения" используется для обозначения любого доступного инструмента для системного введения лекарственного средства пациенту, в том числе без ограничения предварительно заполненного шприца, флакона и шприца, шприц-ручки, автоинжектора, капельницы и пакета для i. v. введения, помпы, пластыря/помпы и т. д. С помощью таких предметов пациент может самостоятельно вводить лекарственное средство (т. е. вводить лекарственное средство себе самостоятельно), или лекарственное средство может вводить лицо, обеспечивающее уход за пациентом, или врач.The phrase "administration means" is used to refer to any available device for the systemic administration of a drug to a patient, including, without limitation, a pre-filled syringe, vial and syringe, pen, auto-injector, dropper, and i. v. injection, pump, patch/pump, etc. With these items, the patient may self-administer the drug (i.e., self-administer the drug), or the drug may be administered by a caregiver or physician.
В данном документе раскрыты наборы для лечения пациента с повреждением тканей, содержащие: a) фармацевтическую композицию, содержащую терапевтически эффективное количество белка; b) средства для введения белка пациенту и c) инструкции, предусматривающие подкожное введение белка пациенту, нуждающемуся в этом.Disclosed herein are kits for treating a patient with tissue injury, comprising: a) a pharmaceutical composition containing a therapeutically effective amount of a protein; b) means for administering the protein to the patient; and c) instructions for administering the protein subcutaneously to a patient in need thereof.
ТАБЛИЦА ПОСЛЕДОВАТЕЛЬНОСТЕЙSEQUENCE TABLE
Аминокислотные и нуклеотидные последовательности, применимые для практического осуществления настоящего изобретения, раскрыты в таблице 34.Amino acid and nucleotide sequences applicable to the practice of the present invention are disclosed in Table 34.
--->--->
ПЕРЕЧЕНЬ ПОСЛЕДОВАТЕЛЬНОСТЕЙSEQUENCE LIST
<110> NOVARTIS AG<110> NOVARTIS AG
<120> СОЛЮБИЛИЗИРОВАННЫЕ АПИРАЗЫ, СПОСОБЫ И ПРИМЕНЕНИЕ<120> SOLUBILIZED APIRASES, METHODS AND USES
<130> PAT057510-EP-EPA<130> PAT057510-EP-EPA
<140> EP 18184269.1<140> EP 18184269.1
<141> 18.07.2018<141> 07/18/2018
<160> 253 <160> 253
<170> PatentIn версия 3.5<170> PatentIn version 3.5
<210> 1<210> 1
<211> 510<211> 510
<212> БЕЛОК<212> PROTEIN
<213> Homo sapiens<213> Homo sapiens
<400> 1<400> 1
Met Glu Asp Thr Lys Glu Ser Asn Val Lys Thr Phe Cys Ser Lys Asn Met Glu Asp Thr Lys Glu Ser Asn Val Lys Thr Phe Cys Ser Lys Asn
1 5 10 15 1 5 10 15
Ile Leu Ala Ile Leu Gly Phe Ser Ser Ile Ile Ala Val Ile Ala Leu Ile Leu Ala Ile Leu Gly Phe Ser Ser Ile Ile Ala Val Ile Ala Leu
20 25 30 20 25 30
Leu Ala Val Gly Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Leu Ala Val Gly Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys
35 40 45 35 40 45
Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile
50 55 60 50 55 60
Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His Gln
65 70 75 80 65 70 75 80
Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln
85 90 95 85 90 95
Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala
100 105 110 100 105 110
Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu
115 120 125 115 120 125
Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu
130 135 140 130 135 140
Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro
145 150 155 160 145 150 155 160
Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala
165 170 175 165 170 175
Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys
180 185 190 180 185 190
Thr Arg Trp Phe Ser Ile Val Pro Tyr Glu Thr Asn Asn Gln Glu Thr Thr Arg Trp Phe Ser Ile Val Pro Tyr Glu Thr Asn Asn Gln Glu Thr
195 200 205 195 200 205
Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val
210 215 220 210 215 220
Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg
225 230 235 240 225 230 235 240
Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr
245 250 255 245 250 255
Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val
260 265 270 260 265 270
Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys
275 280 285 275 280 285
Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg
290 295 300 290 295 300
Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly
305 310 315 320 305 310 315 320
Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser
325 330 335 325 330 335
Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro
340 345 350 340 345 350
Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys
355 360 365 355 360 365
Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu
370 375 380 370 375 380
Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser
385 390 395 400 385 390 395 400
Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly
405 410 415 405 410 415
Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp
420 425 430 420 425 430
Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala
435 440 445 435 440 445
Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala
450 455 460 450 455 460
Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Tyr Val Phe Leu Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Tyr Val Phe Leu
465 470 475 480 465 470 475 480
Met Val Leu Phe Ser Leu Val Leu Phe Thr Val Ala Ile Ile Gly Leu Met Val Leu Phe Ser Leu Val Leu Phe Thr Val Ala Ile Ile Gly Leu
485 490 495 485 490 495
Leu Ile Phe His Lys Pro Ser Tyr Phe Trp Lys Asp Met Val Leu Ile Phe His Lys Pro Ser Tyr Phe Trp Lys Asp Met Val
500 505 510 500 505 510
<210> 2<210> 2
<211> 511<211> 511
<212> БЕЛОК<212> PROTEIN
<213> Rattus norvegicus<213> Rattus norvegicus
<400> 2<400> 2
Met Glu Asp Ile Lys Asp Ser Lys Val Lys Arg Phe Cys Ser Lys Asn Met Glu Asp Ile Lys Asp Ser Lys Val Lys Arg Phe Cys Ser Lys Asn
1 5 10 15 1 5 10 15
Ile Leu Ile Ile Leu Gly Phe Ser Ser Val Leu Ala Val Ile Ala Leu Ile Leu Ile Ile Leu Gly Phe Ser Ser Val Leu Ala Val Ile Ala Leu
20 25 30 20 25 30
Ile Ala Val Gly Leu Thr His Asn Lys Pro Leu Pro Glu Asn Val Lys Ile Ala Val Gly Leu Thr His Asn Lys Pro Leu Pro Glu Asn Val Lys
35 40 45 35 40 45
Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Asn Leu Tyr Ile Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Asn Leu Tyr Ile
50 55 60 50 55 60
Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val Gln Leu Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val Gln Leu
65 70 75 80 65 70 75 80
Leu Glu Glu Cys Gln Val Lys Gly Pro Gly Ile Ser Lys Tyr Ala Gln Leu Glu Glu Cys Gln Val Lys Gly Pro Gly Ile Ser Lys Tyr Ala Gln
85 90 95 85 90 95
Lys Thr Asp Glu Ile Ala Ala Tyr Leu Ala Glu Cys Met Lys Met Ser Lys Thr Asp Glu Ile Ala Ala Tyr Leu Ala Glu Cys Met Lys Met Ser
100 105 110 100 105 110
Thr Glu Arg Ile Pro Ala Ser Lys Gln His Gln Thr Pro Val Tyr Leu Thr Glu Arg Ile Pro Ala Ser Lys Gln His Gln Thr Pro Val Tyr Leu
115 120 125 115 120 125
Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Lys Gln Ser Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Lys Gln Ser
130 135 140 130 135 140
Ala Asp Glu Val Leu Ala Ala Val Ser Arg Ser Leu Lys Ser Tyr Pro Ala Asp Glu Val Leu Ala Ala Val Ser Arg Ser Leu Lys Ser Tyr Pro
145 150 155 160 145 150 155 160
Phe Asp Phe Gln Gly Ala Lys Ile Ile Thr Gly Gln Glu Glu Gly Ala Phe Asp Phe Gln Gly Ala Lys Ile Ile Thr Gly Gln Glu Glu Gly Ala
165 170 175 165 170 175
Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Arg Phe Thr Gln Glu Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Arg Phe Thr Gln Glu
180 185 190 180 185 190
Gln Ser Trp Leu Asn Phe Ile Ser Asp Ser Gln Lys Gln Ala Thr Phe Gln Ser Trp Leu Asn Phe Ile Ser Asp Ser Gln Lys Gln Ala Thr Phe
195 200 205 195 200 205
Gly Ala Leu Asp Leu Gly Gly Ser Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ser Ser Thr Gln Val Thr Phe Val Pro
210 215 220 210 215 220
Leu Asn Gln Thr Leu Glu Ala Pro Glu Thr Ser Leu Gln Phe Arg Leu Leu Asn Gln Thr Leu Glu Ala Pro Glu Thr Ser Leu Gln Phe Arg Leu
225 230 235 240 225 230 235 240
Tyr Gly Thr Asp Tyr Thr Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Thr Asp Tyr Thr Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
245 250 255 245 250 255
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Gln Asp Ile Gln Val Ser Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Gln Asp Ile Gln Val Ser
260 265 270 260 265 270
Ser Gly Gly Ile Leu Lys Asp Pro Cys Phe Tyr Pro Gly Tyr Lys Lys Ser Gly Gly Ile Leu Lys Asp Pro Cys Phe Tyr Pro Gly Tyr Lys Lys
275 280 285 275 280 285
Val Val Asn Val Ser Glu Leu Tyr Gly Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Glu Leu Tyr Gly Thr Pro Cys Thr Lys Arg Phe
290 295 300 290 295 300
Glu Lys Lys Leu Pro Phe Asn Gln Phe Gln Val Gln Gly Thr Gly Asp Glu Lys Lys Leu Pro Phe Asn Gln Phe Gln Val Gln Gly Thr Gly Asp
305 310 315 320 305 310 315 320
Tyr Glu Gln Cys His Gln Ser Ile Leu Lys Phe Phe Asn Asn Ser His Tyr Glu Gln Cys His Gln Ser Ile Leu Lys Phe Phe Asn Asn Ser His
325 330 335 325 330 335
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Val Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Val Phe Leu Pro Pro Leu
340 345 350 340 345 350
Gln Gly Ser Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Asp Phe Gln Gly Ser Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Asp Phe
355 360 365 355 360 365
Phe Lys Lys Met Ala Asn Asp Ser Val Ser Ser Gln Glu Lys Met Thr Phe Lys Lys Met Ala Asn Asp Ser Val Ser Ser Gln Glu Lys Met Thr
370 375 380 370 375 380
Glu Ile Thr Lys Asn Phe Cys Ser Lys Pro Trp Glu Glu Val Lys Ala Glu Ile Thr Lys Asn Phe Cys Ser Lys Pro Trp Glu Glu Val Lys Ala
385 390 395 400 385 390 395 400
Ser Tyr Pro Thr Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Ser Tyr Pro Thr Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser
405 410 415 405 410 415
Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr Asn Phe Thr Gly Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr Asn Phe Thr Gly
420 425 430 420 425 430
Thr Ser Trp Asp Gln Ile His Phe Met Gly Lys Ile Lys Asp Ser Asn Thr Ser Trp Asp Gln Ile His Phe Met Gly Lys Ile Lys Asp Ser Asn
435 440 445 435 440 445
Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro
450 455 460 450 455 460
Ala Glu Gln Pro Leu Ser Pro Pro Leu Pro His Ser Thr Tyr Ile Ser Ala Glu Gln Pro Leu Ser Pro Pro Leu Pro His Ser Thr Tyr Ile Ser
465 470 475 480 465 470 475 480
Leu Met Val Leu Phe Ser Leu Val Leu Val Ala Met Val Ile Thr Gly Leu Met Val Leu Phe Ser Leu Val Leu Val Ala Met Val Ile Thr Gly
485 490 495 485 490 495
Leu Phe Ile Phe Ser Lys Pro Ser Tyr Phe Trp Lys Glu Ala Val Leu Phe Ile Phe Ser Lys Pro Ser Tyr Phe Trp Lys Glu Ala Val
500 505 510 500 505 510
<210> 3<210> 3
<211> 441<211> 441
<212> БЕЛОК<212> PROTEIN
<213> Homo sapiens<213> Homo sapiens
<400> 3<400> 3
Gln Ile His Lys Gln Glu Val Leu Pro Pro Gly Leu Lys Tyr Gly Ile Gln Ile His Lys Gln Glu Val Leu Pro Pro Gly Leu Lys Tyr Gly Ile
1 5 10 15 1 5 10 15
Val Leu Asp Ala Gly Ser Ser Arg Thr Thr Val Tyr Val Tyr Gln Trp Val Leu Asp Ala Gly Ser Ser Arg Thr Thr Val Tyr Val Tyr Gln Trp
20 25 30 20 25 30
Pro Ala Glu Lys Glu Asn Asn Thr Gly Val Val Ser Gln Thr Phe Lys Pro Ala Glu Lys Glu Asn Asn Thr Gly Val Val Ser Gln Thr Phe Lys
35 40 45 35 40 45
Cys Ser Val Lys Gly Ser Gly Ile Ser Ser Tyr Gly Asn Asn Pro Gln Cys Ser Val Lys Gly Ser Gly Ile Ser Ser Tyr Gly Asn Asn Pro Gln
50 55 60 50 55 60
Asp Val Pro Arg Ala Phe Glu Glu Cys Met Gln Lys Val Lys Gly Gln Asp Val Pro Arg Ala Phe Glu Glu Cys Met Gln Lys Val Lys Gly Gln
65 70 75 80 65 70 75 80
Val Pro Ser His Leu His Gly Ser Thr Pro Ile His Leu Gly Ala Thr Val Pro Ser His Leu His Gly Ser Thr Pro Ile His Leu Gly Ala Thr
85 90 95 85 90 95
Ala Gly Met Arg Leu Leu Arg Leu Gln Asn Glu Thr Ala Ala Asn Glu Ala Gly Met Arg Leu Leu Arg Leu Gln Asn Glu Thr Ala Ala Asn Glu
100 105 110 100 105 110
Val Leu Glu Ser Ile Gln Ser Tyr Phe Lys Ser Gln Pro Phe Asp Phe Val Leu Glu Ser Ile Gln Ser Tyr Phe Lys Ser Gln Pro Phe Asp Phe
115 120 125 115 120 125
Arg Gly Ala Gln Ile Ile Ser Gly Gln Glu Glu Gly Val Tyr Gly Trp Arg Gly Ala Gln Ile Ile Ser Gly Gln Glu Glu Gly Val Tyr Gly Trp
130 135 140 130 135 140
Ile Thr Ala Asn Tyr Leu Met Gly Asn Phe Leu Glu Lys Asn Leu Trp Ile Thr Ala Asn Tyr Leu Met Gly Asn Phe Leu Glu Lys Asn Leu Trp
145 150 155 160 145 150 155 160
His Met Trp Val His Pro His Gly Val Glu Thr Thr Gly Ala Leu Asp His Met Trp Val His Pro His Gly Val Glu Thr Thr Gly Ala Leu Asp
165 170 175 165 170 175
Leu Gly Gly Ala Ser Thr Gln Ile Ser Phe Val Ala Gly Glu Lys Met Leu Gly Gly Ala Ser Thr Gln Ile Ser Phe Val Ala Gly Glu Lys Met
180 185 190 180 185 190
Asp Leu Asn Thr Ser Asp Ile Met Gln Val Ser Leu Tyr Gly Tyr Val Asp Leu Asn Thr Ser Asp Ile Met Gln Val Ser Leu Tyr Gly Tyr Val
195 200 205 195 200 205
Tyr Thr Leu Tyr Thr His Ser Phe Gln Cys Tyr Gly Arg Asn Glu Ala Tyr Thr Leu Tyr Thr His Ser Phe Gln Cys Tyr Gly Arg Asn Glu Ala
210 215 220 210 215 220
Glu Lys Lys Phe Leu Ala Met Leu Leu Gln Asn Ser Pro Thr Lys Asn Glu Lys Lys Phe Leu Ala Met Leu Leu Gln Asn Ser Pro Thr Lys Asn
225 230 235 240 225 230 235 240
His Leu Thr Asn Pro Cys Tyr Pro Arg Asp Tyr Ser Ile Ser Phe Thr His Leu Thr Asn Pro Cys Tyr Pro Arg Asp Tyr Ser Ile Ser Phe Thr
245 250 255 245 250 255
Met Gly His Val Phe Asp Ser Leu Cys Thr Val Asp Gln Arg Pro Glu Met Gly His Val Phe Asp Ser Leu Cys Thr Val Asp Gln Arg Pro Glu
260 265 270 260 265 270
Ser Tyr Asn Pro Asn Asp Val Ile Thr Phe Glu Gly Thr Gly Asp Pro Ser Tyr Asn Pro Asn Asp Val Ile Thr Phe Glu Gly Thr Gly Asp Pro
275 280 285 275 280 285
Ser Leu Cys Lys Glu Lys Val Ala Ser Ile Phe Asp Phe Lys Ala Cys Ser Leu Cys Lys Glu Lys Val Ala Ser Ile Phe Asp Phe Lys Ala Cys
290 295 300 290 295 300
His Asp Gln Glu Thr Cys Ser Phe Asp Gly Val Tyr Gln Pro Lys Ile His Asp Gln Glu Thr Cys Ser Phe Asp Gly Val Tyr Gln Pro Lys Ile
305 310 315 320 305 310 315 320
Lys Gly Pro Phe Val Ala Phe Ala Gly Phe Tyr Tyr Thr Ala Ser Ala Lys Gly Pro Phe Val Ala Phe Ala Gly Phe Tyr Tyr Thr Ala Ser Ala
325 330 335 325 330 335
Leu Asn Leu Ser Gly Ser Phe Ser Leu Asp Thr Phe Asn Ser Ser Thr Leu Asn Leu Ser Gly Ser Phe Ser Leu Asp Thr Phe Asn Ser Ser Thr
340 345 350 340 345 350
Trp Asn Phe Cys Ser Gln Asn Trp Ser Gln Leu Pro Leu Leu Leu Pro Trp Asn Phe Cys Ser Gln Asn Trp Ser Gln Leu Pro Leu Leu Leu Pro
355 360 365 355 360 365
Lys Phe Asp Glu Val Tyr Ala Arg Ser Tyr Cys Phe Ser Ala Asn Tyr Lys Phe Asp Glu Val Tyr Ala Arg Ser Tyr Cys Phe Ser Ala Asn Tyr
370 375 380 370 375 380
Ile Tyr His Leu Phe Val Asn Gly Tyr Lys Phe Thr Glu Glu Thr Trp Ile Tyr His Leu Phe Val Asn Gly Tyr Lys Phe Thr Glu Glu Thr Trp
385 390 395 400 385 390 395 400
Pro Gln Ile His Phe Glu Lys Glu Val Gly Asn Ser Ser Ile Ala Trp Pro Gln Ile His Phe Glu Lys Glu Val Gly Asn Ser Ser Ile Ala Trp
405 410 415 405 410 415
Ser Leu Gly Tyr Met Leu Ser Leu Thr Asn Gln Ile Pro Ala Glu Ser Ser Leu Gly Tyr Met Leu Ser Leu Thr Asn Gln Ile Pro Ala Glu Ser
420 425 430 420 425 430
Pro Leu Ile Arg Leu Pro Ile Glu Pro Pro Leu Ile Arg Leu Pro Ile Glu Pro
435 440 435 440
<210> 4<210> 4
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 4<400> 4
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 5<210> 5
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 5<400> 5
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140
accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 6<210> 6
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 6<400> 6
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Met Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Met Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 7<210> 7
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 7<400> 7
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccatgga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccatgga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140
accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 8<210> 8
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 8<400> 8
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Met Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Met Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Met Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Met
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 9<210> 9
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 9<400> 9
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccatgga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccatgga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgatggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgatggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccaaggcatc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccaaggcatc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140
accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 10<210> 10
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 10<400> 10
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Met Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Met Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Gly Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Gly Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Arg Thr Pro Leu Ser His Ser Thr Gln Pro Leu Arg Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 11<210> 11
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 11<400> 11
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccatgga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccatgga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agggattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agggattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140
accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgcgc 1260tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgcgc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 12<210> 12
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 12<400> 12
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Ala Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Ala Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Met Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Met Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Arg Thr Pro Leu Ser His Ser Thr Gln Pro Leu Arg Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 13<210> 13
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 13<400> 13
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgcgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgcgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccatgga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccatgga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140
accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagg 1260tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagg 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 14<210> 14
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 14<400> 14
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Met Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Met
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu His Ile His Phe Ile Asp Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Asp Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 15<210> 15
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 15<400> 15
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgatggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgatggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140
accgccgata gctgggagca catccacttc atcgacaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagca catccacttc atcgacaaga ttcagggcag cgacgccggc 1200
tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 16<210> 16
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 16<400> 16
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Ser Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Gly Ile Ser Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Met Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Met
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Arg Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Arg Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 17<210> 17
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 17<400> 17
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatctc cctgaccgac tgcatggaac gggccaggga agtgatcccc 240gtgaacgaga tcggcatctc cctgaccgac tgcatggaac gggccaggga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgatggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgatggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggaaaggac caggctctgc ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggctctgc ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140
accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 18<210> 18
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 18<400> 18
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Glu Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Glu Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Ser Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Gly Ile Tyr Leu Ser Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Ala Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Ala Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Thr Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Thr Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 19<210> 19
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 19<400> 19
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgagg aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgagg aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgtccgac tgcatggaac gggccaggga agtgatcccc 240gtgaacgaga tcggcatcta cctgtccgac tgcatggaac gggccaggga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg cggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg cggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcacc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcacc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140
accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 20<210> 20
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 20<400> 20
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Ala Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Ala Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 21<210> 21
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 21<400> 21
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgattccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgattccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg cggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg cggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggt aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggt aagttcagcc agaagaatca ggaaaccttc 480
ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtagtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtagtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
ccattccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840ccattccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140
accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 22<210> 22
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 22<400> 22
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Arg Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Arg Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 23<210> 23
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 23<400> 23
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggaaaggac caggctctga ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggctctga ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140
accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 24<210> 24
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 24<400> 24
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Thr Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Thr Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 25<210> 25
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 25<400> 25
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta tggaaaggac caggctctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta tggaaaggac caggctctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcacc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcacc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140
accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcctttgagc 1260tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcctttgagc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 26<210> 26
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 26<400> 26
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Met Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Met Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Thr Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Thr Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 27<210> 27
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 27<400> 27
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccatgga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccatgga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcacc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcacc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960
ctgaacctga ctagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ctagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140
accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 28<210> 28
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 28<400> 28
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Asp Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Asp Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Thr Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Thr Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 29<210> 29
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 29<400> 29
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga tatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga tatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcacc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcacc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140
accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 30<210> 30
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 30<400> 30
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Ser Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Ser Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Pro Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Pro Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 31<210> 31
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 31<400> 31
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctactccgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctactccgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgccgcaggg ctaccacttc 1140agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgccgcaggg ctaccacttc 1140
accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 32<210> 32
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 32<400> 32
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Ser Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Ser Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 33<210> 33
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 33<400> 33
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccttgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccttgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctactccgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctactccgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140
accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gttacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260tggacactgg gttacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 34<210> 34
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 34<400> 34
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Lys Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Lys Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Ser Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Ser Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Pro Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Pro Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Ser Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Ser Ala Glu
405 410 415 405 410 415
Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 35<210> 35
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 35<400> 35
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggaaaggac caggcgctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggcgctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaagg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgaagg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgccca tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgccca tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctactccgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctactccgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgccgcaggg ctaccacttc 1140agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgccgcaggg ctaccacttc 1140
accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gctacatgct gaatctgacc aacatgatct ccgccgagca gcccctgagc 1260tggacactgg gctacatgct gaatctgacc aacatgatct ccgccgagca gcccctgagc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 36<210> 36
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 36<400> 36
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Asn Glu Lys Tyr Leu Ser Glu Phe Cys Phe Ser Gly Thr Ala Gly Val Asn Glu Lys Tyr Leu Ser Glu Phe Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 37<210> 37
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 37<400> 37
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccaac cctgggagga aatcaagacc tcctacgctg gcgtgaacga gaagtacctg 1080tgcgcccaac cctgggagga aatcaagacc tcctacgctg gcgtgaacga gaagtacctg 1080
agcgagtttt gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140agcgagtttt gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140
accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 38<210> 38
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 38<400> 38
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Phe Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Phe Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 39<210> 39
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 39<400> 39
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagtttt gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140agcgagtttt gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140
accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 40<210> 40
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 40<400> 40
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Asp Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Asp Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Gln Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Gln Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 41<210> 41
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 41<400> 41
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcgacatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240gtgaacgaga tcgacatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgcagcaggg ctaccacttc 1140agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgcagcaggg ctaccacttc 1140
accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 42<210> 42
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 42<400> 42
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Gln Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Gln Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu Asp Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu Asp Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 43<210> 43
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 43<400> 43
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgcagcaggg ctaccacttc 1140agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgcagcaggg ctaccacttc 1140
accgccgata gctgggagga catccacttc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagga catccacttc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 44<210> 44
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 44<400> 44
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Gly Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Gly Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu His Ile His Ser Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Ser Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 45<210> 45
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 45<400> 45
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacgg gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacgg gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140
accgccgata gctgggagca catccactcc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagca catccactcc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 46<210> 46
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 46<400> 46
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Met Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Met Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Arg Thr Pro Leu Ser His Ser Thr Gln Pro Leu Arg Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 47<210> 47
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 47<400> 47
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccatgga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccatgga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140
accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgcgc 1260tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgcgc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 48<210> 48
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 48<400> 48
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Gly Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Gly Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Gly Thr Pro Leu Ser His Ser Thr Gln Pro Leu Gly Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 49<210> 49
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 49<400> 49
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacgg gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacgg gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140
accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gctacatgtt gaatctgacc aacatgatcc ccgccgagca gcccctgggc 1260tggacactgg gctacatgtt gaatctgacc aacatgatcc ccgccgagca gcccctgggc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 50<210> 50
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 50<400> 50
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Met Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Met Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Arg Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Arg Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu His Ile His Ser Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Ser Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Arg Thr Pro Leu Ser His Ser Thr Gln Pro Leu Arg Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 51<210> 51
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 51<400> 51
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttatgtgcta cggaaaggac caggctctga ggcagaagct ggccaaggac 660acccacagct ttatgtgcta cggaaaggac caggctctga ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgtacca agagattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgtacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140
accgccgata gctgggagca catccactcc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagca catccactcc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgaga 1260tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgaga 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 52<210> 52
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 52<400> 52
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Lys Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Lys Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Gln Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Gln Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu His Asn His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Asn His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 53<210> 53
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 53<400> 53
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaagga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaagga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgcagcaggg ctaccacttc 1140agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgcagcaggg ctaccacttc 1140
accgccgata gctgggagca caaccacttc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagca caaccacttc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 54<210> 54
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 54<400> 54
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Met Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Met Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Asn Glu Lys Tyr Leu Ser Glu Phe Cys Phe Ser Gly Thr Ala Gly Val Asn Glu Lys Tyr Leu Ser Glu Phe Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 55<210> 55
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 55<400> 55
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccatgga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccatgga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccaac cctgggagga aatcaagacc tcctacgctg gcgtgaacga gaagtacctg 1080tgcgcccaac cctgggagga aatcaagacc tcctacgctg gcgtgaacga gaagtacctg 1080
agcgagtttt gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140agcgagtttt gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140
accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 56<210> 56
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 56<400> 56
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Met Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Met Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Phe Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Phe Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 57<210> 57
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 57<400> 57
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccatgga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccatgga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg
acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagtttt gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140agcgagtttt gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140
accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 58<210> 58
<211> 430<211> 430
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 58<400> 58
Ala Pro Thr Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ala Pro Thr Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly
1 5 10 15 1 5 10 15
Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys
20 25 30 20 25 30
Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu
35 40 45 35 40 45
Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val
50 55 60 50 55 60
Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu
65 70 75 80 65 70 75 80
Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala
85 90 95 85 90 95
Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu Glu Leu Ala Asp
100 105 110 100 105 110
Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp
115 120 125 115 120 125
Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly
130 135 140 130 135 140
Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln
145 150 155 160 145 150 155 160
Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr
165 170 175 165 170 175
Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln
180 185 190 180 185 190
Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu
195 200 205 195 200 205
Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile
210 215 220 210 215 220
Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly
225 230 235 240 225 230 235 240
Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr
245 250 255 245 250 255
Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly
260 265 270 260 265 270
Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn
275 280 285 275 280 285
Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu
290 295 300 290 295 300
Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val
305 310 315 320 305 310 315 320
Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val
325 330 335 325 330 335
Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys
340 345 350 340 345 350
Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe
355 360 365 355 360 365
Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr
370 375 380 370 375 380
Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser
385 390 395 400 385 390 395 400
Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile
405 410 415 405 410 415
Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 430 420 425 430
<210> 59<210> 59
<211> 1290<211> 1290
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 59<400> 59
gcccctacca cccagaacaa ggccctgccc gagaacgtga agtacggcat cgtgctggac 60gcccctacca cccagaacaa ggccctgccc gagaacgtga agtacggcat cgtgctggac 60
gccggctcct cccacacctc cctgtacatc tacaagtggc ctgccgagaa agaaaacgac 120gccggctcct cccacacctc cctgtacatc tacaagtggc ctgccgagaa agaaaacgac 120
accggcgtgg tgcaccaagt ggaagagtgc agagtgaagg gccccggcat ctccaagttc 180accggcgtgg tgcaccaagt ggaaagtgc agagtgaagg gccccggcat ctccaagttc 180
gtgcagaaag tgaacgagat cggcatctac ctgaccgact gcatggaacg ggccagagaa 240gtgcagaaag tgaacgagat cggcatctac ctgaccgact gcatggaacg ggccagagaa 240
gtgatccctc ggtcccagca ccaggaaacc cctgtctacc tgggcgccac cgccggcatg 300gtgatccctc ggtcccagca cggaaacc cctgtctacc tgggcgccac cgccggcatg 300
cggctgctgc ggatggaatc cgaggaactg gccgaccggg tgctggacgt ggtggaacgg 360cggctgctgc ggatggaatc cgaggaactg gccgaccggg tgctggacgt ggtggaacgg 360
tccctgtcca actacccatt cgattttcaa ggcgccagaa tcatcaccgg ccaggaagag 420tccctgtcca actacccatt cgattttcaa ggcgccagaa tcatcaccgg cggaagag 420
ggcgcctacg gctggatcac catcaactac ctgctgggca agttctccca gaagaatcag 480ggcgcctacg gctggatcac catcaactac ctgctgggca agttctccca gaagaatcag 480
gaaaccttcg gcgccctgga cctgggcgga gccagcaccc aagtcacatt cgtgccccag 540gaaaccttcg gcgccctgga cctgggcgga gccagcaccc aagtcacatt cgtgccccag 540
aaccagacca tcgagagccc cgacaacgcc ctgcagttcc ggctgtacgg caaggactac 600aaccagacca tcgagagccc cgacaacgcc ctgcagttcc ggctgtacgg caaggactac 600
aacgtgtaca cccacagctt tctgtgctac ggcaaggacc aggccctgtg gcagaagctg 660aacgtgtaca cccacagctt tctgtgctac ggcaaggacc aggccctgtg gcagaagctg 660
gccaaggaca tccaagtggc ctccaacgag atcctgcggg acccctgctt ccaccccggc 720gccaaggaca tccaagtggc ctccaacgag atcctgcggg acccctgctt ccaccccggc 720
tacaagaaag tggtcaacgt gtccgacctg tacaagaccc cttgcaccaa gagattcgag 780tacaagaaag tggtcaacgt gtccgacctg tacaagaccc cttgcaccaa gagattcgag 780
atgaccctgc ccttccagca gttcgagatc cagggcatcg gcaactacca gcagtgccac 840atgaccctgc ccttccagca gttcgagatc cagggcatcg gcaactacca gcagtgccac 840
cagtccatcc tggaactgtt caacacctcc tactgcccct actcccagtg cgccttcaac 900cagtccatcc tggaactgtt caacacctcc tactgcccct actcccagtg cgccttcaac 900
ggcatcttcc tgcctccact gcagggcgac ttcggcgcct tctccgcctt ctacttcgtg 960ggcatcttcc tgcctccact gcagggcgac ttcggcgcct tctccgcctt ctacttcgtg 960
atgaagttcc tgaacctgac ctccgagaaa gtgtcccagg aaaaagtgac cgagatgatg 1020atgaagttcc tgaacctgac ctccgagaaa gtgtcccagg aaaaagtgac cgagatgatg 1020
aagaagttct gcgcccagcc ctgggaggaa atcaagacct cctacgctgg cgtgaaagag 1080aagaagttct gcgcccagcc ctgggaggaa atcaagacct cctacgctgg cgtgaaagag 1080
aagtacctgt ccgagtactg cttctccggc acctacatcc tgtccctgct gctgcagggc 1140aagtacctgt ccgagtactg cttctccggc acctacatcc tgtccctgct gctgcaggggc 1140
taccacttca ccgccgacag ctgggagcac atccacttca tcggcaagat ccagggatcc 1200taccacttca ccgccgacag ctgggagcac atccacttca tcggcaagat ccagggatcc 1200
gacgctggct ggaccctggg ctacatgctg aatctgacca acatgatccc cgccgagcag 1260gacgctggct ggaccctggg ctacatgctg aatctgacca acatgatccc cgccgagcag 1260
cccctgtcca cccctctgtc tcactccacc 1290cccctgtcca cccctctgtc tcactccacc 1290
<210> 60<210> 60
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 60<400> 60
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Ser Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Ser Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Phe Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Phe Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 61<210> 61
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 61<400> 61
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccttgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccttgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctactccgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctactccgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagtttt gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140agcgagtttt gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140
accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gttacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260tggacactgg gttacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 62<210> 62
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 62<400> 62
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Thr Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Thr Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Gln Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Gln Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu Asp Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu Asp Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 63<210> 63
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 63<400> 63
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcacc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcacc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgcagcaggg ctaccacttc 1140agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgcagcaggg ctaccacttc 1140
accgccgata gctgggagga catccacttc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagga catccacttc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 64<210> 64
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 64<400> 64
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Ser Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Ser Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Gln Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Gln Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 65<210> 65
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 65<400> 65
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccttgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccttgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctactccgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctactccgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgcagcaggg ctaccacttc 1140agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgcagcaggg ctaccacttc 1140
accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gttacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260tggacactgg gttacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 66<210> 66
<211> 442<211> 442
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 66<400> 66
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Thr Ser Ser Thr Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Thr Ser Ser Thr
1 5 10 15 1 5 10 15
Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Asp Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Asp
20 25 30 20 25 30
Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Glu Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Glu
35 40 45 35 40 45
Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Val Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Val
50 55 60 50 55 60
Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Gly Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Gly
65 70 75 80 65 70 75 80
Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Arg Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Arg
85 90 95 85 90 95
Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Met Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Met
100 105 110 100 105 110
Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Asp Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Asp
115 120 125 115 120 125
Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Ala Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Ala
130 135 140 130 135 140
Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ile Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ile
145 150 155 160 145 150 155 160
Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Gly Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Gly
165 170 175 165 170 175
Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gln Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gln
180 185 190 180 185 190
Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Tyr Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Tyr
195 200 205 195 200 205
Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Lys Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Lys
210 215 220 210 215 220
Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Ser Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Ser
225 230 235 240 225 230 235 240
Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Val Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Val
245 250 255 245 250 255
Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Glu Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Glu
260 265 270 260 265 270
Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Tyr Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Tyr
275 280 285 275 280 285
Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Cys Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Cys
290 295 300 290 295 300
Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Gln Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Gln
305 310 315 320 305 310 315 320
Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Leu Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Leu
325 330 335 325 330 335
Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Met Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Met
340 345 350 340 345 350
Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Ala Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Ala
355 360 365 355 360 365
Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Tyr Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Tyr
370 375 380 370 375 380
Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Trp Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Trp
385 390 395 400 385 390 395 400
Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp
405 410 415 405 410 415
Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Gln Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Gln
420 425 430 420 425 430
Pro Leu Ser Thr Pro Leu Ser His Ser Thr Pro Leu Ser Thr Pro Leu Ser His Ser Thr
435 440 435 440
<210> 67<210> 67
<211> 1326<211> 1326
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 67<400> 67
gcccctacca gcagcagcac caagaaaacc cagctgacca gcagcaccca gaacaaggcc 60gcccctacca gcagcagcac caagaaaacc cagctgacca gcagcaccca gaacaaggcc 60
ctgcccgaga acgtgaagta cggcatcgtg ctggatgccg gcagcagcca caccagcctg 120ctgccgaga acgtgaagta cggcatcgtg ctggatgccg gcagcagcca caccagcctg 120
tacatctaca agtggcctgc cgagaaagaa aacgacaccg gcgtggtgca tcaggtggaa 180tacatctaca agtggcctgc cgagaaagaa aacgacaccg gcgtggtgca tcaggtggaa 180
gagtgcagag tgaagggccc tggcatcagc aagttcgtgc agaaagtgaa cgagatcggc 240gagtgcagag tgaagggccc tggcatcagc aagttcgtgc agaaagtgaa cgagatcggc 240
atctacctga ccgactgcat ggaacgggcc agggaagtga tccccagaag ccagcaccag 300atctacctga ccgactgcat ggaacgggcc agggaagtga tccccagaag ccagcaccag 300
gaaacccccg tgtatctggg agccaccgcc ggcatgagac tgctgagaat ggaaagcgag 360gaaacccccg tgtatctggg agccaccgcc ggcatgagac tgctgagaat ggaaagcgag 360
gaactggccg accgggtgct ggacgtggtg gaaagaagcc tgagcaacta cccattcgat 420gaactggccg accgggtgct ggacgtggtg gaaagaagcc tgagcaacta cccattcgat 420
tttcaaggcg ccagaatcat caccggccag gaagaaggcg cctacggctg gatcaccatc 480tttcaaggcg ccagaatcat caccggccag gaagaaggcg cctacggctg gatcaccatc 480
aactacctgc tgggcaagtt cagccagaag aatcaggaaa ccttcggcgc cctggacctg 540aactacctgc tgggcaagtt cagccagaag aatcaggaaa ccttcggcgc cctggacctg 540
ggcggagctt ctacccaagt gaccttcgtg ccccagaatc agaccatcga gagccccgac 600ggcggagctt ctacccaagt gaccttcgtg ccccagaatc agaccatcga gagccccgac 600
aacgccctgc agttccggct gtacggcaag gactacaatg tgtacaccca cagctttctg 660aacgccctgc agttccggct gtacggcaag gactacaatg tgtacaccca cagctttctg 660
tgctacggaa aggaccaggc tctgtggcag aagctggcca aggacatcca ggtggccagc 720tgctacggaa aggaccaggc tctgtggcag aagctggcca aggacatcca ggtggccagc 720
aacgagatcc tgcgggaccc ttgcttccac cccggctaca agaaagtcgt gaacgtgtcc 780aacgagatcc tgcgggaccc ttgcttccac cccggctaca agaaagtcgt gaacgtgtcc 780
gacctgtaca agaccccctg caccaagaga ttcgagatga ccctgccctt ccagcagttc 840gacctgtaca agaccccctg caccaagaga ttcgagatga ccctgccctt ccagcagttc 840
gagatccagg gcatcggcaa ttaccagcag tgccaccaga gcatcctgga actgttcaac 900gagatccagg gcatcggcaa ttaccagcag tgccaccaga gcatcctgga actgttcaac 900
accagctact gcccctacag ccagtgcgcc ttcaacggca tcttcctgcc acctctgcag 960accagctact gcccctacag ccagtgcgcc ttcaacggca tcttcctgcc acctctgcag 960
ggggatttcg gcgccttcag cgccttctac ttcgtgatga agttcctgaa cctgaccagc 1020ggggatttcg gcgccttcag cgccttctac ttcgtgatga agttcctgaa cctgaccagc 1020
gagaaggtgt cccaggaaaa agtgacagag atgatgaaga agttctgcgc ccagccctgg 10801080
gaggaaatca agacctccta cgctggcgtg aaagagaagt acctgagcga gtactgcttc 1140gaggaaatca agacctccta cgctggcgtg aaagagaagt acctgagcga gtactgcttc 1140
agcggcacct acatcctgag cctgctgctg cagggctacc acttcaccgc cgatagctgg 1200agcggcacct acatcctgag cctgctgctg cagggctacc acttcaccgc cgatagctgg 1200
gagcacatcc acttcatcgg caagattcag ggcagcgacg ccggctggac actgggctac 1260gagcacatcc acttcatcgg caagattcag ggcagcgacg ccggctggac actgggctac 1260
atgctgaatc tgaccaacat gatccccgcc gagcagcccc tgagcacacc tctgagccac 1320atgctgaatc tgaccaacat gatccccgcc gagcagcccc tgagcacacc tctgagccac 1320
agcacc 1326agcacc 1326
<210> 68<210> 68
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 68<400> 68
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Phe Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Phe Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Gln Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Gln Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu Asp Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu Asp Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 69<210> 69
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 69<400> 69
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagtttt gcttcagcgg cacctacatc ctgagcctgc tgcagcaggg ctaccacttc 1140agcgagtttt gcttcagcgg cacctacatc ctgagcctgc tgcagcaggg ctaccacttc 1140
accgccgata gctgggagga catccacttc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagga catccacttc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 70<210> 70
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 70<400> 70
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Phe Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Phe Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Gln Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Gln Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 71<210> 71
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 71<400> 71
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagtttt gcttcagcgg cacctacatc ctgagcctgc tgcagcaggg ctaccacttc 1140agcgagtttt gcttcagcgg cacctacatc ctgagcctgc tgcagcaggg ctaccacttc 1140
accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 72<210> 72
<211> 443<211> 443
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 72<400> 72
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Thr Ser Ser Gly Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Thr Ser Ser Gly
1 5 10 15 1 5 10 15
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
20 25 30 20 25 30
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
35 40 45 35 40 45
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
50 55 60 50 55 60
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
65 70 75 80 65 70 75 80
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro
85 90 95 85 90 95
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
100 105 110 100 105 110
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
115 120 125 115 120 125
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
130 135 140 130 135 140
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
145 150 155 160 145 150 155 160
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
165 170 175 165 170 175
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
180 185 190 180 185 190
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
195 200 205 195 200 205
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
210 215 220 210 215 220
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
225 230 235 240 225 230 235 240
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
245 250 255 245 250 255
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
260 265 270 260 265 270
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn
275 280 285 275 280 285
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
290 295 300 290 295 300
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
305 310 315 320 305 310 315 320
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe
325 330 335 325 330 335
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
340 345 350 340 345 350
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
355 360 365 355 360 365
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr
370 375 380 370 375 380
Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser
385 390 395 400 385 390 395 400
Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
405 410 415 405 410 415
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
420 425 430 420 425 430
Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
435 440 435 440
<210> 73<210> 73
<211> 1329<211> 1329
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 73<400> 73
gcccctacct cctccagcac caagaaaacc cagctgacct ccagcggcac ccagaacaag 60gcccctacct ccctccagcac caagaaaacc cagctgacct ccagcggcac ccagaacaag 60
gccctgcccg agaacgtgaa gtacggcatc gtgctggacg ccggctcctc ccacacctcc 120gccctgcccg agaacgtgaa gtacggcatc gtgctggacg ccggctcctc ccacacctcc 120
ctgtacatct acaagtggcc tgccgagaaa gaaaacgaca ccggcgtggt gcaccaagtg 180ctgtacatct acaagtggcc tgccgagaaa gaaaacgaca ccggcgtggt gcaccaagtg 180
gaagagtgca gagtgaaggg ccccggcatc tccaagttcg tgcagaaagt gaacgagatc 240gaagagtgca gagtgaaggg ccccggcatc tccaagttcg tgcagaaagt gaacgagatc 240
ggcatctacc tgaccgactg catggaacgg gccagagaag tgatccctcg gtcccagcac 300ggcatctacc tgaccgactg catggaacgg gccagagaag tgatccctcg gtcccagcac 300
caggaaaccc ctgtctacct gggcgccacc gccggcatgc ggctgctgcg gatggaatcc 360caggaaaccc ctgtctacct gggcgccacc gccggcatgc ggctgctgcg gatggaatcc 360
gaggaactgg ccgaccgggt gctggacgtg gtggaacggt ccctgtccaa ctacccattc 420gaggaactgg ccgaccgggt gctggacgtg gtggaacggt ccctgtccaa ctacccattc 420
gattttcaag gcgccagaat catcaccggc caggaagagg gcgcctacgg ctggatcacc 480gattttcaag gcgccagaat catcaccggc caggaagagg gcgcctacgg ctggatcacc 480
atcaactacc tgctgggcaa gttctcccag aagaatcagg aaaccttcgg cgccctggac 540atcaactacc tgctgggcaa gttctcccag aagaatcagg aaaccttcgg cgccctggac 540
ctgggcggag ccagcaccca agtcacattc gtgccccaga accagaccat cgagagcccc 600ctgggcggag ccagcaccca agtcacattc gtgccccaga accagaccat cgagagcccc 600
gacaacgccc tgcagttccg gctgtacggc aaggactaca acgtgtacac ccacagcttt 660660
ctgtgctacg gcaaggacca ggccctgtgg cagaagctgg ccaaggacat ccaagtggcc 720ctgtgctacg gcaaggacca ggccctgtgg cagaagctgg ccaaggacat ccaagtggcc 720
tccaacgaga tcctgcggga cccctgcttc caccccggct acaagaaagt ggtcaacgtg 780tccaacgaga tcctgcggga cccctgcttc caccccggct acaagaaagt ggtcaacgtg 780
tccgacctgt acaagacccc ttgcaccaag agattcgaga tgaccctgcc cttccagcag 840tccgacctgt acaagacccc ttgcaccaag agattcgaga tgaccctgcc cttccagcag 840
ttcgagatcc agggcatcgg caactaccag cagtgccacc agtccatcct ggaactgttc 900ttcgagatcc agggcatcgg caactaccag cagtgccacc agtccatcct ggaactgttc 900
aacacctcct actgccccta ctcccagtgc gccttcaacg gcatcttcct gcctccactg 960aacacctcct actgccccta ctcccagtgc gccttcaacg gcatcttcct gcctccactg 960
cagggcgact tcggcgcctt ctccgccttc tacttcgtga tgaagttcct gaacctgacc 1020cagggcgact tcggcgcctt ctccgccttc tacttcgtga tgaagttcct gaacctgacc 1020
tccgagaaag tgtcccagga aaaagtgacc gagatgatga agaagttctg cgcccagccc 1080tccgagaaag tgtccgga aaaagtgacc
tgggaggaaa tcaagacctc ctacgctggc gtgaaagaga agtacctgtc cgagtactgc 1140tgggaggaaa tcaagacctc ctacgctggc gtgaaagaga agtacctgtc cgagtactgc 1140
ttctccggca cctacatcct gtccctgctg ctgcagggct accacttcac cgccgacagc 1200ttctccggca cctacatcct gtccctgctg ctgcaggggct accacttcac cgccgacagc 1200
tgggagcaca tccacttcat cggcaagatc cagggatccg acgctggctg gaccctgggc 1260tgggagcaca tccacttcat cggcaagatc cagggatccg acgctggctg gaccctgggc 1260
tacatgctga atctgaccaa catgatcccc gccgagcagc ccctgtccac ccctctgtct 1320tacatgctga atctgaccaa catgatcccc gccgagcagc ccctgtccac ccctctgtct 1320
cactccacc 1329cactccacc 1329
<210> 74<210> 74
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 74<400> 74
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Met Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Met Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Ser Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Ser Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Gln Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Gln Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 75<210> 75
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 75<400> 75
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccatgga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccatgga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctactccgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctactccgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgcagcaggg ctaccacttc 1140agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgcagcaggg ctaccacttc 1140
accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 76<210> 76
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 76<400> 76
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Met Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Met Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Phe Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Phe Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Gln Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Gln Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 77<210> 77
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 77<400> 77
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccatgga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccatgga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagttct gcttcagcgg cacctacatc ctgagcctgc tgcagcaggg ctaccacttc 1140agcgagttct gcttcagcgg cacctacatc ctgagcctgc tgcagcaggg ctaccacttc 1140
accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 78<210> 78
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 78<400> 78
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Met Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Met Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Ser Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Ser Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 79<210> 79
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 79<400> 79
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccatgga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccatgga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccttgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccttgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctactccgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctactccgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140
accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gttacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260tggacactgg gttacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 80<210> 80
<211> 433<211> 433
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 80<400> 80
Ala Pro Thr Ser Ser Ser Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Ala Pro Thr Ser Ser Ser Thr Gln Asn Lys Ala Leu Pro Glu Asn Val
1 5 10 15 1 5 10 15
Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr
20 25 30 20 25 30
Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His
35 40 45 35 40 45
Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val
50 55 60 50 55 60
Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg
65 70 75 80 65 70 75 80
Ala Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr Ala Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr
85 90 95 85 90 95
Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu
100 105 110 100 105 110
Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr
115 120 125 115 120 125
Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly
130 135 140 130 135 140
Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln
145 150 155 160 145 150 155 160
Lys Asn Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Lys Asn Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr
165 170 175 165 170 175
Gln Val Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Gln Val Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn
180 185 190 180 185 190
Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His
195 200 205 195 200 205
Ser Phe Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Ser Phe Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala
210 215 220 210 215 220
Lys Asp Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe Lys Asp Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe
225 230 235 240 225 230 235 240
His Pro Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr His Pro Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr
245 250 255 245 250 255
Pro Cys Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Pro Cys Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu
260 265 270 260 265 270
Ile Gln Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Ile Gln Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu
275 280 285 275 280 285
Leu Phe Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Leu Phe Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly
290 295 300 290 295 300
Ile Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Ile Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe
305 310 315 320 305 310 315 320
Tyr Phe Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Tyr Phe Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln
325 330 335 325 330 335
Glu Lys Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Lys Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu
340 345 350 340 345 350
Glu Ile Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Glu Ile Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu
355 360 365 355 360 365
Tyr Cys Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr Tyr Cys Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr
370 375 380 370 375 380
His Phe Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile His Phe Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile
385 390 395 400 385 390 395 400
Gln Gly Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Gln Gly Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr
405 410 415 405 410 415
Asn Met Ile Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Asn Met Ile Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser
420 425 430 420 425 430
Thr Thr
<210> 81<210> 81
<211> 1299<211> 1299
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 81<400> 81
gcccctacca gcagcagcac ccagaacaag gccctgcccg agaacgtgaa gtacggcatc 60gcccctacca gcagcagcac ccagaacaag gccctgcccg agaacgtgaa gtacggcatc 60
gtgctggatg ccggcagcag ccacaccagc ctgtacatct acaagtggcc tgccgagaaa 120gtgctggatg ccggcagcag ccacaccagc ctgtacatct acaagtggcc tgccgagaaa 120
gaaaacgaca ccggcgtggt gcatcaggtg gaagagtgca gagtgaaggg ccctggcatc 180gaaaacgaca ccggcgtggt gcatcaggtg gaagagtgca gagtgaaggg ccctggcatc 180
agcaagttcg tgcagaaagt gaacgagatc ggcatctacc tgaccgactg catggaacgg 240agcaagttcg tgcagaaagt gaacgagatc ggcatctacc tgaccgactg catggaacgg 240
gccagggaag tgatccccag aagccagcac caggaaaccc ccgtgtatct gggagccacc 300gccagggaag tgatccccag aagccagcac caggaaaccc ccgtgtatct gggagccacc 300
gccggcatga gactgctgag aatggaaagc gaggaactgg ccgaccgggt gctggacgtg 360gccggcatga gactgctgag aatggaaagc gaggaactgg ccgaccgggt gctggacgtg 360
gtggaaagaa gcctgagcaa ctacccattc gattttcaag gcgccagaat catcaccggc 420gtggaaagaa gcctgagcaa ctacccattc gattttcaag gcgccagaat catcaccggc 420
caggaagaag gcgcctacgg ctggatcacc atcaactacc tgctgggcaa gttcagccag 480caggaagaag gcgcctacgg ctggatcacc atcaactacc tgctgggcaa gttcagccag 480
aagaatcagg aaaccttcgg cgccctggac ctgggcggag cttctaccca agtgaccttc 540aagaatcagg aaaccttcgg cgccctggac ctgggcggag cttctaccca agtgaccttc 540
gtgccccaga atcagaccat cgagagcccc gacaacgccc tgcagttccg gctgtacggc 600gtgccccaga atcagaccat cgagagcccc gacaacgccc tgcagttccg gctgtacggc 600
aaggactaca atgtgtacac ccacagcttt ctgtgctacg gaaaggacca ggctctgtgg 660aaggactaca atgtgtacac ccacagcttt ctgtgctacg gaaaggacca ggctctgtgg 660
cagaagctgg ccaaggacat ccaggtggcc agcaacgaga tcctgcggga cccttgcttc 720cagaagctgg ccaaggacat ccaggtggcc agcaacgaga tcctgcggga cccttgcttc 720
caccccggct acaagaaagt cgtgaacgtg tccgacctgt acaagacccc ctgcaccaag 780caccccggct acaagaaagt cgtgaacgtg tccgacctgt acaagacccc ctgcaccaag 780
agattcgaga tgaccctgcc cttccagcag ttcgagatcc agggcatcgg caattaccag 840agattcgaga tgaccctgcc cttccagcag ttcgagatcc agggcatcgg caattaccag 840
cagtgccacc agagcatcct ggaactgttc aacaccagct actgccccta cagccagtgc 900cagtgccacc agagcatcct ggaactgttc aacaccagct actgccccta cagccagtgc 900
gccttcaacg gcatcttcct gccacctctg cagggggatt tcggcgcctt cagcgccttc 960gccttcaacg gcatcttcct gccacctctg cagggggatt tcggcgcctt cagcgccttc 960
tacttcgtga tgaagttcct gaacctgacc agcgagaagg tgtcccagga aaaagtgaca 1020tacttcgtga tgaagttcct gaacctgacc agcgagaagg tgtcccagga aaaagtgaca 1020
gagatgatga agaagttctg cgcccagccc tgggaggaaa tcaagacctc ctacgctggc 1080gagatgatga agaagttctg cgcccagccc tgggaggaaa tcaagacctc ctacgctggc 1080
gtgaaagaga agtacctgag cgagtactgc ttcagcggca cctacatcct gagcctgctg 1140gtgaaagaga agtacctgag cgagtactgc ttcagcggca cctacatcct gagcctgctg 1140
ctgcagggct accacttcac cgccgatagc tgggagcaca tccacttcat cggcaagatt 1200ctgcagggct accacttcac cgccgatagc tgggagcaca tccacttcat cggcaagatt 1200
cagggcagcg acgccggctg gacactgggc tacatgctga atctgaccaa catgatcccc 1260cagggcagcg acgccggctg gacactgggc tacatgctga atctgaccaa catgatcccc 1260
gccgagcagc ccctgagcac acctctgagc cacagcacc 1299gccgagcagc ccctgagcac acctctgagc cacagcacc 1299
<210> 82<210> 82
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 82<400> 82
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Ala Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Ala Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 83<210> 83
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 83<400> 83
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaagc cggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaagc cggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140
accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 84<210> 84
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 84<400> 84
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Ala Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Ala Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ala Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ala Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 85<210> 85
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 85<400> 85
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaagc cggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaagc cggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccctgg acctgggcgg agctgctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccctgg acctgggcgg agctgctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctacttcgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140
accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 86<210> 86
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 86<400> 86
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Gln Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Gln Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Ser Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Ser Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 87<210> 87
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 87<400> 87
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaacagga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaacagga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctactccgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctactccgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140
accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 88<210> 88
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 88<400> 88
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Ala Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Ala Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Ser Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Ser Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 89<210> 89
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 89<400> 89
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcaggcc 540ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcaggcc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctactccgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctactccgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140
accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 90<210> 90
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 90<400> 90
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Gln Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Gln Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Ser Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Ser Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 91<210> 91
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 91<400> 91
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgcagg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgcagg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctactccgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctactccgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140
accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 92<210> 92
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 92<400> 92
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Gln Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Gln Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Ser Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Ser Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 93<210> 93
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 93<400> 93
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tccagaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tccagaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctactccgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctactccgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140
accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 94<210> 94
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 94<400> 94
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Ser Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Ser Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Gln Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Gln Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 95<210> 95
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 95<400> 95
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctactccgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctactccgt gatgaagttc 960
ctgcagctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgcagctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140
accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260tggacactgg gctacatgct gaatctgacc aacatgatcc ccgccgagca gcccctgagc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 96<210> 96
<211> 427<211> 427
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 96<400> 96
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Ser Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Ser Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr
355 360 365 355 360 365
Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser
370 375 380 370 375 380
Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly
385 390 395 400 385 390 395 400
Trp Thr Leu Gly Tyr Met Leu Gln Leu Thr Asn Met Ile Pro Ala Glu Trp Thr Leu Gly Tyr Met Leu Gln Leu Thr Asn Met Ile Pro Ala Glu
405 410 415 405 410 415
Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 97<210> 97
<211> 1281<211> 1281
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 97<400> 97
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggaaaggac caggctctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcatc ggcaattacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctactccgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcgcct tctactccgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080tgcgcccagc cctgggagga aatcaagacc tcctacgctg gcgtgaaaga gaagtacctg 1080
agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140agcgagtact gcttcagcgg cacctacatc ctgagcctgc tgctgcaggg ctaccacttc 1140
accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200accgccgata gctgggagca catccacttc atcggcaaga ttcagggcag cgacgccggc 1200
tggacactgg gctacatgct gcagctgacc aacatgatcc ccgccgagca gcccctgagc 1260tggacactgg gctacatgct gcagctgacc aacatgatcc ccgccgagca gcccctgagc 1260
acacctctga gccacagcac c 1281acacctctga gccacagcac c 1281
<210> 98<210> 98
<211> 69<211> 69
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 98<400> 98
tgccctacga gacaaacaat caggaaacct tcggcgccct ggacctgggc ggagcttcta 60tgccctacga gacaaaccaat caggaaacct tcggcgccct ggacctgggc ggagcttcta 60
cccaagtga 69cccaagtga 69
<210> 99<210> 99
<211> 431<211> 431
<212> БЕЛОК<212> PROTEIN
<213> Homo sapiens<213> Homo sapiens
<400> 99<400> 99
Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Asp Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Asp
1 5 10 15 1 5 10 15
Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Glu Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Glu
20 25 30 20 25 30
Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Val Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Val
35 40 45 35 40 45
Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Gly Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Gly
50 55 60 50 55 60
Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Arg Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Arg
65 70 75 80 65 70 75 80
Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Met Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Met
85 90 95 85 90 95
Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Asp Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Asp
100 105 110 100 105 110
Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Ala Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Ala
115 120 125 115 120 125
Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ile Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ile
130 135 140 130 135 140
Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Thr Arg Trp Phe Ser Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Thr Arg Trp Phe Ser Ile
145 150 155 160 145 150 155 160
Val Pro Tyr Glu Thr Asn Asn Gln Glu Thr Phe Gly Ala Leu Asp Leu Val Pro Tyr Glu Thr Asn Asn Gln Glu Thr Phe Gly Ala Leu Asp Leu
165 170 175 165 170 175
Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gln Asn Gln Thr Ile Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gln Asn Gln Thr Ile
180 185 190 180 185 190
Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp Tyr
195 200 205 195 200 205
Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Lys Asp Gln Ala Leu Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Lys Asp Gln Ala Leu
210 215 220 210 215 220
Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Ser Asn Glu Ile Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Ser Asn Glu Ile Leu
225 230 235 240 225 230 235 240
Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Val Val Asn Val Ser Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Val Val Asn Val Ser
245 250 255 245 250 255
Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Glu Met Thr Leu Pro Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Glu Met Thr Leu Pro
260 265 270 260 265 270
Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Tyr Gln Gln Cys His Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Tyr Gln Gln Cys His
275 280 285 275 280 285
Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Cys Pro Tyr Ser Gln
290 295 300 290 295 300
Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly
305 310 315 320 305 310 315 320
Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Leu Asn Leu Thr Ser Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Leu Asn Leu Thr Ser
325 330 335 325 330 335
Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Met Lys Lys Phe Cys Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Met Lys Lys Phe Cys
340 345 350 340 345 350
Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Ala Gly Val Lys Glu Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Ala Gly Val Lys Glu
355 360 365 355 360 365
Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Tyr Ile Leu Ser Leu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Tyr Ile Leu Ser Leu
370 375 380 370 375 380
Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Trp Glu His Ile His Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Trp Glu His Ile His
385 390 395 400 385 390 395 400
Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Thr Leu Gly Tyr Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Thr Leu Gly Tyr
405 410 415 405 410 415
Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Gln Pro Leu Ser Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Gln Pro Leu Ser
420 425 430 420 425 430
<210> 100<210> 100
<211> 1293<211> 1293
<212> ДНК<212> DNA
<213> Homo sapiens<213> Homo sapiens
<400> 100<400> 100
cagaacaaag ccctgcccga gaacgtgaag tacggcatcg tgctggatgc cggcagcagc 60cagaacaaag ccctgcccga gaacgtgaag tacggcatcg tgctggatgc cggcagcagc 60
cacaccagcc tgtacatcta caagtggcct gccgagaaag aaaacgatac cggtgtcgtg 120cacaccagcc tgtacatcta caagtggcct gccgagaaag aaaacgatac cggtgtcgtg 120
caccaggtgg aagagtgcag agtgaagggc cctggcatca gcaagttcgt gcagaaagtg 180caccaggtgg aagagtgcag agtgaagggc cctggcatca gcaagttcgt gcagaaagtg 180
aacgagatcg gcatctacct gaccgactgc atggaacggg ccagagaagt gatccccaga 240aacgagatcg gcatctacct gaccgactgc atggaacggg ccagagaagt gatccccaga 240
agccagcacc aggaaacccc cgtgtacctg ggagccacag ccggcatgag actgctgcgg 300agccagcacc aggaaacccc cgtgtacctg ggagccacag ccggcatgag actgctgcgg 300
atggaaagcg aggaactggc cgacagagtg ctggacgtgg tggaaagaag cctgagcaac 360atggaaagcg aggaactggc cgacagagtg ctggacgtgg tggaaagaag cctgagcaac 360
tacccattcg attttcaagg ggccagaatc atcaccggcc aggaagaggg cgcttacggc 420tacccattcg attttcaagg ggccagaatc atcaccggcc aggaagaggg cgcttacggc 420
tggatcacca tcaactacct gctgggcaag ttcagccaga aaacccggtg gttcagcatc 480tggatcacca tcaactacct gctgggcaag ttcagccaga aaacccggtg gttcagcatc 480
gtgccctacg agacaaacaa tcaggaaacc ttcggagccc tggacctggg cggagcctct 540gtgccctacg agacaaacaa tcaggaaacc ttcggagccc tggacctggg cggagcctct 540
acccaagtga ccttcgtgcc ccagaatcag accatcgaga gccccgacaa cgccctgcag 600acccaagtga ccttcgtgcc ccagaatcag accatcgaga gccccgacaa cgccctgcag 600
ttccggctgt acggcaagga ctacaatgtg tacacccaca gctttctgtg ctacggaaag 660ttccggctgt acggcaagga ctacaatgtg tacacccaca gctttctgtg ctacggaaag 660
gaccaggccc tgtggcagaa gctggccaag gacatccagg tggccagcaa cgagatcctg 720gaccaggccc tgtggcagaa gctggccaag gacatccagg tggccagcaa cgagatcctg 720
cgggaccctt gcttccaccc cggctacaag aaagtcgtga acgtgtccga cctgtacaag 780cgggaccctt gcttccaccc cggctacaag aaagtcgtga acgtgtccga cctgtacaag 780
accccctgca ccaagagatt cgagatgacc ctgcccttcc agcagttcga gatccagggc 840accccctgca ccaagagatt cgagatgacc ctgcccttcc agcagttcga gatccaggggc 840
atcggcaact accagcagtg ccaccagagc atcctggaac tgttcaacac cagctactgc 900atcggcaact accagcagtg ccaccagagc atcctggaac tgttcaacac cagctactgc 900
ccctacagcc agtgcgcctt caacggcatc ttcctgccac ctctgcaggg ggacttcggc 960ccctacagcc agtgcgcctt caacggcatc ttcctgccac ctctgcaggg ggacttcggc 960
gctttcagcg ccttctactt cgtgatgaag ttcctgaacc tgaccagcga gaaggtgtcc 1020gctttcagcg ccttctactt cgtgatgaag ttcctgaacc tgaccagcga gaaggtgtcc 1020
caggaaaaag tgacagagat gatgaagaag ttctgcgccc agccctggga ggaaatcaag 1080caggaaaaag tgacagagat gatgaagaag ttctgcgccc agccctggga ggaaatcaag 1080
acctcctacg ctggcgtgaa agagaagtac ctgagcgagt actgcttcag cggtacctac 1140acctcctacg ctggcgtgaa agagaagtac ctgagcgagt actgcttcag cggtacctac 1140
atcctgagcc tgctgctgca gggctaccac ttcaccgccg atagctggga gcacatccac 1200atcctgagcc tgctgctgca gggctaccac ttcaccgccg atagctggga gcacatccac 1200
ttcatcggca agattcaggg cagcgacgcc ggctggacac tgggctacat gctgaatctg 1260ttcatcggca agattcaggg cagcgacgcc ggctggacac tgggctacat gctgaatctg 1260
accaacatga tccccgccga gcagcccctg agc 1293accaacatga tccccgccga gcagcccctg agc 1293
<210> 101<210> 101
<211> 431<211> 431
<212> БЕЛОК<212> PROTEIN
<213> Homo sapiens<213> Homo sapiens
<400> 101<400> 101
Asn Val Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Asn Val Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser
1 5 10 15 1 5 10 15
Leu Tyr Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Leu Tyr Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val
20 25 30 20 25 30
Val His Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Val His Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys
35 40 45 35 40 45
Phe Val Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Phe Val Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met
50 55 60 50 55 60
Glu Arg Ala Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Glu Arg Ala Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro
65 70 75 80 65 70 75 80
Val Tyr Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Val Tyr Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser
85 90 95 85 90 95
Glu Glu Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Glu Glu Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser
100 105 110 100 105 110
Asn Tyr Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Asn Tyr Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu
115 120 125 115 120 125
Glu Gly Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Glu Gly Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe
130 135 140 130 135 140
Ser Gln Lys Thr Arg Trp Phe Ser Ile Val Pro Tyr Glu Thr Asn Asn Ser Gln Lys Thr Arg Trp Phe Ser Ile Val Pro Tyr Glu Thr Asn Asn
145 150 155 160 145 150 155 160
Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val
165 170 175 165 170 175
Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu
180 185 190 180 185 190
Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe
195 200 205 195 200 205
Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp
210 215 220 210 215 220
Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro
225 230 235 240 225 230 235 240
Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys
245 250 255 245 250 255
Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln
260 265 270 260 265 270
Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe
275 280 285 275 280 285
Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe
290 295 300 290 295 300
Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe
305 310 315 320 305 310 315 320
Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys
325 330 335 325 330 335
Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile
340 345 350 340 345 350
Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys
355 360 365 355 360 365
Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe
370 375 380 370 375 380
Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly
385 390 395 400 385 390 395 400
Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met
405 410 415 405 410 415
Ile Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Ile Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 430 420 425 430
<210> 102<210> 102
<211> 1293<211> 1293
<212> ДНК<212> DNA
<213> Homo sapiens<213> Homo sapiens
<400> 102<400> 102
aacgtgaagt acggcatcgt gctggatgcc ggcagcagcc acaccagcct gtacatctac 60aacgtgaagt acggcatcgt gctggatgcc ggcagcagcc acaccagcct gtacatctac 60
aagtggcctg ccgagaaaga aaacgatacc ggtgtcgtgc accaggtgga agagtgcaga 120aagtggcctg ccgagaaaga aaacgatacc ggtgtcgtgc accaggtgga agagtgcaga 120
gtgaagggcc ctggcatcag caagttcgtg cagaaagtga acgagatcgg catctacctg 180gtgaagggcc ctggcatcag caagttcgtg cagaaagtga acgagatcgg catctacctg 180
accgactgca tggaacgggc cagagaagtg atccccagaa gccagcacca ggaaaccccc 240accgactgca tggaacgggc cagagaagtg atccccagaa gccagcacca ggaaaccccc 240
gtgtacctgg gagccacagc cggcatgaga ctgctgcgga tggaaagcga ggaactggcc 300gtgtacctgg gagccacagc cggcatgaga ctgctgcgga tggaaagcga ggaactggcc 300
gacagagtgc tggacgtggt ggaaagaagc ctgagcaact acccattcga ttttcaaggg 360gacagagtgc tggacgtggt ggaaagaagc ctgagcaact acccattcga ttttcaaggg 360
gccagaatca tcaccggcca ggaagagggc gcttacggct ggatcaccat caactacctg 420gccagaatca tcaccggcca ggaagaggggc gcttacggct ggatcaccat caactacctg 420
ctgggcaagt tcagccagaa aacccggtgg ttcagcatcg tgccctacga gacaaacaat 480ctgggcaagt tcagccagaa aacccggtgg ttcagcatcg tgccctacga gacaaacaat 480
caggaaacct tcggagccct ggacctgggc ggagcctcta cccaagtgac cttcgtgccc 540caggaaacct tcggagccct ggacctgggc ggagcctcta cccaagtgac cttcgtgccc 540
cagaatcaga ccatcgagag ccccgacaac gccctgcagt tccggctgta cggcaaggac 600cagaatcaga ccatcgagag ccccgacaac gccctgcagt tccggctgta cggcaaggac 600
tacaatgtgt acacccacag ctttctgtgc tacggaaagg accaggccct gtggcagaag 660tacaatgtgt acacccacag ctttctgtgc tacggaaagg accaggccct gtggcagaag 660
ctggccaagg acatccaggt ggccagcaac gagatcctgc gggacccttg cttccacccc 720ctggccaagg acatccaggt ggccagcaac gagatcctgc gggacccttg cttccacccc 720
ggctacaaga aagtcgtgaa cgtgtccgac ctgtacaaga ccccctgcac caagagattc 780ggctacaaga aagtcgtgaa cgtgtccgac ctgtacaaga ccccctgcac caagagattc 780
gagatgaccc tgcccttcca gcagttcgag atccagggca tcggcaacta ccagcagtgc 840gagatgaccc tgcccttcca gcagttcgag atccagggca tcggcaacta ccagcagtgc 840
caccagagca tcctggaact gttcaacacc agctactgcc cctacagcca gtgcgccttc 900caccagagca tcctggaact gttcaacacc agctactgcc cctacagcca gtgcgccttc 900
aacggcatct tcctgccacc tctgcagggg gacttcggcg ctttcagcgc cttctacttc 960aacggcatct tcctgccacc tctgcagggg gacttcggcg ctttcagcgc cttctacttc 960
gtgatgaagt tcctgaacct gaccagcgag aaggtgtccc aggaaaaagt gacagagatg 1020gtgatgaagt tcctgaacct gaccagcgag aaggtgtccc aggaaaaagt gacagagatg 1020
atgaagaagt tctgcgccca gccctgggag gaaatcaaga cctcctacgc tggcgtgaaa 1080atgaagaagt tctgcgccca gccctgggag gaaatcaaga cctcctacgc tggcgtgaaa 1080
gagaagtacc tgagcgagta ctgcttcagc ggtacctaca tcctgagcct gctgctgcag 1140gagaagtacc tgagcgagta ctgcttcagc ggtacctaca tcctgagcct gctgctgcag 1140
ggctaccact tcaccgccga tagctgggag cacatccact tcatcggcaa gattcagggc 1200ggctaccact tcaccgccga tagctgggag cacatccact tcatcggcaa gattcaggggc 1200
agcgacgccg gctggacact gggctacatg ctgaatctga ccaacatgat ccccgccgag 1260agcgacgccg gctggacact gggctacatg ctgaatctga ccaacatgat ccccgccgag 1260
cagcccctga gcacacctct gtctcacagc acc 1293cagcccctga gcacacctct gtctcacagc acc 1293
<210> 103<210> 103
<211> 416<211> 416
<212> БЕЛОК<212> PROTEIN
<213> Homo sapiens<213> Homo sapiens
<400> 103<400> 103
Asn Val Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Asn Val Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser
1 5 10 15 1 5 10 15
Leu Tyr Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Leu Tyr Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val
20 25 30 20 25 30
Val His Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Val His Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys
35 40 45 35 40 45
Phe Val Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Phe Val Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met
50 55 60 50 55 60
Glu Arg Ala Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Glu Arg Ala Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro
65 70 75 80 65 70 75 80
Val Tyr Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Val Tyr Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser
85 90 95 85 90 95
Glu Glu Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Glu Glu Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser
100 105 110 100 105 110
Asn Tyr Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Asn Tyr Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu
115 120 125 115 120 125
Glu Gly Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Glu Gly Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe
130 135 140 130 135 140
Ser Gln Lys Thr Arg Trp Phe Ser Ile Val Pro Tyr Glu Thr Asn Asn Ser Gln Lys Thr Arg Trp Phe Ser Ile Val Pro Tyr Glu Thr Asn Asn
145 150 155 160 145 150 155 160
Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val
165 170 175 165 170 175
Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu
180 185 190 180 185 190
Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe
195 200 205 195 200 205
Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp
210 215 220 210 215 220
Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro
225 230 235 240 225 230 235 240
Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys
245 250 255 245 250 255
Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln
260 265 270 260 265 270
Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe
275 280 285 275 280 285
Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe
290 295 300 290 295 300
Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe
305 310 315 320 305 310 315 320
Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys
325 330 335 325 330 335
Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile
340 345 350 340 345 350
Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys
355 360 365 355 360 365
Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe
370 375 380 370 375 380
Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly
385 390 395 400 385 390 395 400
Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met
405 410 415 405 410 415
<210> 104<210> 104
<211> 1248<211> 1248
<212> ДНК<212> DNA
<213> Homo sapiens<213> Homo sapiens
<400> 104<400> 104
aacgtgaagt acggcatcgt gctggatgcc ggcagcagcc acaccagcct gtacatctac 60aacgtgaagt acggcatcgt gctggatgcc ggcagcagcc acaccagcct gtacatctac 60
aagtggcctg ccgagaaaga aaacgatacc ggtgtcgtgc accaggtgga agagtgcaga 120aagtggcctg ccgagaaaga aaacgatacc ggtgtcgtgc accaggtgga agagtgcaga 120
gtgaagggcc ctggcatcag caagttcgtg cagaaagtga acgagatcgg catctacctg 180gtgaagggcc ctggcatcag caagttcgtg cagaaagtga acgagatcgg catctacctg 180
accgactgca tggaacgggc cagagaagtg atccccagaa gccagcacca ggaaaccccc 240accgactgca tggaacgggc cagagaagtg atccccagaa gccagcacca ggaaaccccc 240
gtgtacctgg gagccacagc cggcatgaga ctgctgcgga tggaaagcga ggaactggcc 300gtgtacctgg gagccacagc cggcatgaga ctgctgcgga tggaaagcga ggaactggcc 300
gacagagtgc tggacgtggt ggaaagaagc ctgagcaact acccattcga ttttcaaggg 360gacagagtgc tggacgtggt ggaaagaagc ctgagcaact acccattcga ttttcaaggg 360
gccagaatca tcaccggcca ggaagagggc gcttacggct ggatcaccat caactacctg 420gccagaatca tcaccggcca ggaagaggggc gcttacggct ggatcaccat caactacctg 420
ctgggcaagt tcagccagaa aacccggtgg ttcagcatcg tgccctacga gacaaacaat 480ctgggcaagt tcagccagaa aacccggtgg ttcagcatcg tgccctacga gacaaacaat 480
caggaaacct tcggagccct ggacctgggc ggagcctcta cccaagtgac cttcgtgccc 540caggaaacct tcggagccct ggacctgggc ggagcctcta cccaagtgac cttcgtgccc 540
cagaatcaga ccatcgagag ccccgacaac gccctgcagt tccggctgta cggcaaggac 600cagaatcaga ccatcgagag ccccgacaac gccctgcagt tccggctgta cggcaaggac 600
tacaatgtgt acacccacag ctttctgtgc tacggaaagg accaggccct gtggcagaag 660tacaatgtgt acacccacag ctttctgtgc tacggaaagg accaggccct gtggcagaag 660
ctggccaagg acatccaggt ggccagcaac gagatcctgc gggacccttg cttccacccc 720ctggccaagg acatccaggt ggccagcaac gagatcctgc gggacccttg cttccacccc 720
ggctacaaga aagtcgtgaa cgtgtccgac ctgtacaaga ccccctgcac caagagattc 780ggctacaaga aagtcgtgaa cgtgtccgac ctgtacaaga ccccctgcac caagagattc 780
gagatgaccc tgcccttcca gcagttcgag atccagggca tcggcaacta ccagcagtgc 840gagatgaccc tgcccttcca gcagttcgag atccagggca tcggcaacta ccagcagtgc 840
caccagagca tcctggaact gttcaacacc agctactgcc cctacagcca gtgcgccttc 900caccagagca tcctggaact gttcaacacc agctactgcc cctacagcca gtgcgccttc 900
aacggcatct tcctgccacc tctgcagggg gacttcggcg ctttcagcgc cttctacttc 960aacggcatct tcctgccacc tctgcagggg gacttcggcg ctttcagcgc cttctacttc 960
gtgatgaagt tcctgaacct gaccagcgag aaggtgtccc aggaaaaagt gacagagatg 1020gtgatgaagt tcctgaacct gaccagcgag aaggtgtccc aggaaaaagt gacagagatg 1020
atgaagaagt tctgcgccca gccctgggag gaaatcaaga cctcctacgc tggcgtgaaa 1080atgaagaagt tctgcgccca gccctgggag gaaatcaaga cctcctacgc tggcgtgaaa 1080
gagaagtacc tgagcgagta ctgcttcagc ggtacctaca tcctgagcct gctgctgcag 1140gagaagtacc tgagcgagta ctgcttcagc ggtacctaca tcctgagcct gctgctgcag 1140
ggctaccact tcaccgccga tagctgggag cacatccact tcatcggcaa gattcagggc 1200ggctaccact tcaccgccga tagctgggag cacatccact tcatcggcaa gattcaggggc 1200
agcgacgccg gctggacact gggctacatg ctgaatctga ccaacatg 1248agcgacgccg gctggacact gggctacatg ctgaatctga ccaacatg 1248
<210> 105<210> 105
<211> 404<211> 404
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 105<400> 105
Asn Val Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Asn Val Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser
1 5 10 15 1 5 10 15
Leu Tyr Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Leu Tyr Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val
20 25 30 20 25 30
Val His Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Val His Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys
35 40 45 35 40 45
Phe Val Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Phe Val Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met
50 55 60 50 55 60
Glu Arg Ala Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Glu Arg Ala Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro
65 70 75 80 65 70 75 80
Val Tyr Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Val Tyr Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser
85 90 95 85 90 95
Glu Glu Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Glu Glu Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser
100 105 110 100 105 110
Asn Tyr Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Asn Tyr Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu
115 120 125 115 120 125
Glu Gly Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Glu Gly Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe
130 135 140 130 135 140
Ser Gln Lys Asn Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Gln Lys Asn Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala
145 150 155 160 145 150 155 160
Ser Thr Gln Val Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Ser Thr Gln Val Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro
165 170 175 165 170 175
Asp Asn Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Asp Asn Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr
180 185 190 180 185 190
Thr His Ser Phe Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Thr His Ser Phe Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys
195 200 205 195 200 205
Leu Ala Lys Asp Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Leu Ala Lys Asp Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro
210 215 220 210 215 220
Cys Phe His Pro Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Cys Phe His Pro Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr
225 230 235 240 225 230 235 240
Lys Thr Pro Cys Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Lys Thr Pro Cys Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln
245 250 255 245 250 255
Phe Glu Ile Gln Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Phe Glu Ile Gln Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile
260 265 270 260 265 270
Leu Glu Leu Phe Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Leu Glu Leu Phe Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe
275 280 285 275 280 285
Asn Gly Ile Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Asn Gly Ile Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser
290 295 300 290 295 300
Ala Phe Tyr Phe Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ala Phe Tyr Phe Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val
305 310 315 320 305 310 315 320
Ser Gln Glu Lys Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Ser Gln Glu Lys Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro
325 330 335 325 330 335
Trp Glu Glu Ile Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Trp Glu Glu Ile Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu
340 345 350 340 345 350
Ser Glu Tyr Cys Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Ser Glu Tyr Cys Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln
355 360 365 355 360 365
Gly Tyr His Phe Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Gly Tyr His Phe Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly
370 375 380 370 375 380
Lys Ile Gln Gly Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Lys Ile Gln Gly Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn
385 390 395 400 385 390 395 400
Leu Thr Asn Met Leu Thr Asn Met
<210> 106<210> 106
<211> 1212<211> 1212
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 106<400> 106
aacgtgaagt acggcatcgt gctggatgcc ggcagcagcc acaccagcct gtacatctac 60aacgtgaagt acggcatcgt gctggatgcc ggcagcagcc acaccagcct gtacatctac 60
aagtggcctg ccgagaaaga aaacgatacc ggtgtcgtgc accaggtgga agagtgcaga 120aagtggcctg ccgagaaaga aaacgatacc ggtgtcgtgc accaggtgga agagtgcaga 120
gtgaagggcc ctggcatcag caagttcgtg cagaaagtga acgagatcgg catctacctg 180gtgaagggcc ctggcatcag caagttcgtg cagaaagtga acgagatcgg catctacctg 180
accgactgca tggaacgggc cagagaagtg atccccagaa gccagcacca ggaaaccccc 240accgactgca tggaacgggc cagagaagtg atccccagaa gccagcacca ggaaaccccc 240
gtgtacctgg gagccacagc cggcatgaga ctgctgcgga tggaaagcga ggaactggcc 300gtgtacctgg gagccacagc cggcatgaga ctgctgcgga tggaaagcga ggaactggcc 300
gacagagtgc tggacgtggt ggaaagaagc ctgagcaact acccattcga ttttcaaggg 360gacagagtgc tggacgtggt ggaaagaagc ctgagcaact acccattcga ttttcaaggg 360
gccagaatca tcaccggcca ggaagagggc gcttacggct ggatcaccat caactacctg 420gccagaatca tcaccggcca ggaagaggggc gcttacggct ggatcaccat caactacctg 420
ctgggcaagt tcagccagaa aaatcaggaa accttcggag ccctggacct gggcggagcc 480ctgggcaagt tcagccagaa aaatcaggaa accttcggag ccctggacct gggcggagcc 480
tctacccaag tgaccttcgt gccccagaat cagaccatcg agagccccga caacgccctg 540tctacccaag tgaccttcgt gccccagaat cagaccatcg agagccccga caacgccctg 540
cagttccggc tgtacggcaa ggactacaat gtgtacaccc acagctttct gtgctacgga 600cagttccggc tgtacggcaa ggactacaat gtgtacaccc acagctttct gtgctacgga 600
aaggaccagg ccctgtggca gaagctggcc aaggacatcc aggtggccag caacgagatc 660aaggaccagg ccctgtggca gaagctggcc aaggacatcc aggtggccag caacgagatc 660
ctgcgggacc cttgcttcca ccccggctac aagaaagtcg tgaacgtgtc cgacctgtac 720ctgcgggacc cttgcttcca ccccggctac aagaaagtcg tgaacgtgtc cgacctgtac 720
aagaccccct gcaccaagag attcgagatg accctgccct tccagcagtt cgagatccag 780aagaccccct gcaccaagag attcgagatg accctgccct tccagcagtt cgagatccag 780
ggcatcggca actaccagca gtgccaccag agcatcctgg aactgttcaa caccagctac 840ggcatcggca actaccagca gtgccaccag agcatcctgg aactgttcaa caccagctac 840
tgcccctaca gccagtgcgc cttcaacggc atcttcctgc cacctctgca gggggacttc 900tgcccctaca gccagtgcgc cttcaacggc atcttcctgc cacctctgca gggggacttc 900
ggcgctttca gcgccttcta cttcgtgatg aagttcctga acctgaccag cgagaaggtg 960ggcgctttca gcgccttcta cttcgtgatg aagttcctga acctgaccag cgagaaggtg 960
tcccaggaaa aagtgacaga gatgatgaag aagttctgcg cccagccctg ggaggaaatc 1020tccaggaaa aagtgacaga gatgatgaag aagttctgcg cccagccctg ggaggaaatc 1020
aagacctcct acgctggcgt gaaagagaag tacctgagcg agtactgctt cagcggtacc 1080aagacctcct acgctggcgt gaaagagaag tacctgagcg agtactgctt cagcggtacc 1080
tacatcctga gcctgctgct gcagggctac cacttcaccg ccgatagctg ggagcacatc 1140tacatcctga gcctgctgct gcagggctac cacttcaccg ccgatagctg ggagcacatc 1140
cacttcatcg gcaagattca gggcagcgac gccggctgga cactgggcta catgctgaat 1200cacttcatcg gcaagattca gggcagcgac gccggctgga cactgggcta catgctgaat 1200
ctgaccaaca tg 1212ctgaccaaca tg 1212
<210> 107<210> 107
<211> 416<211> 416
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 107<400> 107
Asn Val Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Asn Val Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser
1 5 10 15 1 5 10 15
Leu Tyr Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Leu Tyr Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val
20 25 30 20 25 30
Val His Gln Val Glu Glu Ala Arg Val Lys Gly Pro Gly Ile Ser Lys Val His Gln Val Glu Glu Ala Arg Val Lys Gly Pro Gly Ile Ser Lys
35 40 45 35 40 45
Phe Val Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Ala Met Phe Val Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Ala Met
50 55 60 50 55 60
Glu Arg Ala Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Glu Arg Ala Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro
65 70 75 80 65 70 75 80
Val Tyr Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Val Tyr Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser
85 90 95 85 90 95
Glu Glu Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Glu Glu Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser
100 105 110 100 105 110
Asn Tyr Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Asn Tyr Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu
115 120 125 115 120 125
Glu Gly Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Glu Gly Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe
130 135 140 130 135 140
Ser Gln Lys Thr Arg Trp Phe Ser Ile Val Pro Tyr Glu Thr Asn Asn Ser Gln Lys Thr Arg Trp Phe Ser Ile Val Pro Tyr Glu Thr Asn Asn
145 150 155 160 145 150 155 160
Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val
165 170 175 165 170 175
Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu
180 185 190 180 185 190
Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe
195 200 205 195 200 205
Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp
210 215 220 210 215 220
Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro
225 230 235 240 225 230 235 240
Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys
245 250 255 245 250 255
Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln
260 265 270 260 265 270
Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe
275 280 285 275 280 285
Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe
290 295 300 290 295 300
Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe
305 310 315 320 305 310 315 320
Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys
325 330 335 325 330 335
Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile
340 345 350 340 345 350
Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys
355 360 365 355 360 365
Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe
370 375 380 370 375 380
Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly
385 390 395 400 385 390 395 400
Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met
405 410 415 405 410 415
<210> 108<210> 108
<211> 1248<211> 1248
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 108<400> 108
aacgtgaagt acggcatcgt gctggatgcc ggcagcagcc acaccagcct gtacatctac 60aacgtgaagt acggcatcgt gctggatgcc ggcagcagcc acaccagcct gtacatctac 60
aagtggcctg ccgagaaaga aaacgatacc ggtgtcgtgc accaggtgga agaggccaga 120aagtggcctg ccgagaaaga aaacgatacc ggtgtcgtgc accaggtgga agaggccaga 120
gtgaagggcc ctggcatcag caagttcgtg cagaaagtga acgagatcgg catctacctg 180gtgaagggcc ctggcatcag caagttcgtg cagaaagtga acgagatcgg catctacctg 180
accgacgcca tggaacgggc cagagaagtg atccccagaa gccagcacca ggaaaccccc 240accgacgcca tggaacgggc cagagaagtg atccccagaa gccagcacca ggaaaccccc 240
gtgtacctgg gagccacagc cggcatgaga ctgctgcgga tggaaagcga ggaactggcc 300gtgtacctgg gagccacagc cggcatgaga ctgctgcgga tggaaagcga ggaactggcc 300
gacagagtgc tggacgtggt ggaaagaagc ctgagcaact acccattcga ttttcaaggg 360gacagagtgc tggacgtggt ggaaagaagc ctgagcaact acccattcga ttttcaaggg 360
gccagaatca tcaccggcca ggaagagggc gcttacggct ggatcaccat caactacctg 420gccagaatca tcaccggcca ggaagaggggc gcttacggct ggatcaccat caactacctg 420
ctgggcaagt tcagccagaa aacccggtgg ttcagcatcg tgccctacga gacaaacaat 480ctgggcaagt tcagccagaa aacccggtgg ttcagcatcg tgccctacga gacaaacaat 480
caggaaacct tcggagccct ggacctgggc ggagcctcta cccaagtgac cttcgtgccc 540caggaaacct tcggagccct ggacctgggc ggagcctcta cccaagtgac cttcgtgccc 540
cagaatcaga ccatcgagag ccccgacaac gccctgcagt tccggctgta cggcaaggac 600cagaatcaga ccatcgagag ccccgacaac gccctgcagt tccggctgta cggcaaggac 600
tacaatgtgt acacccacag ctttctgtgc tacggaaagg accaggccct gtggcagaag 660tacaatgtgt acacccacag ctttctgtgc tacggaaagg accaggccct gtggcagaag 660
ctggccaagg acatccaggt ggccagcaac gagatcctgc gggacccttg cttccacccc 720ctggccaagg acatccaggt ggccagcaac gagatcctgc gggacccttg cttccacccc 720
ggctacaaga aagtcgtgaa cgtgtccgac ctgtacaaga ccccctgcac caagagattc 780ggctacaaga aagtcgtgaa cgtgtccgac ctgtacaaga ccccctgcac caagagattc 780
gagatgaccc tgcccttcca gcagttcgag atccagggca tcggcaacta ccagcagtgc 840gagatgaccc tgcccttcca gcagttcgag atccagggca tcggcaacta ccagcagtgc 840
caccagagca tcctggaact gttcaacacc agctactgcc cctacagcca gtgcgccttc 900caccagagca tcctggaact gttcaacacc agctactgcc cctacagcca gtgcgccttc 900
aacggcatct tcctgccacc tctgcagggg gacttcggcg ctttcagcgc cttctacttc 960aacggcatct tcctgccacc tctgcagggg gacttcggcg ctttcagcgc cttctacttc 960
gtgatgaagt tcctgaacct gaccagcgag aaggtgtccc aggaaaaagt gacagagatg 1020gtgatgaagt tcctgaacct gaccagcgag aaggtgtccc aggaaaaagt gacagagatg 1020
atgaagaagt tctgcgccca gccctgggag gaaatcaaga cctcctacgc tggcgtgaaa 1080atgaagaagt tctgcgccca gccctgggag gaaatcaaga cctcctacgc tggcgtgaaa 1080
gagaagtacc tgagcgagta ctgcttcagc ggtacctaca tcctgagcct gctgctgcag 1140gagaagtacc tgagcgagta ctgcttcagc ggtacctaca tcctgagcct gctgctgcag 1140
ggctaccact tcaccgccga tagctgggag cacatccact tcatcggcaa gattcagggc 1200ggctaccact tcaccgccga tagctgggag cacatccact tcatcggcaa gattcaggggc 1200
agcgacgccg gctggacact gggctacatg ctgaatctga ccaacatg 1248agcgacgccg gctggacact gggctacatg ctgaatctga ccaacatg 1248
<210> 109<210> 109
<211> 416<211> 416
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 109<400> 109
Asn Val Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Asn Val Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser
1 5 10 15 1 5 10 15
Leu Tyr Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Leu Tyr Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val
20 25 30 20 25 30
Val His Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Val His Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys
35 40 45 35 40 45
Phe Val Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Phe Val Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met
50 55 60 50 55 60
Glu Arg Ala Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Glu Arg Ala Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro
65 70 75 80 65 70 75 80
Val Tyr Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Val Tyr Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser
85 90 95 85 90 95
Glu Glu Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Glu Glu Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser
100 105 110 100 105 110
Asn Tyr Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Asn Tyr Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu
115 120 125 115 120 125
Glu Gly Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Glu Gly Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe
130 135 140 130 135 140
Ser Gln Lys Thr Arg Trp Phe Ser Ile Val Pro Tyr Glu Thr Asn Asn Ser Gln Lys Thr Arg Trp Phe Ser Ile Val Pro Tyr Glu Thr Asn Asn
145 150 155 160 145 150 155 160
Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val
165 170 175 165 170 175
Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu
180 185 190 180 185 190
Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe
195 200 205 195 200 205
Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp
210 215 220 210 215 220
Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Ala Phe His Pro Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Ala Phe His Pro
225 230 235 240 225 230 235 240
Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys
245 250 255 245 250 255
Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln
260 265 270 260 265 270
Gly Ile Gly Asn Tyr Gln Gln Ala His Gln Ser Ile Leu Glu Leu Phe Gly Ile Gly Asn Tyr Gln Gln Ala His Gln Ser Ile Leu Glu Leu Phe
275 280 285 275 280 285
Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe
290 295 300 290 295 300
Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe
305 310 315 320 305 310 315 320
Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys
325 330 335 325 330 335
Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile
340 345 350 340 345 350
Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys
355 360 365 355 360 365
Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe
370 375 380 370 375 380
Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly
385 390 395 400 385 390 395 400
Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met
405 410 415 405 410 415
<210> 110<210> 110
<211> 1248<211> 1248
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 110<400> 110
aacgtgaagt acggcatcgt gctggatgcc ggcagcagcc acaccagcct gtacatctac 60aacgtgaagt acggcatcgt gctggatgcc ggcagcagcc acaccagcct gtacatctac 60
aagtggcctg ccgagaaaga aaacgatacc ggtgtcgtgc accaggtgga agagtgcaga 120aagtggcctg ccgagaaaga aaacgatacc ggtgtcgtgc accaggtgga agagtgcaga 120
gtgaagggcc ctggcatcag caagttcgtg cagaaagtga acgagatcgg catctacctg 180gtgaagggcc ctggcatcag caagttcgtg cagaaagtga acgagatcgg catctacctg 180
accgactgca tggaacgggc cagagaagtg atccccagaa gccagcacca ggaaaccccc 240accgactgca tggaacgggc cagagaagtg atccccagaa gccagcacca ggaaaccccc 240
gtgtacctgg gagccacagc cggcatgaga ctgctgcgga tggaaagcga ggaactggcc 300gtgtacctgg gagccacagc cggcatgaga ctgctgcgga tggaaagcga ggaactggcc 300
gacagagtgc tggacgtggt ggaaagaagc ctgagcaact acccattcga ttttcaaggg 360gacagagtgc tggacgtggt ggaaagaagc ctgagcaact acccattcga ttttcaaggg 360
gccagaatca tcaccggcca ggaagagggc gcttacggct ggatcaccat caactacctg 420gccagaatca tcaccggcca ggaagaggggc gcttacggct ggatcaccat caactacctg 420
ctgggcaagt tcagccagaa aacccggtgg ttcagcatcg tgccctacga gacaaacaat 480ctgggcaagt tcagccagaa aacccggtgg ttcagcatcg tgccctacga gacaaacaat 480
caggaaacct tcggagccct ggacctgggc ggagcctcta cccaagtgac cttcgtgccc 540caggaaacct tcggagccct ggacctgggc ggagcctcta cccaagtgac cttcgtgccc 540
cagaatcaga ccatcgagag ccccgacaac gccctgcagt tccggctgta cggcaaggac 600cagaatcaga ccatcgagag ccccgacaac gccctgcagt tccggctgta cggcaaggac 600
tacaatgtgt acacccacag ctttctgtgc tacggaaagg accaggccct gtggcagaag 660tacaatgtgt acacccacag ctttctgtgc tacggaaagg accaggccct gtggcagaag 660
ctggccaagg acatccaggt ggccagcaac gagatcctgc gggaccctgc cttccacccc 720ctggccaagg acatccaggt ggccagcaac gagatcctgc gggaccctgc cttccacccc 720
ggctacaaga aagtcgtgaa cgtgtccgac ctgtacaaga ccccctgcac caagagattc 780ggctacaaga aagtcgtgaa cgtgtccgac ctgtacaaga ccccctgcac caagagattc 780
gagatgaccc tgcccttcca gcagttcgag atccagggca tcggcaacta ccagcaggcc 840gagatgaccc tgcccttcca gcagttcgag atccagggca tcggcaacta ccagcaggcc 840
caccagagca tcctggaact gttcaacacc agctactgcc cctacagcca gtgcgccttc 900caccagagca tcctggaact gttcaacacc agctactgcc cctacagcca gtgcgccttc 900
aacggcatct tcctgccacc tctgcagggg gacttcggcg ctttcagcgc cttctacttc 960aacggcatct tcctgccacc tctgcagggg gacttcggcg ctttcagcgc cttctacttc 960
gtgatgaagt tcctgaacct gaccagcgag aaggtgtccc aggaaaaagt gacagagatg 1020gtgatgaagt tcctgaacct gaccagcgag aaggtgtccc aggaaaaagt gacagagatg 1020
atgaagaagt tctgcgccca gccctgggag gaaatcaaga cctcctacgc tggcgtgaaa 1080atgaagaagt tctgcgccca gccctgggag gaaatcaaga cctcctacgc tggcgtgaaa 1080
gagaagtacc tgagcgagta ctgcttcagc ggtacctaca tcctgagcct gctgctgcag 1140gagaagtacc tgagcgagta ctgcttcagc ggtacctaca tcctgagcct gctgctgcag 1140
ggctaccact tcaccgccga tagctgggag cacatccact tcatcggcaa gattcagggc 1200ggctaccact tcaccgccga tagctgggag cacatccact tcatcggcaa gattcaggggc 1200
agcgacgccg gctggacact gggctacatg ctgaatctga ccaacatg 1248agcgacgccg gctggacact gggctacatg ctgaatctga ccaacatg 1248
<210> 111<210> 111
<211> 416<211> 416
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 111<400> 111
Asn Val Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Asn Val Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser
1 5 10 15 1 5 10 15
Leu Tyr Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Leu Tyr Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val
20 25 30 20 25 30
Val His Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Val His Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys
35 40 45 35 40 45
Phe Val Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Phe Val Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met
50 55 60 50 55 60
Glu Arg Ala Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Glu Arg Ala Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro
65 70 75 80 65 70 75 80
Val Tyr Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Val Tyr Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser
85 90 95 85 90 95
Glu Glu Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Glu Glu Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser
100 105 110 100 105 110
Asn Tyr Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Asn Tyr Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu
115 120 125 115 120 125
Glu Gly Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Glu Gly Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe
130 135 140 130 135 140
Ser Gln Lys Thr Arg Trp Phe Ser Ile Val Pro Tyr Glu Thr Asn Asn Ser Gln Lys Thr Arg Trp Phe Ser Ile Val Pro Tyr Glu Thr Asn Asn
145 150 155 160 145 150 155 160
Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val
165 170 175 165 170 175
Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu
180 185 190 180 185 190
Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe
195 200 205 195 200 205
Leu Ala Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Leu Ala Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp
210 215 220 210 215 220
Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro
225 230 235 240 225 230 235 240
Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Ala Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Ala
245 250 255 245 250 255
Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln
260 265 270 260 265 270
Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe
275 280 285 275 280 285
Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe
290 295 300 290 295 300
Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe
305 310 315 320 305 310 315 320
Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys
325 330 335 325 330 335
Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile
340 345 350 340 345 350
Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys
355 360 365 355 360 365
Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe
370 375 380 370 375 380
Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly
385 390 395 400 385 390 395 400
Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met
405 410 415 405 410 415
<210> 112<210> 112
<211> 1248<211> 1248
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 112<400> 112
aacgtgaagt acggcatcgt gctggatgcc ggcagcagcc acaccagcct gtacatctac 60aacgtgaagt acggcatcgt gctggatgcc ggcagcagcc acaccagcct gtacatctac 60
aagtggcctg ccgagaaaga aaacgatacc ggtgtcgtgc accaggtgga agagtgcaga 120aagtggcctg ccgagaaaga aaacgatacc ggtgtcgtgc accaggtgga agagtgcaga 120
gtgaagggcc ctggcatcag caagttcgtg cagaaagtga acgagatcgg catctacctg 180gtgaagggcc ctggcatcag caagttcgtg cagaaagtga acgagatcgg catctacctg 180
accgactgca tggaacgggc cagagaagtg atccccagaa gccagcacca ggaaaccccc 240accgactgca tggaacgggc cagagaagtg atccccagaa gccagcacca ggaaaccccc 240
gtgtacctgg gagccacagc cggcatgaga ctgctgcgga tggaaagcga ggaactggcc 300gtgtacctgg gagccacagc cggcatgaga ctgctgcgga tggaaagcga ggaactggcc 300
gacagagtgc tggacgtggt ggaaagaagc ctgagcaact acccattcga ttttcaaggg 360gacagagtgc tggacgtggt ggaaagaagc ctgagcaact acccattcga ttttcaaggg 360
gccagaatca tcaccggcca ggaagagggc gcttacggct ggatcaccat caactacctg 420gccagaatca tcaccggcca ggaagaggggc gcttacggct ggatcaccat caactacctg 420
ctgggcaagt tcagccagaa aacccggtgg ttcagcatcg tgccctacga gacaaacaat 480ctgggcaagt tcagccagaa aacccggtgg ttcagcatcg tgccctacga gacaaacaat 480
caggaaacct tcggagccct ggacctgggc ggagcctcta cccaagtgac cttcgtgccc 540caggaaacct tcggagccct ggacctgggc ggagcctcta cccaagtgac cttcgtgccc 540
cagaatcaga ccatcgagag ccccgacaac gccctgcagt tccggctgta cggcaaggac 600cagaatcaga ccatcgagag ccccgacaac gccctgcagt tccggctgta cggcaaggac 600
tacaatgtgt acacccacag ctttctggcc tacggaaagg accaggccct gtggcagaag 660tacaatgtgt acacccacag ctttctggcc tacggaaagg accaggccct gtggcagaag 660
ctggccaagg acatccaggt ggccagcaac gagatcctgc gggacccttg cttccacccc 720ctggccaagg acatccaggt ggccagcaac gagatcctgc gggacccttg cttccacccc 720
ggctacaaga aagtcgtgaa cgtgtccgac ctgtacaaga cccccgccac caagagattc 780ggctacaaga aagtcgtgaa cgtgtccgac ctgtacaaga cccccgccac caagagattc 780
gagatgaccc tgcccttcca gcagttcgag atccagggca tcggcaacta ccagcagtgc 840gagatgaccc tgcccttcca gcagttcgag atccagggca tcggcaacta ccagcagtgc 840
caccagagca tcctggaact gttcaacacc agctactgcc cctacagcca gtgcgccttc 900caccagagca tcctggaact gttcaacacc agctactgcc cctacagcca gtgcgccttc 900
aacggcatct tcctgccacc tctgcagggg gacttcggcg ctttcagcgc cttctacttc 960aacggcatct tcctgccacc tctgcagggg gacttcggcg ctttcagcgc cttctacttc 960
gtgatgaagt tcctgaacct gaccagcgag aaggtgtccc aggaaaaagt gacagagatg 1020gtgatgaagt tcctgaacct gaccagcgag aaggtgtccc aggaaaaagt gacagagatg 1020
atgaagaagt tctgcgccca gccctgggag gaaatcaaga cctcctacgc tggcgtgaaa 1080atgaagaagt tctgcgccca gccctgggag gaaatcaaga cctcctacgc tggcgtgaaa 1080
gagaagtacc tgagcgagta ctgcttcagc ggtacctaca tcctgagcct gctgctgcag 1140gagaagtacc tgagcgagta ctgcttcagc ggtacctaca tcctgagcct gctgctgcag 1140
ggctaccact tcaccgccga tagctgggag cacatccact tcatcggcaa gattcagggc 1200ggctaccact tcaccgccga tagctgggag cacatccact tcatcggcaa gattcaggggc 1200
agcgacgccg gctggacact gggctacatg ctgaatctga ccaacatg 1248agcgacgccg gctggacact gggctacatg ctgaatctga ccaacatg 1248
<210> 113<210> 113
<211> 416<211> 416
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 113<400> 113
Asn Val Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Asn Val Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser
1 5 10 15 1 5 10 15
Leu Tyr Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Leu Tyr Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val
20 25 30 20 25 30
Val His Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Val His Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys
35 40 45 35 40 45
Phe Val Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Phe Val Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met
50 55 60 50 55 60
Glu Arg Ala Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Glu Arg Ala Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro
65 70 75 80 65 70 75 80
Val Tyr Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Val Tyr Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser
85 90 95 85 90 95
Glu Glu Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Glu Glu Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser
100 105 110 100 105 110
Asn Tyr Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Asn Tyr Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu
115 120 125 115 120 125
Glu Gly Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Glu Gly Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe
130 135 140 130 135 140
Ser Gln Lys Thr Arg Trp Phe Ser Ile Val Pro Tyr Glu Thr Asn Asn Ser Gln Lys Thr Arg Trp Phe Ser Ile Val Pro Tyr Glu Thr Asn Asn
145 150 155 160 145 150 155 160
Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val
165 170 175 165 170 175
Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu
180 185 190 180 185 190
Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe
195 200 205 195 200 205
Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp
210 215 220 210 215 220
Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro
225 230 235 240 225 230 235 240
Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys
245 250 255 245 250 255
Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln
260 265 270 260 265 270
Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe
275 280 285 275 280 285
Asn Thr Ser Tyr Ala Pro Tyr Ser Gln Ala Ala Phe Asn Gly Ile Phe Asn Thr Ser Tyr Ala Pro Tyr Ser Gln Ala Ala Phe Asn Gly Ile Phe
290 295 300 290 295 300
Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe
305 310 315 320 305 310 315 320
Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys
325 330 335 325 330 335
Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile
340 345 350 340 345 350
Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys
355 360 365 355 360 365
Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe
370 375 380 370 375 380
Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly
385 390 395 400 385 390 395 400
Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met
405 410 415 405 410 415
<210> 114<210> 114
<211> 1248<211> 1248
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 114<400> 114
aacgtgaagt acggcatcgt gctggatgcc ggcagcagcc acaccagcct gtacatctac 60aacgtgaagt acggcatcgt gctggatgcc ggcagcagcc acaccagcct gtacatctac 60
aagtggcctg ccgagaaaga aaacgatacc ggtgtcgtgc accaggtgga agagtgcaga 120aagtggcctg ccgagaaaga aaacgatacc ggtgtcgtgc accaggtgga agagtgcaga 120
gtgaagggcc ctggcatcag caagttcgtg cagaaagtga acgagatcgg catctacctg 180gtgaagggcc ctggcatcag caagttcgtg cagaaagtga acgagatcgg catctacctg 180
accgactgca tggaacgggc cagagaagtg atccccagaa gccagcacca ggaaaccccc 240accgactgca tggaacgggc cagagaagtg atccccagaa gccagcacca ggaaaccccc 240
gtgtacctgg gagccacagc cggcatgaga ctgctgcgga tggaaagcga ggaactggcc 300gtgtacctgg gagccacagc cggcatgaga ctgctgcgga tggaaagcga ggaactggcc 300
gacagagtgc tggacgtggt ggaaagaagc ctgagcaact acccattcga ttttcaaggg 360gacagagtgc tggacgtggt ggaaagaagc ctgagcaact acccattcga ttttcaaggg 360
gccagaatca tcaccggcca ggaagagggc gcttacggct ggatcaccat caactacctg 420gccagaatca tcaccggcca ggaagaggggc gcttacggct ggatcaccat caactacctg 420
ctgggcaagt tcagccagaa aacccggtgg ttcagcatcg tgccctacga gacaaacaat 480ctgggcaagt tcagccagaa aacccggtgg ttcagcatcg tgccctacga gacaaacaat 480
caggaaacct tcggagccct ggacctgggc ggagcctcta cccaagtgac cttcgtgccc 540caggaaacct tcggagccct ggacctgggc ggagcctcta cccaagtgac cttcgtgccc 540
cagaatcaga ccatcgagag ccccgacaac gccctgcagt tccggctgta cggcaaggac 600cagaatcaga ccatcgagag ccccgacaac gccctgcagt tccggctgta cggcaaggac 600
tacaatgtgt acacccacag ctttctgtgc tacggaaagg accaggccct gtggcagaag 660tacaatgtgt acacccacag ctttctgtgc tacggaaagg accaggccct gtggcagaag 660
ctggccaagg acatccaggt ggccagcaac gagatcctgc gggacccttg cttccacccc 720ctggccaagg acatccaggt ggccagcaac gagatcctgc gggacccttg cttccacccc 720
ggctacaaga aagtcgtgaa cgtgtccgac ctgtacaaga ccccctgcac caagagattc 780ggctacaaga aagtcgtgaa cgtgtccgac ctgtacaaga ccccctgcac caagagattc 780
gagatgaccc tgcccttcca gcagttcgag atccagggca tcggcaacta ccagcagtgc 840gagatgaccc tgcccttcca gcagttcgag atccagggca tcggcaacta ccagcagtgc 840
caccagagca tcctggaact gttcaacacc agctacgccc cctacagcca ggccgccttc 900caccagagca tcctggaact gttcaacacc agctacgccc cctacagcca ggccgccttc 900
aacggcatct tcctgccacc tctgcagggg gacttcggcg ctttcagcgc cttctacttc 960aacggcatct tcctgccacc tctgcagggg gacttcggcg ctttcagcgc cttctacttc 960
gtgatgaagt tcctgaacct gaccagcgag aaggtgtccc aggaaaaagt gacagagatg 1020gtgatgaagt tcctgaacct gaccagcgag aaggtgtccc aggaaaaagt gacagagatg 1020
atgaagaagt tctgcgccca gccctgggag gaaatcaaga cctcctacgc tggcgtgaaa 1080atgaagaagt tctgcgccca gccctgggag gaaatcaaga cctcctacgc tggcgtgaaa 1080
gagaagtacc tgagcgagta ctgcttcagc ggtacctaca tcctgagcct gctgctgcag 1140gagaagtacc tgagcgagta ctgcttcagc ggtacctaca tcctgagcct gctgctgcag 1140
ggctaccact tcaccgccga tagctgggag cacatccact tcatcggcaa gattcagggc 1200ggctaccact tcaccgccga tagctgggag cacatccact tcatcggcaa gattcaggggc 1200
agcgacgccg gctggacact gggctacatg ctgaatctga ccaacatg 1248agcgacgccg gctggacact gggctacatg ctgaatctga ccaacatg 1248
<210> 115<210> 115
<211> 416<211> 416
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 115<400> 115
Asn Val Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Asn Val Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser
1 5 10 15 1 5 10 15
Leu Tyr Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Leu Tyr Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val
20 25 30 20 25 30
Val His Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Val His Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys
35 40 45 35 40 45
Phe Val Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Phe Val Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met
50 55 60 50 55 60
Glu Arg Ala Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Glu Arg Ala Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro
65 70 75 80 65 70 75 80
Val Tyr Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Val Tyr Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser
85 90 95 85 90 95
Glu Glu Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Glu Glu Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser
100 105 110 100 105 110
Asn Tyr Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Asn Tyr Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu
115 120 125 115 120 125
Glu Gly Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Glu Gly Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe
130 135 140 130 135 140
Ser Gln Lys Thr Arg Trp Phe Ser Ile Val Pro Tyr Glu Thr Asn Asn Ser Gln Lys Thr Arg Trp Phe Ser Ile Val Pro Tyr Glu Thr Asn Asn
145 150 155 160 145 150 155 160
Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val
165 170 175 165 170 175
Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu
180 185 190 180 185 190
Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe
195 200 205 195 200 205
Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp
210 215 220 210 215 220
Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro
225 230 235 240 225 230 235 240
Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys
245 250 255 245 250 255
Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln
260 265 270 260 265 270
Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe
275 280 285 275 280 285
Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe
290 295 300 290 295 300
Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe
305 310 315 320 305 310 315 320
Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys
325 330 335 325 330 335
Val Thr Glu Met Met Lys Lys Phe Ala Ala Gln Pro Trp Glu Glu Ile Val Thr Glu Met Met Lys Lys Phe Ala Ala Gln Pro Trp Glu Glu Ile
340 345 350 340 345 350
Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Ala Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Ala
355 360 365 355 360 365
Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe
370 375 380 370 375 380
Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly
385 390 395 400 385 390 395 400
Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met
405 410 415 405 410 415
<210> 116<210> 116
<211> 1248<211> 1248
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 116<400> 116
aacgtgaagt acggcatcgt gctggatgcc ggcagcagcc acaccagcct gtacatctac 60aacgtgaagt acggcatcgt gctggatgcc ggcagcagcc acaccagcct gtacatctac 60
aagtggcctg ccgagaaaga aaacgatacc ggtgtcgtgc accaggtgga agagtgcaga 120aagtggcctg ccgagaaaga aaacgatacc ggtgtcgtgc accaggtgga agagtgcaga 120
gtgaagggcc ctggcatcag caagttcgtg cagaaagtga acgagatcgg catctacctg 180gtgaagggcc ctggcatcag caagttcgtg cagaaagtga acgagatcgg catctacctg 180
accgactgca tggaacgggc cagagaagtg atccccagaa gccagcacca ggaaaccccc 240accgactgca tggaacgggc cagagaagtg atccccagaa gccagcacca ggaaaccccc 240
gtgtacctgg gagccacagc cggcatgaga ctgctgcgga tggaaagcga ggaactggcc 300gtgtacctgg gagccacagc cggcatgaga ctgctgcgga tggaaagcga ggaactggcc 300
gacagagtgc tggacgtggt ggaaagaagc ctgagcaact acccattcga ttttcaaggg 360gacagagtgc tggacgtggt ggaaagaagc ctgagcaact acccattcga ttttcaaggg 360
gccagaatca tcaccggcca ggaagagggc gcttacggct ggatcaccat caactacctg 420gccagaatca tcaccggcca ggaagaggggc gcttacggct ggatcaccat caactacctg 420
ctgggcaagt tcagccagaa aacccggtgg ttcagcatcg tgccctacga gacaaacaat 480ctgggcaagt tcagccagaa aacccggtgg ttcagcatcg tgccctacga gacaaacaat 480
caggaaacct tcggagccct ggacctgggc ggagcctcta cccaagtgac cttcgtgccc 540caggaaacct tcggagccct ggacctgggc ggagcctcta cccaagtgac cttcgtgccc 540
cagaatcaga ccatcgagag ccccgacaac gccctgcagt tccggctgta cggcaaggac 600cagaatcaga ccatcgagag ccccgacaac gccctgcagt tccggctgta cggcaaggac 600
tacaatgtgt acacccacag ctttctgtgc tacggaaagg accaggccct gtggcagaag 660tacaatgtgt acacccacag ctttctgtgc tacggaaagg accaggccct gtggcagaag 660
ctggccaagg acatccaggt ggccagcaac gagatcctgc gggacccttg cttccacccc 720ctggccaagg acatccaggt ggccagcaac gagatcctgc gggacccttg cttccacccc 720
ggctacaaga aagtcgtgaa cgtgtccgac ctgtacaaga ccccctgcac caagagattc 780ggctacaaga aagtcgtgaa cgtgtccgac ctgtacaaga ccccctgcac caagagattc 780
gagatgaccc tgcccttcca gcagttcgag atccagggca tcggcaacta ccagcagtgc 840gagatgaccc tgcccttcca gcagttcgag atccagggca tcggcaacta ccagcagtgc 840
caccagagca tcctggaact gttcaacacc agctactgcc cctacagcca gtgcgccttc 900caccagagca tcctggaact gttcaacacc agctactgcc cctacagcca gtgcgccttc 900
aacggcatct tcctgccacc tctgcagggg gacttcggcg ctttcagcgc cttctacttc 960aacggcatct tcctgccacc tctgcagggg gacttcggcg ctttcagcgc cttctacttc 960
gtgatgaagt tcctgaacct gaccagcgag aaggtgtccc aggaaaaagt gacagagatg 1020gtgatgaagt tcctgaacct gaccagcgag aaggtgtccc aggaaaaagt gacagagatg 1020
atgaagaagt tcgccgccca gccctgggag gaaatcaaga cctcctacgc tggcgtgaaa 1080atgaagaagt tcgccgccca gccctgggag gaaatcaaga cctcctacgc tggcgtgaaa 1080
gagaagtacc tgagcgagta cgccttcagc ggtacctaca tcctgagcct gctgctgcag 1140gagaagtacc tgagcgagta cgccttcagc ggtacctaca tcctgagcct gctgctgcag 1140
ggctaccact tcaccgccga tagctgggag cacatccact tcatcggcaa gattcagggc 1200ggctaccact tcaccgccga tagctgggag cacatccact tcatcggcaa gattcaggggc 1200
agcgacgccg gctggacact gggctacatg ctgaatctga ccaacatg 1248agcgacgccg gctggacact gggctacatg ctgaatctga ccaacatg 1248
<210> 117<210> 117
<211> 404<211> 404
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 117<400> 117
Asn Val Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Asn Val Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser
1 5 10 15 1 5 10 15
Leu Tyr Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Leu Tyr Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val
20 25 30 20 25 30
Val His Gln Val Glu Glu Ala Arg Val Lys Gly Pro Gly Ile Ser Lys Val His Gln Val Glu Glu Ala Arg Val Lys Gly Pro Gly Ile Ser Lys
35 40 45 35 40 45
Phe Val Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Ala Met Phe Val Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Ala Met
50 55 60 50 55 60
Glu Arg Ala Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Glu Arg Ala Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro
65 70 75 80 65 70 75 80
Val Tyr Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Val Tyr Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser
85 90 95 85 90 95
Glu Glu Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Glu Glu Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser
100 105 110 100 105 110
Asn Tyr Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Asn Tyr Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu
115 120 125 115 120 125
Glu Gly Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Glu Gly Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe
130 135 140 130 135 140
Ser Gln Lys Asn Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Gln Lys Asn Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala
145 150 155 160 145 150 155 160
Ser Thr Gln Val Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Ser Thr Gln Val Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro
165 170 175 165 170 175
Asp Asn Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Asp Asn Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr
180 185 190 180 185 190
Thr His Ser Phe Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Thr His Ser Phe Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys
195 200 205 195 200 205
Leu Ala Lys Asp Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Leu Ala Lys Asp Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro
210 215 220 210 215 220
Cys Phe His Pro Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Cys Phe His Pro Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr
225 230 235 240 225 230 235 240
Lys Thr Pro Cys Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Lys Thr Pro Cys Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln
245 250 255 245 250 255
Phe Glu Ile Gln Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Phe Glu Ile Gln Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile
260 265 270 260 265 270
Leu Glu Leu Phe Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Leu Glu Leu Phe Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe
275 280 285 275 280 285
Asn Gly Ile Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Asn Gly Ile Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser
290 295 300 290 295 300
Ala Phe Tyr Phe Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ala Phe Tyr Phe Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val
305 310 315 320 305 310 315 320
Ser Gln Glu Lys Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Ser Gln Glu Lys Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro
325 330 335 325 330 335
Trp Glu Glu Ile Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Trp Glu Glu Ile Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu
340 345 350 340 345 350
Ser Glu Tyr Cys Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Ser Glu Tyr Cys Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln
355 360 365 355 360 365
Gly Tyr His Phe Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Gly Tyr His Phe Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly
370 375 380 370 375 380
Lys Ile Gln Gly Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Lys Ile Gln Gly Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn
385 390 395 400 385 390 395 400
Leu Thr Asn Met Leu Thr Asn Met
<210> 118<210> 118
<211> 1212<211> 1212
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 118<400> 118
aacgtgaagt acggcatcgt gctggatgcc ggcagcagcc acaccagcct gtacatctac 60aacgtgaagt acggcatcgt gctggatgcc ggcagcagcc acaccagcct gtacatctac 60
aagtggcctg ccgagaaaga aaacgatacc ggtgtcgtgc accaggtgga agaggccaga 120aagtggcctg ccgagaaaga aaacgatacc ggtgtcgtgc accaggtgga agaggccaga 120
gtgaagggcc ctggcatcag caagttcgtg cagaaagtga acgagatcgg catctacctg 180gtgaagggcc ctggcatcag caagttcgtg cagaaagtga acgagatcgg catctacctg 180
accgacgcca tggaacgggc cagagaagtg atccccagaa gccagcacca ggaaaccccc 240accgacgcca tggaacgggc cagagaagtg atccccagaa gccagcacca ggaaaccccc 240
gtgtacctgg gagccacagc cggcatgaga ctgctgcgga tggaaagcga ggaactggcc 300gtgtacctgg gagccacagc cggcatgaga ctgctgcgga tggaaagcga ggaactggcc 300
gacagagtgc tggacgtggt ggaaagaagc ctgagcaact acccattcga ttttcaaggg 360gacagagtgc tggacgtggt ggaaagaagc ctgagcaact acccattcga ttttcaaggg 360
gccagaatca tcaccggcca ggaagagggc gcttacggct ggatcaccat caactacctg 420gccagaatca tcaccggcca ggaagaggggc gcttacggct ggatcaccat caactacctg 420
ctgggcaagt tcagccagaa aaatcaggaa accttcggag ccctggacct gggcggagcc 480ctgggcaagt tcagccagaa aaatcaggaa accttcggag ccctggacct gggcggagcc 480
tctacccaag tgaccttcgt gccccagaat cagaccatcg agagccccga caacgccctg 540tctacccaag tgaccttcgt gccccagaat cagaccatcg agagccccga caacgccctg 540
cagttccggc tgtacggcaa ggactacaat gtgtacaccc acagctttct gtgctacgga 600cagttccggc tgtacggcaa ggactacaat gtgtacaccc acagctttct gtgctacgga 600
aaggaccagg ccctgtggca gaagctggcc aaggacatcc aggtggccag caacgagatc 660aaggaccagg ccctgtggca gaagctggcc aaggacatcc aggtggccag caacgagatc 660
ctgcgggacc cttgcttcca ccccggctac aagaaagtcg tgaacgtgtc cgacctgtac 720ctgcgggacc cttgcttcca ccccggctac aagaaagtcg tgaacgtgtc cgacctgtac 720
aagaccccct gcaccaagag attcgagatg accctgccct tccagcagtt cgagatccag 780aagaccccct gcaccaagag attcgagatg accctgccct tccagcagtt cgagatccag 780
ggcatcggca actaccagca gtgccaccag agcatcctgg aactgttcaa caccagctac 840ggcatcggca actaccagca gtgccaccag agcatcctgg aactgttcaa caccagctac 840
tgcccctaca gccagtgcgc cttcaacggc atcttcctgc cacctctgca gggggacttc 900tgcccctaca gccagtgcgc cttcaacggc atcttcctgc cacctctgca gggggacttc 900
ggcgctttca gcgccttcta cttcgtgatg aagttcctga acctgaccag cgagaaggtg 960ggcgctttca gcgccttcta cttcgtgatg aagttcctga acctgaccag cgagaaggtg 960
tcccaggaaa aagtgacaga gatgatgaag aagttctgcg cccagccctg ggaggaaatc 1020tccaggaaa aagtgacaga gatgatgaag aagttctgcg cccagccctg ggaggaaatc 1020
aagacctcct acgctggcgt gaaagagaag tacctgagcg agtactgctt cagcggtacc 1080aagacctcct acgctggcgt gaaagagaag tacctgagcg agtactgctt cagcggtacc 1080
tacatcctga gcctgctgct gcagggctac cacttcaccg ccgatagctg ggagcacatc 1140tacatcctga gcctgctgct gcagggctac cacttcaccg ccgatagctg ggagcacatc 1140
cacttcatcg gcaagattca gggcagcgac gccggctgga cactgggcta catgctgaat 1200cacttcatcg gcaagattca gggcagcgac gccggctgga cactgggcta catgctgaat 1200
ctgaccaaca tg 1212ctgaccaaca tg 1212
<210> 119<210> 119
<211> 404<211> 404
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 119<400> 119
Asn Val Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Asn Val Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser
1 5 10 15 1 5 10 15
Leu Tyr Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Leu Tyr Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val
20 25 30 20 25 30
Val His Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Val His Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys
35 40 45 35 40 45
Phe Val Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Phe Val Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met
50 55 60 50 55 60
Glu Arg Ala Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Glu Arg Ala Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro
65 70 75 80 65 70 75 80
Val Tyr Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Val Tyr Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser
85 90 95 85 90 95
Glu Glu Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Glu Glu Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser
100 105 110 100 105 110
Asn Tyr Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Asn Tyr Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu
115 120 125 115 120 125
Glu Gly Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Glu Gly Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe
130 135 140 130 135 140
Ser Gln Lys Asn Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Gln Lys Asn Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala
145 150 155 160 145 150 155 160
Ser Thr Gln Val Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Ser Thr Gln Val Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro
165 170 175 165 170 175
Asp Asn Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Asp Asn Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr
180 185 190 180 185 190
Thr His Ser Phe Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Thr His Ser Phe Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys
195 200 205 195 200 205
Leu Ala Lys Asp Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Leu Ala Lys Asp Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro
210 215 220 210 215 220
Ala Phe His Pro Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Ala Phe His Pro Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr
225 230 235 240 225 230 235 240
Lys Thr Pro Cys Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Lys Thr Pro Cys Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln
245 250 255 245 250 255
Phe Glu Ile Gln Gly Ile Gly Asn Tyr Gln Gln Ala His Gln Ser Ile Phe Glu Ile Gln Gly Ile Gly Asn Tyr Gln Gln Ala His Gln Ser Ile
260 265 270 260 265 270
Leu Glu Leu Phe Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Leu Glu Leu Phe Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe
275 280 285 275 280 285
Asn Gly Ile Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Asn Gly Ile Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser
290 295 300 290 295 300
Ala Phe Tyr Phe Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ala Phe Tyr Phe Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val
305 310 315 320 305 310 315 320
Ser Gln Glu Lys Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Ser Gln Glu Lys Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro
325 330 335 325 330 335
Trp Glu Glu Ile Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Trp Glu Glu Ile Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu
340 345 350 340 345 350
Ser Glu Tyr Cys Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Ser Glu Tyr Cys Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln
355 360 365 355 360 365
Gly Tyr His Phe Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Gly Tyr His Phe Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly
370 375 380 370 375 380
Lys Ile Gln Gly Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Lys Ile Gln Gly Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn
385 390 395 400 385 390 395 400
Leu Thr Asn Met Leu Thr Asn Met
<210> 120<210> 120
<211> 1212<211> 1212
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 120<400> 120
aacgtgaagt acggcatcgt gctggatgcc ggcagcagcc acaccagcct gtacatctac 60aacgtgaagt acggcatcgt gctggatgcc ggcagcagcc acaccagcct gtacatctac 60
aagtggcctg ccgagaaaga aaacgatacc ggtgtcgtgc accaggtgga agagtgcaga 120aagtggcctg ccgagaaaga aaacgatacc ggtgtcgtgc accaggtgga agagtgcaga 120
gtgaagggcc ctggcatcag caagttcgtg cagaaagtga acgagatcgg catctacctg 180gtgaagggcc ctggcatcag caagttcgtg cagaaagtga acgagatcgg catctacctg 180
accgactgca tggaacgggc cagagaagtg atccccagaa gccagcacca ggaaaccccc 240accgactgca tggaacgggc cagagaagtg atccccagaa gccagcacca ggaaaccccc 240
gtgtacctgg gagccacagc cggcatgaga ctgctgcgga tggaaagcga ggaactggcc 300gtgtacctgg gagccacagc cggcatgaga ctgctgcgga tggaaagcga ggaactggcc 300
gacagagtgc tggacgtggt ggaaagaagc ctgagcaact acccattcga ttttcaaggg 360gacagagtgc tggacgtggt ggaaagaagc ctgagcaact acccattcga ttttcaaggg 360
gccagaatca tcaccggcca ggaagagggc gcttacggct ggatcaccat caactacctg 420gccagaatca tcaccggcca ggaagaggggc gcttacggct ggatcaccat caactacctg 420
ctgggcaagt tcagccagaa aaatcaggaa accttcggag ccctggacct gggcggagcc 480ctgggcaagt tcagccagaa aaatcaggaa accttcggag ccctggacct gggcggagcc 480
tctacccaag tgaccttcgt gccccagaat cagaccatcg agagccccga caacgccctg 540tctacccaag tgaccttcgt gccccagaat cagaccatcg agagccccga caacgccctg 540
cagttccggc tgtacggcaa ggactacaat gtgtacaccc acagctttct gtgctacgga 600cagttccggc tgtacggcaa ggactacaat gtgtacaccc acagctttct gtgctacgga 600
aaggaccagg ccctgtggca gaagctggcc aaggacatcc aggtggccag caacgagatc 660aaggaccagg ccctgtggca gaagctggcc aaggacatcc aggtggccag caacgagatc 660
ctgcgggacc ctgccttcca ccccggctac aagaaagtcg tgaacgtgtc cgacctgtac 720ctgcgggacc ctgccttcca ccccggctac aagaaagtcg tgaacgtgtc cgacctgtac 720
aagaccccct gcaccaagag attcgagatg accctgccct tccagcagtt cgagatccag 780aagaccccct gcaccaagag attcgagatg accctgccct tccagcagtt cgagatccag 780
ggcatcggca actaccagca ggcccaccag agcatcctgg aactgttcaa caccagctac 840ggcatcggca actaccagca ggcccaccag agcatcctgg aactgttcaa caccagctac 840
tgcccctaca gccagtgcgc cttcaacggc atcttcctgc cacctctgca gggggacttc 900tgcccctaca gccagtgcgc cttcaacggc atcttcctgc cacctctgca gggggacttc 900
ggcgctttca gcgccttcta cttcgtgatg aagttcctga acctgaccag cgagaaggtg 960ggcgctttca gcgccttcta cttcgtgatg aagttcctga acctgaccag cgagaaggtg 960
tcccaggaaa aagtgacaga gatgatgaag aagttctgcg cccagccctg ggaggaaatc 1020tccaggaaa aagtgacaga gatgatgaag aagttctgcg cccagccctg ggaggaaatc 1020
aagacctcct acgctggcgt gaaagagaag tacctgagcg agtactgctt cagcggtacc 1080aagacctcct acgctggcgt gaaagagaag tacctgagcg agtactgctt cagcggtacc 1080
tacatcctga gcctgctgct gcagggctac cacttcaccg ccgatagctg ggagcacatc 1140tacatcctga gcctgctgct gcagggctac cacttcaccg ccgatagctg ggagcacatc 1140
cacttcatcg gcaagattca gggcagcgac gccggctgga cactgggcta catgctgaat 1200cacttcatcg gcaagattca gggcagcgac gccggctgga cactgggcta catgctgaat 1200
ctgaccaaca tg 1212ctgaccaaca tg 1212
<210> 121<210> 121
<211> 404<211> 404
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 121<400> 121
Asn Val Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Asn Val Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser
1 5 10 15 1 5 10 15
Leu Tyr Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Leu Tyr Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val
20 25 30 20 25 30
Val His Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Val His Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys
35 40 45 35 40 45
Phe Val Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Phe Val Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met
50 55 60 50 55 60
Glu Arg Ala Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Glu Arg Ala Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro
65 70 75 80 65 70 75 80
Val Tyr Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Val Tyr Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser
85 90 95 85 90 95
Glu Glu Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Glu Glu Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser
100 105 110 100 105 110
Asn Tyr Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Asn Tyr Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu
115 120 125 115 120 125
Glu Gly Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Glu Gly Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe
130 135 140 130 135 140
Ser Gln Lys Asn Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Gln Lys Asn Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala
145 150 155 160 145 150 155 160
Ser Thr Gln Val Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Ser Thr Gln Val Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro
165 170 175 165 170 175
Asp Asn Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Asp Asn Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr
180 185 190 180 185 190
Thr His Ser Phe Leu Ala Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Thr His Ser Phe Leu Ala Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys
195 200 205 195 200 205
Leu Ala Lys Asp Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Leu Ala Lys Asp Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro
210 215 220 210 215 220
Cys Phe His Pro Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Cys Phe His Pro Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr
225 230 235 240 225 230 235 240
Lys Thr Pro Ala Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Lys Thr Pro Ala Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln
245 250 255 245 250 255
Phe Glu Ile Gln Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Phe Glu Ile Gln Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile
260 265 270 260 265 270
Leu Glu Leu Phe Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Leu Glu Leu Phe Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe
275 280 285 275 280 285
Asn Gly Ile Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Asn Gly Ile Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser
290 295 300 290 295 300
Ala Phe Tyr Phe Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ala Phe Tyr Phe Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val
305 310 315 320 305 310 315 320
Ser Gln Glu Lys Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Ser Gln Glu Lys Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro
325 330 335 325 330 335
Trp Glu Glu Ile Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Trp Glu Glu Ile Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu
340 345 350 340 345 350
Ser Glu Tyr Cys Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Ser Glu Tyr Cys Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln
355 360 365 355 360 365
Gly Tyr His Phe Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Gly Tyr His Phe Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly
370 375 380 370 375 380
Lys Ile Gln Gly Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Lys Ile Gln Gly Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn
385 390 395 400 385 390 395 400
Leu Thr Asn Met Leu Thr Asn Met
<210> 122<210> 122
<211> 1212<211> 1212
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 122<400> 122
aacgtgaagt acggcatcgt gctggatgcc ggcagcagcc acaccagcct gtacatctac 60aacgtgaagt acggcatcgt gctggatgcc ggcagcagcc acaccagcct gtacatctac 60
aagtggcctg ccgagaaaga aaacgatacc ggtgtcgtgc accaggtgga agagtgcaga 120aagtggcctg ccgagaaaga aaacgatacc ggtgtcgtgc accaggtgga agagtgcaga 120
gtgaagggcc ctggcatcag caagttcgtg cagaaagtga acgagatcgg catctacctg 180gtgaagggcc ctggcatcag caagttcgtg cagaaagtga acgagatcgg catctacctg 180
accgactgca tggaacgggc cagagaagtg atccccagaa gccagcacca ggaaaccccc 240accgactgca tggaacgggc cagagaagtg atccccagaa gccagcacca ggaaaccccc 240
gtgtacctgg gagccacagc cggcatgaga ctgctgcgga tggaaagcga ggaactggcc 300gtgtacctgg gagccacagc cggcatgaga ctgctgcgga tggaaagcga ggaactggcc 300
gacagagtgc tggacgtggt ggaaagaagc ctgagcaact acccattcga ttttcaaggg 360gacagagtgc tggacgtggt ggaaagaagc ctgagcaact acccattcga ttttcaaggg 360
gccagaatca tcaccggcca ggaagagggc gcttacggct ggatcaccat caactacctg 420gccagaatca tcaccggcca ggaagaggggc gcttacggct ggatcaccat caactacctg 420
ctgggcaagt tcagccagaa aaatcaggaa accttcggag ccctggacct gggcggagcc 480ctgggcaagt tcagccagaa aaatcaggaa accttcggag ccctggacct gggcggagcc 480
tctacccaag tgaccttcgt gccccagaat cagaccatcg agagccccga caacgccctg 540tctacccaag tgaccttcgt gccccagaat cagaccatcg agagccccga caacgccctg 540
cagttccggc tgtacggcaa ggactacaat gtgtacaccc acagctttct ggcctacgga 600cagttccggc tgtacggcaa ggactacaat gtgtacaccc acagctttct ggcctacgga 600
aaggaccagg ccctgtggca gaagctggcc aaggacatcc aggtggccag caacgagatc 660aaggaccagg ccctgtggca gaagctggcc aaggacatcc aggtggccag caacgagatc 660
ctgcgggacc cttgcttcca ccccggctac aagaaagtcg tgaacgtgtc cgacctgtac 720ctgcgggacc cttgcttcca ccccggctac aagaaagtcg tgaacgtgtc cgacctgtac 720
aagacccccg ccaccaagag attcgagatg accctgccct tccagcagtt cgagatccag 780aagacccccg ccaccaagag attcgagatg accctgccct tccagcagtt cgagatccag 780
ggcatcggca actaccagca gtgccaccag agcatcctgg aactgttcaa caccagctac 840ggcatcggca actaccagca gtgccaccag agcatcctgg aactgttcaa caccagctac 840
tgcccctaca gccagtgcgc cttcaacggc atcttcctgc cacctctgca gggggacttc 900tgcccctaca gccagtgcgc cttcaacggc atcttcctgc cacctctgca gggggacttc 900
ggcgctttca gcgccttcta cttcgtgatg aagttcctga acctgaccag cgagaaggtg 960ggcgctttca gcgccttcta cttcgtgatg aagttcctga acctgaccag cgagaaggtg 960
tcccaggaaa aagtgacaga gatgatgaag aagttctgcg cccagccctg ggaggaaatc 1020tccaggaaa aagtgacaga gatgatgaag aagttctgcg cccagccctg ggaggaaatc 1020
aagacctcct acgctggcgt gaaagagaag tacctgagcg agtactgctt cagcggtacc 1080aagacctcct acgctggcgt gaaagagaag tacctgagcg agtactgctt cagcggtacc 1080
tacatcctga gcctgctgct gcagggctac cacttcaccg ccgatagctg ggagcacatc 1140tacatcctga gcctgctgct gcagggctac cacttcaccg ccgatagctg ggagcacatc 1140
cacttcatcg gcaagattca gggcagcgac gccggctgga cactgggcta catgctgaat 1200cacttcatcg gcaagattca gggcagcgac gccggctgga cactgggcta catgctgaat 1200
ctgaccaaca tg 1212ctgaccaaca tg 1212
<210> 123<210> 123
<211> 404<211> 404
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 123<400> 123
Asn Val Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Asn Val Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser
1 5 10 15 1 5 10 15
Leu Tyr Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Leu Tyr Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val
20 25 30 20 25 30
Val His Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Val His Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys
35 40 45 35 40 45
Phe Val Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Phe Val Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met
50 55 60 50 55 60
Glu Arg Ala Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Glu Arg Ala Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro
65 70 75 80 65 70 75 80
Val Tyr Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Val Tyr Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser
85 90 95 85 90 95
Glu Glu Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Glu Glu Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser
100 105 110 100 105 110
Asn Tyr Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Asn Tyr Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu
115 120 125 115 120 125
Glu Gly Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Glu Gly Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe
130 135 140 130 135 140
Ser Gln Lys Asn Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Gln Lys Asn Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala
145 150 155 160 145 150 155 160
Ser Thr Gln Val Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Ser Thr Gln Val Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro
165 170 175 165 170 175
Asp Asn Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Asp Asn Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr
180 185 190 180 185 190
Thr His Ser Phe Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Thr His Ser Phe Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys
195 200 205 195 200 205
Leu Ala Lys Asp Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Leu Ala Lys Asp Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro
210 215 220 210 215 220
Cys Phe His Pro Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Cys Phe His Pro Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr
225 230 235 240 225 230 235 240
Lys Thr Pro Cys Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Lys Thr Pro Cys Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln
245 250 255 245 250 255
Phe Glu Ile Gln Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Phe Glu Ile Gln Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile
260 265 270 260 265 270
Leu Glu Leu Phe Asn Thr Ser Tyr Ala Pro Tyr Ser Gln Ala Ala Phe Leu Glu Leu Phe Asn Thr Ser Tyr Ala Pro Tyr Ser Gln Ala Ala Phe
275 280 285 275 280 285
Asn Gly Ile Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Asn Gly Ile Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser
290 295 300 290 295 300
Ala Phe Tyr Phe Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ala Phe Tyr Phe Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val
305 310 315 320 305 310 315 320
Ser Gln Glu Lys Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Ser Gln Glu Lys Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro
325 330 335 325 330 335
Trp Glu Glu Ile Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Trp Glu Glu Ile Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu
340 345 350 340 345 350
Ser Glu Tyr Cys Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Ser Glu Tyr Cys Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln
355 360 365 355 360 365
Gly Tyr His Phe Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Gly Tyr His Phe Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly
370 375 380 370 375 380
Lys Ile Gln Gly Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Lys Ile Gln Gly Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn
385 390 395 400 385 390 395 400
Leu Thr Asn Met Leu Thr Asn Met
<210> 124<210> 124
<211> 1212<211> 1212
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 124<400> 124
aacgtgaagt acggcatcgt gctggatgcc ggcagcagcc acaccagcct gtacatctac 60aacgtgaagt acggcatcgt gctggatgcc ggcagcagcc acaccagcct gtacatctac 60
aagtggcctg ccgagaaaga aaacgatacc ggtgtcgtgc accaggtgga agagtgcaga 120aagtggcctg ccgagaaaga aaacgatacc ggtgtcgtgc accaggtgga agagtgcaga 120
gtgaagggcc ctggcatcag caagttcgtg cagaaagtga acgagatcgg catctacctg 180gtgaagggcc ctggcatcag caagttcgtg cagaaagtga acgagatcgg catctacctg 180
accgactgca tggaacgggc cagagaagtg atccccagaa gccagcacca ggaaaccccc 240accgactgca tggaacgggc cagagaagtg atccccagaa gccagcacca ggaaaccccc 240
gtgtacctgg gagccacagc cggcatgaga ctgctgcgga tggaaagcga ggaactggcc 300gtgtacctgg gagccacagc cggcatgaga ctgctgcgga tggaaagcga ggaactggcc 300
gacagagtgc tggacgtggt ggaaagaagc ctgagcaact acccattcga ttttcaaggg 360gacagagtgc tggacgtggt ggaaagaagc ctgagcaact acccattcga ttttcaaggg 360
gccagaatca tcaccggcca ggaagagggc gcttacggct ggatcaccat caactacctg 420gccagaatca tcaccggcca ggaagaggggc gcttacggct ggatcaccat caactacctg 420
ctgggcaagt tcagccagaa aaatcaggaa accttcggag ccctggacct gggcggagcc 480ctgggcaagt tcagccagaa aaatcaggaa accttcggag ccctggacct gggcggagcc 480
tctacccaag tgaccttcgt gccccagaat cagaccatcg agagccccga caacgccctg 540tctacccaag tgaccttcgt gccccagaat cagaccatcg agagccccga caacgccctg 540
cagttccggc tgtacggcaa ggactacaat gtgtacaccc acagctttct gtgctacgga 600cagttccggc tgtacggcaa ggactacaat gtgtacaccc acagctttct gtgctacgga 600
aaggaccagg ccctgtggca gaagctggcc aaggacatcc aggtggccag caacgagatc 660aaggaccagg ccctgtggca gaagctggcc aaggacatcc aggtggccag caacgagatc 660
ctgcgggacc cttgcttcca ccccggctac aagaaagtcg tgaacgtgtc cgacctgtac 720ctgcgggacc cttgcttcca ccccggctac aagaaagtcg tgaacgtgtc cgacctgtac 720
aagaccccct gcaccaagag attcgagatg accctgccct tccagcagtt cgagatccag 780aagaccccct gcaccaagag attcgagatg accctgccct tccagcagtt cgagatccag 780
ggcatcggca actaccagca gtgccaccag agcatcctgg aactgttcaa caccagctac 840ggcatcggca actaccagca gtgccaccag agcatcctgg aactgttcaa caccagctac 840
gccccctaca gccaggccgc cttcaacggc atcttcctgc cacctctgca gggggacttc 900gccccctaca gccaggccgc cttcaacggc atcttcctgc cacctctgca gggggacttc 900
ggcgctttca gcgccttcta cttcgtgatg aagttcctga acctgaccag cgagaaggtg 960ggcgctttca gcgccttcta cttcgtgatg aagttcctga acctgaccag cgagaaggtg 960
tcccaggaaa aagtgacaga gatgatgaag aagttctgcg cccagccctg ggaggaaatc 1020tccaggaaa aagtgacaga gatgatgaag aagttctgcg cccagccctg ggaggaaatc 1020
aagacctcct acgctggcgt gaaagagaag tacctgagcg agtactgctt cagcggtacc 1080aagacctcct acgctggcgt gaaagagaag tacctgagcg agtactgctt cagcggtacc 1080
tacatcctga gcctgctgct gcagggctac cacttcaccg ccgatagctg ggagcacatc 1140tacatcctga gcctgctgct gcagggctac cacttcaccg ccgatagctg ggagcacatc 1140
cacttcatcg gcaagattca gggcagcgac gccggctgga cactgggcta catgctgaat 1200cacttcatcg gcaagattca gggcagcgac gccggctgga cactgggcta catgctgaat 1200
ctgaccaaca tg 1212ctgaccaaca tg 1212
<210> 125<210> 125
<211> 404<211> 404
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 125<400> 125
Asn Val Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Asn Val Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser
1 5 10 15 1 5 10 15
Leu Tyr Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Leu Tyr Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val
20 25 30 20 25 30
Val His Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Val His Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys
35 40 45 35 40 45
Phe Val Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Phe Val Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met
50 55 60 50 55 60
Glu Arg Ala Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Glu Arg Ala Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro
65 70 75 80 65 70 75 80
Val Tyr Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Val Tyr Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser
85 90 95 85 90 95
Glu Glu Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Glu Glu Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser
100 105 110 100 105 110
Asn Tyr Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Asn Tyr Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu
115 120 125 115 120 125
Glu Gly Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Glu Gly Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe
130 135 140 130 135 140
Ser Gln Lys Asn Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Gln Lys Asn Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala
145 150 155 160 145 150 155 160
Ser Thr Gln Val Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Ser Thr Gln Val Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro
165 170 175 165 170 175
Asp Asn Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Asp Asn Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr
180 185 190 180 185 190
Thr His Ser Phe Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Thr His Ser Phe Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys
195 200 205 195 200 205
Leu Ala Lys Asp Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Leu Ala Lys Asp Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro
210 215 220 210 215 220
Cys Phe His Pro Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Cys Phe His Pro Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr
225 230 235 240 225 230 235 240
Lys Thr Pro Cys Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Lys Thr Pro Cys Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln
245 250 255 245 250 255
Phe Glu Ile Gln Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Phe Glu Ile Gln Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile
260 265 270 260 265 270
Leu Glu Leu Phe Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Leu Glu Leu Phe Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe
275 280 285 275 280 285
Asn Gly Ile Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Asn Gly Ile Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser
290 295 300 290 295 300
Ala Phe Tyr Phe Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ala Phe Tyr Phe Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val
305 310 315 320 305 310 315 320
Ser Gln Glu Lys Val Thr Glu Met Met Lys Lys Phe Ala Ala Gln Pro Ser Gln Glu Lys Val Thr Glu Met Met Lys Lys Phe Ala Ala Gln Pro
325 330 335 325 330 335
Trp Glu Glu Ile Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Trp Glu Glu Ile Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu
340 345 350 340 345 350
Ser Glu Tyr Ala Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Ser Glu Tyr Ala Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln
355 360 365 355 360 365
Gly Tyr His Phe Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Gly Tyr His Phe Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly
370 375 380 370 375 380
Lys Ile Gln Gly Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Lys Ile Gln Gly Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn
385 390 395 400 385 390 395 400
Leu Thr Asn Met Leu Thr Asn Met
<210> 126<210> 126
<211> 1212<211> 1212
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 126<400> 126
aacgtgaagt acggcatcgt gctggatgcc ggcagcagcc acaccagcct gtacatctac 60aacgtgaagt acggcatcgt gctggatgcc ggcagcagcc acaccagcct gtacatctac 60
aagtggcctg ccgagaaaga aaacgatacc ggtgtcgtgc accaggtgga agagtgcaga 120aagtggcctg ccgagaaaga aaacgatacc ggtgtcgtgc accaggtgga agagtgcaga 120
gtgaagggcc ctggcatcag caagttcgtg cagaaagtga acgagatcgg catctacctg 180gtgaagggcc ctggcatcag caagttcgtg cagaaagtga acgagatcgg catctacctg 180
accgactgca tggaacgggc cagagaagtg atccccagaa gccagcacca ggaaaccccc 240accgactgca tggaacgggc cagagaagtg atccccagaa gccagcacca ggaaaccccc 240
gtgtacctgg gagccacagc cggcatgaga ctgctgcgga tggaaagcga ggaactggcc 300gtgtacctgg gagccacagc cggcatgaga ctgctgcgga tggaaagcga ggaactggcc 300
gacagagtgc tggacgtggt ggaaagaagc ctgagcaact acccattcga ttttcaaggg 360gacagagtgc tggacgtggt ggaaagaagc ctgagcaact acccattcga ttttcaaggg 360
gccagaatca tcaccggcca ggaagagggc gcttacggct ggatcaccat caactacctg 420gccagaatca tcaccggcca ggaagaggggc gcttacggct ggatcaccat caactacctg 420
ctgggcaagt tcagccagaa aaatcaggaa accttcggag ccctggacct gggcggagcc 480ctgggcaagt tcagccagaa aaatcaggaa accttcggag ccctggacct gggcggagcc 480
tctacccaag tgaccttcgt gccccagaat cagaccatcg agagccccga caacgccctg 540tctacccaag tgaccttcgt gccccagaat cagaccatcg agagccccga caacgccctg 540
cagttccggc tgtacggcaa ggactacaat gtgtacaccc acagctttct gtgctacgga 600cagttccggc tgtacggcaa ggactacaat gtgtacaccc acagctttct gtgctacgga 600
aaggaccagg ccctgtggca gaagctggcc aaggacatcc aggtggccag caacgagatc 660aaggaccagg ccctgtggca gaagctggcc aaggacatcc aggtggccag caacgagatc 660
ctgcgggacc cttgcttcca ccccggctac aagaaagtcg tgaacgtgtc cgacctgtac 720ctgcgggacc cttgcttcca ccccggctac aagaaagtcg tgaacgtgtc cgacctgtac 720
aagaccccct gcaccaagag attcgagatg accctgccct tccagcagtt cgagatccag 780aagaccccct gcaccaagag attcgagatg accctgccct tccagcagtt cgagatccag 780
ggcatcggca actaccagca gtgccaccag agcatcctgg aactgttcaa caccagctac 840ggcatcggca actaccagca gtgccaccag agcatcctgg aactgttcaa caccagctac 840
tgcccctaca gccagtgcgc cttcaacggc atcttcctgc cacctctgca gggggacttc 900tgcccctaca gccagtgcgc cttcaacggc atcttcctgc cacctctgca gggggacttc 900
ggcgctttca gcgccttcta cttcgtgatg aagttcctga acctgaccag cgagaaggtg 960ggcgctttca gcgccttcta cttcgtgatg aagttcctga acctgaccag cgagaaggtg 960
tcccaggaaa aagtgacaga gatgatgaag aagttcgccg cccagccctg ggaggaaatc 1020tccggaaa aagtgacaga gatgatgaag aagttcgccg cccagccctg ggaggaaatc 1020
aagacctcct acgctggcgt gaaagagaag tacctgagcg agtacgcctt cagcggtacc 1080aagacctcct acgctggcgt gaaagagaag tacctgagcg agtacgcctt cagcggtacc 1080
tacatcctga gcctgctgct gcagggctac cacttcaccg ccgatagctg ggagcacatc 1140tacatcctga gcctgctgct gcagggctac cacttcaccg ccgatagctg ggagcacatc 1140
cacttcatcg gcaagattca gggcagcgac gccggctgga cactgggcta catgctgaat 1200cacttcatcg gcaagattca gggcagcgac gccggctgga cactgggcta catgctgaat 1200
ctgaccaaca tg 1212ctgaccaaca tg 1212
<210> 127<210> 127
<211> 431<211> 431
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 127<400> 127
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Thr Arg Trp Phe Ser Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Thr Arg Trp Phe Ser
145 150 155 160 145 150 155 160
Ile Val Pro Tyr Glu Thr Asn Asn Gln Glu Thr Phe Gly Ala Leu Asp Ile Val Pro Tyr Glu Thr Asn Asn Gln Glu Thr Phe Gly Ala Leu Asp
165 170 175 165 170 175
Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gln Asn Gln Thr Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gln Asn Gln Thr
180 185 190 180 185 190
Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp
195 200 205 195 200 205
Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Lys Asp Gln Ala Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Lys Asp Gln Ala
210 215 220 210 215 220
Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Ser Asn Glu Ile Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Ser Asn Glu Ile
225 230 235 240 225 230 235 240
Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Val Val Asn Val Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Val Val Asn Val
245 250 255 245 250 255
Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Glu Met Thr Leu Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Glu Met Thr Leu
260 265 270 260 265 270
Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Tyr Gln Gln Cys Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Tyr Gln Gln Cys
275 280 285 275 280 285
His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Phe Asn Gly Ile Phe His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Phe Asn Gly Ile Phe
290 295 300 290 295 300
Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe
305 310 315 320 305 310 315 320
Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys
325 330 335 325 330 335
Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile
340 345 350 340 345 350
Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys
355 360 365 355 360 365
Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe
370 375 380 370 375 380
Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly
385 390 395 400 385 390 395 400
Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met
405 410 415 405 410 415
Ile Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Ile Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 430 420 425 430
<210> 128<210> 128
<211> 1293<211> 1293
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 128<400> 128
acacagaaca aagccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acacagaaca aagccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga taccggtgtc 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga taccggtgtc 120
gtgcaccagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcaccagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccagaga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccagaga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtac ctgggagcca cagccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtac ctgggagcca cagccggcat gagactgctg 300
cggatggaaa gcgaggaact ggccgacaga gtgctggacg tggtggaaag aagcctgagc 360cggatggaaa gcgaggaact ggccgacaga gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggggccaga atcatcaccg gccaggaaga gggcgcttac 420aactacccat tcgattttca aggggccaga atcatcaccg gccaggaaga gggcgcttac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaaaacccg gtggttcagc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaaaacccg gtggttcagc 480
atcgtgccct acgagacaaa caatcaggaa accttcggag ccctggacct gggcggagcc 540atcgtgccct acgagacaaa caatcaggaa accttcggag ccctggacct gggcggagcc 540
tctacccaag tgaccttcgt gccccagaat cagaccatcg agagccccga caacgccctg 600tctacccaag tgaccttcgt gccccagaat cagaccatcg agagccccga caacgccctg 600
cagttccggc tgtacggcaa ggactacaat gtgtacaccc acagctttct gtgctacgga 660cagttccggc tgtacggcaa ggactacaat gtgtacaccc acagctttct gtgctacgga 660
aaggaccagg ccctgtggca gaagctggcc aaggacatcc aggtggccag caacgagatc 720aaggaccagg ccctgtggca gaagctggcc aaggacatcc aggtggccag caacgagatc 720
ctgcgggacc cttgcttcca ccccggctac aagaaagtcg tgaacgtgtc cgacctgtac 780ctgcgggacc cttgcttcca ccccggctac aagaaagtcg tgaacgtgtc cgacctgtac 780
aagaccccct gcaccaagag attcgagatg accctgccct tccagcagtt cgagatccag 840aagaccccct gcaccaagag attcgagatg accctgccct tccagcagtt cgagatccag 840
ggcatcggca actaccagca gtgccaccag agcatcctgg aactgttcaa caccagcttc 900ggcatcggca actaccagca gtgccaccag agcatcctgg aactgttcaa caccagcttc 900
aacggcatct tcctgccacc tctgcagggg gacttcggcg ctttcagcgc cttctacttc 960aacggcatct tcctgccacc tctgcagggg gacttcggcg ctttcagcgc cttctacttc 960
gtgatgaagt tcctgaacct gaccagcgag aaggtgtccc aggaaaaagt gacagagatg 1020gtgatgaagt tcctgaacct gaccagcgag aaggtgtccc aggaaaaagt gacagagatg 1020
atgaagaagt tctgcgccca gccctgggag gaaatcaaga cctcctacgc tggcgtgaaa 1080atgaagaagt tctgcgccca gccctgggag gaaatcaaga cctcctacgc tggcgtgaaa 1080
gagaagtacc tgagcgagta ctgcttcagc ggtacctaca tcctgagcct gctgctgcag 1140gagaagtacc tgagcgagta ctgcttcagc ggtacctaca tcctgagcct gctgctgcag 1140
ggctaccact tcaccgccga tagctgggag cacatccact tcatcggcaa gattcagggc 1200ggctaccact tcaccgccga tagctgggag cacatccact tcatcggcaa gattcaggggc 1200
agcgacgccg gctggacact gggctacatg ctgaatctga ccaacatgat ccccgccgag 1260agcgacgccg gctggacact gggctacatg ctgaatctga ccaacatgat ccccgccgag 1260
cagcccctga gcacacctct gtctcacagc acc 1293cagcccctga gcacacctct gtctcacagc acc 1293
<210> 129<210> 129
<211> 439<211> 439
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 129<400> 129
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Thr Arg Trp Phe Ser Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Thr Arg Trp Phe Ser
145 150 155 160 145 150 155 160
Ile Val Pro Tyr Glu Thr Asn Asn Gln Glu Thr Phe Gly Ala Leu Asp Ile Val Pro Tyr Glu Thr Asn Asn Gln Glu Thr Phe Gly Ala Leu Asp
165 170 175 165 170 175
Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gln Asn Gln Thr Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gln Asn Gln Thr
180 185 190 180 185 190
Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp
195 200 205 195 200 205
Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Lys Asp Gln Ala Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Lys Asp Gln Ala
210 215 220 210 215 220
Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Ser Asn Glu Ile Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Ser Asn Glu Ile
225 230 235 240 225 230 235 240
Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Val Val Asn Val Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Val Val Asn Val
245 250 255 245 250 255
Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Glu Met Thr Leu Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Glu Met Thr Leu
260 265 270 260 265 270
Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Tyr Gln Gln Cys Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Tyr Gln Gln Cys
275 280 285 275 280 285
His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Ala Pro Tyr Ser His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Ala Pro Tyr Ser
290 295 300 290 295 300
Gln Ala Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Gln Gly Asp Phe Gln Ala Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Gln Gly Asp Phe
305 310 315 320 305 310 315 320
Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Leu Asn Leu Thr Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Leu Asn Leu Thr
325 330 335 325 330 335
Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Met Lys Lys Phe Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Met Lys Lys Phe
340 345 350 340 345 350
Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Ala Gly Val Lys Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Ala Gly Val Lys
355 360 365 355 360 365
Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Tyr Ile Leu Ser Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Tyr Ile Leu Ser
370 375 380 370 375 380
Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Trp Glu His Ile Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Trp Glu His Ile
385 390 395 400 385 390 395 400
His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Thr Leu Gly His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Thr Leu Gly
405 410 415 405 410 415
Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Gln Pro Leu Ser Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Gln Pro Leu Ser
420 425 430 420 425 430
Thr Pro Leu Ser His Ser Thr Thr Pro Leu Ser His Ser Thr
435 435
<210> 130<210> 130
<211> 1317<211> 1317
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 130<400> 130
acacagaaca aagccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acacagaaca aagccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga taccggtgtc 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga taccggtgtc 120
gtgcaccagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcaccagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccagaga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccagaga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtac ctgggagcca cagccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtac ctgggagcca cagccggcat gagactgctg 300
cggatggaaa gcgaggaact ggccgacaga gtgctggacg tggtggaaag aagcctgagc 360cggatggaaa gcgaggaact ggccgacaga gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggggccaga atcatcaccg gccaggaaga gggcgcttac 420aactacccat tcgattttca aggggccaga atcatcaccg gccaggaaga gggcgcttac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaaaacccg gtggttcagc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaaaacccg gtggttcagc 480
atcgtgccct acgagacaaa caatcaggaa accttcggag ccctggacct gggcggagcc 540atcgtgccct acgagacaaa caatcaggaa accttcggag ccctggacct gggcggagcc 540
tctacccaag tgaccttcgt gccccagaat cagaccatcg agagccccga caacgccctg 600tctacccaag tgaccttcgt gccccagaat cagaccatcg agagccccga caacgccctg 600
cagttccggc tgtacggcaa ggactacaat gtgtacaccc acagctttct gtgctacgga 660cagttccggc tgtacggcaa ggactacaat gtgtacaccc acagctttct gtgctacgga 660
aaggaccagg ccctgtggca gaagctggcc aaggacatcc aggtggccag caacgagatc 720aaggaccagg ccctgtggca gaagctggcc aaggacatcc aggtggccag caacgagatc 720
ctgcgggacc cttgcttcca ccccggctac aagaaagtcg tgaacgtgtc cgacctgtac 780ctgcgggacc cttgcttcca ccccggctac aagaaagtcg tgaacgtgtc cgacctgtac 780
aagaccccct gcaccaagag attcgagatg accctgccct tccagcagtt cgagatccag 840aagaccccct gcaccaagag attcgagatg accctgccct tccagcagtt cgagatccag 840
ggcatcggca actaccagca gtgccaccag agcatcctgg aactgttcaa caccagctac 900ggcatcggca actaccagca gtgccaccag agcatcctgg aactgttcaa caccagctac 900
gccccctaca gccaggccgc cttcaacggc atcttcctgc cacctctgca gggggacttc 960gccccctaca gccaggccgc cttcaacggc atcttcctgc cacctctgca gggggacttc 960
ggcgctttca gcgccttcta cttcgtgatg aagttcctga acctgaccag cgagaaggtg 1020ggcgctttca gcgccttcta cttcgtgatg aagttcctga acctgaccag cgagaaggtg 1020
tcccaggaaa aagtgacaga gatgatgaag aagttctgcg cccagccctg ggaggaaatc 1080tccggaaa aagtgacaga gatgatgaag aagttctgcg cccagccctg ggaggaaatc 1080
aagacctcct acgctggcgt gaaagagaag tacctgagcg agtactgctt cagcggtacc 1140aagacctcct acgctggcgt gaaagagaag tacctgagcg agtactgctt cagcggtacc 1140
tacatcctga gcctgctgct gcagggctac cacttcaccg ccgatagctg ggagcacatc 1200tacatcctga gcctgctgct gcagggctac cacttcaccg ccgatagctg ggagcacatc 1200
cacttcatcg gcaagattca gggcagcgac gccggctgga cactgggcta catgctgaat 1260cacttcatcg gcaagattca gggcagcgac gccggctgga cactgggcta catgctgaat 1260
ctgaccaaca tgatccccgc cgagcagccc ctgagcacac ctctgtctca cagcacc 1317ctgaccaaca tgatccccgc cgagcagccc ctgagcacac ctctgtctca cagcacc 1317
<210> 131<210> 131
<211> 16<211> 16
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический пептид"synthetic peptide
<400> 131<400> 131
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Thr Ser Ser Gly Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Thr Ser Ser Gly
1 5 10 15 1 5 10 15
<210> 132<210> 132
<211> 48<211> 48
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический олигонуклеотид"Synthetic oligonucleotide"
<400> 132<400> 132
gcccccacca gcagcagcac caagaagacc cagctgacca gcagcggc 48gcccccacca gcagcagcac caagaagacc cagctgacca gcagcggc 48
<210> 133<210> 133
<211> 15<211> 15
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический пептид"synthetic peptide
<400> 133<400> 133
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Thr Ser Ser Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Thr Ser Ser
1 5 10 15 1 5 10 15
<210> 134<210> 134
<211> 45<211> 45
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический олигонуклеотид"Synthetic oligonucleotide"
<400> 134<400> 134
gcccctacca gcagcagcac caagaaaacc cagctgacca gcagc 45gcccctacca gcagcagcac caagaaaacc cagctgacca gcagc 45
<210> 135<210> 135
<211> 6<211> 6
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический пептид"synthetic peptide"
<400> 135<400> 135
Ala Pro Thr Ser Ser Ser Ala Pro Thr Ser Ser Ser
1 5 15
<210> 136<210> 136
<211> 18<211> 18
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический олигонуклеотид"Synthetic oligonucleotide"
<400> 136<400> 136
gcccctacca gcagcagc 18gcccctacca gcagcagc 18
<210> 137<210> 137
<211> 3<211> 3
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический пептид"synthetic peptide"
<400> 137<400> 137
Ala Pro Thr Ala Pro Thr
1 1
<210> 138<210> 138
<211> 9<211> 9
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический олигонуклеотид"Synthetic oligonucleotide"
<400> 138<400> 138
gcccctacc 9gcccctacc 9
<210> 139<210> 139
<211> 9<211> 9
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический пептид"synthetic peptide"
<400> 139<400> 139
Ala Pro Thr Ser Ser Ser Thr Lys Lys Ala Pro Thr Ser Ser Ser Thr Lys Lys
1 5 15
<210> 140<210> 140
<211> 27<211> 27
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический олигонуклеотид"Synthetic oligonucleotide"
<400> 140<400> 140
gcccctacca gcagcagcac caagaaa 27gcccctacca gcagcagcac caagaaa 27
<210> 141<210> 141
<211> 12<211> 12
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический пептид"synthetic peptide"
<400> 141<400> 141
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu
1 5 10 1 5 10
<210> 142<210> 142
<211> 36<211> 36
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический олигонуклеотид"Synthetic oligonucleotide"
<400> 142<400> 142
gcccctacca gcagcagcac caagaaaacc cagctg 36gcccctacca gcagcagcac caagaaaacc cagctg 36
<210> 143<210> 143
<211> 9<211> 9
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический пептид"synthetic peptide
<400> 143<400> 143
Ser Ser Ser Thr Lys Lys Thr Gln Leu Ser Ser Ser Thr Lys Lys Thr Gln Leu
1 5 15
<210> 144<210> 144
<211> 27<211> 27
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический олигонуклеотид"Synthetic oligonucleotide"
<400> 144<400> 144
agcagcagca ccaagaaaac ccagctg 27agcagcagca ccaagaaaac ccagctg 27
<210> 145<210> 145
<211> 426<211> 426
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 145<400> 145
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Asp Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Asp Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe
145 150 155 160 145 150 155 160
Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro
165 170 175 165 170 175
Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu
180 185 190 180 185 190
Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly
195 200 205 195 200 205
Arg Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Arg Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala
210 215 220 210 215 220
Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys
225 230 235 240 225 230 235 240
Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe
245 250 255 245 250 255
Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn
260 265 270 260 265 270
Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr
275 280 285 275 280 285
Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu
290 295 300 290 295 300
Gln Gly Asp Phe Gly Ala Phe Ser Asn Phe Tyr Tyr Val Met Lys Phe Gln Gly Asp Phe Gly Ala Phe Ser Asn Phe Tyr Tyr Val Met Lys Phe
305 310 315 320 305 310 315 320
Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met
325 330 335 325 330 335
Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr
340 345 350 340 345 350
Ala Gly Gln Glu Arg Trp Leu Arg Asp Tyr Cys Phe Ser Gly Thr Tyr Ala Gly Gln Glu Arg Trp Leu Arg Asp Tyr Cys Phe Ser Gly Thr Tyr
355 360 365 355 360 365
Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Trp Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Trp
370 375 380 370 375 380
Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp
385 390 395 400 385 390 395 400
Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Gln Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Gln
405 410 415 405 410 415
Pro Leu Ser Thr Pro Leu Ser His Ser Thr Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 420 425
<210> 146<210> 146
<211> 1278<211> 1278
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 146<400> 146
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccagaga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccagaga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggacga gggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggacga gggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaatca ggaaaccttc 480
ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540ggcgccctgg acctgggcgg agcttctacc caagtgacct tcgtgcccca gaatcagacc 540
atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600atcgagagcc ccgacaacgc cctgcagttc cggctgtacg gcaaggacta caatgtgtac 600
acccacagct ttctgtgcta cggccgggac caggctctgt ggcagaagct ggccaaggac 660acccacagct ttctgtgcta cggccgggac caggctctgt ggcagaagct ggccaaggac 660
atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720atccaggtgg ccagcaacga gatcctgcgg gacccttgct tccaccccgg ctacaagaaa 720
gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780gtcgtgaacg tgtccgacct gtacaagacc ccctgcacca agagattcga gatgaccctg 780
cccttccagc agttcgagat ccagggcatc ggcaactacc agcagtgcca ccagagcatc 840cccttccagc agttcgagat ccagggcatc ggcaactacc agcagtgcca ccagagcatc 840
ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900ctggaactgt tcaacaccag ctactgcccc tacagccagt gcgccttcaa cggcatcttc 900
ctgccacctc tgcaggggga tttcggcgcc ttcagcaact tctactacgt gatgaagttc 960ctgccacctc tgcaggggga tttcggcgcc ttcagcaact tctactacgt gatgaagttc 960
ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020ctgaacctga ccagcgagaa ggtgtcccag gaaaaagtga cagagatgat gaagaagttc 1020
tgcgcccagc cctgggagga aatcaagacc tcttacgccg gacaggaacg gtggctgcgg 10801080
gactactgtt tcagcggcac ctacatcctg tccctgctgc tgcagggcta ccacttcacc 1140gactactgtt tcagcggcac ctacatcctg tccctgctgc tgcaggggcta ccacttcacc 1140
gccgatagct gggagcacat ccacttcatc ggcaagattc agggcagcga cgccggctgg 1200gccgatagct gggagcacat ccacttcatc ggcaagattc agggcagcga cgccggctgg 1200
acactgggct acatgctgaa tctgaccaac atgatccccg ccgagcagcc cctgagcaca 1260acactgggct acatgctgaa tctgaccaac atgatccccg ccgagcagcc cctgagcaca 1260
cctctgtctc acagcacc 1278cctctgtctc acagcacc 1278
<210> 147<210> 147
<211> 537<211> 537
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 147<400> 147
Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
1 5 10 15 1 5 10 15
Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
20 25 30 20 25 30
Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
35 40 45 35 40 45
Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
50 55 60 50 55 60
Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
65 70 75 80 65 70 75 80
His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
85 90 95 85 90 95
Val Thr Lys Ser Phe Asn Arg Gly Glu Gly Gly Gly Gly Ser Thr Gln Val Thr Lys Ser Phe Asn Arg Gly Glu Gly Gly Gly Gly Ser Thr Gln
100 105 110 100 105 110
Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Asp Ala Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Asp Ala
115 120 125 115 120 125
Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Glu Lys Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Glu Lys
130 135 140 130 135 140
Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Val Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Val Lys
145 150 155 160 145 150 155 160
Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Gly Ile Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Gly Ile
165 170 175 165 170 175
Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Arg Ser Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Arg Ser
180 185 190 180 185 190
Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Met Arg Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Met Arg
195 200 205 195 200 205
Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Asp Val Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Asp Val
210 215 220 210 215 220
Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Ala Arg Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Ala Arg
225 230 235 240 225 230 235 240
Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ile Asn Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ile Asn
245 250 255 245 250 255
Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Gly Ala Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Gly Ala
260 265 270 260 265 270
Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gln Asn Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gln Asn
275 280 285 275 280 285
Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Tyr Gly Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Tyr Gly
290 295 300 290 295 300
Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Lys Asp Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Lys Asp
305 310 315 320 305 310 315 320
Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Ser Asn Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Ser Asn
325 330 335 325 330 335
Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Val Val Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Val Val
340 345 350 340 345 350
Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Glu Met Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Glu Met
355 360 365 355 360 365
Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Tyr Gln Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Tyr Gln
370 375 380 370 375 380
Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Cys Pro Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Cys Pro
385 390 395 400 385 390 395 400
Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Gln Gly Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Gln Gly
405 410 415 405 410 415
Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Leu Asn Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Leu Asn
420 425 430 420 425 430
Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Met Lys Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Met Lys
435 440 445 435 440 445
Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Ala Gly Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Ala Gly
450 455 460 450 455 460
Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Tyr Ile Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Tyr Ile
465 470 475 480 465 470 475 480
Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Trp Glu Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Trp Glu
485 490 495 485 490 495
His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Thr His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Thr
500 505 510 500 505 510
Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Gln Pro Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Gln Pro
515 520 525 515 520 525
Leu Ser Thr Pro Leu Ser His Ser Thr Leu Ser Thr Pro Leu Ser His Ser Thr
530 535 530 535
<210> 148<210> 148
<211> 1611<211> 1611
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 148<400> 148
acggtggccg ctcccagcgt gttcatcttc ccccccagcg acgagcagct gaagagcggc 60acggtggccg ctcccagcgt gttcatcttc ccccccagcg acgagcagct gaagagcggc 60
accgccagcg tggtgtgcct gctgaacaac ttctaccccc gggaggccaa ggtgcagtgg 120accgccagcg tggtgtgcct gctgaacaac ttctaccccc gggaggccaa ggtgcagtgg 120
aaggtggaca acgccctgca gagcggcaac agccaggaaa gcgtcaccga gcaggacagc 180aaggtggaca acgccctgca gagcggcaac agcggaaa gcgtcaccga gcaggacagc 180
aaggactcca cctacagcct gagcagcacc ctgaccctga gcaaggccga ctacgagaag 240aaggactcca cctacagcct gagcagcacc ctgaccctga gcaaggccga ctacgagaag 240
cacaaggtgt acgcctgcga ggtgacccac cagggcctgt ccagccccgt gaccaagagc 300cacaaggtgt acgcctgcga ggtgacccac cagggcctgt ccagccccgt gaccaagagc 300
ttcaaccggg gcgagggagg cggaggatct acccagaaca aggccctgcc cgagaacgtg 360ttcaaccgggg gcgagggagg cggaggatct acccagaaca aggccctgcc cgagaacgtg 360
aagtacggca tcgtgctgga tgccggcagc agccacacca gcctgtacat ctacaagtgg 420aagtacggca tcgtgctgga tgccggcagc agccacacca gcctgtacat ctacaagtgg 420
cctgccgaga aagaaaacga caccggcgtg gtgcatcagg tggaagagtg cagagtgaag 480cctgccgaga aagaaaacga caccggcgtg gtgcatcagg tggaagagtg cagagtgaag 480
ggccctggca tcagcaagtt cgtgcagaaa gtgaacgaga tcggcatcta cctgaccgac 540ggccctggca tcagcaagtt cgtgcagaaa gtgaacgaga tcggcatcta cctgaccgac 540
tgcatggaac gggccaggga agtgatcccc agaagccagc accaggaaac ccccgtgtat 600tgcatggaac gggccaggga agtgatcccc agaagccagc accaggaaac ccccgtgtat 600
ctgggagcca ccgccggcat gagactgctg agaatggaaa gcgaggaact ggccgaccgg 660ctgggagcca ccgccggcat gagactgctg agaatggaaa gcgaggaact ggccgaccgg 660
gtgctggacg tggtggaaag aagcctgagc aactacccat tcgattttca aggcgccaga 720gtgctggacg tggtggaaag aagcctgagc aactacccat tcgattttca aggcgccaga 720
atcatcaccg gccaggaaga aggcgcctac ggctggatca ccatcaacta cctgctgggc 780atcatcaccg gccaggaaga aggcgcctac ggctggatca ccatcaacta cctgctgggc 780
aagttcagcc agaagaatca ggaaaccttc ggcgccctgg acctgggcgg agcttctacc 840aagttcagcc agaagaatca ggaaaccttc ggcgccctgg acctgggcgg agcttctacc 840
caagtgacct tcgtgcccca gaatcagacc atcgagagcc ccgacaacgc cctgcagttc 900caagtgacct tcgtgcccca gaatcagacc atcgagagcc ccgacaacgc cctgcagttc 900
cggctgtacg gcaaggacta caatgtgtac acccacagct ttctgtgcta cggaaaggac 960cggctgtacg gcaaggacta caatgtgtac acccacagct ttctgtgcta cggaaaggac 960
caggctctgt ggcagaagct ggccaaggac atccaggtgg ccagcaacga gatcctgcgg 1020caggctctgt ggcagaagct ggccaaggac atccaggtgg ccagcaacga gatcctgcgg 1020
gacccttgct tccaccccgg ctacaagaaa gtcgtgaacg tgtccgacct gtacaagacc 1080gacccttgct tccaccccgg ctacaagaaa gtcgtgaacg tgtccgacct gtacaagacc 1080
ccctgcacca agagattcga gatgaccctg cccttccagc agttcgagat ccagggcatc 1140ccctgcacca agagattcga gatgaccctg cccttccagc agttcgagat ccagggcatc 1140
ggcaattacc agcagtgcca ccagagcatc ctggaactgt tcaacaccag ctactgcccc 1200ggcaattacc agcagtgcca ccagagcatc ctggaactgt tcaacaccag ctactgcccc 1200
tacagccagt gcgccttcaa cggcatcttc ctgccacctc tgcaggggga tttcggcgcc 1260tacagccagt gcgccttcaa cggcatcttc ctgccacctc tgcaggggga tttcggcgcc 1260
ttcagcgcct tctacttcgt gatgaagttc ctgaacctga ccagcgagaa ggtgtcccag 1320ttcagcgcct tctacttcgt gatgaagttc ctgaacctga ccagcgagaa ggtgtcccag 1320
gaaaaagtga cagagatgat gaagaagttc tgcgcccagc cctgggagga aatcaagacc 1380gaaaaagtga cagagatgat gaagaagttc tgcgcccagc cctgggagga aatcaagacc 1380
tcctacgctg gcgtgaaaga gaagtacctg agcgagtact gcttcagcgg cacctacatc 1440tcctacgctg gcgtgaaaga gaagtacctg agcgagtact gcttcagcgg cacctacatc 1440
ctgagcctgc tgctgcaggg ctaccacttc accgccgata gctgggagca catccacttc 1500ctgagcctgc tgctgcaggg ctaccacttc accgccgata gctgggagca catccacttc 1500
atcggcaaga ttcagggcag cgacgccggc tggacactgg gctacatgct gaatctgacc 1560atcggcaaga ttcagggcag cgacgccggc tggacactgg gctacatgct gaatctgacc 1560
aacatgatcc ccgccgagca gcccctgagc acacctctga gccacagcac c 1611aacatgatcc ccgccgagca gcccctgagc acacctctga gccacagcac c 1611
<210> 149<210> 149
<211> 508<211> 508
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 149<400> 149
Met Gln Ile Phe Val Lys Thr Leu Thr Gly Lys Thr Ile Thr Leu Glu Met Gln Ile Phe Val Lys Thr Leu Thr Gly Lys Thr Ile Thr Leu Glu
1 5 10 15 1 5 10 15
Val Glu Pro Ser Asp Thr Ile Glu Asn Val Lys Ala Lys Ile Gln Asp Val Glu Pro Ser Asp Thr Ile Glu Asn Val Lys Ala Lys Ile Gln Asp
20 25 30 20 25 30
Lys Glu Gly Ile Pro Pro Asp Gln Gln Arg Leu Ile Phe Ala Gly Lys Lys Glu Gly Ile Pro Pro Asp Gln Gln Arg Leu Ile Phe Ala Gly Lys
35 40 45 35 40 45
Gln Leu Glu Asp Gly Arg Thr Leu Ser Asp Tyr Asn Ile Gln Lys Glu Gln Leu Glu Asp Gly Arg Thr Leu Ser Asp Tyr Asn Ile Gln Lys Glu
50 55 60 50 55 60
Ser Thr Leu His Leu Val Leu Arg Leu Arg Gly Gly Gly Gly Gly Gly Ser Thr Leu His Leu Val Leu Arg Leu Arg Gly Gly Gly Gly Gly Gly
65 70 75 80 65 70 75 80
Ser Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Ser Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val
85 90 95 85 90 95
Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro
100 105 110 100 105 110
Ala Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Ala Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys
115 120 125 115 120 125
Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu
130 135 140 130 135 140
Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile
145 150 155 160 145 150 155 160
Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala
165 170 175 165 170 175
Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val
180 185 190 180 185 190
Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln
195 200 205 195 200 205
Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile
210 215 220 210 215 220
Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr
225 230 235 240 225 230 235 240
Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val
245 250 255 245 250 255
Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg
260 265 270 260 265 270
Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr
275 280 285 275 280 285
Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val
290 295 300 290 295 300
Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys
305 310 315 320 305 310 315 320
Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg
325 330 335 325 330 335
Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly
340 345 350 340 345 350
Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser
355 360 365 355 360 365
Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro
370 375 380 370 375 380
Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys
385 390 395 400 385 390 395 400
Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu
405 410 415 405 410 415
Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser
420 425 430 420 425 430
Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly
435 440 445 435 440 445
Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp
450 455 460 450 455 460
Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala
465 470 475 480 465 470 475 480
Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala
485 490 495 485 490 495
Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
500 505 500 505
<210> 150<210> 150
<211> 1524<211> 1524
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 150<400> 150
atgcaaatct tcgtgaagac cctgactggt aagaccatca ccctcgaggt ggagcccagt 60atgcaaatct tcgtgaagac cctgactggt aagaccatca ccctcgaggt ggagcccagt 60
gacaccatcg agaatgtcaa ggcaaagatc caagataagg aaggcatccc tcctgatcag 120gacaccatcg agaatgtcaa ggcaaagatc caagataagg aaggcatccc tcctgatcag 120
cagaggttga tctttgctgg gaaacagctg gaagatggac gcaccctgtc tgactacaac 180cagaggttga tctttgctgg gaaacagctg gaagatggac gcaccctgtc tgactacaac 180
atccagaaag agtccactct gcacttggtc ctgcgcttga gggggggtgg aggcggagga 240atccagaaag agtccactct gcacttggtc ctgcgcttga gggggggtgg aggcggagga 240
tctacccaga acaaggccct gcccgagaac gtgaagtacg gcatcgtgct ggatgccggc 300tctacccaga acaaggccct gcccgagaac gtgaagtacg gcatcgtgct ggatgccggc 300
agcagccaca ccagcctgta catctacaag tggcctgccg agaaagaaaa cgacaccggc 360agcagccaca ccagcctgta catctacaag tggcctgccg agaaagaaaa cgacaccggc 360
gtggtgcatc aggtggaaga gtgcagagtg aagggccctg gcatcagcaa gttcgtgcag 420gtggtgcatc aggtggaaga gtgcagagtg aagggccctg gcatcagcaa gttcgtgcag 420
aaagtgaacg agatcggcat ctacctgacc gactgcatgg aacgggccag ggaagtgatc 480aaagtgaacg agatcggcat ctacctgacc gactgcatgg aacgggccag ggaagtgatc 480
cccagaagcc agcaccagga aacccccgtg tatctgggag ccaccgccgg catgagactg 540cccagaagcc agcaccagga aacccccgtg tatctgggag ccaccgccgg catgagactg 540
ctgagaatgg aaagcgagga actggccgac cgggtgctgg acgtggtgga aagaagcctg 600ctgagaatgg aaagcgagga actggccgac cgggtgctgg acgtggtgga aagaagcctg 600
agcaactacc cattcgattt tcaaggcgcc agaatcatca ccggccagga agaaggcgcc 660agcaactacc cattcgattt tcaaggcgcc agaatcatca ccggccagga agaaggcgcc 660
tacggctgga tcaccatcaa ctacctgctg ggcaagttca gccagaagaa tcaggaaacc 720tacggctgga tcaccatcaa ctacctgctg ggcaagttca gccagaagaa tcaggaaacc 720
ttcggcgccc tggacctggg cggagcttct acccaagtga ccttcgtgcc ccagaatcag 780ttcggcgccc tggacctggg cggagcttct acccaagtga ccttcgtgcc ccagaatcag 780
accatcgaga gccccgacaa cgccctgcag ttccggctgt acggcaagga ctacaatgtg 840accatcgaga gccccgacaa cgccctgcag ttccggctgt acggcaagga ctacaatgtg 840
tacacccaca gctttctgtg ctacggaaag gaccaggctc tgtggcagaa gctggccaag 900tacacccaca gctttctgtg ctacggaaag gaccaggctc tgtggcagaa gctggccaag 900
gacatccagg tggccagcaa cgagatcctg cgggaccctt gcttccaccc cggctacaag 960gacatccagg tggccagcaa cgagatcctg cgggaccctt gcttccaccc cggctacaag 960
aaagtcgtga acgtgtccga cctgtacaag accccctgca ccaagagatt cgagatgacc 1020aaagtcgtga acgtgtccga cctgtacaag accccctgca ccaagagatt cgagatgacc 1020
ctgcccttcc agcagttcga gatccagggc atcggcaatt accagcagtg ccaccagagc 1080ctgcccttcc agcagttcga gatccagggc atcggcaatt accagcagtg ccaccagagc 1080
atcctggaac tgttcaacac cagctactgc ccctacagcc agtgcgcctt caacggcatc 1140atcctggaac tgttcaacac cagctactgc ccctacagcc agtgcgcctt caacggcatc 1140
ttcctgccac ctctgcaggg ggatttcggc gccttcagcg ccttctactt cgtgatgaag 1200ttcctgccac ctctgcaggg ggatttcggc gccttcagcg ccttctactt cgtgatgaag 1200
ttcctgaacc tgaccagcga gaaggtgtcc caggaaaaag tgacagagat gatgaagaag 1260ttcctgaacc tgaccagcga gaaggtgtcc caggaaaaag tgacagagat gatgaagaag 1260
ttctgcgccc agccctggga ggaaatcaag acctcctacg ctggcgtgaa agagaagtac 1320ttctgcgccc agccctggga ggaaatcaag acctcctacg ctggcgtgaa agagaagtac 1320
ctgagcgagt actgcttcag cggcacctac atcctgagcc tgctgctgca gggctaccac 1380ctgagcgagt actgcttcag cggcacctac atcctgagcc tgctgctgca gggctaccac 1380
ttcaccgccg atagctggga gcacatccac ttcatcggca agattcaggg cagcgacgcc 1440ttcaccgccg atagctggga gcacatccac ttcatcggca agattcaggg cagcgacgcc 1440
ggctggacac tgggctacat gctgaatctg accaacatga tccccgccga gcagcccctg 1500ggctggacac tgggctacat gctgaatctg accaacatga tccccgccga gcagcccctg 1500
agcacacctc tgagccacag cacc 1524agcacacctc tgagccacag cacc 1524
<210> 151<210> 151
<211> 618<211> 618
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 151<400> 151
Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu
1 5 10 15 1 5 10 15
Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln
20 25 30 20 25 30
Gln Ser Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu Gln Ser Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu
35 40 45 35 40 45
Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys
50 55 60 50 55 60
Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu
65 70 75 80 65 70 75 80
Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro
85 90 95 85 90 95
Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu
100 105 110 100 105 110
Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His
115 120 125 115 120 125
Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg
130 135 140 130 135 140
Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg
145 150 155 160 145 150 155 160
Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala
165 170 175 165 170 175
Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Gly Gly Gly Gly Ser Thr Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Gly Gly Gly Gly Ser Thr
180 185 190 180 185 190
Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Asp Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Asp
195 200 205 195 200 205
Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Glu Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Glu
210 215 220 210 215 220
Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Val Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Val
225 230 235 240 225 230 235 240
Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Gly Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Gly
245 250 255 245 250 255
Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Arg Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Arg
260 265 270 260 265 270
Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Met Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Met
275 280 285 275 280 285
Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Asp Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Asp
290 295 300 290 295 300
Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Ala Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Ala
305 310 315 320 305 310 315 320
Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ile Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ile
325 330 335 325 330 335
Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Gly Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Gly
340 345 350 340 345 350
Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gln Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gln
355 360 365 355 360 365
Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Tyr Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Tyr
370 375 380 370 375 380
Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Lys Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Lys
385 390 395 400 385 390 395 400
Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Ser Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Ser
405 410 415 405 410 415
Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Val Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Val
420 425 430 420 425 430
Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Glu Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Glu
435 440 445 435 440 445
Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Tyr Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Tyr
450 455 460 450 455 460
Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Cys Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Cys
465 470 475 480 465 470 475 480
Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Gln Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Gln
485 490 495 485 490 495
Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Leu Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Leu
500 505 510 500 505 510
Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Met Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Met
515 520 525 515 520 525
Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Ala Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Ala
530 535 540 530 535 540
Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Tyr Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Tyr
545 550 555 560 545 550 555 560
Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Trp Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Trp
565 570 575 565 570 575
Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp
580 585 590 580 585 590
Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Gln Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Gln
595 600 605 595 600 605
Pro Leu Ser Thr Pro Leu Ser His Ser Thr Pro Leu Ser Thr Pro Leu Ser His Ser Thr
610 615 610 615
<210> 152<210> 152
<211> 1854<211> 1854
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 152<400> 152
gacgcccaca agagcgaggt ggcccaccgg ttcaaggacc tgggcgagga aaacttcaag 60gacgcccaca agagcgaggt ggcccaccgg ttcaaggacc tgggcgagga aaacttcaag 60
gccctggtgc tgatcgcctt cgcccagtac ctgcagcaga gccccttcga agatcacgta 120gccctggtgc tgatcgcctt cgcccagtac ctgcagcaga gccccttcga agatcacgta 120
aagttagtca acgaggttac ggaattcgca aagacatgcg ttgctgacga atccgctgag 180aagttagtca acgaggttac ggaattcgca aagacatgcg ttgctgacga atccgctgag 180
aattgtgaca agagtttgca cactttattc ggagataagt tgtgtactgt agctactttg 240aattgtgaca agagtttgca cactttattc ggagataagt tgtgtactgt agctactttg 240
agagagactt acggtgaaat ggctgactgc tgtgcaaaac aggaaccaga acgtaacgaa 300agagagactt acggtgaaat ggctgactgc tgtgcaaaac aggaaccaga acgtaacgaa 300
tgtttccttc agcataagga tgataaccct aaccttccaa ggcttgttag gccagaagtc 360tgtttccttc agcataagga tgataaccct aaccttccaa ggcttgttag gccagaagtc 360
gacgtgatgt gcaccgcctt ccatgataat gaagagactt ttcttaaaaa gtacctatac 420gacgtgatgt gcaccgcctt ccatgataat gaagagactt ttcttaaaaa gtacctatac 420
gagattgcaa ggcgtcatcc atatttttac gccccagagc tgttgttttt cgcaaagaga 480gagattgcaa ggcgtcatcc atatttttac gccccagagc tgttgttttt cgcaaagaga 480
tacaaagctg catttactga gtgttgccaa gctgccgaca aggccgcttg tttgctacca 540tacaaagctg catttactga gtgttgccaa gctgccgaca aggccgcttg tttgctacca 540
aagttggacg aattgagagg aggcggagga tctacccaga acaaggccct gcccgagaac 600aagttggacg aattgagagg aggcggagga tctacccaga acaaggccct gcccgagaac 600
gtgaagtacg gcatcgtgct ggatgccggc agcagccaca ccagcctgta catctacaag 660gtgaagtacg gcatcgtgct ggatgccggc agcagccaca ccagcctgta catctacaag 660
tggcctgccg agaaagaaaa cgacaccggc gtggtgcatc aggtggaaga gtgcagagtg 720tggcctgccg agaaagaaaa cgacaccggc gtggtgcatc aggtggaaga gtgcagagtg 720
aagggccctg gcatcagcaa gttcgtgcag aaagtgaacg agatcggcat ctacctgacc 780aagggccctg gcatcagcaa gttcgtgcag aaagtgaacg agatcggcat ctacctgacc 780
gactgcatgg aacgggccag ggaagtgatc cccagaagcc agcaccagga aacccccgtg 840gactgcatgg aacgggccag ggaagtgatc cccagaagcc agcaccagga aacccccgtg 840
tatctgggag ccaccgccgg catgagactg ctgagaatgg aaagcgagga actggccgac 900tatctgggag ccaccgccgg catgagactg ctgagaatgg aaagcgagga actggccgac 900
cgggtgctgg acgtggtgga aagaagcctg agcaactacc cattcgattt tcaaggcgcc 960cgggtgctgg acgtggtgga aagaagcctg agcaactacc cattcgattt tcaaggcgcc 960
agaatcatca ccggccagga agaaggcgcc tacggctgga tcaccatcaa ctacctgctg 1020agaatcatca ccggccagga agaaggcgcc tacggctgga tcaccatcaa ctacctgctg 1020
ggcaagttca gccagaagaa tcaggaaacc ttcggcgccc tggacctggg cggagcttct 1080ggcaagttca gccagaagaa tcaggaaacc ttcggcgccc tggacctggg cggagcttct 1080
acccaagtga ccttcgtgcc ccagaatcag accatcgaga gccccgacaa cgccctgcag 1140acccaagtga ccttcgtgcc ccagaatcag accatcgaga gccccgacaa cgccctgcag 1140
ttccggctgt acggcaagga ctacaatgtg tacacccaca gctttctgtg ctacggaaag 1200ttccggctgt acggcaagga ctacaatgtg tacacccaca gctttctgtg ctacggaaag 1200
gaccaggctc tgtggcagaa gctggccaag gacatccagg tggccagcaa cgagatcctg 1260gaccaggctc tgtggcagaa gctggccaag gacatccagg tggccagcaa cgagatcctg 1260
cgggaccctt gcttccaccc cggctacaag aaagtcgtga acgtgtccga cctgtacaag 1320cgggaccctt gcttccaccc cggctacaag aaagtcgtga acgtgtccga cctgtacaag 1320
accccctgca ccaagagatt cgagatgacc ctgcccttcc agcagttcga gatccagggc 1380accccctgca ccaagagatt cgagatgacc ctgcccttcc agcagttcga gatccaggggc 1380
atcggcaatt accagcagtg ccaccagagc atcctggaac tgttcaacac cagctactgc 1440atcggcaatt accagcagtg ccaccagagc atcctggaac tgttcaacac cagctactgc 1440
ccctacagcc agtgcgcctt caacggcatc ttcctgccac ctctgcaggg ggatttcggc 1500ccctacagcc agtgcgcctt caacggcatc ttcctgccac ctctgcaggg ggatttcggc 1500
gccttcagcg ccttctactt cgtgatgaag ttcctgaacc tgaccagcga gaaggtgtcc 1560gccttcagcg ccttctactt cgtgatgaag ttcctgaacc tgaccagcga gaaggtgtcc 1560
caggaaaaag tgacagagat gatgaagaag ttctgcgccc agccctggga ggaaatcaag 1620caggaaaaag tgacagagat gatgaagaag ttctgcgccc agccctggga ggaaatcaag 1620
acctcctacg ctggcgtgaa agagaagtac ctgagcgagt actgcttcag cggcacctac 1680acctcctacg ctggcgtgaa agagaagtac ctgagcgagt actgcttcag cggcacctac 1680
atcctgagcc tgctgctgca gggctaccac ttcaccgccg atagctggga gcacatccac 1740atcctgagcc tgctgctgca gggctaccac ttcaccgccg atagctggga gcacatccac 1740
ttcatcggca agattcaggg cagcgacgcc ggctggacac tgggctacat gctgaatctg 1800ttcatcggca agattcaggg cagcgacgcc ggctggacac tgggctacat gctgaatctg 1800
accaacatga tccccgccga gcagcccctg agcacacctc tgagccacag cacc 1854accaacatga tccccgccga gcagcccctg agcacacctc tgagccacag cacc 1854
<210> 153<210> 153
<211> 625<211> 625
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 153<400> 153
Asp Glu Gly Lys Ala Ser Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Asp Glu Gly Lys Ala Ser Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser
1 5 10 15 1 5 10 15
Leu Gln Lys Phe Gly Glu Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Gln Lys Phe Gly Glu Arg Ala Phe Lys Ala Trp Ala Val Ala Arg
20 25 30 20 25 30
Leu Ser Gln Arg Phe Pro Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Leu Ser Gln Arg Phe Pro Lys Ala Glu Phe Ala Glu Val Ser Lys Leu
35 40 45 35 40 45
Val Thr Asp Leu Thr Lys Val His Thr Glu Cys Cys His Gly Asp Leu Val Thr Asp Leu Thr Lys Val His Thr Glu Cys Cys His Gly Asp Leu
50 55 60 50 55 60
Leu Glu Cys Ala Asp Asp Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Leu Glu Cys Ala Asp Asp Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu
65 70 75 80 65 70 75 80
Asn Gln Asp Ser Ile Ser Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Asn Gln Asp Ser Ile Ser Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro
85 90 95 85 90 95
Leu Leu Glu Lys Ser His Cys Ile Ala Glu Val Glu Asn Asp Glu Met Leu Leu Glu Lys Ser His Cys Ile Ala Glu Val Glu Asn Asp Glu Met
100 105 110 100 105 110
Pro Ala Asp Leu Pro Ser Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Pro Ala Asp Leu Pro Ser Leu Ala Ala Asp Phe Val Glu Ser Lys Asp
115 120 125 115 120 125
Val Cys Lys Asn Tyr Ala Glu Ala Lys Asp Val Phe Leu Gly Met Phe Val Cys Lys Asn Tyr Ala Glu Ala Lys Asp Val Phe Leu Gly Met Phe
130 135 140 130 135 140
Leu Tyr Glu Tyr Ala Arg Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Tyr Glu Tyr Ala Arg Arg His Pro Asp Tyr Ser Val Val Leu Leu
145 150 155 160 145 150 155 160
Leu Arg Leu Ala Lys Thr Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Leu Arg Leu Ala Lys Thr Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala
165 170 175 165 170 175
Ala Ala Asp Pro His Glu Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Ala Ala Asp Pro His Glu Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys
180 185 190 180 185 190
Pro Gly Gly Gly Gly Ser Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Pro Gly Gly Gly Gly Ser Thr Gln Asn Lys Ala Leu Pro Glu Asn Val
195 200 205 195 200 205
Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr
210 215 220 210 215 220
Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His
225 230 235 240 225 230 235 240
Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val
245 250 255 245 250 255
Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg
260 265 270 260 265 270
Ala Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr Ala Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr
275 280 285 275 280 285
Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu
290 295 300 290 295 300
Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr
305 310 315 320 305 310 315 320
Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly
325 330 335 325 330 335
Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln
340 345 350 340 345 350
Lys Asn Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Lys Asn Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr
355 360 365 355 360 365
Gln Val Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Gln Val Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn
370 375 380 370 375 380
Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His
385 390 395 400 385 390 395 400
Ser Phe Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Ser Phe Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala
405 410 415 405 410 415
Lys Asp Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe Lys Asp Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe
420 425 430 420 425 430
His Pro Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr His Pro Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr
435 440 445 435 440 445
Pro Cys Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Pro Cys Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu
450 455 460 450 455 460
Ile Gln Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Ile Gln Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu
465 470 475 480 465 470 475 480
Leu Phe Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Leu Phe Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly
485 490 495 485 490 495
Ile Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Ile Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe
500 505 510 500 505 510
Tyr Phe Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Tyr Phe Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln
515 520 525 515 520 525
Glu Lys Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Lys Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu
530 535 540 530 535 540
Glu Ile Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Glu Ile Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu
545 550 555 560 545 550 555 560
Tyr Cys Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr Tyr Cys Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr
565 570 575 565 570 575
His Phe Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile His Phe Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile
580 585 590 580 585 590
Gln Gly Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Gln Gly Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr
595 600 605 595 600 605
Asn Met Ile Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Asn Met Ile Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser
610 615 620 610 615 620
Thr Thr
625 625
<210> 154<210> 154
<211> 1875<211> 1875
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 154<400> 154
gacgagggta aggcatcatc tgccaagcag agattaaaat gtgcatcttt gcaaaaattt 60gacgagggta aggcatcatc tgccaagcag agattaaaat gtgcatcttt gcaaaaattt 60
ggagagagag cttttaaggc atgggctgtt gcccgactaa gccaaagatt cccaaaagcc 120ggagagagag cttttaaggc atgggctgtt gcccgactaa gccaaagatt cccaaaagcc 120
gaatttgctg aagtatccaa gctggtgact gatttgacta aagtacatac agaatgttgc 180gaatttgctg aagtatccaa gctggtgact gatttgacta aagtacatac agaatgttgc 180
catggcgacc ttttagaatg tgctgatgac agagcagatt tggctaagta tatctgcgaa 240catggcgacc ttttagaatg tgctgatgac agagcagatt tggctaagta tatctgcgaa 240
aatcaagatt caatcagctc taagctgaag gaatgttgcg agaaaccact gttagaaaaa 300aatcaagatt caatcagctc taagctgaag gaatgttgcg agaaaccact gttagaaaaa 300
tcgcattgta ttgctgaagt tgaaaatgat gagatgcctg ctgacttgcc ttctcttgcc 360tcgcattgta ttgctgaagt tgaaaatgat gagatgcctg ctgacttgcc ttctcttgcc 360
gctgattttg ttgagtcgaa ggatgtctgt aagaattatg ctgaagctaa agacgttttc 420gctgattttg ttgagtcgaa ggatgtctgt aagaattatg ctgaagctaa agacgttttc 420
ctgggtatgt tcttatatga gtacgcaaga cgtcacccag attactctgt ggttctgcta 480ctgggtatgt tcttatatga gtacgcaaga cgtcacccag attactctgt ggttctgcta 480
ctgagattgg ctaaaacata cgagacaacg ctggagaagt gctgtgctgc cgctgaccct 540ctgagattgg ctaaaacata cgagacaacg ctggagaagt gctgtgctgc cgctgaccct 540
catgagtgct atgcaaaggt ttttgatgaa ttcaaaccag gaggcggagg atctacccag 600catgagtgct atgcaaaggt ttttgatgaa ttcaaaccag gaggcgggagg atctacccag 600
aacaaggccc tgcccgagaa cgtgaagtac ggcatcgtgc tggatgccgg cagcagccac 660aacaaggccc tgcccgagaa cgtgaagtac ggcatcgtgc tggatgccgg cagcagccac 660
accagcctgt acatctacaa gtggcctgcc gagaaagaaa acgacaccgg cgtggtgcat 720accagcctgt acatctacaa gtggcctgcc gagaaagaaa acgacaccgg cgtggtgcat 720
caggtggaag agtgcagagt gaagggccct ggcatcagca agttcgtgca gaaagtgaac 780caggtggaag agtgcagagt gaagggccct ggcatcagca agttcgtgca gaaagtgaac 780
gagatcggca tctacctgac cgactgcatg gaacgggcca gggaagtgat ccccagaagc 840gagatcggca tctacctgac cgactgcatg gaacggggcca gggaagtgat ccccagaagc 840
cagcaccagg aaacccccgt gtatctggga gccaccgccg gcatgagact gctgagaatg 900cagcaccagg aaacccccgt gtatctggga gccaccgccg gcatgagact gctgagaatg 900
gaaagcgagg aactggccga ccgggtgctg gacgtggtgg aaagaagcct gagcaactac 960gaaagcgagg aactggccga ccgggtgctg gacgtggtgg aaagaagcct gagcaactac 960
ccattcgatt ttcaaggcgc cagaatcatc accggccagg aagaaggcgc ctacggctgg 1020ccattcgatt ttcaaggcgc cagaatcatc accggccagg aagaaggcgc ctacggctgg 1020
atcaccatca actacctgct gggcaagttc agccagaaga atcaggaaac cttcggcgcc 1080atcaccatca actacctgct gggcaagttc agccagaaga atcaggaaac cttcggcgcc 1080
ctggacctgg gcggagcttc tacccaagtg accttcgtgc cccagaatca gaccatcgag 1140ctggacctgg gcggagcttc tacccaagtg accttcgtgc cccagaatca gaccatcgag 1140
agccccgaca acgccctgca gttccggctg tacggcaagg actacaatgt gtacacccac 1200agccccgaca acgccctgca gttccggctg tacggcaagg actacaatgt gtacacccac 1200
agctttctgt gctacggaaa ggaccaggct ctgtggcaga agctggccaa ggacatccag 1260agctttctgt gctacggaaa ggaccaggct ctgtggcaga agctggccaa ggacatccag 1260
gtggccagca acgagatcct gcgggaccct tgcttccacc ccggctacaa gaaagtcgtg 1320gtggccagca acgagatcct gcgggaccct tgcttccacc ccggctacaa gaaagtcgtg 1320
aacgtgtccg acctgtacaa gaccccctgc accaagagat tcgagatgac cctgcccttc 1380aacgtgtccg acctgtacaa gaccccctgc acccaagagat tcgagatgac cctgcccttc 1380
cagcagttcg agatccaggg catcggcaat taccagcagt gccaccagag catcctggaa 1440cagcagttcg agatccaggg catcggcaat taccagcagt gccaccagag catcctggaa 1440
ctgttcaaca ccagctactg cccctacagc cagtgcgcct tcaacggcat cttcctgcca 1500ctgttcaaca ccagctactg cccctacagc cagtgcgcct tcaacggcat cttcctgcca 1500
cctctgcagg gggatttcgg cgccttcagc gccttctact tcgtgatgaa gttcctgaac 1560cctctgcagg gggatttcgg cgccttcagc gccttctact tcgtgatgaa gttcctgaac 1560
ctgaccagcg agaaggtgtc ccaggaaaaa gtgacagaga tgatgaagaa gttctgcgcc 1620ctgaccagcg agaaggtgtc cggaaaaa gtgacagaga tgatgaagaa gttctgcgcc 1620
cagccctggg aggaaatcaa gacctcctac gctggcgtga aagagaagta cctgagcgag 1680cagccctggg aggaaatcaa gacctcctac gctggcgtga aagagaagta cctgagcgag 1680
tactgcttca gcggcaccta catcctgagc ctgctgctgc agggctacca cttcaccgcc 1740tactgcttca gcggcaccta catcctgagc ctgctgctgc agggctacca cttcaccgcc 1740
gatagctggg agcacatcca cttcatcggc aagattcagg gcagcgacgc cggctggaca 1800gatagctggg agcacatcca cttcatcggc aagattcagg gcagcgacgc cggctggaca 1800
ctgggctaca tgctgaatct gaccaacatg atccccgccg agcagcccct gagcacacct 1860ctgggctaca tgctgaatct gaccaacatg atccccgccg agcagcccct gagcacacct 1860
ctgagccaca gcacc 1875ctgagccaca gcacc 1875
<210> 155<210> 155
<211> 439<211> 439
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 155<400> 155
Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu
1 5 10 15 1 5 10 15
Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala
20 25 30 20 25 30
Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg
35 40 45 35 40 45
Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile
50 55 60 50 55 60
Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro
65 70 75 80 65 70 75 80
Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly
85 90 95 85 90 95
Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu
100 105 110 100 105 110
Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly
115 120 125 115 120 125
Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr
130 135 140 130 135 140
Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Thr Arg Trp Phe Ser Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Thr Arg Trp Phe Ser
145 150 155 160 145 150 155 160
Ile Val Pro Tyr Glu Thr Asn Asn Gln Glu Thr Phe Gly Ala Leu Asp Ile Val Pro Tyr Glu Thr Asn Asn Gln Glu Thr Phe Gly Ala Leu Asp
165 170 175 165 170 175
Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gln Asn Gln Thr Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gln Asn Gln Thr
180 185 190 180 185 190
Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp
195 200 205 195 200 205
Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Lys Asp Gln Ala Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Lys Asp Gln Ala
210 215 220 210 215 220
Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Ser Asn Glu Ile Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Ser Asn Glu Ile
225 230 235 240 225 230 235 240
Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Val Val Asn Val Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Val Val Asn Val
245 250 255 245 250 255
Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Glu Met Thr Leu Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Glu Met Thr Leu
260 265 270 260 265 270
Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Tyr Gln Gln Cys Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Tyr Gln Gln Cys
275 280 285 275 280 285
His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Cys Pro Tyr Ser His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Cys Pro Tyr Ser
290 295 300 290 295 300
Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Gln Gly Asp Phe Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Gln Gly Asp Phe
305 310 315 320 305 310 315 320
Gly Ala Phe Ser Ala Phe Tyr Ser Val Met Lys Phe Leu Asn Leu Thr Gly Ala Phe Ser Ala Phe Tyr Ser Val Met Lys Phe Leu Asn Leu Thr
325 330 335 325 330 335
Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Met Lys Lys Phe Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Met Lys Lys Phe
340 345 350 340 345 350
Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Ala Gly Val Lys Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Ala Gly Val Lys
355 360 365 355 360 365
Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Tyr Ile Leu Ser Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Ser Gly Thr Tyr Ile Leu Ser
370 375 380 370 375 380
Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Trp Glu His Ile Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Trp Glu His Ile
385 390 395 400 385 390 395 400
His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Thr Leu Gly His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Thr Leu Gly
405 410 415 405 410 415
Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Gln Pro Leu Ser Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Gln Pro Leu Ser
420 425 430 420 425 430
Thr Pro Leu Ser His Ser Thr Thr Pro Leu Ser His Ser Thr
435 435
<210> 156<210> 156
<211> 1317<211> 1317
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 156<400> 156
acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60acccagaaca aggccctgcc cgagaacgtg aagtacggca tcgtgctgga tgccggcagc 60
agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120agccacacca gcctgtacat ctacaagtgg cctgccgaga aagaaaacga caccggcgtg 120
gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180gtgcatcagg tggaagagtg cagagtgaag ggccctggca tcagcaagtt cgtgcagaaa 180
gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240gtgaacgaga tcggcatcta cctgaccgac tgcatggaac gggccaggga agtgatcccc 240
agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300agaagccagc accaggaaac ccccgtgtat ctgggagcca ccgccggcat gagactgctg 300
agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360agaatggaaa gcgaggaact ggccgaccgg gtgctggacg tggtggaaag aagcctgagc 360
aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420aactacccat tcgattttca aggcgccaga atcatcaccg gccaggaaga aggcgcctac 420
ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaccag atggttcagc 480ggctggatca ccatcaacta cctgctgggc aagttcagcc agaagaccag atggttcagc 480
atcgtgccct acgagacaaa caatcaggaa accttcggcg ccctggacct gggcggagct 540atcgtgccct acgagacaaa caatcaggaa accttcggcg ccctggacct gggcggagct 540
tctacccaag tgaccttcgt gccccagaat cagaccatcg agagccccga caacgccctg 600tctacccaag tgaccttcgt gccccagaat cagaccatcg agagccccga caacgccctg 600
cagttccggc tgtacggcaa ggactacaat gtgtacaccc acagctttct gtgctacgga 660cagttccggc tgtacggcaa ggactacaat gtgtacaccc acagctttct gtgctacgga 660
aaggaccagg ctctgtggca gaagctggcc aaggacatcc aggtggccag caacgagatc 720aaggaccagg ctctgtggca gaagctggcc aaggacatcc aggtggccag caacgagatc 720
ctgcgggacc cttgcttcca ccccggctac aagaaagtcg tgaacgtgtc cgacctgtac 780ctgcgggacc cttgcttcca ccccggctac aagaaagtcg tgaacgtgtc cgacctgtac 780
aagaccccct gcaccaagag attcgagatg accctgccct tccagcagtt cgagatccag 840aagaccccct gcaccaagag attcgagatg accctgccct tccagcagtt cgagatccag 840
ggcatcggca attaccagca gtgccaccag agcatcctgg aactgttcaa caccagctac 900ggcatcggca attaccagca gtgccaccag agcatcctgg aactgttcaa caccagctac 900
tgcccctaca gccagtgcgc cttcaacggc atcttcctgc cacctctgca gggggatttc 960tgcccctaca gccagtgcgc cttcaacggc atcttcctgc cacctctgca gggggatttc 960
ggcgccttca gcgccttcta ctccgtgatg aagttcctga acctgaccag cgagaaggtg 1020ggcgccttca gcgccttcta ctccgtgatg aagttcctga acctgaccag cgagaaggtg 1020
tcccaggaaa aagtgacaga gatgatgaag aagttctgcg cccagccctg ggaggaaatc 1080tccggaaa aagtgacaga gatgatgaag aagttctgcg cccagccctg ggaggaaatc 1080
aagacctcct acgctggcgt gaaagagaag tacctgagcg agtactgctt cagcggcacc 1140aagacctcct acgctggcgt gaaagagaag tacctgagcg agtactgctt cagcggcacc 1140
tacatcctga gcctgctgct gcagggctac cacttcaccg ccgatagctg ggagcacatc 1200tacatcctga gcctgctgct gcagggctac cacttcaccg ccgatagctg ggagcacatc 1200
cacttcatcg gcaagattca gggcagcgac gccggctgga cactgggcta catgctgaat 1260cacttcatcg gcaagattca gggcagcgac gccggctgga cactgggcta catgctgaat 1260
ctgaccaaca tgatccccgc cgagcagccc ctgagcacac ctctgagcca cagcacc 1317ctgaccaaca tgatccccgc cgagcagccc ctgagcacac ctctgagcca cagcacc 1317
<210> 157<210> 157
<211> 90<211> 90
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 157<400> 157
tcgcgatcct ggaaggcgtg cactgcgccc ctaccagcag cagcaccaag aaaacccagc 60tcgcgatcct ggaaggcgtg cactgcgccc ctaccagcag cagcaccaag aaaacccagc 60
tgaccagcag cacccagaac aaggccctgc 90tgaccagcag cacccagaac aaggccctgc 90
<210> 158<210> 158
<211> 18<211> 18
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 158<400> 158
tagaaggcac agtcgagg 18tagaaggcac agtcgagg 18
<210> 159<210> 159
<211> 66<211> 66
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 159<400> 159
ctggtcgcga tcctggaagg cgtgcactgc gcccctacca gcagcagcac ccagaacaag 60ctggtcgcga tcctggaagg cgtgcactgc gcccctacca gcagcagcac ccagaacaag 60
gccctg 66gccctg 66
<210> 160<210> 160
<211> 66<211> 66
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 160<400> 160
ctggtcgcga tcctggaagg cgtgcactgc gcccctacca gcagcagcac ccagaacaag 60ctggtcgcga tcctggaagg cgtgcactgc gcccctacca gcagcagcac ccagaacaag 60
gccctg 66gccctg 66
<210> 161<210> 161
<211> 57<211> 57
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 161<400> 161
ctggtcgcga tcctggaagg cgtgcactgc gcccctacca cccagaacaa ggccctg 57ctggtcgcga tcctggaagg cgtgcactgc gcccctacca cccagaacaa ggccctg 57
<210> 162<210> 162
<211> 75<211> 75
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 162<400> 162
ctggtcgcga tcctggaagg cgtgcactgc gcccctacca gcagcagcac caagaaaacc 60ctggtcgcga tcctggaagg cgtgcactgc gcccctacca gcagcagcac caagaaaacc 60
cagaacaagg ccctg 75cagaacaagg ccctg 75
<210> 163<210> 163
<211> 84<211> 84
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 163<400> 163
ctggtcgcga tcctggaagg cgtgcactgc gcccctacca gcagcagcac caagaaaacc 60ctggtcgcga tcctggaagg cgtgcactgc gcccctacca gcagcagcac caagaaaacc 60
cagctgaccc agaacaaggc cctg 84cagctgaccc agaacaaggc cctg 84
<210> 164<210> 164
<211> 75<211> 75
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 164<400> 164
ctggtcgcga tcctggaagg cgtgcactgc agcagcagca ccaagaaaac ccagctgacc 60ctggtcgcga tcctggaagg cgtgcactgc agcagcagca ccaagaaaac ccagctgacc 60
cagaacaagg ccctg 75cagaacaagg ccctg 75
<210> 165<210> 165
<211> 16<211> 16
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 165<400> 165
catacgattt aggtga 16catacgatt aggtga 16
<210> 166<210> 166
<211> 18<211> 18
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 166<400> 166
tagaaggcac agtcgagg 18tagaaggcac agtcgagg 18
<210> 167<210> 167
<211> 76<211> 76
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 167<400> 167
Met Gln Ile Phe Val Lys Thr Leu Thr Gly Lys Thr Ile Thr Leu Glu Met Gln Ile Phe Val Lys Thr Leu Thr Gly Lys Thr Ile Thr Leu Glu
1 5 10 15 1 5 10 15
Val Glu Pro Ser Asp Thr Ile Glu Asn Val Lys Ala Lys Ile Gln Asp Val Glu Pro Ser Asp Thr Ile Glu Asn Val Lys Ala Lys Ile Gln Asp
20 25 30 20 25 30
Lys Glu Gly Ile Pro Pro Asp Gln Gln Arg Leu Ile Phe Ala Gly Lys Lys Glu Gly Ile Pro Pro Asp Gln Gln Arg Leu Ile Phe Ala Gly Lys
35 40 45 35 40 45
Gln Leu Glu Asp Gly Arg Thr Leu Ser Asp Tyr Asn Ile Gln Lys Glu Gln Leu Glu Asp Gly Arg Thr Leu Ser Asp Tyr Asn Ile Gln Lys Glu
50 55 60 50 55 60
Ser Thr Leu His Leu Val Leu Arg Leu Arg Gly Gly Ser Thr Leu His Leu Val Leu Arg Leu Arg Gly Gly
65 70 75 65 70 75
<210> 168<210> 168
<211> 105<211> 105
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 168<400> 168
Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
1 5 10 15 1 5 10 15
Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
20 25 30 20 25 30
Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
35 40 45 35 40 45
Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
50 55 60 50 55 60
Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
65 70 75 80 65 70 75 80
His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
85 90 95 85 90 95
Val Thr Lys Ser Phe Asn Arg Gly Glu Val Thr Lys Ser Phe Asn Arg Gly Glu
100 105 100 105
<210> 169<210> 169
<211> 186<211> 186
<212> БЕЛОК<212> PROTEIN
<213> Homo sapiens<213> Homo sapiens
<400> 169<400> 169
Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu
1 5 10 15 1 5 10 15
Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln
20 25 30 20 25 30
Gln Ser Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu Gln Ser Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu
35 40 45 35 40 45
Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys
50 55 60 50 55 60
Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu
65 70 75 80 65 70 75 80
Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro
85 90 95 85 90 95
Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu
100 105 110 100 105 110
Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His
115 120 125 115 120 125
Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg
130 135 140 130 135 140
Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg
145 150 155 160 145 150 155 160
Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala
165 170 175 165 170 175
Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg
180 185 180 185
<210> 170<210> 170
<211> 193<211> 193
<212> БЕЛОК<212> PROTEIN
<213> Homo sapiens<213> Homo sapiens
<400> 170<400> 170
Asp Glu Gly Lys Ala Ser Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Asp Glu Gly Lys Ala Ser Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser
1 5 10 15 1 5 10 15
Leu Gln Lys Phe Gly Glu Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Gln Lys Phe Gly Glu Arg Ala Phe Lys Ala Trp Ala Val Ala Arg
20 25 30 20 25 30
Leu Ser Gln Arg Phe Pro Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Leu Ser Gln Arg Phe Pro Lys Ala Glu Phe Ala Glu Val Ser Lys Leu
35 40 45 35 40 45
Val Thr Asp Leu Thr Lys Val His Thr Glu Cys Cys His Gly Asp Leu Val Thr Asp Leu Thr Lys Val His Thr Glu Cys Cys His Gly Asp Leu
50 55 60 50 55 60
Leu Glu Cys Ala Asp Asp Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Leu Glu Cys Ala Asp Asp Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu
65 70 75 80 65 70 75 80
Asn Gln Asp Ser Ile Ser Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Asn Gln Asp Ser Ile Ser Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro
85 90 95 85 90 95
Leu Leu Glu Lys Ser His Cys Ile Ala Glu Val Glu Asn Asp Glu Met Leu Leu Glu Lys Ser His Cys Ile Ala Glu Val Glu Asn Asp Glu Met
100 105 110 100 105 110
Pro Ala Asp Leu Pro Ser Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Pro Ala Asp Leu Pro Ser Leu Ala Ala Asp Phe Val Glu Ser Lys Asp
115 120 125 115 120 125
Val Cys Lys Asn Tyr Ala Glu Ala Lys Asp Val Phe Leu Gly Met Phe Val Cys Lys Asn Tyr Ala Glu Ala Lys Asp Val Phe Leu Gly Met Phe
130 135 140 130 135 140
Leu Tyr Glu Tyr Ala Arg Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Tyr Glu Tyr Ala Arg Arg His Pro Asp Tyr Ser Val Val Leu Leu
145 150 155 160 145 150 155 160
Leu Arg Leu Ala Lys Thr Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Leu Arg Leu Ala Lys Thr Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala
165 170 175 165 170 175
Ala Ala Asp Pro His Glu Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Ala Ala Asp Pro His Glu Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys
180 185 190 180 185 190
Pro Pro
<210> 171<210> 171
<211> 30<211> 30
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 171<400> 171
ctgccgagaa agaacaggac accggcgtgg 30ctgccgagaa agaacaggac accggcgtgg 30
<210> 172<210> 172
<211> 30<211> 30
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 172<400> 172
ccacgccggt gtcctgttct ttctcggcag 30ccacgccggt gtcctgttct ttctcggcag 30
<210> 173<210> 173
<211> 29<211> 29
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 173<400> 173
cgtgccccag aatcaggcca tcgagagcc 29cgtgccccag aatcaggcca tcgagagcc 29
<210> 174<210> 174
<211> 29<211> 29
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 174<400> 174
ggctctcgat ggcctgattc tggggcacg 29ggctctcgat ggcctgattc tggggcacg 29
<210> 175<210> 175
<211> 41<211> 41
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 175<400> 175
ggctacaaga aagtcgtgca ggtgtccgac ctgtacaaga c 41ggctacaaga aagtcgtgca ggtgtccgac ctgtacaaga c 41
<210> 176<210> 176
<211> 41<211> 41
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 176<400> 176
gtcttgtaca ggtcggacac ctgcacgact ttcttgtagc c 41gtcttgtaca ggtcggacac ctgcacgact ttcttgtagc c 41
<210> 177<210> 177
<211> 35<211> 35
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 177<400> 177
gcatcctgga actgttccag accagctact gcccc 35gcatcctgga actgttccag accagctact gcccc 35
<210> 178<210> 178
<211> 35<211> 35
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 178<400> 178
ggggcagtag ctggtctgga acagttccag gatgc 35ggggcagtag ctggtctgga acagttccag gatgc 35
<210> 179<210> 179
<211> 35<211> 35
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 179<400> 179
ccgtgatgaa gttcctgcag ctgaccagcg agaag 35ccgtgatgaa gttcctgcag ctgaccagcg agaag 35
<210> 180<210> 180
<211> 35<211> 35
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 180<400> 180
cttctcgctg gtcagctgca ggaacttcat cacgg 35cttctcgctg gtcagctgca ggaacttcat cacgg 35
<210> 181<210> 181
<211> 36<211> 36
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 181<400> 181
cactgggcta catgctgcag ctgaccaaca tgatcc 36cactgggcta catgctgcag ctgaccaaca tgatcc 36
<210> 182<210> 182
<211> 36<211> 36
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 182<400> 182
ggatcatgtt ggtcagctgc agcatgtagc ccagtg 36ggatcatgtt ggtcagctgc agcatgtagc ccagtg 36
<210> 183<210> 183
<211> 39<211> 39
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 183<400> 183
ctacatcctg agcctgctgc agcagggcta ccacttcac 39ctacatcctg agcctgctgc agcagggcta ccacttcac 39
<210> 184<210> 184
<211> 39<211> 39
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 184<400> 184
gtgaagtggt agccctgctg cagcaggctc aggatgtag 39gtgaagtggt agccctgctg cagcaggctc aggatgtag 39
<210> 185<210> 185
<211> 43<211> 43
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 185<400> 185
gagaagtacc tgagcgagtt ttgcttcagc ggcacctaca tcc 43gagaagtacc tgagcgagtt ttgcttcagc ggcacctaca tcc 43
<210> 186<210> 186
<211> 43<211> 43
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 186<400> 186
ggatgtaggt gccgctgaag caaaactcgc tcaggtactt ctc 43ggatgtaggt gccgctgaag caaaactcgc tcaggtactt ctc 43
<210> 187<210> 187
<211> 36<211> 36
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 187<400> 187
gttcgagatc cagggcaccg gcaattacca gcagtg 36gttcgagatc cagggcaccg gcaattacca gcagtg 36
<210> 188<210> 188
<211> 36<211> 36
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 188<400> 188
cactgctggt aattgccggt gccctggatc tcgaac 36cactgctggt aattgccggt gccctggatc tcgaac 36
<210> 189<210> 189
<211> 37<211> 37
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 189<400> 189
cgccgatagc tgggagcaca tccacttcat cggcaag 37cgccgatagc tgggagcaca tccacttcat cggcaag 37
<210> 190<210> 190
<211> 37<211> 37
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 190<400> 190
cttgccgatg aagtggatgt gctcccagct atcggcg 37cttgccgatg aagtggatgt gctcccagct atcggcg 37
<210> 191<210> 191
<211> 120<211> 120
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 191<400> 191
gagatcggca tctacctgac cgactgcatg gaacgggcca tggaagtgat ccccagaagc 60gagatcggca tctacctgac cgactgcatg gaacgggcca tggaagtgat ccccagaagc 60
cagcaccagg aaacccccgt gtatctggga gccaccgccg gcatgagact gctgagaatg 120cagcaccagg aaacccccgt gtatctggga gccaccgccg gcatgagact gctgagaatg 120
<210> 192<210> 192
<211> 25<211> 25
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 192<400> 192
gagatcggca tctacctgac cgact 25gagatcggca tctacctgac cgact 25
<210> 193<210> 193
<211> 18<211> 18
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 193<400> 193
cattctcagc agtctcat 18cattctcagc agtctcat 18
<210> 194<210> 194
<211> 120<211> 120
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 194<400> 194
cttcagcgcc ttctactccg tgatgaagtt cctgaacctg accagcgaga aggtgtccca 60cttcagcgcc ttctactccg tgatgaagtt cctgaacctg accagcgaga aggtgtccca 60
ggaaaaagtg acagagatga tgaagaagtt ctgcgcccag ccctgggagg aaatcaagac 120ggaaaaagtg acagagatga tgaagaagtt ctgcgcccag ccctgggagg aaatcaagac 120
<210> 195<210> 195
<211> 19<211> 19
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 195<400> 195
cttcagcgcc ttctactcc 19cttcagcgcc ttctactcc 19
<210> 196<210> 196
<211> 19<211> 19
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 196<400> 196
ggtcttgatt tcctcccag 19ggtcttgatt tcctcccag 19
<210> 197<210> 197
<211> 119<211> 119
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 197<400> 197
ctgggaggaa atcaagacct cctacgctgg cgtgaaagag aagtacctga gcgagttctg 60ctgggaggaa atcaagacct cctacgctgg cgtgaaagag aagtacctga gcgagttctg 60
cttcagcggc acctacatcc tgagcctgct gctgcagggc taccacttca ccgccgata 119cttcagcggc acctacatcc tgagcctgct gctgcaggggc taccacttca ccgccgata 119
<210> 198<210> 198
<211> 119<211> 119
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 198<400> 198
ctgggaggaa atcaagacct cctacgctgg cgtgaaagag aagtacctga gcgagtactg 60ctgggaggaa atcaagacct cctacgctgg cgtgaaagag aagtacctga gcgagtactg 60
cttcagcggc acctacatcc tgagcctgct gcagcagggc taccacttca ccgccgata 119cttcagcggc acctacatcc tgagcctgct gcagcagggc taccacttca ccgccgata 119
<210> 199<210> 199
<211> 119<211> 119
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 199<400> 199
ctgggaggaa atcaagacct cctacgctgg cgtgaaagag aagtacctga gcgagttctg 60ctgggaggaa atcaagacct cctacgctgg cgtgaaagag aagtacctga gcgagttctg 60
cttcagcggc acctacatcc tgagcctgct gcagcagggc taccacttca ccgccgata 119cttcagcggc acctacatcc tgagcctgct gcagcagggc taccacttca ccgccgata 119
<210> 200<210> 200
<211> 19<211> 19
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 200<400> 200
ctgggaggaa atcaagacc 19ctgggaggaa atcaagacc 19
<210> 201<210> 201
<211> 19<211> 19
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 201<400> 201
tatcggcggt gaagtggta 19tatcggcggt gaagtggta 19
<210> 202<210> 202
<211> 119<211> 119
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 202<400> 202
ctgggaggaa atcaagacct cctacgctgg cgtgaaagag aagtacctga gcgagtactg 60ctgggaggaa atcaagacct cctacgctgg cgtgaaagag aagtacctga gcgagtactg 60
cttcagcggc acctacatcc tgagcctgct gctgcagggc taccacttca ccgccgata 119cttcagcggc acctacatcc tgagcctgct gctgcaggggc taccacttca ccgccgata 119
<210> 203<210> 203
<211> 26<211> 26
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 203<400> 203
caccggccag gaagccggcg cctacg 26caccggccag gaagccggcg cctacg 26
<210> 204<210> 204
<211> 26<211> 26
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 204<400> 204
cgtaggcgcc ggcttcctgg ccggtg 26cgtaggcgcc ggcttcctgg ccggtg 26
<210> 205<210> 205
<211> 34<211> 34
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 205<400> 205
ggacctgggc ggagctgcta cccaagtgac cttc 34ggacctgggc ggagctgcta cccaagtgac cttc 34
<210> 206<210> 206
<211> 34<211> 34
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 206<400> 206
gaaggtcact tgggtagcag ctccgcccag gtcc 34gaaggtcact tgggtagcag ctccgcccag gtcc 34
<210> 207<210> 207
<211> 80<211> 80
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 207<400> 207
ctggatcacc atcaactacc tgctgggcaa gttcagccag aagaccagat ggttcagcat 60ctggatcacc atcaactacc tgctgggcaa gttcagccag aagaccagat ggttcagcat 60
cgtgccctac gagacaaaca 80cgtgccctac gagacaaaca 80
<210> 208<210> 208
<211> 69<211> 69
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический праймер"Synthetic primer"
<400> 208<400> 208
tcacttgggt agaagctccg cccaggtcca gggcgccgaa ggtttcctga ttgtttgtct 60tcacttgggt agaagctccg cccaggtcca gggcgccgaa ggtttcctga ttgtttgtct 60
cgtagggca 69cgtagggca 69
<210> 209<210> 209
<211> 430<211> 430
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 209<400> 209
Ala Pro Thr Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ala Pro Thr Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly
1 5 10 15 1 5 10 15
Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys
20 25 30 20 25 30
Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu
35 40 45 35 40 45
Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val
50 55 60 50 55 60
Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Met Glu Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Met Glu
65 70 75 80 65 70 75 80
Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala
85 90 95 85 90 95
Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu Glu Leu Ala Asp
100 105 110 100 105 110
Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp
115 120 125 115 120 125
Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly
130 135 140 130 135 140
Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln
145 150 155 160 145 150 155 160
Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr
165 170 175 165 170 175
Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln
180 185 190 180 185 190
Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu
195 200 205 195 200 205
Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile
210 215 220 210 215 220
Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly
225 230 235 240 225 230 235 240
Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr
245 250 255 245 250 255
Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly
260 265 270 260 265 270
Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn
275 280 285 275 280 285
Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu
290 295 300 290 295 300
Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val
305 310 315 320 305 310 315 320
Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val
325 330 335 325 330 335
Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys
340 345 350 340 345 350
Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe
355 360 365 355 360 365
Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr
370 375 380 370 375 380
Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser
385 390 395 400 385 390 395 400
Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile
405 410 415 405 410 415
Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 430 420 425 430
<210> 210<210> 210
<211> 1290<211> 1290
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 210<400> 210
gcccctacca cccagaacaa ggccctgccc gagaacgtga agtacggcat cgtgctggat 60gcccctacca cccagaacaa ggccctgccc gagaacgtga agtacggcat
gccggcagca gccacaccag cctgtacatc tacaagtggc ctgccgagaa agaaaacgac 120gccggcagca gccacaccag cctgtacatc tacaagtggc ctgccgagaa agaaaacgac 120
accggcgtgg tgcatcaggt ggaagagtgc agagtgaagg gccctggcat cagcaagttc 180accggcgtgg tgcatcaggt ggaaagtgc agagtgaagg gccctggcat cagcaagttc 180
gtgcagaaag tgaacgagat cggcatctac ctgaccgact gcatggaacg ggccatggaa 240gtgcagaaag tgaacgagat cggcatctac ctgaccgact gcatggaacg ggccatggaa 240
gtgatcccca gaagccagca ccaggaaacc cccgtgtatc tgggagccac cgccggcatg 300gtgatcccca gaagccagca cggaaacc cccgtgtatc tgggagccac cgccggcatg 300
agactgctga gaatggaaag cgaggaactg gccgaccggg tgctggacgt ggtggaaaga 360agactgctga gaatggaaag cgaggaactg gccgaccggg tgctggacgt ggtggaaaga 360
agcctgagca actacccatt cgattttcaa ggcgccagaa tcatcaccgg ccaggaagaa 420agcctgagca actacccatt cgattttcaa ggcgccagaa tcatcaccgg cggaagaa 420
ggcgcctacg gctggatcac catcaactac ctgctgggca agttcagcca gaagaatcag 480ggcgcctacg gctggatcac catcaactac ctgctgggca agttcagcca gaagaatcag 480
gaaaccttcg gcgccctgga cctgggcgga gcttctaccc aagtgacctt cgtgccccag 540gaaaccttcg gcgccctgga cctgggcgga gcttctaccc aagtgacctt cgtgccccag 540
aatcagacca tcgagagccc cgacaacgcc ctgcagttcc ggctgtacgg caaggactac 600aatcagacca tcgagagccc cgacaacgcc ctgcagttcc ggctgtacgg caaggactac 600
aatgtgtaca cccacagctt tctgtgctac ggaaaggacc aggctctgtg gcagaagctg 660aatgtgtaca cccacagctt tctgtgctac ggaaaggacc aggctctgtg gcagaagctg 660
gccaaggaca tccaggtggc cagcaacgag atcctgcggg acccttgctt ccaccccggc 720gccaaggaca tccaggtggc cagcaacgag atcctgcggg acccttgctt ccaccccggc 720
tacaagaaag tcgtgaacgt gtccgacctg tacaagaccc cctgcaccaa gagattcgag 780tacaagaaag tcgtgaacgt gtccgacctg tacaagaccc cctgcaccaa gagattcgag 780
atgaccctgc ccttccagca gttcgagatc cagggcatcg gcaattacca gcagtgccac 840atgaccctgc ccttccagca gttcgagatc cagggcatcg gcaattacca gcagtgccac 840
cagagcatcc tggaactgtt caacaccagc tactgcccct acagccagtg cgccttcaac 900cagagcatcc tggaactgtt caacaccagc tactgcccct acagccagtg cgccttcaac 900
ggcatcttcc tgccacctct gcagggggat ttcggcgcct tcagcgcctt ctacttcgtg 960ggcatcttcc tgccacctct gcagggggat ttcggcgcct tcagcgcctt ctacttcgtg 960
atgaagttcc tgaacctgac cagcgagaag gtgtcccagg aaaaagtgac agagatgatg 1020atgaagttcc tgaacctgac cagcgagaag gtgtcccagg aaaaagtgac agagatgatg 1020
aagaagttct gcgcccagcc ctgggaggaa atcaagacct cctacgctgg cgtgaaagag 1080aagaagttct gcgcccagcc ctgggaggaa atcaagacct cctacgctgg cgtgaaagag 1080
aagtacctga gcgagtactg cttcagcggc acctacatcc tgagcctgct gctgcagggc 1140aagtacctga gcgagtactg cttcagcggc acctacatcc tgagcctgct gctgcaggggc 1140
taccacttca ccgccgatag ctgggagcac atccacttca tcggcaagat tcagggcagc 1200taccacttca ccgccgatag ctgggagcac atccacttca tcggcaagat tcagggcagc 1200
gacgccggct ggacactggg ctacatgctg aatctgacca acatgatccc cgccgagcag 1260gacgccggct ggacactggg ctacatgctg aatctgacca acatgatccc cgccgagcag 1260
cccctgagca cacctctgag ccacagcacc 1290cccctgagca cacctctgag cccagcacc 1290
<210> 211<210> 211
<211> 430<211> 430
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 211<400> 211
Ala Pro Thr Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ala Pro Thr Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly
1 5 10 15 1 5 10 15
Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys
20 25 30 20 25 30
Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu
35 40 45 35 40 45
Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val
50 55 60 50 55 60
Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Met Glu Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Met Glu
65 70 75 80 65 70 75 80
Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala
85 90 95 85 90 95
Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu Glu Leu Ala Asp
100 105 110 100 105 110
Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp
115 120 125 115 120 125
Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly
130 135 140 130 135 140
Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln
145 150 155 160 145 150 155 160
Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr
165 170 175 165 170 175
Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln
180 185 190 180 185 190
Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu
195 200 205 195 200 205
Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile
210 215 220 210 215 220
Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly
225 230 235 240 225 230 235 240
Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr
245 250 255 245 250 255
Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly
260 265 270 260 265 270
Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn
275 280 285 275 280 285
Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu
290 295 300 290 295 300
Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val
305 310 315 320 305 310 315 320
Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val
325 330 335 325 330 335
Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys
340 345 350 340 345 350
Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Phe Cys Phe Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Phe Cys Phe
355 360 365 355 360 365
Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr
370 375 380 370 375 380
Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser
385 390 395 400 385 390 395 400
Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile
405 410 415 405 410 415
Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 430 420 425 430
<210> 212<210> 212
<211> 1290<211> 1290
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 212<400> 212
gcccctacca cccagaacaa ggccctgccc gagaacgtga agtacggcat cgtgctggat 60gcccctacca cccagaacaa ggccctgccc gagaacgtga agtacggcat cgtgctggat 60
gccggcagca gccacaccag cctgtacatc tacaagtggc ctgccgagaa agaaaacgac 120gccggcagca gccacaccag cctgtacatc tacaagtggc ctgccgagaa agaaaacgac 120
accggcgtgg tgcatcaggt ggaagagtgc agagtgaagg gccctggcat cagcaagttc 180accggcgtgg tgcatcaggt ggaaagtgc agagtgaagg gccctggcat cagcaagttc 180
gtgcagaaag tgaacgagat cggcatctac ctgaccgact gcatggaacg ggccatggaa 240gtgcagaaag tgaacgagat cggcatctac ctgaccgact gcatggaacg ggccatggaa 240
gtgatcccca gaagccagca ccaggaaacc cccgtgtatc tgggagccac cgccggcatg 300gtgatcccca gaagccagca cggaaacc cccgtgtatc tgggagccac cgccggcatg 300
agactgctga gaatggaaag cgaggaactg gccgaccggg tgctggacgt ggtggaaaga 360agactgctga gaatggaaag cgaggaactg gccgaccggg tgctggacgt ggtggaaaga 360
agcctgagca actacccatt cgattttcaa ggcgccagaa tcatcaccgg ccaggaagaa 420agcctgagca actacccatt cgattttcaa ggcgccagaa tcatcaccgg cggaagaa 420
ggcgcctacg gctggatcac catcaactac ctgctgggca agttcagcca gaagaatcag 480ggcgcctacg gctggatcac catcaactac ctgctgggca agttcagcca gaagaatcag 480
gaaaccttcg gcgccctgga cctgggcgga gcttctaccc aagtgacctt cgtgccccag 540gaaaccttcg gcgccctgga cctgggcgga gcttctaccc aagtgacctt cgtgccccag 540
aatcagacca tcgagagccc cgacaacgcc ctgcagttcc ggctgtacgg caaggactac 600aatcagacca tcgagagccc cgacaacgcc ctgcagttcc ggctgtacgg caaggactac 600
aatgtgtaca cccacagctt tctgtgctac ggaaaggacc aggctctgtg gcagaagctg 660aatgtgtaca cccacagctt tctgtgctac ggaaaggacc aggctctgtg gcagaagctg 660
gccaaggaca tccaggtggc cagcaacgag atcctgcggg acccttgctt ccaccccggc 720gccaaggaca tccaggtggc cagcaacgag atcctgcggg acccttgctt ccaccccggc 720
tacaagaaag tcgtgaacgt gtccgacctg tacaagaccc cctgcaccaa gagattcgag 780tacaagaaag tcgtgaacgt gtccgacctg tacaagaccc cctgcaccaa gagattcgag 780
atgaccctgc ccttccagca gttcgagatc cagggcatcg gcaattacca gcagtgccac 840atgaccctgc ccttccagca gttcgagatc cagggcatcg gcaattacca gcagtgccac 840
cagagcatcc tggaactgtt caacaccagc tactgcccct acagccagtg cgccttcaac 900cagagcatcc tggaactgtt caacaccagc tactgcccct acagccagtg cgccttcaac 900
ggcatcttcc tgccacctct gcagggggat ttcggcgcct tcagcgcctt ctacttcgtg 960ggcatcttcc tgccacctct gcagggggat ttcggcgcct tcagcgcctt ctacttcgtg 960
atgaagttcc tgaacctgac cagcgagaag gtgtcccagg aaaaagtgac agagatgatg 1020atgaagttcc tgaacctgac cagcgagaag gtgtcccagg aaaaagtgac agagatgatg 1020
aagaagttct gcgcccagcc ctgggaggaa atcaagacct cctacgctgg cgtgaaagag 1080aagaagttct gcgcccagcc ctgggaggaa atcaagacct cctacgctgg cgtgaaagag 1080
aagtacctga gcgagttttg cttcagcggc acctacatcc tgagcctgct gctgcagggc 1140aagtacctga gcgagttttg cttcagcggc acctacatcc tgagcctgct gctgcaggggc 1140
taccacttca ccgccgatag ctgggagcac atccacttca tcggcaagat tcagggcagc 1200taccacttca ccgccgatag ctgggagcac atccacttca tcggcaagat tcagggcagc 1200
gacgccggct ggacactggg ctacatgctg aatctgacca acatgatccc cgccgagcag 1260gacgccggct ggacactggg ctacatgctg aatctgacca acatgatccc cgccgagcag 1260
cccctgagca cacctctgag ccacagcacc 1290cccctgagca cacctctgag cccagcacc 1290
<210> 213<210> 213
<211> 433<211> 433
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 213<400> 213
Ala Pro Thr Ser Ser Ser Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Ala Pro Thr Ser Ser Ser Thr Gln Asn Lys Ala Leu Pro Glu Asn Val
1 5 10 15 1 5 10 15
Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr
20 25 30 20 25 30
Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His
35 40 45 35 40 45
Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val
50 55 60 50 55 60
Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg
65 70 75 80 65 70 75 80
Ala Met Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr Ala Met Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr
85 90 95 85 90 95
Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu
100 105 110 100 105 110
Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr
115 120 125 115 120 125
Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly
130 135 140 130 135 140
Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln
145 150 155 160 145 150 155 160
Lys Asn Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Lys Asn Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr
165 170 175 165 170 175
Gln Val Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Gln Val Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn
180 185 190 180 185 190
Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His
195 200 205 195 200 205
Ser Phe Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Ser Phe Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala
210 215 220 210 215 220
Lys Asp Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe Lys Asp Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe
225 230 235 240 225 230 235 240
His Pro Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr His Pro Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr
245 250 255 245 250 255
Pro Cys Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Pro Cys Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu
260 265 270 260 265 270
Ile Gln Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Ile Gln Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu
275 280 285 275 280 285
Leu Phe Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Leu Phe Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly
290 295 300 290 295 300
Ile Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Ile Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe
305 310 315 320 305 310 315 320
Tyr Phe Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Tyr Phe Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln
325 330 335 325 330 335
Glu Lys Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Lys Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu
340 345 350 340 345 350
Glu Ile Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Glu Ile Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu
355 360 365 355 360 365
Phe Cys Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr Phe Cys Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr
370 375 380 370 375 380
His Phe Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile His Phe Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile
385 390 395 400 385 390 395 400
Gln Gly Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Gln Gly Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr
405 410 415 405 410 415
Asn Met Ile Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Asn Met Ile Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser
420 425 430 420 425 430
Thr Thr
<210> 214<210> 214
<211> 1299<211> 1299
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 214<400> 214
gcccctacca gcagcagcac ccagaacaag gccctgcccg agaacgtgaa gtacggcatc 60gcccctacca gcagcagcac ccagaacaag gccctgcccg agaacgtgaa gtacggcatc 60
gtgctggatg ccggcagcag ccacaccagc ctgtacatct acaagtggcc tgccgagaaa 120gtgctggatg ccggcagcag ccacaccagc ctgtacatct acaagtggcc tgccgagaaa 120
gaaaacgaca ccggcgtggt gcatcaggtg gaagagtgca gagtgaaggg ccctggcatc 180gaaaacgaca ccggcgtggt gcatcaggtg gaagagtgca gagtgaaggg ccctggcatc 180
agcaagttcg tgcagaaagt gaacgagatc ggcatctacc tgaccgactg catggaacgg 240agcaagttcg tgcagaaagt gaacgagatc ggcatctacc tgaccgactg catggaacgg 240
gccatggaag tgatccccag aagccagcac caggaaaccc ccgtgtatct gggagccacc 300gccatggaag tgatccccag aagccagcac caggaaaccc ccgtgtatct gggagccacc 300
gccggcatga gactgctgag aatggaaagc gaggaactgg ccgaccgggt gctggacgtg 360gccggcatga gactgctgag aatggaaagc gaggaactgg ccgaccgggt gctggacgtg 360
gtggaaagaa gcctgagcaa ctacccattc gattttcaag gcgccagaat catcaccggc 420gtggaaagaa gcctgagcaa ctacccattc gattttcaag gcgccagaat catcaccggc 420
caggaagaag gcgcctacgg ctggatcacc atcaactacc tgctgggcaa gttcagccag 480caggaagaag gcgcctacgg ctggatcacc atcaactacc tgctgggcaa gttcagccag 480
aagaatcagg aaaccttcgg cgccctggac ctgggcggag cttctaccca agtgaccttc 540aagaatcagg aaaccttcgg cgccctggac ctgggcggag cttctaccca agtgaccttc 540
gtgccccaga atcagaccat cgagagcccc gacaacgccc tgcagttccg gctgtacggc 600gtgccccaga atcagaccat cgagagcccc gacaacgccc tgcagttccg gctgtacggc 600
aaggactaca atgtgtacac ccacagcttt ctgtgctacg gaaaggacca ggctctgtgg 660aaggactaca atgtgtacac ccacagcttt ctgtgctacg gaaaggacca ggctctgtgg 660
cagaagctgg ccaaggacat ccaggtggcc agcaacgaga tcctgcggga cccttgcttc 720cagaagctgg ccaaggacat ccaggtggcc agcaacgaga tcctgcggga cccttgcttc 720
caccccggct acaagaaagt cgtgaacgtg tccgacctgt acaagacccc ctgcaccaag 780caccccggct acaagaaagt cgtgaacgtg tccgacctgt acaagacccc ctgcaccaag 780
agattcgaga tgaccctgcc cttccagcag ttcgagatcc agggcatcgg caattaccag 840agattcgaga tgaccctgcc cttccagcag ttcgagatcc agggcatcgg caattaccag 840
cagtgccacc agagcatcct ggaactgttc aacaccagct actgccccta cagccagtgc 900cagtgccacc agagcatcct ggaactgttc aacaccagct actgccccta cagccagtgc 900
gccttcaacg gcatcttcct gccacctctg cagggggatt tcggcgcctt cagcgccttc 960gccttcaacg gcatcttcct gccacctctg cagggggatt tcggcgcctt cagcgccttc 960
tacttcgtga tgaagttcct gaacctgacc agcgagaagg tgtcccagga aaaagtgaca 1020tacttcgtga tgaagttcct gaacctgacc agcgagaagg tgtcccagga aaaagtgaca 1020
gagatgatga agaagttctg cgcccagccc tgggaggaaa tcaagacctc ctacgctggc 1080gagatgatga agaagttctg cgcccagccc tgggaggaaa tcaagacctc ctacgctggc 1080
gtgaaagaga agtacctgag cgagttctgc ttcagcggca cctacatcct gagcctgctg 1140gtgaaagaga agtacctgag cgagttctgc ttcagcggca cctacatcct gagcctgctg 1140
ctgcagggct accacttcac cgccgatagc tgggagcaca tccacttcat cggcaagatt 1200ctgcagggct accacttcac cgccgatagc tgggagcaca tccacttcat cggcaagatt 1200
cagggcagcg acgccggctg gacactgggc tacatgctga atctgaccaa catgatcccc 1260cagggcagcg acgccggctg gacactgggc tacatgctga atctgaccaa catgatcccc 1260
gccgagcagc ccctgagcac acctctgagc cacagcacc 1299gccgagcagc ccctgagcac acctctgagc cacagcacc 1299
<210> 215<210> 215
<211> 442<211> 442
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 215<400> 215
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Thr Ser Ser Thr Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Thr Ser Ser Thr
1 5 10 15 1 5 10 15
Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Asp Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Asp
20 25 30 20 25 30
Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Glu Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Glu
35 40 45 35 40 45
Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Val Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Val
50 55 60 50 55 60
Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Gly Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Gly
65 70 75 80 65 70 75 80
Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Met Glu Val Ile Pro Arg Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Met Glu Val Ile Pro Arg
85 90 95 85 90 95
Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Met Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Met
100 105 110 100 105 110
Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Asp Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Asp
115 120 125 115 120 125
Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Ala Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Ala
130 135 140 130 135 140
Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ile Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ile
145 150 155 160 145 150 155 160
Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Gly Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Gly
165 170 175 165 170 175
Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gln Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gln
180 185 190 180 185 190
Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Tyr Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Tyr
195 200 205 195 200 205
Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Lys Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Lys
210 215 220 210 215 220
Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Ser Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Ser
225 230 235 240 225 230 235 240
Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Val Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Val
245 250 255 245 250 255
Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Glu Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Glu
260 265 270 260 265 270
Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Tyr Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Tyr
275 280 285 275 280 285
Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Cys Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Cys
290 295 300 290 295 300
Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Gln Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Gln
305 310 315 320 305 310 315 320
Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Leu Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Leu
325 330 335 325 330 335
Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Met Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Met
340 345 350 340 345 350
Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Ala Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Ala
355 360 365 355 360 365
Gly Val Asn Glu Lys Tyr Leu Ser Glu Phe Cys Phe Ser Gly Thr Tyr Gly Val Asn Glu Lys Tyr Leu Ser Glu Phe Cys Phe Ser Gly Thr Tyr
370 375 380 370 375 380
Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Trp Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Trp
385 390 395 400 385 390 395 400
Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp
405 410 415 405 410 415
Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Gln Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Gln
420 425 430 420 425 430
Pro Leu Ser Thr Pro Leu Ser His Ser Thr Pro Leu Ser Thr Pro Leu Ser His Ser Thr
435 440 435 440
<210> 216<210> 216
<211> 1326<211> 1326
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 216<400> 216
gcccctacca gcagcagcac caagaaaacc cagctgacca gcagcaccca gaacaaggcc 60gcccctacca gcagcagcac caagaaaacc cagctgacca gcagcaccca gaacaaggcc 60
ctgcccgaga acgtgaagta cggcatcgtg ctggatgccg gcagcagcca caccagcctg 120ctgccgaga acgtgaagta cggcatcgtg ctggatgccg gcagcagcca caccagcctg 120
tacatctaca agtggcctgc cgagaaagaa aacgacaccg gcgtggtgca tcaggtggaa 180tacatctaca agtggcctgc cgagaaagaa aacgacaccg gcgtggtgca tcaggtggaa 180
gagtgcagag tgaagggccc tggcatcagc aagttcgtgc agaaagtgaa cgagatcggc 240gagtgcagag tgaagggccc tggcatcagc aagttcgtgc agaaagtgaa cgagatcggc 240
atctacctga ccgactgcat ggaacgggcc atggaagtga tccccagaag ccagcaccag 300atctacctga ccgactgcat ggaacggggcc atggaagtga tccccagaag ccagcaccag 300
gaaacccccg tgtatctggg agccaccgcc ggcatgagac tgctgagaat ggaaagcgag 360gaaacccccg tgtatctggg agccaccgcc ggcatgagac tgctgagaat ggaaagcgag 360
gaactggccg accgggtgct ggacgtggtg gaaagaagcc tgagcaacta cccattcgat 420gaactggccg accgggtgct ggacgtggtg gaaagaagcc tgagcaacta cccattcgat 420
tttcaaggcg ccagaatcat caccggccag gaagaaggcg cctacggctg gatcaccatc 480tttcaaggcg ccagaatcat caccggccag gaagaaggcg cctacggctg gatcaccatc 480
aactacctgc tgggcaagtt cagccagaag aatcaggaaa ccttcggcgc cctggacctg 540aactacctgc tgggcaagtt cagccagaag aatcaggaaa ccttcggcgc cctggacctg 540
ggcggagctt ctacccaagt gaccttcgtg ccccagaatc agaccatcga gagccccgac 600ggcggagctt ctacccaagt gaccttcgtg ccccagaatc agaccatcga gagccccgac 600
aacgccctgc agttccggct gtacggcaag gactacaatg tgtacaccca cagctttctg 660aacgccctgc agttccggct gtacggcaag gactacaatg tgtacaccca cagctttctg 660
tgctacggaa aggaccaggc tctgtggcag aagctggcca aggacatcca ggtggccagc 720tgctacggaa aggaccaggc tctgtggcag aagctggcca aggacatcca ggtggccagc 720
aacgagatcc tgcgggaccc ttgcttccac cccggctaca agaaagtcgt gaacgtgtcc 780aacgagatcc tgcgggaccc ttgcttccac cccggctaca agaaagtcgt gaacgtgtcc 780
gacctgtaca agaccccctg caccaagaga ttcgagatga ccctgccctt ccagcagttc 840gacctgtaca agaccccctg caccaagaga ttcgagatga ccctgccctt ccagcagttc 840
gagatccagg gcatcggcaa ttaccagcag tgccaccaga gcatcctgga actgttcaac 900gagatccagg gcatcggcaa ttaccagcag tgccaccaga gcatcctgga actgttcaac 900
accagctact gcccctacag ccagtgcgcc ttcaacggca tcttcctgcc acctctgcag 960accagctact gcccctacag ccagtgcgcc ttcaacggca tcttcctgcc acctctgcag 960
ggggatttcg gcgccttcag cgccttctac ttcgtgatga agttcctgaa cctgaccagc 1020ggggatttcg gcgccttcag cgccttctac ttcgtgatga agttcctgaa cctgaccagc 1020
gagaaggtgt cccaggaaaa agtgacagag atgatgaaga agttctgcgc ccaaccctgg 10801080
gaggaaatca agacctccta cgctggcgtg aacgagaagt acctgagcga gttttgcttc 1140gaggaaatca agacctccta cgctggcgtg aacgagaagt acctgagcga gttttgcttc 1140
agcggcacct acatcctgag cctgctgctg cagggctacc acttcaccgc cgatagctgg 1200agcggcacct acatcctgag cctgctgctg cagggctacc acttcaccgc cgatagctgg 1200
gagcacatcc acttcatcgg caagattcag ggcagcgacg ccggctggac actgggctac 1260gagcacatcc acttcatcgg caagattcag ggcagcgacg ccggctggac actgggctac 1260
atgctgaatc tgaccaacat gatccccgcc gagcagcccc tgagcacacc tctgagccac 1320atgctgaatc tgaccaacat gatccccgcc gagcagcccc tgagcacacc tctgagccac 1320
agcacc 1326agcacc 1326
<210> 217<210> 217
<211> 430<211> 430
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 217<400> 217
Ala Pro Thr Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ala Pro Thr Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly
1 5 10 15 1 5 10 15
Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys
20 25 30 20 25 30
Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu
35 40 45 35 40 45
Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val
50 55 60 50 55 60
Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Met Glu Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Met Glu
65 70 75 80 65 70 75 80
Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala
85 90 95 85 90 95
Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu Glu Leu Ala Asp
100 105 110 100 105 110
Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp
115 120 125 115 120 125
Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly
130 135 140 130 135 140
Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln
145 150 155 160 145 150 155 160
Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr
165 170 175 165 170 175
Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln
180 185 190 180 185 190
Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu
195 200 205 195 200 205
Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile
210 215 220 210 215 220
Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly
225 230 235 240 225 230 235 240
Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr
245 250 255 245 250 255
Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly
260 265 270 260 265 270
Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn
275 280 285 275 280 285
Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu
290 295 300 290 295 300
Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val
305 310 315 320 305 310 315 320
Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val
325 330 335 325 330 335
Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys
340 345 350 340 345 350
Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Phe Cys Phe Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Phe Cys Phe
355 360 365 355 360 365
Ser Gly Thr Tyr Ile Leu Ser Leu Leu Gln Gln Gly Tyr His Phe Thr Ser Gly Thr Tyr Ile Leu Ser Leu Leu Gln Gln Gly Tyr His Phe Thr
370 375 380 370 375 380
Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser
385 390 395 400 385 390 395 400
Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile
405 410 415 405 410 415
Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 430 420 425 430
<210> 218<210> 218
<211> 1290<211> 1290
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 218<400> 218
gcccctacca cccagaacaa ggccctgccc gagaacgtga agtacggcat cgtgctggat 60gcccctacca cccagaacaa ggccctgccc gagaacgtga agtacggcat cgtgctggat 60
gccggcagca gccacaccag cctgtacatc tacaagtggc ctgccgagaa agaaaacgac 120gccggcagca gccacaccag cctgtacatc tacaagtggc ctgccgagaa agaaaacgac 120
accggcgtgg tgcatcaggt ggaagagtgc agagtgaagg gccctggcat cagcaagttc 180accggcgtgg tgcatcaggt ggaaagtgc agagtgaagg gccctggcat cagcaagttc 180
gtgcagaaag tgaacgagat cggcatctac ctgaccgact gcatggaacg ggccatggaa 240gtgcagaaag tgaacgagat cggcatctac ctgaccgact gcatggaacg ggccatggaa 240
gtgatcccca gaagccagca ccaggaaacc cccgtgtatc tgggagccac cgccggcatg 300gtgatcccca gaagccagca cggaaacc cccgtgtatc tgggagccac cgccggcatg 300
agactgctga gaatggaaag cgaggaactg gccgaccggg tgctggacgt ggtggaaaga 360agactgctga gaatggaaag cgaggaactg gccgaccggg tgctggacgt ggtggaaaga 360
agcctgagca actacccatt cgattttcaa ggcgccagaa tcatcaccgg ccaggaagaa 420agcctgagca actacccatt cgattttcaa ggcgccagaa tcatcaccgg cggaagaa 420
ggcgcctacg gctggatcac catcaactac ctgctgggca agttcagcca gaagaatcag 480ggcgcctacg gctggatcac catcaactac ctgctgggca agttcagcca gaagaatcag 480
gaaaccttcg gcgccctgga cctgggcgga gcttctaccc aagtgacctt cgtgccccag 540gaaaccttcg gcgccctgga cctgggcgga gcttctaccc aagtgacctt cgtgccccag 540
aatcagacca tcgagagccc cgacaacgcc ctgcagttcc ggctgtacgg caaggactac 600aatcagacca tcgagagccc cgacaacgcc ctgcagttcc ggctgtacgg caaggactac 600
aatgtgtaca cccacagctt tctgtgctac ggaaaggacc aggctctgtg gcagaagctg 660aatgtgtaca cccacagctt tctgtgctac ggaaaggacc aggctctgtg gcagaagctg 660
gccaaggaca tccaggtggc cagcaacgag atcctgcggg acccttgctt ccaccccggc 720gccaaggaca tccaggtggc cagcaacgag atcctgcggg acccttgctt ccaccccggc 720
tacaagaaag tcgtgaacgt gtccgacctg tacaagaccc cctgcaccaa gagattcgag 780tacaagaaag tcgtgaacgt gtccgacctg tacaagaccc cctgcaccaa gagattcgag 780
atgaccctgc ccttccagca gttcgagatc cagggcatcg gcaattacca gcagtgccac 840atgaccctgc ccttccagca gttcgagatc cagggcatcg gcaattacca gcagtgccac 840
cagagcatcc tggaactgtt caacaccagc tactgcccct acagccagtg cgccttcaac 900cagagcatcc tggaactgtt caacaccagc tactgcccct acagccagtg cgccttcaac 900
ggcatcttcc tgccacctct gcagggggat ttcggcgcct tcagcgcctt ctacttcgtg 960ggcatcttcc tgccacctct gcagggggat ttcggcgcct tcagcgcctt ctacttcgtg 960
atgaagttcc tgaacctgac cagcgagaag gtgtcccagg aaaaagtgac agagatgatg 1020atgaagttcc tgaacctgac cagcgagaag gtgtcccagg aaaaagtgac agagatgatg 1020
aagaagttct gcgcccagcc ctgggaggaa atcaagacct cctacgctgg cgtgaaagag 1080aagaagttct gcgcccagcc ctgggaggaa atcaagacct cctacgctgg cgtgaaagag 1080
aagtacctga gcgagttctg cttcagcggc acctacatcc tgagcctgct gcagcagggc 1140aagtacctga gcgagttctg cttcagcggc acctacatcc tgagcctgct gcagcaggggc 1140
taccacttca ccgccgatag ctgggagcac atccacttca tcggcaagat tcagggcagc 1200taccacttca ccgccgatag ctgggagcac atccacttca tcggcaagat tcagggcagc 1200
gacgccggct ggacactggg ctacatgctg aatctgacca acatgatccc cgccgagcag 1260gacgccggct ggacactggg ctacatgctg aatctgacca acatgatccc cgccgagcag 1260
cccctgagca cacctctgag ccacagcacc 1290cccctgagca cacctctgag cccagcacc 1290
<210> 219<210> 219
<211> 433<211> 433
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 219<400> 219
Ala Pro Thr Ser Ser Ser Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Ala Pro Thr Ser Ser Ser Thr Gln Asn Lys Ala Leu Pro Glu Asn Val
1 5 10 15 1 5 10 15
Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr
20 25 30 20 25 30
Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His
35 40 45 35 40 45
Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val
50 55 60 50 55 60
Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg
65 70 75 80 65 70 75 80
Ala Met Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr Ala Met Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr
85 90 95 85 90 95
Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu
100 105 110 100 105 110
Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr
115 120 125 115 120 125
Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly
130 135 140 130 135 140
Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln
145 150 155 160 145 150 155 160
Lys Asn Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Lys Asn Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr
165 170 175 165 170 175
Gln Val Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Gln Val Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn
180 185 190 180 185 190
Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His
195 200 205 195 200 205
Ser Phe Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Ser Phe Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala
210 215 220 210 215 220
Lys Asp Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe Lys Asp Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe
225 230 235 240 225 230 235 240
His Pro Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr His Pro Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr
245 250 255 245 250 255
Pro Cys Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Pro Cys Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu
260 265 270 260 265 270
Ile Gln Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Ile Gln Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu
275 280 285 275 280 285
Leu Phe Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Leu Phe Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly
290 295 300 290 295 300
Ile Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Ile Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe
305 310 315 320 305 310 315 320
Tyr Phe Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Tyr Phe Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln
325 330 335 325 330 335
Glu Lys Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Lys Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu
340 345 350 340 345 350
Glu Ile Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Glu Ile Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu
355 360 365 355 360 365
Phe Cys Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Gln Gln Gly Tyr Phe Cys Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Gln Gln Gly Tyr
370 375 380 370 375 380
His Phe Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile His Phe Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile
385 390 395 400 385 390 395 400
Gln Gly Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Gln Gly Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr
405 410 415 405 410 415
Asn Met Ile Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Asn Met Ile Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser
420 425 430 420 425 430
Thr Thr
<210> 220<210> 220
<211> 1299<211> 1299
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 220<400> 220
gcccctacca gcagcagcac ccagaacaag gccctgcccg agaacgtgaa gtacggcatc 60gcccctacca gcagcagcac ccagaacaag gccctgcccg agaacgtgaa gtacggcatc 60
gtgctggatg ccggcagcag ccacaccagc ctgtacatct acaagtggcc tgccgagaaa 120gtgctggatg ccggcagcag ccacaccagc ctgtacatct acaagtggcc tgccgagaaa 120
gaaaacgaca ccggcgtggt gcatcaggtg gaagagtgca gagtgaaggg ccctggcatc 180gaaaacgaca ccggcgtggt gcatcaggtg gaagagtgca gagtgaaggg ccctggcatc 180
agcaagttcg tgcagaaagt gaacgagatc ggcatctacc tgaccgactg catggaacgg 240agcaagttcg tgcagaaagt gaacgagatc ggcatctacc tgaccgactg catggaacgg 240
gccatggaag tgatccccag aagccagcac caggaaaccc ccgtgtatct gggagccacc 300gccatggaag tgatccccag aagccagcac caggaaaccc ccgtgtatct gggagccacc 300
gccggcatga gactgctgag aatggaaagc gaggaactgg ccgaccgggt gctggacgtg 360gccggcatga gactgctgag aatggaaagc gaggaactgg ccgaccgggt gctggacgtg 360
gtggaaagaa gcctgagcaa ctacccattc gattttcaag gcgccagaat catcaccggc 420gtggaaagaa gcctgagcaa ctacccattc gattttcaag gcgccagaat catcaccggc 420
caggaagaag gcgcctacgg ctggatcacc atcaactacc tgctgggcaa gttcagccag 480caggaagaag gcgcctacgg ctggatcacc atcaactacc tgctgggcaa gttcagccag 480
aagaatcagg aaaccttcgg cgccctggac ctgggcggag cttctaccca agtgaccttc 540aagaatcagg aaaccttcgg cgccctggac ctgggcggag cttctaccca agtgaccttc 540
gtgccccaga atcagaccat cgagagcccc gacaacgccc tgcagttccg gctgtacggc 600gtgccccaga atcagaccat cgagagcccc gacaacgccc tgcagttccg gctgtacggc 600
aaggactaca atgtgtacac ccacagcttt ctgtgctacg gaaaggacca ggctctgtgg 660aaggactaca atgtgtacac ccacagcttt ctgtgctacg gaaaggacca ggctctgtgg 660
cagaagctgg ccaaggacat ccaggtggcc agcaacgaga tcctgcggga cccttgcttc 720cagaagctgg ccaaggacat ccaggtggcc agcaacgaga tcctgcggga cccttgcttc 720
caccccggct acaagaaagt cgtgaacgtg tccgacctgt acaagacccc ctgcaccaag 780caccccggct acaagaaagt cgtgaacgtg tccgacctgt acaagacccc ctgcaccaag 780
agattcgaga tgaccctgcc cttccagcag ttcgagatcc agggcatcgg caattaccag 840agattcgaga tgaccctgcc cttccagcag ttcgagatcc agggcatcgg caattaccag 840
cagtgccacc agagcatcct ggaactgttc aacaccagct actgccccta cagccagtgc 900cagtgccacc agagcatcct ggaactgttc aacaccagct actgccccta cagccagtgc 900
gccttcaacg gcatcttcct gccacctctg cagggggatt tcggcgcctt cagcgccttc 960gccttcaacg gcatcttcct gccacctctg cagggggatt tcggcgcctt cagcgccttc 960
tacttcgtga tgaagttcct gaacctgacc agcgagaagg tgtcccagga aaaagtgaca 1020tacttcgtga tgaagttcct gaacctgacc agcgagaagg tgtcccagga aaaagtgaca 1020
gagatgatga agaagttctg cgcccagccc tgggaggaaa tcaagacctc ctacgctggc 1080gagatgatga agaagttctg cgcccagccc tgggaggaaa tcaagacctc ctacgctggc 1080
gtgaaagaga agtacctgag cgagttctgc ttcagcggca cctacatcct gagcctgctg 1140gtgaaagaga agtacctgag cgagttctgc ttcagcggca cctacatcct gagcctgctg 1140
cagcagggct accacttcac cgccgatagc tgggagcaca tccacttcat cggcaagatt 1200cagcagggct accacttcac cgccgatagc tgggagcaca tccacttcat cggcaagatt 1200
cagggcagcg acgccggctg gacactgggc tacatgctga atctgaccaa catgatcccc 1260cagggcagcg acgccggctg gacactgggc tacatgctga atctgaccaa catgatcccc 1260
gccgagcagc ccctgagcac acctctgagc cacagcacc 1299gccgagcagc ccctgagcac acctctgagc cacagcacc 1299
<210> 221<210> 221
<211> 430<211> 430
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 221<400> 221
Ala Pro Thr Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ala Pro Thr Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly
1 5 10 15 1 5 10 15
Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys
20 25 30 20 25 30
Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu
35 40 45 35 40 45
Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val
50 55 60 50 55 60
Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Met Glu Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Met Glu
65 70 75 80 65 70 75 80
Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala
85 90 95 85 90 95
Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu Glu Leu Ala Asp
100 105 110 100 105 110
Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp
115 120 125 115 120 125
Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly
130 135 140 130 135 140
Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln
145 150 155 160 145 150 155 160
Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr
165 170 175 165 170 175
Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln
180 185 190 180 185 190
Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu
195 200 205 195 200 205
Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile
210 215 220 210 215 220
Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly
225 230 235 240 225 230 235 240
Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr
245 250 255 245 250 255
Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly
260 265 270 260 265 270
Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn
275 280 285 275 280 285
Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu
290 295 300 290 295 300
Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Ser Val Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Ser Val
305 310 315 320 305 310 315 320
Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val
325 330 335 325 330 335
Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys
340 345 350 340 345 350
Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe
355 360 365 355 360 365
Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr
370 375 380 370 375 380
Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser
385 390 395 400 385 390 395 400
Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile
405 410 415 405 410 415
Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 430 420 425 430
<210> 222<210> 222
<211> 1290<211> 1290
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 222<400> 222
gcccctacca cccagaacaa ggccctgccc gagaacgtga agtacggcat cgtgctggat 60gcccctacca cccagaacaa ggccctgccc gagaacgtga agtacggcat cgtgctggat 60
gccggcagca gccacaccag cctgtacatc tacaagtggc ctgccgagaa agaaaacgac 120gccggcagca gccacaccag cctgtacatc tacaagtggc ctgccgagaa agaaaacgac 120
accggcgtgg tgcatcaggt ggaagagtgc agagtgaagg gccctggcat cagcaagttc 180accggcgtgg tgcatcaggt ggaaagtgc agagtgaagg gccctggcat cagcaagttc 180
gtgcagaaag tgaacgagat cggcatctac ctgaccgact gcatggaacg ggccatggaa 240gtgcagaaag tgaacgagat cggcatctac ctgaccgact gcatggaacg ggccatggaa 240
gtgatcccca gaagccagca ccaggaaacc cccgtgtatc tgggagccac cgccggcatg 300gtgatcccca gaagccagca cggaaacc cccgtgtatc tgggagccac cgccggcatg 300
agactgctga gaatggaaag cgaggaactg gccgaccggg tgctggacgt ggtggaaaga 360agactgctga gaatggaaag cgaggaactg gccgaccggg tgctggacgt ggtggaaaga 360
agcctgagca actacccatt cgattttcaa ggcgccagaa tcatcaccgg ccaggaagaa 420agcctgagca actacccatt cgattttcaa ggcgccagaa tcatcaccgg cggaagaa 420
ggcgcctacg gctggatcac catcaactac ctgctgggca agttcagcca gaagaatcag 480ggcgcctacg gctggatcac catcaactac ctgctgggca agttcagcca gaagaatcag 480
gaaaccttcg gcgccttgga cctgggcgga gcttctaccc aagtgacctt cgtgccccag 540gaaaccttcg gcgccttgga cctgggcgga gcttctaccc aagtgacctt cgtgccccag 540
aatcagacca tcgagagccc cgacaacgcc ctgcagttcc ggctgtacgg caaggactac 600aatcagacca tcgagagccc cgacaacgcc ctgcagttcc ggctgtacgg caaggactac 600
aatgtgtaca cccacagctt tctgtgctac ggaaaggacc aggctctgtg gcagaagctg 660aatgtgtaca cccacagctt tctgtgctac ggaaaggacc aggctctgtg gcagaagctg 660
gccaaggaca tccaggtggc cagcaacgag atcctgcggg acccttgctt ccaccccggc 720gccaaggaca tccaggtggc cagcaacgag atcctgcggg acccttgctt ccaccccggc 720
tacaagaaag tcgtgaacgt gtccgacctg tacaagaccc cctgcaccaa gagattcgag 780tacaagaaag tcgtgaacgt gtccgacctg tacaagaccc cctgcaccaa gagattcgag 780
atgaccctgc ccttccagca gttcgagatc cagggcatcg gcaattacca gcagtgccac 840atgaccctgc ccttccagca gttcgagatc cagggcatcg gcaattacca gcagtgccac 840
cagagcatcc tggaactgtt caacaccagc tactgcccct acagccagtg cgccttcaac 900cagagcatcc tggaactgtt caacaccagc tactgcccct acagccagtg cgccttcaac 900
ggcatcttcc tgccacctct gcagggggat ttcggcgcct tcagcgcctt ctactccgtg 960ggcatcttcc tgccacctct gcagggggat ttcggcgcct tcagcgcctt ctactccgtg 960
atgaagttcc tgaacctgac cagcgagaag gtgtcccagg aaaaagtgac agagatgatg 1020atgaagttcc tgaacctgac cagcgagaag gtgtcccagg aaaaagtgac agagatgatg 1020
aagaagttct gcgcccagcc ctgggaggaa atcaagacct cctacgctgg cgtgaaagag 1080aagaagttct gcgcccagcc ctgggaggaa atcaagacct cctacgctgg cgtgaaagag 1080
aagtacctga gcgagtactg cttcagcggc acctacatcc tgagcctgct gctgcagggc 1140aagtacctga gcgagtactg cttcagcggc acctacatcc tgagcctgct gctgcaggggc 1140
taccacttca ccgccgatag ctgggagcac atccacttca tcggcaagat tcagggcagc 1200taccacttca ccgccgatag ctgggagcac atccacttca tcggcaagat tcagggcagc 1200
gacgccggct ggacactggg ttacatgctg aatctgacca acatgatccc cgccgagcag 1260gacgccggct ggacactgggg ttacatgctg aatctgacca acatgatccc cgccgagcag 1260
cccctgagca cacctctgag ccacagcacc 1290cccctgagca cacctctgag cccagcacc 1290
<210> 223<210> 223
<211> 433<211> 433
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 223<400> 223
Ala Pro Thr Ser Ser Ser Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Ala Pro Thr Ser Ser Ser Thr Gln Asn Lys Ala Leu Pro Glu Asn Val
1 5 10 15 1 5 10 15
Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr
20 25 30 20 25 30
Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His
35 40 45 35 40 45
Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val
50 55 60 50 55 60
Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg
65 70 75 80 65 70 75 80
Ala Met Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr Ala Met Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr
85 90 95 85 90 95
Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu
100 105 110 100 105 110
Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr
115 120 125 115 120 125
Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly
130 135 140 130 135 140
Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln
145 150 155 160 145 150 155 160
Lys Asn Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Lys Asn Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr
165 170 175 165 170 175
Gln Val Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Gln Val Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn
180 185 190 180 185 190
Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His
195 200 205 195 200 205
Ser Phe Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Ser Phe Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala
210 215 220 210 215 220
Lys Asp Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe Lys Asp Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe
225 230 235 240 225 230 235 240
His Pro Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr His Pro Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr
245 250 255 245 250 255
Pro Cys Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Pro Cys Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu
260 265 270 260 265 270
Ile Gln Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Ile Gln Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu
275 280 285 275 280 285
Leu Phe Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Leu Phe Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly
290 295 300 290 295 300
Ile Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Ile Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe
305 310 315 320 305 310 315 320
Tyr Ser Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Tyr Ser Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln
325 330 335 325 330 335
Glu Lys Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Lys Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu
340 345 350 340 345 350
Glu Ile Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Glu Ile Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu
355 360 365 355 360 365
Tyr Cys Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr Tyr Cys Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr
370 375 380 370 375 380
His Phe Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile His Phe Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile
385 390 395 400 385 390 395 400
Gln Gly Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Gln Gly Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr
405 410 415 405 410 415
Asn Met Ile Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Asn Met Ile Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser
420 425 430 420 425 430
Thr Thr
<210> 224<210> 224
<211> 1299<211> 1299
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 224<400> 224
gcccctacca gcagcagcac ccagaacaag gccctgcccg agaacgtgaa gtacggcatc 60gcccctacca gcagcagcac ccagaacaag gccctgcccg agaacgtgaa gtacggcatc 60
gtgctggatg ccggcagcag ccacaccagc ctgtacatct acaagtggcc tgccgagaaa 120gtgctggatg ccggcagcag ccacaccagc ctgtacatct acaagtggcc tgccgagaaa 120
gaaaacgaca ccggcgtggt gcatcaggtg gaagagtgca gagtgaaggg ccctggcatc 180gaaaacgaca ccggcgtggt gcatcaggtg gaagagtgca gagtgaaggg ccctggcatc 180
agcaagttcg tgcagaaagt gaacgagatc ggcatctacc tgaccgactg catggaacgg 240agcaagttcg tgcagaaagt gaacgagatc ggcatctacc tgaccgactg catggaacgg 240
gccatggaag tgatccccag aagccagcac caggaaaccc ccgtgtatct gggagccacc 300gccatggaag tgatccccag aagccagcac caggaaaccc ccgtgtatct gggagccacc 300
gccggcatga gactgctgag aatggaaagc gaggaactgg ccgaccgggt gctggacgtg 360gccggcatga gactgctgag aatggaaagc gaggaactgg ccgaccgggt gctggacgtg 360
gtggaaagaa gcctgagcaa ctacccattc gattttcaag gcgccagaat catcaccggc 420gtggaaagaa gcctgagcaa ctacccattc gattttcaag gcgccagaat catcaccggc 420
caggaagaag gcgcctacgg ctggatcacc atcaactacc tgctgggcaa gttcagccag 480caggaagaag gcgcctacgg ctggatcacc atcaactacc tgctgggcaa gttcagccag 480
aagaatcagg aaaccttcgg cgccttggac ctgggcggag cttctaccca agtgaccttc 540aagaatcagg aaaccttcgg cgccttggac ctgggcggag cttctaccca agtgaccttc 540
gtgccccaga atcagaccat cgagagcccc gacaacgccc tgcagttccg gctgtacggc 600gtgccccaga atcagaccat cgagagcccc gacaacgccc tgcagttccg gctgtacggc 600
aaggactaca atgtgtacac ccacagcttt ctgtgctacg gaaaggacca ggctctgtgg 660aaggactaca atgtgtacac ccacagcttt ctgtgctacg gaaaggacca ggctctgtgg 660
cagaagctgg ccaaggacat ccaggtggcc agcaacgaga tcctgcggga cccttgcttc 720cagaagctgg ccaaggacat ccaggtggcc agcaacgaga tcctgcggga cccttgcttc 720
caccccggct acaagaaagt cgtgaacgtg tccgacctgt acaagacccc ctgcaccaag 780caccccggct acaagaaagt cgtgaacgtg tccgacctgt acaagacccc ctgcaccaag 780
agattcgaga tgaccctgcc cttccagcag ttcgagatcc agggcatcgg caattaccag 840agattcgaga tgaccctgcc cttccagcag ttcgagatcc agggcatcgg caattaccag 840
cagtgccacc agagcatcct ggaactgttc aacaccagct actgccccta cagccagtgc 900cagtgccacc agagcatcct ggaactgttc aacaccagct actgccccta cagccagtgc 900
gccttcaacg gcatcttcct gccacctctg cagggggatt tcggcgcctt cagcgccttc 960gccttcaacg gcatcttcct gccacctctg cagggggatt tcggcgcctt cagcgccttc 960
tactccgtga tgaagttcct gaacctgacc agcgagaagg tgtcccagga aaaagtgaca 1020tactccgtga tgaagttcct gaacctgacc agcgagaagg tgtccgga aaaagtgaca 1020
gagatgatga agaagttctg cgcccagccc tgggaggaaa tcaagacctc ctacgctggc 1080gagatgatga agaagttctg cgcccagccc tgggaggaaa tcaagacctc ctacgctggc 1080
gtgaaagaga agtacctgag cgagtactgc ttcagcggca cctacatcct gagcctgctg 1140gtgaaagaga agtacctgag cgagtactgc ttcagcggca cctacatcct gagcctgctg 1140
ctgcagggct accacttcac cgccgatagc tgggagcaca tccacttcat cggcaagatt 1200ctgcagggct accacttcac cgccgatagc tgggagcaca tccacttcat cggcaagatt 1200
cagggcagcg acgccggctg gacactgggt tacatgctga atctgaccaa catgatcccc 1260cagggcagcg acgccggctg gacactgggt tacatgctga atctgaccaa catgatcccc 1260
gccgagcagc ccctgagcac acctctgagc cacagcacc 1299gccgagcagc ccctgagcac acctctgagc cacagcacc 1299
<210> 225<210> 225
<211> 430<211> 430
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 225<400> 225
Ala Pro Thr Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ala Pro Thr Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly
1 5 10 15 1 5 10 15
Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys
20 25 30 20 25 30
Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu
35 40 45 35 40 45
Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val
50 55 60 50 55 60
Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu
65 70 75 80 65 70 75 80
Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala
85 90 95 85 90 95
Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu Glu Leu Ala Asp
100 105 110 100 105 110
Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp
115 120 125 115 120 125
Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly
130 135 140 130 135 140
Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln
145 150 155 160 145 150 155 160
Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr
165 170 175 165 170 175
Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln
180 185 190 180 185 190
Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu
195 200 205 195 200 205
Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile
210 215 220 210 215 220
Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly
225 230 235 240 225 230 235 240
Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr
245 250 255 245 250 255
Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly
260 265 270 260 265 270
Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn
275 280 285 275 280 285
Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu
290 295 300 290 295 300
Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val
305 310 315 320 305 310 315 320
Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val
325 330 335 325 330 335
Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys
340 345 350 340 345 350
Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Phe Cys Phe Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Phe Cys Phe
355 360 365 355 360 365
Ser Gly Thr Tyr Ile Leu Ser Leu Leu Gln Gln Gly Tyr His Phe Thr Ser Gly Thr Tyr Ile Leu Ser Leu Leu Gln Gln Gly Tyr His Phe Thr
370 375 380 370 375 380
Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser
385 390 395 400 385 390 395 400
Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile
405 410 415 405 410 415
Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 430 420 425 430
<210> 226<210> 226
<211> 1290<211> 1290
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 226<400> 226
gcccctacca cccagaacaa ggccctgccc gagaacgtga agtacggcat cgtgctggat 60gcccctacca cccagaacaa ggccctgccc gagaacgtga agtacggcat cgtgctggat 60
gccggcagca gccacaccag cctgtacatc tacaagtggc ctgccgagaa agaaaacgac 120gccggcagca gccacaccag cctgtacatc tacaagtggc ctgccgagaa agaaaacgac 120
accggcgtgg tgcatcaggt ggaagagtgc agagtgaagg gccctggcat cagcaagttc 180accggcgtgg tgcatcaggt ggaaagtgc agagtgaagg gccctggcat cagcaagttc 180
gtgcagaaag tgaacgagat cggcatctac ctgaccgact gcatggaacg ggccagggaa 240gtgcagaaag tgaacgagat cggcatctac ctgaccgact gcatggaacg ggccagggaa 240
gtgatcccca gaagccagca ccaggaaacc cccgtgtatc tgggagccac cgccggcatg 300gtgatcccca gaagccagca cggaaacc cccgtgtatc tgggagccac cgccggcatg 300
agactgctga gaatggaaag cgaggaactg gccgaccggg tgctggacgt ggtggaaaga 360agactgctga gaatggaaag cgaggaactg gccgaccggg tgctggacgt ggtggaaaga 360
agcctgagca actacccatt cgattttcaa ggcgccagaa tcatcaccgg ccaggaagaa 420agcctgagca actacccatt cgattttcaa ggcgccagaa tcatcaccgg cggaagaa 420
ggcgcctacg gctggatcac catcaactac ctgctgggca agttcagcca gaagaatcag 480ggcgcctacg gctggatcac catcaactac ctgctgggca agttcagcca gaagaatcag 480
gaaaccttcg gcgccctgga cctgggcgga gcttctaccc aagtgacctt cgtgccccag 540gaaaccttcg gcgccctgga cctgggcgga gcttctaccc aagtgacctt cgtgccccag 540
aatcagacca tcgagagccc cgacaacgcc ctgcagttcc ggctgtacgg caaggactac 600aatcagacca tcgagagccc cgacaacgcc ctgcagttcc ggctgtacgg caaggactac 600
aatgtgtaca cccacagctt tctgtgctac ggaaaggacc aggctctgtg gcagaagctg 660aatgtgtaca cccacagctt tctgtgctac ggaaaggacc aggctctgtg gcagaagctg 660
gccaaggaca tccaggtggc cagcaacgag atcctgcggg acccttgctt ccaccccggc 720gccaaggaca tccaggtggc cagcaacgag atcctgcggg acccttgctt ccaccccggc 720
tacaagaaag tcgtgaacgt gtccgacctg tacaagaccc cctgcaccaa gagattcgag 780tacaagaaag tcgtgaacgt gtccgacctg tacaagaccc cctgcaccaa gagattcgag 780
atgaccctgc ccttccagca gttcgagatc cagggcatcg gcaattacca gcagtgccac 840atgaccctgc ccttccagca gttcgagatc cagggcatcg gcaattacca gcagtgccac 840
cagagcatcc tggaactgtt caacaccagc tactgcccct acagccagtg cgccttcaac 900cagagcatcc tggaactgtt caacaccagc tactgcccct acagccagtg cgccttcaac 900
ggcatcttcc tgccacctct gcagggggat ttcggcgcct tcagcgcctt ctacttcgtg 960ggcatcttcc tgccacctct gcagggggat ttcggcgcct tcagcgcctt ctacttcgtg 960
atgaagttcc tgaacctgac cagcgagaag gtgtcccagg aaaaagtgac agagatgatg 1020atgaagttcc tgaacctgac cagcgagaag gtgtcccagg aaaaagtgac agagatgatg 1020
aagaagttct gcgcccagcc ctgggaggaa atcaagacct cctacgctgg cgtgaaagag 1080aagaagttct gcgcccagcc ctgggaggaa atcaagacct cctacgctgg cgtgaaagag 1080
aagtacctga gcgagttttg cttcagcggc acctacatcc tgagcctgct gcagcagggc 1140aagtacctga gcgagttttg cttcagcggc acctacatcc tgagcctgct gcagcaggggc 1140
taccacttca ccgccgatag ctgggagcac atccacttca tcggcaagat tcagggcagc 1200taccacttca ccgccgatag ctgggagcac atccacttca tcggcaagat tcagggcagc 1200
gacgccggct ggacactggg ctacatgctg aatctgacca acatgatccc cgccgagcag 1260gacgccggct ggacactggg ctacatgctg aatctgacca acatgatccc cgccgagcag 1260
cccctgagca cacctctgag ccacagcacc 1290cccctgagca cacctctgag cccagcacc 1290
<210> 227<210> 227
<211> 433<211> 433
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 227<400> 227
Ala Pro Thr Ser Ser Ser Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Ala Pro Thr Ser Ser Ser Thr Gln Asn Lys Ala Leu Pro Glu Asn Val
1 5 10 15 1 5 10 15
Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr
20 25 30 20 25 30
Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His
35 40 45 35 40 45
Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val
50 55 60 50 55 60
Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg
65 70 75 80 65 70 75 80
Ala Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr Ala Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr
85 90 95 85 90 95
Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu
100 105 110 100 105 110
Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr
115 120 125 115 120 125
Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly
130 135 140 130 135 140
Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln
145 150 155 160 145 150 155 160
Lys Asn Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Lys Asn Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr
165 170 175 165 170 175
Gln Val Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Gln Val Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn
180 185 190 180 185 190
Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His
195 200 205 195 200 205
Ser Phe Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Ser Phe Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala
210 215 220 210 215 220
Lys Asp Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe Lys Asp Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe
225 230 235 240 225 230 235 240
His Pro Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr His Pro Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr
245 250 255 245 250 255
Pro Cys Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Pro Cys Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu
260 265 270 260 265 270
Ile Gln Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Ile Gln Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu
275 280 285 275 280 285
Leu Phe Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Leu Phe Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly
290 295 300 290 295 300
Ile Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Ile Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe
305 310 315 320 305 310 315 320
Tyr Phe Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Tyr Phe Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln
325 330 335 325 330 335
Glu Lys Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Lys Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu
340 345 350 340 345 350
Glu Ile Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Glu Ile Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu
355 360 365 355 360 365
Phe Cys Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Gln Gln Gly Tyr Phe Cys Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Gln Gln Gly Tyr
370 375 380 370 375 380
His Phe Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile His Phe Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile
385 390 395 400 385 390 395 400
Gln Gly Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Gln Gly Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr
405 410 415 405 410 415
Asn Met Ile Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Asn Met Ile Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser
420 425 430 420 425 430
Thr Thr
<210> 228<210> 228
<211> 1299<211> 1299
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 228<400> 228
gcccctacca gcagcagcac ccagaacaag gccctgcccg agaacgtgaa gtacggcatc 60gcccctacca gcagcagcac ccagaacaag gccctgcccg agaacgtgaa gtacggcatc 60
gtgctggatg ccggcagcag ccacaccagc ctgtacatct acaagtggcc tgccgagaaa 120gtgctggatg ccggcagcag ccacaccagc ctgtacatct acaagtggcc tgccgagaaa 120
gaaaacgaca ccggcgtggt gcatcaggtg gaagagtgca gagtgaaggg ccctggcatc 180gaaaacgaca ccggcgtggt gcatcaggtg gaagagtgca gagtgaaggg ccctggcatc 180
agcaagttcg tgcagaaagt gaacgagatc ggcatctacc tgaccgactg catggaacgg 240agcaagttcg tgcagaaagt gaacgagatc ggcatctacc tgaccgactg catggaacgg 240
gccagggaag tgatccccag aagccagcac caggaaaccc ccgtgtatct gggagccacc 300gccagggaag tgatccccag aagccagcac caggaaaccc ccgtgtatct gggagccacc 300
gccggcatga gactgctgag aatggaaagc gaggaactgg ccgaccgggt gctggacgtg 360gccggcatga gactgctgag aatggaaagc gaggaactgg ccgaccgggt gctggacgtg 360
gtggaaagaa gcctgagcaa ctacccattc gattttcaag gcgccagaat catcaccggc 420gtggaaagaa gcctgagcaa ctacccattc gattttcaag gcgccagaat catcaccggc 420
caggaagaag gcgcctacgg ctggatcacc atcaactacc tgctgggcaa gttcagccag 480caggaagaag gcgcctacgg ctggatcacc atcaactacc tgctgggcaa gttcagccag 480
aagaatcagg aaaccttcgg cgccctggac ctgggcggag cttctaccca agtgaccttc 540aagaatcagg aaaccttcgg cgccctggac ctgggcggag cttctaccca agtgaccttc 540
gtgccccaga atcagaccat cgagagcccc gacaacgccc tgcagttccg gctgtacggc 600gtgccccaga atcagaccat cgagagcccc gacaacgccc tgcagttccg gctgtacggc 600
aaggactaca atgtgtacac ccacagcttt ctgtgctacg gaaaggacca ggctctgtgg 660aaggactaca atgtgtacac ccacagcttt ctgtgctacg gaaaggacca ggctctgtgg 660
cagaagctgg ccaaggacat ccaggtggcc agcaacgaga tcctgcggga cccttgcttc 720cagaagctgg ccaaggacat ccaggtggcc agcaacgaga tcctgcggga cccttgcttc 720
caccccggct acaagaaagt cgtgaacgtg tccgacctgt acaagacccc ctgcaccaag 780caccccggct acaagaaagt cgtgaacgtg tccgacctgt acaagacccc ctgcaccaag 780
agattcgaga tgaccctgcc cttccagcag ttcgagatcc agggcatcgg caattaccag 840agattcgaga tgaccctgcc cttccagcag ttcgagatcc agggcatcgg caattaccag 840
cagtgccacc agagcatcct ggaactgttc aacaccagct actgccccta cagccagtgc 900cagtgccacc agagcatcct ggaactgttc aacaccagct actgccccta cagccagtgc 900
gccttcaacg gcatcttcct gccacctctg cagggggatt tcggcgcctt cagcgccttc 960gccttcaacg gcatcttcct gccacctctg cagggggatt tcggcgcctt cagcgccttc 960
tacttcgtga tgaagttcct gaacctgacc agcgagaagg tgtcccagga aaaagtgaca 1020tacttcgtga tgaagttcct gaacctgacc agcgagaagg tgtcccagga aaaagtgaca 1020
gagatgatga agaagttctg cgcccagccc tgggaggaaa tcaagacctc ctacgctggc 1080gagatgatga agaagttctg cgcccagccc tgggaggaaa tcaagacctc ctacgctggc 1080
gtgaaagaga agtacctgag cgagttttgc ttcagcggca cctacatcct gagcctgctg 1140gtgaaagaga agtacctgag cgagttttgc ttcagcggca cctacatcct gagcctgctg 1140
cagcagggct accacttcac cgccgatagc tgggagcaca tccacttcat cggcaagatt 1200cagcagggct accacttcac cgccgatagc tgggagcaca tccacttcat cggcaagatt 1200
cagggcagcg acgccggctg gacactgggc tacatgctga atctgaccaa catgatcccc 1260cagggcagcg acgccggctg gacactgggc tacatgctga atctgaccaa catgatcccc 1260
gccgagcagc ccctgagcac acctctgagc cacagcacc 1299gccgagcagc ccctgagcac acctctgagc cacagcacc 1299
<210> 229<210> 229
<211> 430<211> 430
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 229<400> 229
Ala Pro Thr Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ala Pro Thr Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly
1 5 10 15 1 5 10 15
Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys
20 25 30 20 25 30
Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu
35 40 45 35 40 45
Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val
50 55 60 50 55 60
Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu
65 70 75 80 65 70 75 80
Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala
85 90 95 85 90 95
Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu Glu Leu Ala Asp
100 105 110 100 105 110
Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp
115 120 125 115 120 125
Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly
130 135 140 130 135 140
Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln
145 150 155 160 145 150 155 160
Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr
165 170 175 165 170 175
Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln
180 185 190 180 185 190
Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu
195 200 205 195 200 205
Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile
210 215 220 210 215 220
Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly
225 230 235 240 225 230 235 240
Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr
245 250 255 245 250 255
Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly
260 265 270 260 265 270
Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn
275 280 285 275 280 285
Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu
290 295 300 290 295 300
Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Ser Val Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Ser Val
305 310 315 320 305 310 315 320
Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val
325 330 335 325 330 335
Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys
340 345 350 340 345 350
Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe
355 360 365 355 360 365
Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr
370 375 380 370 375 380
Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser
385 390 395 400 385 390 395 400
Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile
405 410 415 405 410 415
Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 430 420 425 430
<210> 230<210> 230
<211> 1290<211> 1290
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 230<400> 230
gcccctacca cccagaacaa ggccctgccc gagaacgtga agtacggcat cgtgctggac 60gcccctacca cccagaacaa ggccctgccc gagaacgtga agtacggcat cgtgctggac 60
gccggctcct cccacacctc cctgtacatc tacaagtggc ctgccgagaa agaaaacgac 120gccggctcct cccacacctc cctgtacatc tacaagtggc ctgccgagaa agaaaacgac 120
accggcgtgg tgcaccaagt ggaagagtgc agagtgaagg gccccggcat ctccaagttc 180accggcgtgg tgcaccaagt ggaaagtgc agagtgaagg gccccggcat ctccaagttc 180
gtgcagaaag tgaacgagat cggcatctac ctgaccgact gcatggaacg ggccagagaa 240gtgcagaaag tgaacgagat cggcatctac ctgaccgact gcatggaacg ggccagagaa 240
gtgatccctc ggtcccagca ccaggaaacc cctgtctacc tgggcgccac cgccggcatg 300gtgatccctc ggtcccagca cggaaacc cctgtctacc tgggcgccac cgccggcatg 300
cggctgctgc ggatggaatc cgaggaactg gccgaccggg tgctggacgt ggtggaacgg 360cggctgctgc ggatggaatc cgaggaactg gccgaccggg tgctggacgt ggtggaacgg 360
tccctgtcca actacccatt cgattttcaa ggcgccagaa tcatcaccgg ccaggaagag 420tccctgtcca actacccatt cgattttcaa ggcgccagaa tcatcaccgg cggaagag 420
ggcgcctacg gctggatcac catcaactac ctgctgggca agttctccca gaagaatcag 480ggcgcctacg gctggatcac catcaactac ctgctgggca agttctccca gaagaatcag 480
gaaaccttcg gcgccctgga cctgggcgga gccagcaccc aagtcacatt cgtgccccag 540gaaaccttcg gcgccctgga cctgggcgga gccagcaccc aagtcacatt cgtgccccag 540
aaccagacca tcgagagccc cgacaacgcc ctgcagttcc ggctgtacgg caaggactac 600aaccagacca tcgagagccc cgacaacgcc ctgcagttcc ggctgtacgg caaggactac 600
aacgtgtaca cccacagctt tctgtgctac ggcaaggacc aggccctgtg gcagaagctg 660aacgtgtaca cccacagctt tctgtgctac ggcaaggacc aggccctgtg gcagaagctg 660
gccaaggaca tccaagtggc ctccaacgag atcctgcggg acccctgctt ccaccccggc 720gccaaggaca tccaagtggc ctccaacgag atcctgcggg acccctgctt ccaccccggc 720
tacaagaaag tggtcaacgt gtccgacctg tacaagaccc cttgcaccaa gagattcgag 780tacaagaaag tggtcaacgt gtccgacctg tacaagaccc cttgcaccaa gagattcgag 780
atgaccctgc ccttccagca gttcgagatc cagggcatcg gcaactacca gcagtgccac 840atgaccctgc ccttccagca gttcgagatc cagggcatcg gcaactacca gcagtgccac 840
cagtccatcc tggaactgtt caacacctcc tactgcccct actcccagtg cgccttcaac 900cagtccatcc tggaactgtt caacacctcc tactgcccct actcccagtg cgccttcaac 900
ggcatcttcc tgcctccact gcagggcgac ttcggcgcct tctccgcctt ctactccgtg 960ggcatcttcc tgcctccact gcagggcgac ttcggcgcct tctccgcctt ctactccgtg 960
atgaagttcc tgaacctgac ctccgagaaa gtgtcccagg aaaaagtgac cgagatgatg 1020atgaagttcc tgaacctgac ctccgagaaa gtgtcccagg aaaaagtgac cgagatgatg 1020
aagaagttct gcgcccagcc ctgggaggaa atcaagacct cctacgctgg cgtgaaagag 1080aagaagttct gcgcccagcc ctgggaggaa atcaagacct cctacgctgg cgtgaaagag 1080
aagtacctgt ccgagtactg cttctccggc acctacatcc tgtccctgct gctgcagggc 1140aagtacctgt ccgagtactg cttctccggc acctacatcc tgtccctgct gctgcaggggc 1140
taccacttca ccgccgacag ctgggagcac atccacttca tcggcaagat ccagggatcc 1200taccacttca ccgccgacag ctgggagcac atccacttca tcggcaagat ccagggatcc 1200
gacgctggct ggaccctggg ctacatgctg aatctgacca acatgatccc cgccgagcag 1260gacgctggct ggaccctggg ctacatgctg aatctgacca acatgatccc cgccgagcag 1260
cccctgtcca cccctctgtc tcactccacc 1290cccctgtcca cccctctgtc tcactccacc 1290
<210> 231<210> 231
<211> 433<211> 433
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 231<400> 231
Ala Pro Thr Ser Ser Ser Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Ala Pro Thr Ser Ser Ser Thr Gln Asn Lys Ala Leu Pro Glu Asn Val
1 5 10 15 1 5 10 15
Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr
20 25 30 20 25 30
Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His
35 40 45 35 40 45
Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val
50 55 60 50 55 60
Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg
65 70 75 80 65 70 75 80
Ala Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr Ala Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr
85 90 95 85 90 95
Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu
100 105 110 100 105 110
Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr
115 120 125 115 120 125
Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly
130 135 140 130 135 140
Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln
145 150 155 160 145 150 155 160
Lys Asn Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Lys Asn Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr
165 170 175 165 170 175
Gln Val Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Gln Val Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn
180 185 190 180 185 190
Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His
195 200 205 195 200 205
Ser Phe Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Ser Phe Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala
210 215 220 210 215 220
Lys Asp Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe Lys Asp Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe
225 230 235 240 225 230 235 240
His Pro Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr His Pro Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr
245 250 255 245 250 255
Pro Cys Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Pro Cys Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu
260 265 270 260 265 270
Ile Gln Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Ile Gln Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu
275 280 285 275 280 285
Leu Phe Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Leu Phe Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly
290 295 300 290 295 300
Ile Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Ile Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe
305 310 315 320 305 310 315 320
Tyr Ser Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Tyr Ser Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln
325 330 335 325 330 335
Glu Lys Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Lys Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu
340 345 350 340 345 350
Glu Ile Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Glu Ile Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu
355 360 365 355 360 365
Tyr Cys Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr Tyr Cys Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr
370 375 380 370 375 380
His Phe Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile His Phe Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile
385 390 395 400 385 390 395 400
Gln Gly Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Gln Gly Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr
405 410 415 405 410 415
Asn Met Ile Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Asn Met Ile Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser
420 425 430 420 425 430
Thr Thr
<210> 232<210> 232
<211> 1299<211> 1299
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 232<400> 232
gcccctacca gcagcagcac ccagaacaag gccctgcccg agaacgtgaa gtacggcatc 60gcccctacca gcagcagcac ccagaacaag gccctgcccg agaacgtgaa gtacggcatc 60
gtgctggatg ccggcagcag ccacaccagc ctgtacatct acaagtggcc tgccgagaaa 120gtgctggatg ccggcagcag ccacaccagc ctgtacatct acaagtggcc tgccgagaaa 120
gaaaacgaca ccggcgtggt gcatcaggtg gaagagtgca gagtgaaggg ccctggcatc 180gaaaacgaca ccggcgtggt gcatcaggtg gaagagtgca gagtgaaggg ccctggcatc 180
agcaagttcg tgcagaaagt gaacgagatc ggcatctacc tgaccgactg catggaacgg 240agcaagttcg tgcagaaagt gaacgagatc ggcatctacc tgaccgactg catggaacgg 240
gccagggaag tgatccccag aagccagcac caggaaaccc ccgtgtatct gggagccacc 300gccagggaag tgatccccag aagccagcac caggaaaccc ccgtgtatct gggagccacc 300
gccggcatga gactgctgag aatggaaagc gaggaactgg ccgaccgggt gctggacgtg 360gccggcatga gactgctgag aatggaaagc gaggaactgg ccgaccgggt gctggacgtg 360
gtggaaagaa gcctgagcaa ctacccattc gattttcaag gcgccagaat catcaccggc 420gtggaaagaa gcctgagcaa ctacccattc gattttcaag gcgccagaat catcaccggc 420
caggaagaag gcgcctacgg ctggatcacc atcaactacc tgctgggcaa gttcagccag 480caggaagaag gcgcctacgg ctggatcacc atcaactacc tgctgggcaa gttcagccag 480
aagaatcagg aaaccttcgg cgccttggac ctgggcggag cttctaccca agtgaccttc 540aagaatcagg aaaccttcgg cgccttggac ctgggcggag cttctaccca agtgaccttc 540
gtgccccaga atcagaccat cgagagcccc gacaacgccc tgcagttccg gctgtacggc 600gtgccccaga atcagaccat cgagagcccc gacaacgccc tgcagttccg gctgtacggc 600
aaggactaca atgtgtacac ccacagcttt ctgtgctacg gaaaggacca ggctctgtgg 660aaggactaca atgtgtacac ccacagcttt ctgtgctacg gaaaggacca ggctctgtgg 660
cagaagctgg ccaaggacat ccaggtggcc agcaacgaga tcctgcggga cccttgcttc 720cagaagctgg ccaaggacat ccaggtggcc agcaacgaga tcctgcggga cccttgcttc 720
caccccggct acaagaaagt cgtgaacgtg tccgacctgt acaagacccc ctgcaccaag 780caccccggct acaagaaagt cgtgaacgtg tccgacctgt acaagacccc ctgcaccaag 780
agattcgaga tgaccctgcc cttccagcag ttcgagatcc agggcatcgg caattaccag 840agattcgaga tgaccctgcc cttccagcag ttcgagatcc agggcatcgg caattaccag 840
cagtgccacc agagcatcct ggaactgttc aacaccagct actgccccta cagccagtgc 900cagtgccacc agagcatcct ggaactgttc aacaccagct actgccccta cagccagtgc 900
gccttcaacg gcatcttcct gccacctctg cagggggatt tcggcgcctt cagcgccttc 960gccttcaacg gcatcttcct gccacctctg cagggggatt tcggcgcctt cagcgccttc 960
tactccgtga tgaagttcct gaacctgacc agcgagaagg tgtcccagga aaaagtgaca 1020tactccgtga tgaagttcct gaacctgacc agcgagaagg tgtccgga aaaagtgaca 1020
gagatgatga agaagttctg cgcccagccc tgggaggaaa tcaagacctc ctacgctggc 1080gagatgatga agaagttctg cgcccagccc tgggaggaaa tcaagacctc ctacgctggc 1080
gtgaaagaga agtacctgag cgagtactgc ttcagcggca cctacatcct gagcctgctg 1140gtgaaagaga agtacctgag cgagtactgc ttcagcggca cctacatcct gagcctgctg 1140
ctgcagggct accacttcac cgccgatagc tgggagcaca tccacttcat cggcaagatt 1200ctgcagggct accacttcac cgccgatagc tgggagcaca tccacttcat cggcaagatt 1200
cagggcagcg acgccggctg gacactgggt tacatgctga atctgaccaa catgatcccc 1260cagggcagcg acgccggctg gacactgggt tacatgctga atctgaccaa catgatcccc 1260
gccgagcagc ccctgagcac acctctgagc cacagcacc 1299gccgagcagc ccctgagcac acctctgagc cacagcacc 1299
<210> 233<210> 233
<211> 430<211> 430
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 233<400> 233
Ala Pro Thr Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ala Pro Thr Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly
1 5 10 15 1 5 10 15
Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys
20 25 30 20 25 30
Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu
35 40 45 35 40 45
Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val
50 55 60 50 55 60
Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Met Glu Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Met Glu
65 70 75 80 65 70 75 80
Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala
85 90 95 85 90 95
Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu Glu Leu Ala Asp
100 105 110 100 105 110
Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp
115 120 125 115 120 125
Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly
130 135 140 130 135 140
Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln
145 150 155 160 145 150 155 160
Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr
165 170 175 165 170 175
Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln
180 185 190 180 185 190
Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu
195 200 205 195 200 205
Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile
210 215 220 210 215 220
Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly
225 230 235 240 225 230 235 240
Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr
245 250 255 245 250 255
Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly
260 265 270 260 265 270
Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn
275 280 285 275 280 285
Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu
290 295 300 290 295 300
Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Ser Val Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Ser Val
305 310 315 320 305 310 315 320
Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val
325 330 335 325 330 335
Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys
340 345 350 340 345 350
Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe
355 360 365 355 360 365
Ser Gly Thr Tyr Ile Leu Ser Leu Leu Gln Gln Gly Tyr His Phe Thr Ser Gly Thr Tyr Ile Leu Ser Leu Leu Gln Gln Gly Tyr His Phe Thr
370 375 380 370 375 380
Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser
385 390 395 400 385 390 395 400
Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile
405 410 415 405 410 415
Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 430 420 425 430
<210> 234<210> 234
<211> 1290<211> 1290
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 234<400> 234
gcccctacca cccagaacaa ggccctgccc gagaacgtga agtacggcat cgtgctggat 60gcccctacca cccagaacaa ggccctgccc gagaacgtga agtacggcat cgtgctggat 60
gccggcagca gccacaccag cctgtacatc tacaagtggc ctgccgagaa agaaaacgac 120gccggcagca gccacaccag cctgtacatc tacaagtggc ctgccgagaa agaaaacgac 120
accggcgtgg tgcatcaggt ggaagagtgc agagtgaagg gccctggcat cagcaagttc 180accggcgtgg tgcatcaggt ggaaagtgc agagtgaagg gccctggcat cagcaagttc 180
gtgcagaaag tgaacgagat cggcatctac ctgaccgact gcatggaacg ggccatggaa 240gtgcagaaag tgaacgagat cggcatctac ctgaccgact gcatggaacg ggccatggaa 240
gtgatcccca gaagccagca ccaggaaacc cccgtgtatc tgggagccac cgccggcatg 300gtgatcccca gaagccagca cggaaacc cccgtgtatc tgggagccac cgccggcatg 300
agactgctga gaatggaaag cgaggaactg gccgaccggg tgctggacgt ggtggaaaga 360agactgctga gaatggaaag cgaggaactg gccgaccggg tgctggacgt ggtggaaaga 360
agcctgagca actacccatt cgattttcaa ggcgccagaa tcatcaccgg ccaggaagaa 420agcctgagca actacccatt cgattttcaa ggcgccagaa tcatcaccgg cggaagaa 420
ggcgcctacg gctggatcac catcaactac ctgctgggca agttcagcca gaagaatcag 480ggcgcctacg gctggatcac catcaactac ctgctgggca agttcagcca gaagaatcag 480
gaaaccttcg gcgccctgga cctgggcgga gcttctaccc aagtgacctt cgtgccccag 540gaaaccttcg gcgccctgga cctgggcgga gcttctaccc aagtgacctt cgtgccccag 540
aatcagacca tcgagagccc cgacaacgcc ctgcagttcc ggctgtacgg caaggactac 600aatcagacca tcgagagccc cgacaacgcc ctgcagttcc ggctgtacgg caaggactac 600
aatgtgtaca cccacagctt tctgtgctac ggaaaggacc aggctctgtg gcagaagctg 660aatgtgtaca cccacagctt tctgtgctac ggaaaggacc aggctctgtg gcagaagctg 660
gccaaggaca tccaggtggc cagcaacgag atcctgcggg acccttgctt ccaccccggc 720gccaaggaca tccaggtggc cagcaacgag atcctgcggg acccttgctt ccaccccggc 720
tacaagaaag tcgtgaacgt gtccgacctg tacaagaccc cctgcaccaa gagattcgag 780tacaagaaag tcgtgaacgt gtccgacctg tacaagaccc cctgcaccaa gagattcgag 780
atgaccctgc ccttccagca gttcgagatc cagggcatcg gcaattacca gcagtgccac 840atgaccctgc ccttccagca gttcgagatc cagggcatcg gcaattacca gcagtgccac 840
cagagcatcc tggaactgtt caacaccagc tactgcccct acagccagtg cgccttcaac 900cagagcatcc tggaactgtt caacaccagc tactgcccct acagccagtg cgccttcaac 900
ggcatcttcc tgccacctct gcagggggat ttcggcgcct tcagcgcctt ctactccgtg 960ggcatcttcc tgccacctct gcagggggat ttcggcgcct tcagcgcctt ctactccgtg 960
atgaagttcc tgaacctgac cagcgagaag gtgtcccagg aaaaagtgac agagatgatg 1020atgaagttcc tgaacctgac cagcgagaag gtgtcccagg aaaaagtgac agagatgatg 1020
aagaagttct gcgcccagcc ctgggaggaa atcaagacct cctacgctgg cgtgaaagag 1080aagaagttct gcgcccagcc ctgggaggaa atcaagacct cctacgctgg cgtgaaagag 1080
aagtacctga gcgagtactg cttcagcggc acctacatcc tgagcctgct gcagcagggc 1140aagtacctga gcgagtactg cttcagcggc acctacatcc tgagcctgct gcagcaggggc 1140
taccacttca ccgccgatag ctgggagcac atccacttca tcggcaagat tcagggcagc 1200taccacttca ccgccgatag ctgggagcac atccacttca tcggcaagat tcagggcagc 1200
gacgccggct ggacactggg ctacatgctg aatctgacca acatgatccc cgccgagcag 1260gacgccggct ggacactggg ctacatgctg aatctgacca acatgatccc cgccgagcag 1260
cccctgagca cacctctgag ccacagcacc 1290cccctgagca cacctctgag cccagcacc 1290
<210> 235<210> 235
<211> 433<211> 433
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 235<400> 235
Ala Pro Thr Ser Ser Ser Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Ala Pro Thr Ser Ser Ser Thr Gln Asn Lys Ala Leu Pro Glu Asn Val
1 5 10 15 1 5 10 15
Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr
20 25 30 20 25 30
Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His
35 40 45 35 40 45
Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val
50 55 60 50 55 60
Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg
65 70 75 80 65 70 75 80
Ala Met Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr Ala Met Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr
85 90 95 85 90 95
Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu
100 105 110 100 105 110
Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr
115 120 125 115 120 125
Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly
130 135 140 130 135 140
Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln
145 150 155 160 145 150 155 160
Lys Asn Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Lys Asn Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr
165 170 175 165 170 175
Gln Val Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Gln Val Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn
180 185 190 180 185 190
Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His
195 200 205 195 200 205
Ser Phe Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Ser Phe Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala
210 215 220 210 215 220
Lys Asp Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe Lys Asp Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe
225 230 235 240 225 230 235 240
His Pro Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr His Pro Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr
245 250 255 245 250 255
Pro Cys Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Pro Cys Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu
260 265 270 260 265 270
Ile Gln Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Ile Gln Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu
275 280 285 275 280 285
Leu Phe Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Leu Phe Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly
290 295 300 290 295 300
Ile Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Ile Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe
305 310 315 320 305 310 315 320
Tyr Ser Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Tyr Ser Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln
325 330 335 325 330 335
Glu Lys Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Lys Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu
340 345 350 340 345 350
Glu Ile Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Glu Ile Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu
355 360 365 355 360 365
Tyr Cys Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Gln Gln Gly Tyr Tyr Cys Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Gln Gln Gly Tyr
370 375 380 370 375 380
His Phe Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile His Phe Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile
385 390 395 400 385 390 395 400
Gln Gly Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Gln Gly Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr
405 410 415 405 410 415
Asn Met Ile Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Asn Met Ile Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser
420 425 430 420 425 430
Thr Thr
<210> 236<210> 236
<211> 1299<211> 1299
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 236<400> 236
gcccctacca gcagcagcac ccagaacaag gccctgcccg agaacgtgaa gtacggcatc 60gcccctacca gcagcagcac ccagaacaag gccctgcccg agaacgtgaa gtacggcatc 60
gtgctggatg ccggcagcag ccacaccagc ctgtacatct acaagtggcc tgccgagaaa 120gtgctggatg ccggcagcag ccacaccagc ctgtacatct acaagtggcc tgccgagaaa 120
gaaaacgaca ccggcgtggt gcatcaggtg gaagagtgca gagtgaaggg ccctggcatc 180gaaaacgaca ccggcgtggt gcatcaggtg gaagagtgca gagtgaaggg ccctggcatc 180
agcaagttcg tgcagaaagt gaacgagatc ggcatctacc tgaccgactg catggaacgg 240agcaagttcg tgcagaaagt gaacgagatc ggcatctacc tgaccgactg catggaacgg 240
gccatggaag tgatccccag aagccagcac caggaaaccc ccgtgtatct gggagccacc 300gccatggaag tgatccccag aagccagcac caggaaaccc ccgtgtatct gggagccacc 300
gccggcatga gactgctgag aatggaaagc gaggaactgg ccgaccgggt gctggacgtg 360gccggcatga gactgctgag aatggaaagc gaggaactgg ccgaccgggt gctggacgtg 360
gtggaaagaa gcctgagcaa ctacccattc gattttcaag gcgccagaat catcaccggc 420gtggaaagaa gcctgagcaa ctacccattc gattttcaag gcgccagaat catcaccggc 420
caggaagaag gcgcctacgg ctggatcacc atcaactacc tgctgggcaa gttcagccag 480caggaagaag gcgcctacgg ctggatcacc atcaactacc tgctgggcaa gttcagccag 480
aagaatcagg aaaccttcgg cgccctggac ctgggcggag cttctaccca agtgaccttc 540aagaatcagg aaaccttcgg cgccctggac ctgggcggag cttctaccca agtgaccttc 540
gtgccccaga atcagaccat cgagagcccc gacaacgccc tgcagttccg gctgtacggc 600gtgccccaga atcagaccat cgagagcccc gacaacgccc tgcagttccg gctgtacggc 600
aaggactaca atgtgtacac ccacagcttt ctgtgctacg gaaaggacca ggctctgtgg 660aaggactaca atgtgtacac ccacagcttt ctgtgctacg gaaaggacca ggctctgtgg 660
cagaagctgg ccaaggacat ccaggtggcc agcaacgaga tcctgcggga cccttgcttc 720cagaagctgg ccaaggacat ccaggtggcc agcaacgaga tcctgcggga cccttgcttc 720
caccccggct acaagaaagt cgtgaacgtg tccgacctgt acaagacccc ctgcaccaag 780caccccggct acaagaaagt cgtgaacgtg tccgacctgt acaagacccc ctgcaccaag 780
agattcgaga tgaccctgcc cttccagcag ttcgagatcc agggcatcgg caattaccag 840agattcgaga tgaccctgcc cttccagcag ttcgagatcc agggcatcgg caattaccag 840
cagtgccacc agagcatcct ggaactgttc aacaccagct actgccccta cagccagtgc 900cagtgccacc agagcatcct ggaactgttc aacaccagct actgccccta cagccagtgc 900
gccttcaacg gcatcttcct gccacctctg cagggggatt tcggcgcctt cagcgccttc 960gccttcaacg gcatcttcct gccacctctg cagggggatt tcggcgcctt cagcgccttc 960
tactccgtga tgaagttcct gaacctgacc agcgagaagg tgtcccagga aaaagtgaca 1020tactccgtga tgaagttcct gaacctgacc agcgagaagg tgtccgga aaaagtgaca 1020
gagatgatga agaagttctg cgcccagccc tgggaggaaa tcaagacctc ctacgctggc 1080gagatgatga agaagttctg cgcccagccc tgggaggaaa tcaagacctc ctacgctggc 1080
gtgaaagaga agtacctgag cgagtactgc ttcagcggca cctacatcct gagcctgctg 1140gtgaaagaga agtacctgag cgagtactgc ttcagcggca cctacatcct gagcctgctg 1140
cagcagggct accacttcac cgccgatagc tgggagcaca tccacttcat cggcaagatt 1200cagcagggct accacttcac cgccgatagc tgggagcaca tccacttcat cggcaagatt 1200
cagggcagcg acgccggctg gacactgggc tacatgctga atctgaccaa catgatcccc 1260cagggcagcg acgccggctg gacactgggc tacatgctga atctgaccaa catgatcccc 1260
gccgagcagc ccctgagcac acctctgagc cacagcacc 1299gccgagcagc ccctgagcac acctctgagc cacagcacc 1299
<210> 237<210> 237
<211> 430<211> 430
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 237<400> 237
Ala Pro Thr Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ala Pro Thr Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly
1 5 10 15 1 5 10 15
Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys
20 25 30 20 25 30
Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu
35 40 45 35 40 45
Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val
50 55 60 50 55 60
Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu
65 70 75 80 65 70 75 80
Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala
85 90 95 85 90 95
Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu Glu Leu Ala Asp
100 105 110 100 105 110
Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp
115 120 125 115 120 125
Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly
130 135 140 130 135 140
Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln
145 150 155 160 145 150 155 160
Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr
165 170 175 165 170 175
Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln
180 185 190 180 185 190
Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu
195 200 205 195 200 205
Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile
210 215 220 210 215 220
Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly
225 230 235 240 225 230 235 240
Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr
245 250 255 245 250 255
Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly
260 265 270 260 265 270
Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn
275 280 285 275 280 285
Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu
290 295 300 290 295 300
Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val
305 310 315 320 305 310 315 320
Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val
325 330 335 325 330 335
Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys
340 345 350 340 345 350
Thr Ser Tyr Ala Gly Val Asn Glu Lys Tyr Leu Ser Glu Phe Cys Phe Thr Ser Tyr Ala Gly Val Asn Glu Lys Tyr Leu Ser Glu Phe Cys Phe
355 360 365 355 360 365
Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr
370 375 380 370 375 380
Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser
385 390 395 400 385 390 395 400
Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile
405 410 415 405 410 415
Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 430 420 425 430
<210> 238<210> 238
<211> 1290<211> 1290
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 238<400> 238
gcccctacca cccagaacaa ggccctgccc gagaacgtga agtacggcat cgtgctggat 60gcccctacca cccagaacaa ggccctgccc gagaacgtga agtacggcat cgtgctggat 60
gccggcagca gccacaccag cctgtacatc tacaagtggc ctgccgagaa agaaaacgac 120gccggcagca gccacaccag cctgtacatc tacaagtggc ctgccgagaa agaaaacgac 120
accggcgtgg tgcatcaggt ggaagagtgc agagtgaagg gccctggcat cagcaagttc 180accggcgtgg tgcatcaggt ggaaagtgc agagtgaagg gccctggcat cagcaagttc 180
gtgcagaaag tgaacgagat cggcatctac ctgaccgact gcatggaacg ggccagggaa 240gtgcagaaag tgaacgagat cggcatctac ctgaccgact gcatggaacg ggccagggaa 240
gtgatcccca gaagccagca ccaggaaacc cccgtgtatc tgggagccac cgccggcatg 300gtgatcccca gaagccagca cggaaacc cccgtgtatc tgggagccac cgccggcatg 300
agactgctga gaatggaaag cgaggaactg gccgaccggg tgctggacgt ggtggaaaga 360agactgctga gaatggaaag cgaggaactg gccgaccggg tgctggacgt ggtggaaaga 360
agcctgagca actacccatt cgattttcaa ggcgccagaa tcatcaccgg ccaggaagaa 420agcctgagca actacccatt cgattttcaa ggcgccagaa tcatcaccgg cggaagaa 420
ggcgcctacg gctggatcac catcaactac ctgctgggca agttcagcca gaagaatcag 480ggcgcctacg gctggatcac catcaactac ctgctgggca agttcagcca gaagaatcag 480
gaaaccttcg gcgccctgga cctgggcgga gcttctaccc aagtgacctt cgtgccccag 540gaaaccttcg gcgccctgga cctgggcgga gcttctaccc aagtgacctt cgtgccccag 540
aatcagacca tcgagagccc cgacaacgcc ctgcagttcc ggctgtacgg caaggactac 600aatcagacca tcgagagccc cgacaacgcc ctgcagttcc ggctgtacgg caaggactac 600
aatgtgtaca cccacagctt tctgtgctac ggaaaggacc aggctctgtg gcagaagctg 660aatgtgtaca cccacagctt tctgtgctac ggaaaggacc aggctctgtg gcagaagctg 660
gccaaggaca tccaggtggc cagcaacgag atcctgcggg acccttgctt ccaccccggc 720gccaaggaca tccaggtggc cagcaacgag atcctgcggg acccttgctt ccaccccggc 720
tacaagaaag tcgtgaacgt gtccgacctg tacaagaccc cctgcaccaa gagattcgag 780tacaagaaag tcgtgaacgt gtccgacctg tacaagaccc cctgcaccaa gagattcgag 780
atgaccctgc ccttccagca gttcgagatc cagggcatcg gcaattacca gcagtgccac 840atgaccctgc ccttccagca gttcgagatc cagggcatcg gcaattacca gcagtgccac 840
cagagcatcc tggaactgtt caacaccagc tactgcccct acagccagtg cgccttcaac 900cagagcatcc tggaactgtt caacaccagc tactgcccct acagccagtg cgccttcaac 900
ggcatcttcc tgccacctct gcagggggat ttcggcgcct tcagcgcctt ctacttcgtg 960ggcatcttcc tgccacctct gcagggggat ttcggcgcct tcagcgcctt ctacttcgtg 960
atgaagttcc tgaacctgac cagcgagaag gtgtcccagg aaaaagtgac agagatgatg 1020atgaagttcc tgaacctgac cagcgagaag gtgtcccagg aaaaagtgac agagatgatg 1020
aagaagttct gcgcccaacc ctgggaggaa atcaagacct cctacgctgg cgtgaacgag 1080aagaagttct gcgcccaacc ctgggaggaa atcaagacct cctacgctgg cgtgaacgag 1080
aagtacctga gcgagttttg cttcagcggc acctacatcc tgagcctgct gctgcagggc 1140aagtacctga gcgagttttg cttcagcggc acctacatcc tgagcctgct gctgcaggggc 1140
taccacttca ccgccgatag ctgggagcac atccacttca tcggcaagat tcagggcagc 1200taccacttca ccgccgatag ctgggagcac atccacttca tcggcaagat tcagggcagc 1200
gacgccggct ggacactggg ctacatgctg aatctgacca acatgatccc cgccgagcag 1260gacgccggct ggacactggg ctacatgctg aatctgacca acatgatccc cgccgagcag 1260
cccctgagca cacctctgag ccacagcacc 1290cccctgagca cacctctgag cccagcacc 1290
<210> 239<210> 239
<211> 433<211> 433
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 239<400> 239
Ala Pro Thr Ser Ser Ser Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Ala Pro Thr Ser Ser Ser Thr Gln Asn Lys Ala Leu Pro Glu Asn Val
1 5 10 15 1 5 10 15
Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr
20 25 30 20 25 30
Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His
35 40 45 35 40 45
Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val
50 55 60 50 55 60
Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg
65 70 75 80 65 70 75 80
Ala Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr Ala Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr
85 90 95 85 90 95
Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu
100 105 110 100 105 110
Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr
115 120 125 115 120 125
Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly
130 135 140 130 135 140
Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln
145 150 155 160 145 150 155 160
Lys Asn Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Lys Asn Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr
165 170 175 165 170 175
Gln Val Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Gln Val Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn
180 185 190 180 185 190
Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His
195 200 205 195 200 205
Ser Phe Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Ser Phe Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala
210 215 220 210 215 220
Lys Asp Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe Lys Asp Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe
225 230 235 240 225 230 235 240
His Pro Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr His Pro Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr
245 250 255 245 250 255
Pro Cys Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Pro Cys Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu
260 265 270 260 265 270
Ile Gln Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Ile Gln Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu
275 280 285 275 280 285
Leu Phe Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Leu Phe Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly
290 295 300 290 295 300
Ile Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Ile Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe
305 310 315 320 305 310 315 320
Tyr Phe Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Tyr Phe Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln
325 330 335 325 330 335
Glu Lys Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Lys Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu
340 345 350 340 345 350
Glu Ile Lys Thr Ser Tyr Ala Gly Val Asn Glu Lys Tyr Leu Ser Glu Glu Ile Lys Thr Ser Tyr Ala Gly Val Asn Glu Lys Tyr Leu Ser Glu
355 360 365 355 360 365
Phe Cys Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr Phe Cys Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Leu Gln Gly Tyr
370 375 380 370 375 380
His Phe Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile His Phe Thr Ala Asp Ser Trp Glu His Ile His Phe Ile Gly Lys Ile
385 390 395 400 385 390 395 400
Gln Gly Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Gln Gly Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr
405 410 415 405 410 415
Asn Met Ile Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Asn Met Ile Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser
420 425 430 420 425 430
Thr Thr
<210> 240<210> 240
<211> 1299<211> 1299
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 240<400> 240
gcccctacca gcagcagcac ccagaacaag gccctgcccg agaacgtgaa gtacggcatc 60gcccctacca gcagcagcac ccagaacaag gccctgcccg agaacgtgaa gtacggcatc 60
gtgctggatg ccggcagcag ccacaccagc ctgtacatct acaagtggcc tgccgagaaa 120gtgctggatg ccggcagcag ccacaccagc ctgtacatct acaagtggcc tgccgagaaa 120
gaaaacgaca ccggcgtggt gcatcaggtg gaagagtgca gagtgaaggg ccctggcatc 180gaaaacgaca ccggcgtggt gcatcaggtg gaagagtgca gagtgaaggg ccctggcatc 180
agcaagttcg tgcagaaagt gaacgagatc ggcatctacc tgaccgactg catggaacgg 240agcaagttcg tgcagaaagt gaacgagatc ggcatctacc tgaccgactg catggaacgg 240
gccagggaag tgatccccag aagccagcac caggaaaccc ccgtgtatct gggagccacc 300gccagggaag tgatccccag aagccagcac caggaaaccc ccgtgtatct gggagccacc 300
gccggcatga gactgctgag aatggaaagc gaggaactgg ccgaccgggt gctggacgtg 360gccggcatga gactgctgag aatggaaagc gaggaactgg ccgaccgggt gctggacgtg 360
gtggaaagaa gcctgagcaa ctacccattc gattttcaag gcgccagaat catcaccggc 420gtggaaagaa gcctgagcaa ctacccattc gattttcaag gcgccagaat catcaccggc 420
caggaagaag gcgcctacgg ctggatcacc atcaactacc tgctgggcaa gttcagccag 480caggaagaag gcgcctacgg ctggatcacc atcaactacc tgctgggcaa gttcagccag 480
aagaatcagg aaaccttcgg cgccctggac ctgggcggag cttctaccca agtgaccttc 540aagaatcagg aaaccttcgg cgccctggac ctgggcggag cttctaccca agtgaccttc 540
gtgccccaga atcagaccat cgagagcccc gacaacgccc tgcagttccg gctgtacggc 600gtgccccaga atcagaccat cgagagcccc gacaacgccc tgcagttccg gctgtacggc 600
aaggactaca atgtgtacac ccacagcttt ctgtgctacg gaaaggacca ggctctgtgg 660aaggactaca atgtgtacac ccacagcttt ctgtgctacg gaaaggacca ggctctgtgg 660
cagaagctgg ccaaggacat ccaggtggcc agcaacgaga tcctgcggga cccttgcttc 720cagaagctgg ccaaggacat ccaggtggcc agcaacgaga tcctgcggga cccttgcttc 720
caccccggct acaagaaagt cgtgaacgtg tccgacctgt acaagacccc ctgcaccaag 780caccccggct acaagaaagt cgtgaacgtg tccgacctgt acaagacccc ctgcaccaag 780
agattcgaga tgaccctgcc cttccagcag ttcgagatcc agggcatcgg caattaccag 840agattcgaga tgaccctgcc cttccagcag ttcgagatcc agggcatcgg caattaccag 840
cagtgccacc agagcatcct ggaactgttc aacaccagct actgccccta cagccagtgc 900cagtgccacc agagcatcct ggaactgttc aacaccagct actgccccta cagccagtgc 900
gccttcaacg gcatcttcct gccacctctg cagggggatt tcggcgcctt cagcgccttc 960gccttcaacg gcatcttcct gccacctctg cagggggatt tcggcgcctt cagcgccttc 960
tacttcgtga tgaagttcct gaacctgacc agcgagaagg tgtcccagga aaaagtgaca 1020tacttcgtga tgaagttcct gaacctgacc agcgagaagg tgtcccagga aaaagtgaca 1020
gagatgatga agaagttctg cgcccaaccc tgggaggaaa tcaagacctc ctacgctggc 1080gagatgatga agaagttctg cgcccaaccc tgggaggaaa tcaagacctc ctacgctggc 1080
gtgaacgaga agtacctgag cgagttttgc ttcagcggca cctacatcct gagcctgctg 11401140
ctgcagggct accacttcac cgccgatagc tgggagcaca tccacttcat cggcaagatt 1200ctgcagggct accacttcac cgccgatagc tgggagcaca tccacttcat cggcaagatt 1200
cagggcagcg acgccggctg gacactgggc tacatgctga atctgaccaa catgatcccc 1260cagggcagcg acgccggctg gacactgggc tacatgctga atctgaccaa catgatcccc 1260
gccgagcagc ccctgagcac acctctgagc cacagcacc 1299gccgagcagc ccctgagcac acctctgagc cacagcacc 1299
<210> 241<210> 241
<211> 442<211> 442
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 241<400> 241
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Thr Ser Ser Thr Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Thr Ser Ser Thr
1 5 10 15 1 5 10 15
Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Asp Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ile Val Leu Asp
20 25 30 20 25 30
Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Glu Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Trp Pro Ala Glu
35 40 45 35 40 45
Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Val Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Glu Cys Arg Val
50 55 60 50 55 60
Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Gly Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Asn Glu Ile Gly
65 70 75 80 65 70 75 80
Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Arg Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Val Ile Pro Arg
85 90 95 85 90 95
Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Met Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Thr Ala Gly Met
100 105 110 100 105 110
Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Asp Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Arg Val Leu Asp
115 120 125 115 120 125
Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Ala Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Phe Gln Gly Ala
130 135 140 130 135 140
Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ile Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Trp Ile Thr Ile
145 150 155 160 145 150 155 160
Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Gly Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Glu Thr Phe Gly
165 170 175 165 170 175
Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gln Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Phe Val Pro Gln
180 185 190 180 185 190
Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Tyr Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Arg Leu Tyr
195 200 205 195 200 205
Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Lys Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Cys Tyr Gly Lys
210 215 220 210 215 220
Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Ser Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Gln Val Ala Ser
225 230 235 240 225 230 235 240
Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Val Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Tyr Lys Lys Val
245 250 255 245 250 255
Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Glu Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Lys Arg Phe Glu
260 265 270 260 265 270
Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Tyr Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Ile Gly Asn Tyr
275 280 285 275 280 285
Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Cys Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Thr Ser Tyr Cys
290 295 300 290 295 300
Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Gln Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Pro Pro Leu Gln
305 310 315 320 305 310 315 320
Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Leu Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Met Lys Phe Leu
325 330 335 325 330 335
Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Met Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Thr Glu Met Met
340 345 350 340 345 350
Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Ala Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Ser Tyr Ala
355 360 365 355 360 365
Gly Val Asn Glu Lys Tyr Leu Ser Glu Phe Cys Phe Ser Gly Thr Tyr Gly Val Asn Glu Lys Tyr Leu Ser Glu Phe Cys Phe Ser Gly Thr Tyr
370 375 380 370 375 380
Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Trp Ile Leu Ser Leu Leu Leu Gln Gly Tyr His Phe Thr Ala Asp Ser Trp
385 390 395 400 385 390 395 400
Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp Glu His Ile His Phe Ile Gly Lys Ile Gln Gly Ser Asp Ala Gly Trp
405 410 415 405 410 415
Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Gln Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Pro Ala Glu Gln
420 425 430 420 425 430
Pro Leu Ser Thr Pro Leu Ser His Ser Thr Pro Leu Ser Thr Pro Leu Ser His Ser Thr
435 440 435 440
<210> 242<210> 242
<211> 1326<211> 1326
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 242<400> 242
gcccctacca gcagcagcac caagaaaacc cagctgacca gcagcaccca gaacaaggcc 60gcccctacca gcagcagcac caagaaaacc cagctgacca gcagcaccca gaacaaggcc 60
ctgcccgaga acgtgaagta cggcatcgtg ctggatgccg gcagcagcca caccagcctg 120ctgccgaga acgtgaagta cggcatcgtg ctggatgccg gcagcagcca caccagcctg 120
tacatctaca agtggcctgc cgagaaagaa aacgacaccg gcgtggtgca tcaggtggaa 180tacatctaca agtggcctgc cgagaaagaa aacgacaccg gcgtggtgca tcaggtggaa 180
gagtgcagag tgaagggccc tggcatcagc aagttcgtgc agaaagtgaa cgagatcggc 240gagtgcagag tgaagggccc tggcatcagc aagttcgtgc agaaagtgaa cgagatcggc 240
atctacctga ccgactgcat ggaacgggcc agggaagtga tccccagaag ccagcaccag 300atctacctga ccgactgcat ggaacgggcc agggaagtga tccccagaag ccagcaccag 300
gaaacccccg tgtatctggg agccaccgcc ggcatgagac tgctgagaat ggaaagcgag 360gaaacccccg tgtatctggg agccaccgcc ggcatgagac tgctgagaat ggaaagcgag 360
gaactggccg accgggtgct ggacgtggtg gaaagaagcc tgagcaacta cccattcgat 420gaactggccg accgggtgct ggacgtggtg gaaagaagcc tgagcaacta cccattcgat 420
tttcaaggcg ccagaatcat caccggccag gaagaaggcg cctacggctg gatcaccatc 480tttcaaggcg ccagaatcat caccggccag gaagaaggcg cctacggctg gatcaccatc 480
aactacctgc tgggcaagtt cagccagaag aatcaggaaa ccttcggcgc cctggacctg 540aactacctgc tgggcaagtt cagccagaag aatcaggaaa ccttcggcgc cctggacctg 540
ggcggagctt ctacccaagt gaccttcgtg ccccagaatc agaccatcga gagccccgac 600ggcggagctt ctacccaagt gaccttcgtg ccccagaatc agaccatcga gagccccgac 600
aacgccctgc agttccggct gtacggcaag gactacaatg tgtacaccca cagctttctg 660aacgccctgc agttccggct gtacggcaag gactacaatg tgtacaccca cagctttctg 660
tgctacggaa aggaccaggc tctgtggcag aagctggcca aggacatcca ggtggccagc 720tgctacggaa aggaccaggc tctgtggcag aagctggcca aggacatcca ggtggccagc 720
aacgagatcc tgcgggaccc ttgcttccac cccggctaca agaaagtcgt gaacgtgtcc 780aacgagatcc tgcgggaccc ttgcttccac cccggctaca agaaagtcgt gaacgtgtcc 780
gacctgtaca agaccccctg caccaagaga ttcgagatga ccctgccctt ccagcagttc 840gacctgtaca agaccccctg caccaagaga ttcgagatga ccctgccctt ccagcagttc 840
gagatccagg gcatcggcaa ttaccagcag tgccaccaga gcatcctgga actgttcaac 900gagatccagg gcatcggcaa ttaccagcag tgccaccaga gcatcctgga actgttcaac 900
accagctact gcccctacag ccagtgcgcc ttcaacggca tcttcctgcc acctctgcag 960accagctact gcccctacag ccagtgcgcc ttcaacggca tcttcctgcc acctctgcag 960
ggggatttcg gcgccttcag cgccttctac ttcgtgatga agttcctgaa cctgaccagc 1020ggggatttcg gcgccttcag cgccttctac ttcgtgatga agttcctgaa cctgaccagc 1020
gagaaggtgt cccaggaaaa agtgacagag atgatgaaga agttctgcgc ccaaccctgg 10801080
gaggaaatca agacctccta cgctggcgtg aacgagaagt acctgagcga gttttgcttc 1140gaggaaatca agacctccta cgctggcgtg aacgagaagt acctgagcga gttttgcttc 1140
agcggcacct acatcctgag cctgctgctg cagggctacc acttcaccgc cgatagctgg 1200agcggcacct acatcctgag cctgctgctg cagggctacc acttcaccgc cgatagctgg 1200
gagcacatcc acttcatcgg caagattcag ggcagcgacg ccggctggac actgggctac 1260gagcacatcc acttcatcgg caagattcag ggcagcgacg ccggctggac actgggctac 1260
atgctgaatc tgaccaacat gatccccgcc gagcagcccc tgagcacacc tctgagccac 1320atgctgaatc tgaccaacat gatccccgcc gagcagcccc tgagcacacc tctgagccac 1320
agcacc 1326agcacc 1326
<210> 243<210> 243
<211> 430<211> 430
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 243<400> 243
Ala Pro Thr Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly Ala Pro Thr Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Lys Tyr Gly
1 5 10 15 1 5 10 15
Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Ile Tyr Lys
20 25 30 20 25 30
Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His Gln Val Glu
35 40 45 35 40 45
Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Lys Val
50 55 60 50 55 60
Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Ala Arg Glu
65 70 75 80 65 70 75 80
Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr Leu Gly Ala
85 90 95 85 90 95
Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Ala Asp Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu Glu Leu Ala Asp
100 105 110 100 105 110
Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Pro Phe Asp
115 120 125 115 120 125
Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Ala Tyr Gly
130 135 140 130 135 140
Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Lys Asn Gln
145 150 155 160 145 150 155 160
Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Gln Val Thr
165 170 175 165 170 175
Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Ala Leu Gln
180 185 190 180 185 190
Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ser Phe Leu
195 200 205 195 200 205
Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Lys Asp Ile
210 215 220 210 215 220
Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe His Pro Gly
225 230 235 240 225 230 235 240
Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr Pro Cys Thr
245 250 255 245 250 255
Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Ile Gln Gly
260 265 270 260 265 270
Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Leu Phe Asn
275 280 285 275 280 285
Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Ile Phe Leu
290 295 300 290 295 300
Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Tyr Phe Val
305 310 315 320 305 310 315 320
Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Glu Lys Val
325 330 335 325 330 335
Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Ile Lys
340 345 350 340 345 350
Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Tyr Cys Phe
355 360 365 355 360 365
Ser Gly Thr Tyr Ile Leu Ser Leu Leu Gln Gln Gly Tyr His Phe Thr Ser Gly Thr Tyr Ile Leu Ser Leu Leu Gln Gln Gly Tyr His Phe Thr
370 375 380 370 375 380
Ala Asp Ser Trp Glu Asp Ile His Phe Ile Gly Lys Ile Gln Gly Ser Ala Asp Ser Trp Glu Asp Ile His Phe Ile Gly Lys Ile Gln Gly Ser
385 390 395 400 385 390 395 400
Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Asn Met Ile
405 410 415 405 410 415
Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Thr
420 425 430 420 425 430
<210> 244<210> 244
<211> 1290<211> 1290
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 244<400> 244
gcccctacca cccagaacaa ggccctgccc gagaacgtga agtacggcat cgtgctggat 60gcccctacca cccagaacaa ggccctgccc gagaacgtga agtacggcat cgtgctggat 60
gccggcagca gccacaccag cctgtacatc tacaagtggc ctgccgagaa agaaaacgac 120gccggcagca gccacaccag cctgtacatc tacaagtggc ctgccgagaa agaaaacgac 120
accggcgtgg tgcatcaggt ggaagagtgc agagtgaagg gccctggcat cagcaagttc 180accggcgtgg tgcatcaggt ggaaagtgc agagtgaagg gccctggcat cagcaagttc 180
gtgcagaaag tgaacgagat cggcatctac ctgaccgact gcatggaacg ggccagggaa 240gtgcagaaag tgaacgagat cggcatctac ctgaccgact gcatggaacg ggccagggaa 240
gtgatcccca gaagccagca ccaggaaacc cccgtgtatc tgggagccac cgccggcatg 300gtgatcccca gaagccagca cggaaacc cccgtgtatc tgggagccac cgccggcatg 300
agactgctga gaatggaaag cgaggaactg gccgaccggg tgctggacgt ggtggaaaga 360agactgctga gaatggaaag cgaggaactg gccgaccggg tgctggacgt ggtggaaaga 360
agcctgagca actacccatt cgattttcaa ggcgccagaa tcatcaccgg ccaggaagaa 420agcctgagca actacccatt cgattttcaa ggcgccagaa tcatcaccgg cggaagaa 420
ggcgcctacg gctggatcac catcaactac ctgctgggca agttcagcca gaagaatcag 480ggcgcctacg gctggatcac catcaactac ctgctgggca agttcagcca gaagaatcag 480
gaaaccttcg gcgccctgga cctgggcgga gcttctaccc aagtgacctt cgtgccccag 540gaaaccttcg gcgccctgga cctgggcgga gcttctaccc aagtgacctt cgtgccccag 540
aatcagacca tcgagagccc cgacaacgcc ctgcagttcc ggctgtacgg caaggactac 600aatcagacca tcgagagccc cgacaacgcc ctgcagttcc ggctgtacgg caaggactac 600
aatgtgtaca cccacagctt tctgtgctac ggaaaggacc aggctctgtg gcagaagctg 660aatgtgtaca cccacagctt tctgtgctac ggaaaggacc aggctctgtg gcagaagctg 660
gccaaggaca tccaggtggc cagcaacgag atcctgcggg acccttgctt ccaccccggc 720gccaaggaca tccaggtggc cagcaacgag atcctgcggg acccttgctt ccaccccggc 720
tacaagaaag tcgtgaacgt gtccgacctg tacaagaccc cctgcaccaa gagattcgag 780tacaagaaag tcgtgaacgt gtccgacctg tacaagaccc cctgcaccaa gagattcgag 780
atgaccctgc ccttccagca gttcgagatc cagggcatcg gcaattacca gcagtgccac 840atgaccctgc ccttccagca gttcgagatc cagggcatcg gcaattacca gcagtgccac 840
cagagcatcc tggaactgtt caacaccagc tactgcccct acagccagtg cgccttcaac 900cagagcatcc tggaactgtt caacaccagc tactgcccct acagccagtg cgccttcaac 900
ggcatcttcc tgccacctct gcagggggat ttcggcgcct tcagcgcctt ctacttcgtg 960ggcatcttcc tgccacctct gcagggggat ttcggcgcct tcagcgcctt ctacttcgtg 960
atgaagttcc tgaacctgac cagcgagaag gtgtcccagg aaaaagtgac agagatgatg 1020atgaagttcc tgaacctgac cagcgagaag gtgtcccagg aaaaagtgac agagatgatg 1020
aagaagttct gcgcccagcc ctgggaggaa atcaagacct cctacgctgg cgtgaaagag 1080aagaagttct gcgcccagcc ctgggaggaa atcaagacct cctacgctgg cgtgaaagag 1080
aagtacctga gcgagtactg cttcagcggc acctacatcc tgagcctgct gcagcagggc 1140aagtacctga gcgagtactg cttcagcggc acctacatcc tgagcctgct gcagcaggggc 1140
taccacttca ccgccgatag ctgggaggac atccacttca tcggcaagat tcagggcagc 1200taccacttca ccgccgatag ctgggaggac atccacttca tcggcaagat tcagggcagc 1200
gacgccggct ggacactggg ctacatgctg aatctgacca acatgatccc cgccgagcag 1260gacgccggct ggacactggg ctacatgctg aatctgacca acatgatccc cgccgagcag 1260
cccctgagca cacctctgag ccacagcacc 1290cccctgagca cacctctgag cccagcacc 1290
<210> 245<210> 245
<211> 433<211> 433
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полипептид"synthetic polypeptide
<400> 245<400> 245
Ala Pro Thr Ser Ser Ser Thr Gln Asn Lys Ala Leu Pro Glu Asn Val Ala Pro Thr Ser Ser Ser Thr Gln Asn Lys Ala Leu Pro Glu Asn Val
1 5 10 15 1 5 10 15
Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr Lys Tyr Gly Ile Val Leu Asp Ala Gly Ser Ser His Thr Ser Leu Tyr
20 25 30 20 25 30
Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His Ile Tyr Lys Trp Pro Ala Glu Lys Glu Asn Asp Thr Gly Val Val His
35 40 45 35 40 45
Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val Gln Val Glu Glu Cys Arg Val Lys Gly Pro Gly Ile Ser Lys Phe Val
50 55 60 50 55 60
Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg Gln Lys Val Asn Glu Ile Gly Ile Tyr Leu Thr Asp Cys Met Glu Arg
65 70 75 80 65 70 75 80
Ala Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr Ala Arg Glu Val Ile Pro Arg Ser Gln His Gln Glu Thr Pro Val Tyr
85 90 95 85 90 95
Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu Leu Gly Ala Thr Ala Gly Met Arg Leu Leu Arg Met Glu Ser Glu Glu
100 105 110 100 105 110
Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr Leu Ala Asp Arg Val Leu Asp Val Val Glu Arg Ser Leu Ser Asn Tyr
115 120 125 115 120 125
Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly Pro Phe Asp Phe Gln Gly Ala Arg Ile Ile Thr Gly Gln Glu Glu Gly
130 135 140 130 135 140
Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln Ala Tyr Gly Trp Ile Thr Ile Asn Tyr Leu Leu Gly Lys Phe Ser Gln
145 150 155 160 145 150 155 160
Lys Asn Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr Lys Asn Gln Glu Thr Phe Gly Ala Leu Asp Leu Gly Gly Ala Ser Thr
165 170 175 165 170 175
Gln Val Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn Gln Val Thr Phe Val Pro Gln Asn Gln Thr Ile Glu Ser Pro Asp Asn
180 185 190 180 185 190
Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His Ala Leu Gln Phe Arg Leu Tyr Gly Lys Asp Tyr Asn Val Tyr Thr His
195 200 205 195 200 205
Ser Phe Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala Ser Phe Leu Cys Tyr Gly Lys Asp Gln Ala Leu Trp Gln Lys Leu Ala
210 215 220 210 215 220
Lys Asp Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe Lys Asp Ile Gln Val Ala Ser Asn Glu Ile Leu Arg Asp Pro Cys Phe
225 230 235 240 225 230 235 240
His Pro Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr His Pro Gly Tyr Lys Lys Val Val Asn Val Ser Asp Leu Tyr Lys Thr
245 250 255 245 250 255
Pro Cys Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu Pro Cys Thr Lys Arg Phe Glu Met Thr Leu Pro Phe Gln Gln Phe Glu
260 265 270 260 265 270
Ile Gln Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu Ile Gln Gly Ile Gly Asn Tyr Gln Gln Cys His Gln Ser Ile Leu Glu
275 280 285 275 280 285
Leu Phe Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly Leu Phe Asn Thr Ser Tyr Cys Pro Tyr Ser Gln Cys Ala Phe Asn Gly
290 295 300 290 295 300
Ile Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe Ile Phe Leu Pro Pro Leu Gln Gly Asp Phe Gly Ala Phe Ser Ala Phe
305 310 315 320 305 310 315 320
Tyr Phe Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln Tyr Phe Val Met Lys Phe Leu Asn Leu Thr Ser Glu Lys Val Ser Gln
325 330 335 325 330 335
Glu Lys Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu Glu Lys Val Thr Glu Met Met Lys Lys Phe Cys Ala Gln Pro Trp Glu
340 345 350 340 345 350
Glu Ile Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu Glu Ile Lys Thr Ser Tyr Ala Gly Val Lys Glu Lys Tyr Leu Ser Glu
355 360 365 355 360 365
Tyr Cys Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Gln Gln Gly Tyr Tyr Cys Phe Ser Gly Thr Tyr Ile Leu Ser Leu Leu Gln Gln Gly Tyr
370 375 380 370 375 380
His Phe Thr Ala Asp Ser Trp Glu Asp Ile His Phe Ile Gly Lys Ile His Phe Thr Ala Asp Ser Trp Glu Asp Ile His Phe Ile Gly Lys Ile
385 390 395 400 385 390 395 400
Gln Gly Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr Gln Gly Ser Asp Ala Gly Trp Thr Leu Gly Tyr Met Leu Asn Leu Thr
405 410 415 405 410 415
Asn Met Ile Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser Asn Met Ile Pro Ala Glu Gln Pro Leu Ser Thr Pro Leu Ser His Ser
420 425 430 420 425 430
Thr Thr
<210> 246<210> 246
<211> 1299<211> 1299
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический полинуклеотид"synthetic polynucleotide"
<400> 246<400> 246
gcccctacca gcagcagcac ccagaacaag gccctgcccg agaacgtgaa gtacggcatc 60gcccctacca gcagcagcac ccagaacaag gccctgcccg agaacgtgaa gtacggcatc 60
gtgctggatg ccggcagcag ccacaccagc ctgtacatct acaagtggcc tgccgagaaa 120gtgctggatg ccggcagcag ccacaccagc ctgtacatct acaagtggcc tgccgagaaa 120
gaaaacgaca ccggcgtggt gcatcaggtg gaagagtgca gagtgaaggg ccctggcatc 180gaaaacgaca ccggcgtggt gcatcaggtg gaagagtgca gagtgaaggg ccctggcatc 180
agcaagttcg tgcagaaagt gaacgagatc ggcatctacc tgaccgactg catggaacgg 240agcaagttcg tgcagaaagt gaacgagatc ggcatctacc tgaccgactg catggaacgg 240
gccagggaag tgatccccag aagccagcac caggaaaccc ccgtgtatct gggagccacc 300gccagggaag tgatccccag aagccagcac caggaaaccc ccgtgtatct gggagccacc 300
gccggcatga gactgctgag aatggaaagc gaggaactgg ccgaccgggt gctggacgtg 360gccggcatga gactgctgag aatggaaagc gaggaactgg ccgaccgggt gctggacgtg 360
gtggaaagaa gcctgagcaa ctacccattc gattttcaag gcgccagaat catcaccggc 420gtggaaagaa gcctgagcaa ctacccattc gattttcaag gcgccagaat catcaccggc 420
caggaagaag gcgcctacgg ctggatcacc atcaactacc tgctgggcaa gttcagccag 480caggaagaag gcgcctacgg ctggatcacc atcaactacc tgctgggcaa gttcagccag 480
aagaatcagg aaaccttcgg cgccctggac ctgggcggag cttctaccca agtgaccttc 540aagaatcagg aaaccttcgg cgccctggac ctgggcggag cttctaccca agtgaccttc 540
gtgccccaga atcagaccat cgagagcccc gacaacgccc tgcagttccg gctgtacggc 600gtgccccaga atcagaccat cgagagcccc gacaacgccc tgcagttccg gctgtacggc 600
aaggactaca atgtgtacac ccacagcttt ctgtgctacg gaaaggacca ggctctgtgg 660aaggactaca atgtgtacac ccacagcttt ctgtgctacg gaaaggacca ggctctgtgg 660
cagaagctgg ccaaggacat ccaggtggcc agcaacgaga tcctgcggga cccttgcttc 720cagaagctgg ccaaggacat ccaggtggcc agcaacgaga tcctgcggga cccttgcttc 720
caccccggct acaagaaagt cgtgaacgtg tccgacctgt acaagacccc ctgcaccaag 780caccccggct acaagaaagt cgtgaacgtg tccgacctgt acaagacccc ctgcaccaag 780
agattcgaga tgaccctgcc cttccagcag ttcgagatcc agggcatcgg caattaccag 840agattcgaga tgaccctgcc cttccagcag ttcgagatcc agggcatcgg caattaccag 840
cagtgccacc agagcatcct ggaactgttc aacaccagct actgccccta cagccagtgc 900cagtgccacc agagcatcct ggaactgttc aacaccagct actgccccta cagccagtgc 900
gccttcaacg gcatcttcct gccacctctg cagggggatt tcggcgcctt cagcgccttc 960gccttcaacg gcatcttcct gccacctctg cagggggatt tcggcgcctt cagcgccttc 960
tacttcgtga tgaagttcct gaacctgacc agcgagaagg tgtcccagga aaaagtgaca 1020tacttcgtga tgaagttcct gaacctgacc agcgagaagg tgtcccagga aaaagtgaca 1020
gagatgatga agaagttctg cgcccagccc tgggaggaaa tcaagacctc ctacgctggc 1080gagatgatga agaagttctg cgcccagccc tgggaggaaa tcaagacctc ctacgctggc 1080
gtgaaagaga agtacctgag cgagtactgc ttcagcggca cctacatcct gagcctgctg 1140gtgaaagaga agtacctgag cgagtactgc ttcagcggca cctacatcct gagcctgctg 1140
cagcagggct accacttcac cgccgatagc tgggaggaca tccacttcat cggcaagatt 1200cagcagggct accacttcac cgccgatagc tgggaggaca tccacttcat cggcaagatt 1200
cagggcagcg acgccggctg gacactgggc tacatgctga atctgaccaa catgatcccc 1260cagggcagcg acgccggctg gacactgggc tacatgctga atctgaccaa catgatcccc 1260
gccgagcagc ccctgagcac acctctgagc cacagcacc 1299gccgagcagc ccctgagcac acctctgagc cacagcacc 1299
<210> 247<210> 247
<211> 6<211> 6
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический пептид"synthetic peptide
<400> 247<400> 247
Glu Phe Arg His Asp Ser Glu Phe Arg His Asp Ser
1 5 15
<210> 248<210> 248
<211> 18<211> 18
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический олигонуклеотид"Synthetic oligonucleotide"
<400> 248<400> 248
gaattccggc acgacagc 18gaattccggc acgacagc 18
<210> 249<210> 249
<211> 6<211> 6
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетическая 6xHis метка"Synthetic 6xHis label"
<400> 249<400> 249
His His His His His His His His His His His His His
1 5 15
<210> 250<210> 250
<211> 18<211> 18
<212> ДНК<212> DNA
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
Синтетический олигонуклеотид"Synthetic oligonucleotide"
<400> 250<400> 250
catcatcatc atcatcac 18catcatcatc atcatcac 18
<210> 251<210> 251
<211> 5<211> 5
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический пептид"synthetic peptide"
<400> 251<400> 251
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1 5 15
<210> 252<210> 252
<211> 8<211> 8
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический пептид"synthetic peptide"
<400> 252<400> 252
Val Lys Glu Lys Tyr Leu Ser Glu Val Lys Glu Lys Tyr Leu Ser Glu
1 5 15
<210> 253<210> 253
<211> 7<211> 7
<212> БЕЛОК<212> PROTEIN
<213> Искусственная последовательность<213> Artificial sequence
<220><220>
<221> источник<221> source
<223> /примечание="Описание искусственной последовательности: <223> /note="Description of the artificial sequence:
синтетический пептид"synthetic peptide"
<400> 253<400> 253
Gln Glu Arg Trp Leu Arg Asp Gln Glu Arg Trp Leu Arg Asp
1 5 15
<---<---
Claims (20)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18184269.1 | 2018-07-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2021100711A RU2021100711A (en) | 2022-08-18 |
RU2791992C2 true RU2791992C2 (en) | 2023-03-15 |
Family
ID=
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2628725C2 (en) * | 2015-11-02 | 2017-08-21 | Федеральное бюджетное учреждение "Центральная база авиационной охраны лесов "Авиалесоохрана" | Universal fire-fighting ground-blower |
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2628725C2 (en) * | 2015-11-02 | 2017-08-21 | Федеральное бюджетное учреждение "Центральная база авиационной охраны лесов "Авиалесоохрана" | Universal fire-fighting ground-blower |
Non-Patent Citations (2)
Title |
---|
D.MOECKEL et al. Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without increasing bleeding risk, Sci Transl Med, 2014 Aug 6;6(248):248ra105. doi: 10.1126/scitranslmed.3009246. WHISSTOCK J. C. et al. "Prediction of protein function from protein sequence and structure", Quarterly Reviews of Biophysics 36, 3 2003, p.307- 340. DOI:10.1017/S0033583503003901. WITKOWSKI A. et al. "Conversion of a β-Ketoacyl Synthase to a Malonyl Decarboxylase by Replacement of the Active-Site Cysteine with Glutamine", Biochemistry 1999, 38, p.11643-11650, doi:10.1021/bi990993h. SEFFERNICK J. L. et al. "Melamine Deaminase and Atrazine Chlorohydrolase: 98 Percent Identical but Functionally Different", JOURNAL OF BACTERIOLOGY, 2001, v.183, no.8, p.2405-2410, DOI: 10.1128/JB.183.8.2405-2410.2001. * |
СИВУК В.Ф. и др. Очистка и характеристика функциональных свойств растворимой нуклеозидтрифосфатазы (апиразы) из мозга быка, БИОХИМИЯ, том 73, вып.9, 2008, с.1300-1307. * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5902679B2 (en) | Tear lipocalin mutein that binds to IL-4Rα | |
EP3098241B1 (en) | Fusion protein inhibiting angiogenesis or growth and use thereof | |
US11879002B2 (en) | Bi-specific therapeutic proteins, in vivo methods of use thereof and encoding nucleic acids thereof | |
KR20190124656A (en) | Modified mitochondria and use thereof | |
JP2024023297A (en) | Solubilized apyrase, methods and use | |
EP2754718B1 (en) | Vascular endothelial myostatin mutant that mutates at atp binding sites | |
KR20220058588A (en) | Therapeutic Fusion Proteins | |
RU2791992C2 (en) | Solubilized apirases, methods and applications | |
EA023541B1 (en) | Insulin-like growth factor 1 receptor binding peptides | |
EA046596B1 (en) | SOLUBILIZED APYRASES, METHODS AND APPLICATION | |
EA023016B1 (en) | Fusion protein | |
KR101106262B1 (en) | Transmembrane Delivery Peptide Originated from Human Homeodomain Gene and Protein Transduction Vector | |
WO2022253340A1 (en) | Peptide translated by circular rna circ-ace2 and application thereof | |
CN114929731A (en) | RSPO1 protein and application thereof | |
AU2022317144A9 (en) | Ptprs in autoimmunity | |
CN115873127A (en) | Recombinant long-acting human growth hormone fusion protein and preparation method and application thereof | |
JP2007332082A (en) | Protein for cell adhesion/extension |